(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number
WO 2003/062400 A3

(51) International Patent Classification[7]: C12N 15/63, 15/11, 15/85, 7/00, 15/00, C07K 14/00, A23J 1/00, C12P 21/00

(21) International Application Number:
PCT/US2003/002295

(22) International Filing Date: 24 January 2003 (24.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 60/350,388 | 24 January 2002 (24.01.2002) | US |
| 60/391,967 | 26 June 2002 (26.06.2002) | US |

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

| | |
|---|---|
| US | 60/391,967 (CIP) |
| Filed on | 26 June 2002 (26.06.2002) |
| US | 60/350,388 (CIP) |
| Filed on | 24 January 2002 (24.01.2002) |

(71) Applicants *(for all designated States except US)*: **THE SCRIPPS RESEARCH INSTITUTE** [US/US]; 10550 North Torrey Pines Road, TPC-8, La Jolla, CA 92037 (US). **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KALEKO, Michael** [US/US]; 8 Hearthstone Court, Rockville, MD 20854 (US). **NEMEROW, Glen, R.** [US/US]; 462 Cerro Street, Encinitas, CA 92024 (US). **SMITH, Theodore** [US/US]; 3346 Knolls Parkway, Ijamsville, MD 21754 (US). **STEVENSON, Susan, C.** [US/US]; 10974 Horseshoe Drive, Frederick, MD 21701 (US).

(74) Agents: **SEIDMAN, Stephanie, L.** et al.; Fish & Richardson P.C., 12390 El Camino Real, San Diego, CA 92130 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*

(88) Date of publication of the international search report:
27 January 2005

(48) Date of publication of this corrected version:
9 June 2005

(15) Information about Correction:
see PCT Gazette No. 23/2005 of 9 June 2005, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: FIBER SHAFT MODIFICATIONS FOR EFFICIENT TARGETING

(57) Abstract: Provided are adenoviral vectors and the production of such vectors. In particular, fiber shaft modifications for efficient targeting of adenoviral vectors are provided. The fiber shaft modifications can be combined with other modifications, such as fiber knob and/or penton modifications, to produce fully ablated (detargeted) adenoviral vectors. A scale-up method for the propagation of detargeted adenoviral vectors is also provided.

WO 2003/062400 A3

# FIBER SHAFT MODIFICATIONS FOR EFFICIENT TARGETING

## RELATED APPLICATIONS

Benefit of priority is claimed to U.S. provisional application Serial No. 60/350,388, filed 24 January 2002, entitled "FIBER SHAFT MODIFICATIONS FOR EFFICIENT TARGETING," to Stevenson, Susan C., Kaleko, Michael, Smith, Theodore and Nemerow, Glen R., and to U.S. provisional application Serial No. 60/391,967, filed 26 June 2002, entitled "FIBER SHAFT MODIFICATIONS FOR EFFICIENT TARGETING," to Stevenson, Susan C., Kaleko, Michael, Smith, Theodore and Nemerow, Glen R. This application is also related to International PCT application No. (attorney docket number 22908-1236), filed the same day herewith, entitled "FIBER SHAFT MODIFICATIONS FOR EFFICIENT TARGETING," to Stevenson, Susan C., Kaleko, Michael, Smith, Theodore and Nemerow, Glen R. Where permitted, the subject matter of each of these applications is incorporated by reference herein.

## FIELD OF INVENTION

The present invention generally relates to the field of adenoviral vectors and the production of such vectors. In particular, detargeted adenoviral vectors are provided.

## BACKGROUND

Most, if not all, adenoviral vector-mediated gene therapy strategies aim to transduce a specific tissue, such as a tumor or an organ. Systemic delivery will require ablation of the normal virus tropism as well as addition of new specificities. Multiple interactions between adenoviral particles and the host cell are required to promote efficient cell entry (Nemerow (2000) *Virology 274*:1-4). An adenovirus entry pathway is believed to involve two separate cell surface events. First, a high affinity interaction between the adenoviral fiber knob and coxsackie-adenovirus receptor (CAR) mediates the attachment of the adenovirus particle to the cell surface. A subsequent association of penton with the cell surface integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$, which act as co-receptors, potentiates virus internalization. There are a plurality of adenoviral fiber receptors, which interact with the group B (*e.g.*, Ad3) and group C (*e.g.*, Ad5) adenoviruses. Both of these groups of adenoviruses appear to require interaction with integrins for

internalization. CAR ablation, however, does not change biodistribution and toxicity of adenoviral vectors *in vivo* (Alemany *et al.* (2001) *Gene Therapy 8*:1347-1353; U.S. patent application No. 09/870,203, filed May 30, 2001, and published as U.S. Published application No. 20020137213). Thus, the role of CAR interaction for *in vivo* gene transfer is not clear. Recently published studies have described conflicting results (Alemany *et al.* (2001) *Gene Therapy 8*:1347-1353; Leissner *et al.* (2001) *Gene Therapy 8*:49-57; Einfeld *et al.* (2001) *J. Virology 75*:11284-11291). For example,it has been shown that vectors containing an S408E mutation in the Ad5 fiber AB loop yield efficient liver transduction in mice, despite having greatly reduced transduction efficiencies on cells in culture (see, Leissner *et al.* (2001) *Gene Therapy 8*:49-57). In contrast, vectors containing a more extensive fiber AB loop mutation showed a 10-fold reduction in liver gene expression (see, Einfeld *et al.* (2001) *J. Virology 75*:11284-11291).

A doubly ablated adenovirus has been prepared by modifying the CAR binding region in the fiber loop and the integrin binding region in the penton base (Einfeld *et al.* (2001) *J. Virology 75*:11284-11291). This doubly ablated adenovirus, lacking CAR and integrin interactions, was reported not only to lack *in vitro* transduction of various cell types but also to lack *in vivo* transduction of liver cells. Specifically, the doubly ablated adenovirus was reported to have a 700 fold reduction in liver transduction when compared to the non-ablated adenovirus. These results, however, were not reproduced by others.

For many applications, the most clinically useful adenoviral vector would be deliverable systemically, such as into a peripheral vein, and would be targeted to a desired location in the body, and would not have undesirable side effects resulting from targeting to other locations. *In vivo* adenoviral vector targeting is a major goal in gene therapy and a significant effort has been focused on developing strategies to achieve this goal. Successful targeting strategies would direct the entire vector dose to the appropriate site and would be likely to improve the safety profile of the vector by permitting the use of lower, less toxic vector doses, which potentially also can be less immunogenic. Thus, there is a

need to develop adenoviruses which are fully detargeted *in vivo* for use as a base vector for producing redirected adenoviruses.

Therefore, among the objects herein, it is an object herein to provide fully detargeted adenoviral vectors, methods for preparation thereof, and uses thereof.

**SUMMARY**

Detargeted and fully detargeted adenoviral particles, adenovirus vectors from which such particles are produced, methods for preparation of the vectors and particles and uses of the vectors and particles are provided. Provided and described are capsid modifications, such as fiber shaft modifications, and the resuling proteins that, when expressed on adenoviral particles provide for detargeting of adenoviral vectors. The capsid modifications, such as the fiber shaft modifications, can be combined with other modifications, such as fiber knob and/or penton modifications, to produce fully ablated (detargeted) adenoviral particles. Thus, adenoviral vectors and adenovirual particles whose native tropisms are ablated through a modification or modifications of capsid proteins, particularly a fiber shaft region, are provided.

Thus, provided are capsid mutiations, including fiber shaft modifications, that ablate binding to particular receptors, thereby permitting efficient targeting of adenoviral vectors that contain capsids with such modifications. For example, adenoviral vectors in which the fiber shaft's interaction with HSP is ablated (reduced or substantially eliminated), particuarly *in vivo*, are provided. These fiber shaft modifications can be combined with other modifications, such as fiber knob and/or penton modifications, to produce fully ablated (detargeted) adenoviral vectors. Also provided are retargeted vectors and particles that include a ligand or ligands to provide for targeting of the detargeted vectors and particles to selected cells and/or tissues. Retargeting can be effected, for example, by manipulating the fiber protein to redirect the receptor specificity to a particular cell type.

Also provided are nucleic acids encoding the modified fiber proteins and also modified penton proteins. Also provided are nucleic acids encoding the modified fiber shaft protein that has ablated HSP binding and combinations

thereof with other modified fiber regions or other proteins, such as a modified fiber knob region and/or the modified penton protein. The nucleic acids also can contain heterologous nucleic acid sequences, such as promoters or nucleic acid sequences encoding polypeptides. The viral particles that express fibers containing such shaft modifications and other modifications are also provided.

Also provided are methods for making and using the adenoviral particles that express the modified fibers and combinations of modified fibers and modified penton. With the fiber shaft modifications, particularly in combination with the fiber knob modifications and the penton modifications, the adenovirus particles are ablated for binding to their natural cellular receptor(s), *i.e.*, they are detargeted. They can then be "retargeted" to a specific cell type through the addition of a ligand to the virus capsid, which causes the virus to bind to and infect such cell. The ligand can be added, for example, through genetic modification of a capsid protein gene.

Also provided is a method for reducing liver toxicity in adeno-viral-mediated therapy. In contrast to the results of Einfeld *et al.* (Einfeld *et al.* (2001) *J. Virology 75*:11284-11291), it is shown herein that a doubly ablated adenovirus, lacking CAR and integrin interactions, is capable of *in vivo* liver transduction. It is shown herein that ablation of liver transduction requires further and/or alternative modification(s). The method for reducing liver toxicity in adenoviral-mediated therapy includes
modifying an adenoviral vector to ablate native tropism to liver cells *in vivo*. Such vector can be administered to a subject. The modifications include the modifications described herein.

The nucleic acids, proteins, adenoviral particles and adenoviral vectors have a variety of uses. These include *in vivo* and *in vitro* uses to target nucleic acid to particular cells and tissues, for therapeutic purposes, including gene therapy, and also for the identification and study of cell surface receptors and identification of modes of interaction of viruses with cells.

In particular, adenoviral fiber shaft modifications that ablate viral interaction with HSP (Heparin Sulfate Proteoglycans; also referred to as heparin sulfate glycosaminoglycans) are provided. These modifications include

mutations of individual amino acids in the fiber shaft that interact with HSP or mutations of amino acids in the fiber shaft that modify the ability of the HSP binding motif to interact with HSP. Adenoviral fiber shaft modifications also include replacements of fiber shafts using fiber shafts of adenoviruses, such as, for example, Ad3, Ad35 and Ad41 short fiber shaft, that do not contain HSP binding sites.

Also provided are adenoviral fiber shaft modifications that alter, particularly ablate viral interaction with HSP, as described above, in combination with fiber knob modifications that ablate viral interaction with CAR. The fiber knob modifications include: (a) mutations of individual amino acids in the fiber loop that interact with CAR, such as, for example, AB or CD loop modifications; (b) mutations of individual amino acids in the fiber loop that modify the ability of the CAR binding motif to interact with CAR; and (c) replacements of fiber knobs using adenoviruses that do not interact with CAR, such as, for example, Ad3 fiber knob, Ad41 short fiber knob, or Ad35 fiber knob.

Also provided are adenoviral fiber shaft modifications as described above in combination with penton modifications that ablate viral interaction with $a_v$ integrins. The penton modifications include: (a) mutations of individual amino acids that interact with $\alpha_v$ integrins; (b) mutations of individual amino acids that modify the ability of the $\alpha_v$ integrin binding motif to interact with the $\alpha_v$ integrins; and (c) replacement of penton proteins using penton proteins from adenoviruses that do not interact with the $\alpha_v$ integrins.

Also provided are adenoviral fiber shaft modifications as described above in combination with fiber knob modifications as described above and penton modifications as described above.

Also provided is a scale-up method for the propagation of detargeted adenoviral vectors. The method uses polycations and/or bifunctional reagents, which when added to tissue culture medium results in entry of adenoviral particles into the producer cells.

Provided aer recombinant viral particles that contain a modified capid protein whereby binding to heparin sulfate proteoglycans (HSP) is reduced or eliminated compared to particles that contain unmodified capsid proteins. The modified capsid proteins include fibers proteins with modified shafts such that binding to HSP is reduced or eliminated.

Among the particular embodiments the following are provided. Provided are adenovirus capsid proteins that are modified to alter, typically reduce or eliminate, binding to or interaction with *in vivo* and/or *in vitro* to heparin sulfate proteoglycan (HSP). HSPs are expressed on various cells, including hepatocytes. It is shown herein that HSPs provide for or participate in transduction of cells, such as liver cells. Since it can be desirable to eliminate or reduce such transduction, the modifications of the capsid proteins, such as fiber proteins, permit detargeting of particles that express such proteins from such cells.

Thus provided are modified adenovirus fiber proteins that include a mutation, such as an insertion, deletion, change, replacement of amino acids or combinations thereof, whereby binding to or interaction with heparin sulfate proteoglycan (HSP) is altered. In particular, the he binding of the modified fiber protein is eliminated or reduced compared to the unmodified protein. Exemplary of these mutations are mutations in the shaft of a fiber, where the shaft also can include the tail. The mutations can reduce or alter the affinity of the fiber protein for HSP is reduced at least by 2-fold, 5-fold, 10-fold, 100-fold or more, including substantially eliminating it.

As provided herein, fibers from adenoviruses that interact with HSP can include a motif, such as BBXB or BBBXXB, wherethe B is a basic amino acid and X is any amino acid, particularly the consensus sequence KKTK in Ad5 and Ad2. Thus, provided are fibers in which the motif is altered to eliminate or reduce interaction with HSP.

Also provided are modified fiber protein of claim 1 that are chimeras in which the fiber shaft (or fiber shaft and tail) are derived from a fiber, such as Ad3, Ad35, Ad7, Ad11, Ad16, Ad21, Ad34, Ad40, Ad41 or Ad46 fiber, that does not interact with HSP and combined with fiber that does interact, such as

Ad5 or Ad2 fiber, to produce a complete fiber whose binding to HSP is reduced or eliminated.

All of the modified capsids proteins provided herein also can include one or more further modifications that reduce or eliminate interaction of the resulting fiber with one or more cell surface proteins, such as but not limited to, CAR and $\alpha_v$ integrin or other receptor to which a particular native fiber binds, in addition to HSP. These modifications include, but are not limited to, modification to fiber that reduces or eliminates CAR binding and modification to penton that reduces or eliminate $\alpha_v$ integrin binding. The mutations can be in the fiber knob, shaft, tail and shaft, and also in penton.

Any and all of the modified capsid proteins provided herein can further include a ligand that binds to a particular receptor thereby endowing a fiber (or other capsid protein) with binding specificity or the ability to interact with such receptor. The ligand can be inserted into any suitable site in a capsid protein, such as an insertion or replacement. For example, fibers with ligands inserted into the knob region are exemplified. Any such ligand can be employed and a variety are exemplified herein.

A variety of modified capsid proteins are exemplified herein. These include, but are not limited to, fibers containing: the sequence of amino acids set forth in any of SEQ ID Nos. 52, 54, 56, 58, 62, 66, 70 and 72; or a sequence of amino acids having 60%, 70%, 80%, 90%, 95% or greater sequence identity with a sequence of amino acids set forth in any of SEQ ID Nos. 52, 54, 56, 58, 62, 66, 70 and 72; or a sequence of amino acids encoded by a sequence of nucleotides that hybridizes under conditions of high stringency along at least 70% of its length to a sequence of nucleotides that encodes a sequence of amino acids set forth in any of SEQ ID Nos. 52, 54, 56, 58, 62, 66, 70 and 72.

Nucleic acids encoding the capsid proteins, including the fibers are also provided. The nucleic acids can be provided as vectors, particularly as adenovirus vectors. Many adenoviral vectors are known and can be modified as needed in accord with the description herein. Adenoviral vectors include, but are not limited to, early generation adenoviral vectors, such as E1-deleted

vectors, gutless adenoviral vectors and replication-conditional adenoviral vectors, such as oncolytic adenoviral vectors. The adenovirus vectors also can include heterologous nucleic acids that encode or provide products, such as therapeutic products. Any therapeutic product is contemplated and a variety are set forth herein as exemplary. Heterologous nucleic acid can encode a polypeptide or comprise or encode a regulatory sequence, such as a promoter or an RNA, including RNAi, small RNAs, other double-stranded RNAs, antisense RNA, and ribozymes. Promoters include, for example, constitutive and regulated promoters and tissue specific promoter, including tumor specific promoters. The promoter can be operably linked, for example, to a gene of an adenovirus essential for replication.

Cells containing the nucleic acid molecules and cells containing the vectors are also provided. Such cell include packaging cells. The cells can be prokaryotic or eukaryotic cells, including, mammalian cells, such a primate cells, including human cells.

Also provided are adenoviral particles that contain the modified capsid proteins provided herein. The particles have altered interaction or binding with HSP compared to particles that do not contain the modified capsid proteins. In addition to altered binding to HSP, which is typically reduced or eliminated binding, the particles can include further modifications, such as capsid proteins with altered interaction with other receptors as described above. In particular, the particles can have altered, typically reduced or eliminated, interaction with CAR, $\alpha_v$ integrin and/or other receptors. The mutation include mutations in the fiber knob, penton and hexon. Exemplary fiber know mutations are mutations in the AB loop or CD loop, such as KO1 or KO12, which are described herein. In addition, the particles can include additional ligands for retargeting to selected receptors. The adenoviral particles can be from any serotype and subgroup.

Methods for expressing heterologous nucleic acids in a cell are provided. In these methods an adenoviral vector provided herein is transduced into a cell to deliver the nucleic acid and/or encoded products. Transduction can be effected *in vivo* or *in vitro* or *ex vivo*, and can be for a variety of purposes including study of gene expression and genetic therapy. The cells can be

prokaryotic cells, but typically are eukaryotic cells, including mammalian cells, such as primate, including human, cells. The cells can be of a specific type, such as a tumor cell or a cell in a particular tissue. The vectors can be oncolytic vector to effect killing of tumor cells.

Since the modified capsid proteins herein have reduced or eliminated binding to HSP, viral particles containing such proteins exhibit ablated binding to HSP *in vitro* and *in vivo*. Thus provided is a method of reducing transduction of cells that express HSP, such as hepatocytes in the liver, by modifying a capsid protein, such as fiber to eliminate or reduce interaction with or binding to HSP. Such reduction reduces or eliminates transduction of cells that express HSP, including liver cells.

Also provided are scale-up methods for the propagation of detargeted adenoviral particle, such as those provided herein. The method includes the steps of infecting or transducing a cell capable of replicating, maturing and packaging an adenoviral vector with a detargeted adenoviral vector in the presence of a reagent that results in entry of the adenoviral particle into the cell, such as a polycation and/or a bifunctional protein or other such reagent; and culturing the infected cell under conditions suitable for growth, spread and propagation of the adenoviral vector. The resulting adenoviral particles can be recovered. Polycations include, but are not limited to, hexadimethrine bromide, polyethylenimine, protamine sulfate and poly-L-lysine. Bifunctional proteins, include, but are not limited to, an anti-fiber antibody ligand fusion, an anti-fiber-Fab-FGF conjugate, an anti-penton-antibody ligand fusion, an anti-hexon antibody ligand fusion and a polylysine-peptide fusion. The ligand is selected to bind to a particular receptor.

The viral particles that express a modified capsids provided herein can be produced by this method. The modification include, for example, one or more mutations selected from among mutations that reduce or eliminate interactions with one or more of $\alpha_v$ integrins, coxsackie-adenovirus receptors (CAR) and heparin sulfate proteoglycans (HSP). Such mutations include, for example, PD1, KO1, KO12 and S*.

**BRIEF DESCRIPTION OF THE FIGURES**

Figure 1 is a plasmid map for pSKO1.

Figure 2 is a plasmid map for pNDSQ3.1KO1.

Figures 3A-3C are plasmid maps of pAdmireRSVnBg.(Fig. 3A), pSQ1 Fig. 3B) and pSQ1KO12 (Fig. 3C)

Figure 4 is a plasmid map for pSQ1PD1.

Figures 5A-5B are plasmid maps of pSQ1FKO1PD1 (Fig. 5A) and pSQ1KO12PD1 (Fig. 5B).

Figure 6 shows *in vitro* transduction efficiency of A549 cells using adenoviral vectors containing fiber AB loop knob and/or penton, PD1 mutations. The following adenoviral vectors were used in these studies: Av1nBg, Av1nBgFKO1, referred to as FKO1, Av1nBgPD1, referred to as PD1, and Av1nBgFKO1PD1 that is referred to as FKO1PD1.

Figure 7A-7B shows *in vivo* adenoviral-mediated liver gene expression (Fig. 7A) and hexon DNA content (Fig. 7B) using adenoviral vectors containing fiber AB loop knob and/or penton, PD1 mutations. The following adenoviral vectors were used in these studies: Av1nBg, Av1nBgFKO1, referred to as FKO1, Av1nBgPD1, referred to as PD1, Av1nBgFKO1PD1, referred to as FKO1PD1, Av1nBgKO12, referred to as KO12, and Av1nBgKO12PD1 that is referred to as KO12PD1.

Figure 8 is a plasmid map for pFBshuttle(EcoRI).

Figure 9 is a plasmid map for pSQ1HSP.

Figure 10 is a plasmid map for pSQ1HSPKO1.

Figure 11 is a plasmid map for pSQ1HSPPD1.

Figure 12 is a plasmid map for pSQ1HSPKO1PD1.

Figures 13A-13C show the transduction efficiency of A549 and HeLa cells using adenoviral vectors containing fiber shaft, knob and/or penton mutations. Fig. 13A shows the dose response for the transduction efficiency of A549 cells. Fig. 13B shows the transduction efficiency of HeLa cells at 2000 ppc. Figure 13C shows the competition analysis of adenoviral vectors containing fiber shaft mutations.

Figures 14A-14B shows the influence of fiber shaft mutations on *in vivo* adenoviral-mediated liver gene expression (Fig. 14A) and hexon DNA content (Fig. 14B).

Figures 15A-15B are plasmid maps of pSQ1HSPRGD (Fig. 15A) and pSQ1HSPKO1RGD (Fig. 15B).

Figure 16 shows that insertion of a RGD targeting ligand can restore transduction of the vectors containing the HSP binding shaft S* mutation.

Figures 17A-17B are plasmid maps of pSQ1AD35Fiber (Fig. 17A) and pSQ1Ad35FcRGD (Fig. 17B).

Figures 18A-18B are maps of plasmids encoding 35F chimeric fibers. Fig. 18A is a plasmid map of pSQ135T5H, and Fig. 18B is a plasmid map of pSQ15T35H.

Figure 19 shows the results of an *in vitro* analysis of Ad5 vectors containing Ad35 fibers and derivatives thereof.

Figure 20 shows the results of an *in vivo* analysis of Ad5 vectors containing Ad35 fibers and derivatives thereof.

Figures 21A-21B are plasmid maps of pSQ1Ad41sF (Fig. 21A) and pSQ1Ad41sFRGD (Fig. 21B).

Figure 22 shows the results of an *in vivo* analysis of Ad5 vectors containing Ad41 short fiber.

Figure 23 shows the *in vitro* analysis of Ad5 based vectors containing the Ad41 short fiber which has been re-engineered to contain a cRGD ligand in the HI loop.

Figure 24 shows enhanced transduction of AE1-2a cells with the Av3nBgFKO1 detargeted adenoviral vector using hexadimethrine bromide (HB), protamine sulfate (PS) and poly-lysine-RGD (K14) or the anti-penton-TNF$\alpha$ bifunctional protein ($\alpha$pen-TNF).

Figure 25 shows ablation of HSP interaction decreases adenoviral-mediated gene transfer to other organs

Figure 26 shows *in vivo* liver transduction with adenoviral vectors which encode for B-galactosidase and contain various mutations to the fiber and/or penton proteins. Results are plotted as percent transduction as compared to

wild type. Two different methods for determining the level of transduction are shown for each vector.

Figure 27 shows the adenoviral vector biodistribution to the liver and tumor for the vectors containing the S*, KO1S*, and 41sF fibers.

## DETAILED DESCRIPTION

### A. DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention(s) belong. All patents, patent applications, published applications and publications, Genbank sequences, websites and other published materials referred to throughout the entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. In the event that there are a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it understood that such identifiers can change and particular information on the internet can come and go, but equivalent information is known and can be readily accessed, such as by searching the internet and/or appropriate databases. Reference thereto evidences the availability and public dissemination of such information.

As used herein, the term "adenovirus" or "adenoviral particle" is used to include any and all viruses that can be categorized as an adenovirus, including any adenovirus that infects a human or an animal, including all groups, subgroups, and serotypes. Depending upon the context reference to "adenovirus" can include adenoviral vectors. There are at least 51 serotypes of Adenovirus that classified into several subgroups. For example, subgroup A includes adenovirus serotypes 12, 18, and 31. Subgroup C includes adenovirus serotypes 1, 2, 5, and 6. Subgroup D includes adenovirus serotype 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39, and 42-49. Subgroup E includes adenovirus serotype 4. Subgroup F includes adenovirus serotypes 40 and 41. These latter two serotypes have a long and a short fiber protein. Thus, as used herein an adenovirus or adenovirus particle is a packaged vector or genome.

As used herein, "virus," "viral particle," "vector particle," "viral vector particle," and "virion" are used interchangeably to refer to infectious viral particles that are formed when, such as when a vector containing all or a part of a viral genome, is transduced into an appropriate cell or cell line for the generation of such particles. The resulting viral particles have a variety of uses, including, but not limited to, transferring nucleic acids into cells either *in vitro* or *in vivo*. For purposes herein, the viruses are adenoviruses, including recombinant adenoviruses formed when an adenovirus vector, such as any provided herein, is encapsulated in an adenovirus capsid. Thus, a viral particle is a packaged viral genome. An adenovirus viral particle is the minimal structural or functional unit of a virus. A virus can refer to a single particle, a stock of particles or a viral genome. The adenovirus (Ad) particle is relatively complex and may be resolved into various substructures.

Included among adenoviruses and adenoviral particles are any and all viruses that can be categorized as an adenovirus, including any adenovirus that infects a human or an animal, including all groups, subgroups, and serotypes. Thus, as used herein, "adenovirus" and "adenovirus particle" refer to the virus itself and derivatives thereof and cover all serotypes and subtypes and naturally occurring and recombinant forms, except where indicated otherwise. Included are adenoviruses that infect human cells. Adenoviruses can be wildtype or can be modified in various ways known in the art or as disclosed herein. Such modifications include, but are not limited to, modifications to the adenovirus genome that is packaged in the particle in order to make an infectious virus. Exemplary modifications include deletions known in the art, such as deletions in one or more of the E1a, E1b, E2a, E2b, E3, or E4 coding regions. Other exemplary modifications include deletions of all of the coding regions of the adenoviral genome. Such adenoviruses are known as "gutless" adenoviruses. The terms also include replication-conditional adenoviruses, which are viruses that preferentially replicate in certain types of cells or tissues but to a lesser degree or not at all in other types. For example, among the adenoviral particles provided herein, are adenoviral particles that replicate in abnormally proliferating tissue, such as solid tumors and other neoplasms. These include the viruses

disclosed in U.S. Patent No. 5,998,205 and U.S. Patent No. 5,801,029. Such viruses are sometimes referred to as "cytolytic" or "cytopathic" viruses (or vectors), and, if they have such an effect on neoplastic cells, are referred to as "oncolytic" viruses (or vectors).

As used herein, the terms "vector," "polynucleotide vector," "polynucleotide vector construct," "nucleic acid vector construct," and "vector construct" are used interchangeably herein to mean any nucleic acid construct that can be used for gene transfer, as understood by those skilled in the art.

As used herein, the term "viral vector" is used according to its art-recognized meaning. It refers to a nucleic acid vector construct that includes at least one element of viral origin and can be packaged into a viral vector particle. The viral vector particles can be used for the purpose of transferring DNA, RNA or other nucleic acids into cells either in vitro or in vivo. Viral vectors include, but are not limited to, retroviral vectors, vaccinia vectors, lentiviral vectors, herpes virus vectors (e.g., HSV), baculoviral vectors, cytomegalovirus (CMV) vectors, papillomavirus vectors, simian virus (SV40) vectors, Sindbis vectors, semliki forest virus vectors, phage vectors, adenoviral vectors, and adeno-associated viral (AAV) vectors. Suitable viral vectors are described, for example, in U.S. Patent Nos. 6,057,155, 5,543,328 and 5,756,086. The vectors provided herein are adenoviral vectors.

As used herein, "adenovirus vector" and "adenoviral vector" are used interchangeably and are well understood in the art to mean a polynucleotide containing all or a portion of an adenovirus genome. An adenoviral vector, refers to nucleic encoding a complete genome or a modified genome or one that can be used to introduce heterologous nucleic acid when transferred into a cell, particularly when packaged as a particle. An adenoviral vector can be in any of several forms, including, but not limited to, naked DNA, DNA encapsulated in an adenovirus capsid, DNA packaged in another viral or viral-like form (such as herpes simplex, and AAV), DNA encapsulated in liposomes, DNA complexed with polylysine, complexed with synthetic polycationic molecules, conjugated with transferrin, complexed with compounds such as PEG to immunologically

"mask" the molecule and/or increase half-life, or conjugated to a non-viral protein.

As used herein, oncolytic adenoviruses refer to adenoviruses that replicate selectively in tumor cells

As used herein, a variety of vectors with different requirements and purposes are described. For example, one vector is used to deliver particular nucleic acid molecules into a packaging cell line for stable integration into a chromosome. These types of vectors also are referred to as complementing plasmids. A further type of vector carries or delivers nucleic acid molecules in or into a cell line (*e.g.*, a packaging cell line) for the purpose of propagating viral vectors; hence, these vectors also can be referred to herein as delivery plasmids. A third "type" of vector is the vector that is in the form of a virus particle encapsulating a viral nucleic acid and that is comprised of the capsid modified as provided herein. Such vectors also can contain heterologous nucleic acid molecules encoding particular polypeptides, such as therapeutic polypeptides or regulatory proteins or regulatory sequences to specific cells or cell types in a subject in need of treatment.

As used herein, the term "motif" is used to refer to any set of amino acids forming part of a primary sequence of a protein, either contiguous or capable of being aligned to certain positions that are invariant or conserved, that is associated with a particular function. The motif can occur, not only by virture of the primary sequence, but also as a consequence of three-dimensional folding. For example, the motif GXGXXG is associated with nucleotide-binding sites. In this fiber is a trimer, hence the trimeric structure can contribute fornation of a motif. Alternatively, a motif can be considered as a domain of a protein, where domain is a region of a protein molecule delimited on the basis of function without knowledge of and relation to the molecular substructure, as, e.g., the part of a protein molecule that binds to a receptor. As shown herein, the motif KKTK constitutes a consensus sequence for fiber shaft interaction with HSP.

As used herein, the term "bind" or "binding" is used to refer to the binding between a ligand and its receptor, such as the binding of an Ad5 shaft motif with HSP (Heparin Sulfate Proteoglycans), with a $K_d$ in the range of 10-2

to 10-15 mole/l, generally, $10^{-6}$ to $10^{-15}$, $10^{-7}$ to $10^{-15}$ and typically $10^{-8}$ to $10^{-15}$ (and/or a $K_a$ of $10^5$-$10^{12}$, $10^7$-$10^{12}$, $10^8$-$10^{12}$ l/mole).

As used herein, specific binding or selective binding means that a the binding of a particular ligand and one receptor interaction ($k_a$ or $K_{eq}$) is at least 2-fold, generally, 5, 10, 50, 100 or more-fold, greater than for another receptor. A statement that a particular viral vector is targeted to a cell or tissue means that its affinity for such cell or tissue in a host or *in vitro* is at least about 2-fold, generally, 5, 10, 50, 100 or more-fold, greater than for other cells and tissues in the host or under the *in vitro* conditions.

As used herein, the term "ablate" or "ablated" is used to refer to an adenovirus, adenoviral vector or adenoviral particle, in which the ability to bind to a particular cellular receptor is reduced or eliminated, generally substantially eliminated (*i.e.*, reduced more than 10-fold, 100-fold or more) when compared to a coresponding wild-type adenovirus. An ablated adenovirus, adenoviral vector or adenoviral particle also is said to be detargeted, i.e., the modified adenovirus, adenoviral vector or adenoviral particle does not possess the native tropism of the wild-type adenovirus. The reduction or elimination of the ability of the mutated adenovirus fiber protein and/or mutated adenovirus penton protein to bind a cellular receptor as compared to the corresponding wild-type fiber protein and/or wild-type penton protein can be measured or assessed by comparing the transduction efficiency (gene transfer and expression of a marker gene) of an adenovirus particle containing the mutated fiber protein and/or mutated penton protein compared to an adenovirus particle containing the wild-type fiber protein and/or wild-type penton protein for cells having the cellular receptor.

As used herein, tropism with reference to an adenovirus refers to the selective infectivity or binding that is conferred on the particle by a capsid protein, such as the fiber protein and/or penton.

As used herein, "penton" or "penton complex" is used herein to designate a complex of penton base and fiber. The term "penton" can also be used to indicate penton base, as well as penton complex. The meaning of the term "penton" alone should be clear from the context within which it is used.

As used herein, the term "substantially eliminated" refers to a transduction efficiency less than about 11% of the efficiency of the wild-type fiber containing virus on HeLa cells. The transduction efficiency on Hela cells can be measured (see, *e.g.*, Example 1 of U.S. Patent Application Serial No. 09/870,203 filed on 30 May 2001, and published as U.S. Published application No. 20020137213, and of International Patent Application No. PCT/EP01/06286 filed 1 June 2001). Briefly, HeLa cells are infected with the adenoviral vectors containing mutated fiber proteins to evaluate the effects of fiber amino acid mutations on CAR interaction and subsequent gene expression. Monolayers of HeLa cells in 12 well dishes are infected with, for example, 1000 particles per cell for 2 hours at 37° C. in a total volume of, for example, 0.35 ml of the DMEM containing 2% FBS. The infection medium is then aspirated from the monolayers and I ml of complete DMEM containing 10% FBS was added per well. The cells are incubated for an sufficient time, generally about 24 hours, to allow for $\beta$-galactosidase expression, which is measured by a chemiluminescence reporter assay and by histochemical staining with a chromogenic substrate. The relative levels of $\beta$-galactosidase activity are determined using as suitable system, such as the Galacto-Light chemiluminescence reporter assay system (Tropix, Bedford, Mass.) Cell monolayers are washed with PBS and processed according to the manufacturer's protocol. The cell homogenate is transferred to a microfuge tube and centrifuged to remove cellular debris. Total protein concentration is determined, such as by using the bicinchoninic acid(BCA) protein assay (Pierce, Inc., Rockford, Ill.) with bovine serum albumin as the assay standard. An aliquot of each sample is then incubated with the Tropix $\beta$-galactosidase substrate for 45 minutes in a 96 well plate. A luminometer is used determine the relative light units (RLU) emitted per sample and then normalized for the amount of total protein in each sample (RLU/ug total protein). For the histochemical staining procedure, the cell monolayers are fixed with 0.5% glutaraldehyde in PBS, and then were incubated with a mixture of 1 mg of 5-bromo-4-chloro-3-indolyl-$\beta$-D-galactoside (X-gal) per ml, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide and 2 mM $MgCl_2$ in 0.5 ml of PBS. The monolayers are washed with PBS and the blue cells are visualized by light

microscopy, such as with a Zeiss ID03 microscope. Generally, the efficiency is less than about 9%, and typically is less than about 8%.

As used herein, the phrase "reduce" or "reduction" refers to a change in the efficiency of transduction by the adenovirus containing the mutated fiber as compared to the adenovirus containing the wild-type fiber to a level of about 75% or less of the wild-type on HeLa cells. Generally, the change in efficiency is to a level of about 65% or less than wild-type. Typically it is about 55% or less. This system is able to rapidly analyze modified fiber proteins and/or modified penton proteins for desired tropism in the context of the viral particle.

As used herein, the term "mutate" or "mutation" or similar terms refers to the deletion, insertion or change of at least one amino acid in the part of the fiber shaft region interacting with HSP. The amino acid can be changed by substitution or by modification in a way that derivatizes the amino acid. Thus, for example a BBXB motif or BBBXXB motif, where B is a basic amino acid, in an adenovirus is mutated to ablate the viral interaction with HSP.

As used herein, the term "polynucleotide" means a nucleic acid molecule, such as DNA or RNA, that encodes a polynucleotide. The molecule can include regulatory sequences, and is generally DNA. Such polynucleotides are prepared or obtained by techniques known by those skilled in the art in combination with the teachings contained therein.

As used herein, adenoviral genome is intended to include any adenoviral vector or any nucleic acid sequence comprising a modified fiber protein. All adenovirus serotypes are contemplated for use in the vectors and methods herein.

As used herein, the term "viral vector" is used according to its art-recognized meaning. It refers to a nucleic acid vector construct that includes at least one element of viral origin and can be packaged into a viral vector particle. The viral vector particles can be used, for example, for transferring DNA into cells either *in vitro* or *in vivo*.

As used herein, a packaging cell line is a cell line that is able to package adenoviral genomes or modified genomes to produce viral particles. It can provide a missing gene product or its equivalent. Thus, packaging cells can

provide complementing functions for the genes deleted in an adenoviral genome (*e.g.*, the nucleic acids encoding modified fiber proteins) and are able to package the adenoviral genomes into the adenovirus particle. The production of such particles require that the genome be replicated and that those proteins necessary for assembling an infectious virus are produced. The particles also can require certain proteins necessary for the maturation of the viral particle. Such proteins can be provided by the vector or by the packaging cell.

As used herein, detargeted adenoviral particles have ablated (reduced or eliminated) interaction with receptors with which native particles. Fully detargeted particles have two or more specificities altered. It is understood that *in vivo* no particles are fully ablated such that they do not interact with any cells. Degareted and fully degarated have reduced, typically substantiall reduced, or eliminated interaction with native receptors. For purposes herein, detargeted particles have reduced (2-fold, 5-fold, 10-fold, 100-fold or more) binding or virtually no binding to HSP receptors; fully degareted vectors include further capsid modifications to eliminate interactions with other receptors, such as CAR and integrins or other receptors. The particles still bind to cells, but the types of cells and interactions are reduced.

As used herein, pseudotyping describes the production of adenoviral vectors having modified capsid protein or capsid proteins from a different serotype than the serotype of the vector itself. One example, is the production of an adenovirus 5 vector particle containing an Ad37 or Ad35 fiber protein. This can be accomplished by producing the adenoviral vector in packaging cell lines expressing different fiber proteins. As provided herein, detargeting of an adenovirus 5 particle or other serotype group C adenovirus or other adenovirus that binds to HSP to reduce or eliminate binding to HSPs can be effected by replacing all or a portion that includes the shaft or at least the HSP consensus binding sequence of the Ad5 fiber with an adenovirus fiber or portion thereof that does not bind to HSP. Adenoviruses having fiber shafts that do not interact with HSP include (a) adenoviruses of subgroup B, e.g., Ad3, Ad35, Ad7, Ad11, Ad16, Ad21, Ad34 which do not have interaction with HSP, (b) adenoviruses of

subgroup F, e.g., Ad40 and Ad41, specifically the short fiber, and (c) adenoviruses of subgroup D, e.g., Ad46.

As used herein, receptor refers to a biologically active molecule that specifically or selectively binds to (or with) other molecules. The term "receptor protein" can be used to more specifically indicate the proteinaceous nature of a specific receptor.

As used herein, the term "cyclic RGD" (or cRGD) refers to any amino acid that binds to $\alpha_v$ integrins on the surface of cells and contains the sequence RGD (Arg-Gly-Asp).

As used herein, the term "heterologous polynucleotide" means a polynucleotide derived from a biological source other than an adenovirus or from an adenovirus of a different strain or can be a polynucleotide that is in a different locus from wild-type virus. The heterologous polynucleotide can encode a polypeptide, such as a toxin or a therapeutic protein. The heterologous polynucleotide can contain regulatory regions, such as a promoter regions, such as a promoter active in specific cells or tissue, for example, tumor tissue as found in oncolytic adenoviruses. Alternatively, the heterologous polynucleotide can encode a polypeptide and further contain a promoter region operably linked to the coding region.

As used herein, reference to an amino acid in an adenovirus protein or to a nucleotide in an adenovirus genome is with reference to Ad5, unless specified otherwise. Corresponding amino acids and nucleotides in other adenovirus strains and modified strains and in vectors can be identified by those of skill in the art. Thus recitation of a mutation is intended to encompass all adenovirus strains that process a corresponding locus.

As used herein, the KO mutations refer to mutations in fiber that knock out binding to CAR. For example, a KO1 mutation refers to a mutation in the Ad5 fiber and corresponding mutations in other fiber proteins. In Ad5, this mutation results in a substitution of fiber amino acids 408 and 409, changing them from serine and proline to glutamic acid and alanine, respectively. As used herein, a KO12 mutation refers to a mutation in the Ad5 fiber and corresponding mutations in other fiber proteins. In Ad5, this mutation is a four amino acid

substitution as follows: R512S, A515G, E516G, and K517G. Other KO mutations can be identified empirically or are known to those of skill in the art.

As used herein, PD mutations refer to mutations in the penton gene that ablate binding by the encoded to $\alpha_v$ integrin by replacing the RGD tripeptide. The PD1 mutation exemplified herein results in a substitution of amino acids 337 through 344 of the Ad5 penton protein, HAIRGDTF (SEQ ID No. 9), with amino acids SRGYPYDVPDYAGTS (SEQ ID No. 10), thereby replacing the RGD tripeptide.

As used herein, treatment means any manner in which the symptoms of a condition, disorder or disease are ameliorated or otherwise beneficially altered.

As used herein, a therapeutically effective product is a product that is encoded by heterologous DNA that, upon introduction of the DNA into a host, a product is expressed that effectively ameliorates or eliminates the symptoms, manifestations of an inherited or acquired disease or that cures said disease.

As used herein, a subject is an animal, such as a mammal, typically a human, including patients.

As used herein, genetic therapy involves the transfer of heterologous DNA to the certain cells, target cells, of a mammal, particularly a human, with a disorder or conditions for which such therapy is sought. The DNA is introduced into the selected target cells in a manner such that the heterologous DNA is expressed and a therapeutic product encoded thereby is produced. Alternatively, the heterologous DNA may in some manner mediate expression of DNA that encodes the therapeutic product, it may encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product. Genetic therapy may also be used to deliver nucleic acid encoding a gene product to replace a defective gene or supplement a gene product produced by the mammal or the cell in which it is introduced. The introduced nucleic acid may encode a therapeutic compound, such as a growth factor inhibitor thereof, or a tumor necrosis factor or inhibitor thereof, such as a receptor therefor, that is not normally produced in the mammalian host or that is not produced in therapeutically effective amounts or at a therapeutically useful time. The heterologous DNA encoding the therapeutic product may be modified

prior to introduction into the cells of the afflicted host in order to enhance or otherwise alter the product or expression thereof.

As used herein, a therapeutic nuucleic acid is a nucleic acid that endes a therapeutic product. The product can be nucleic acid, such as a regulatory sequence or gene, or can encode a protein that has a therapeutic activity or effect. For example, therapeutic nucleic acid can be a ribozyme, antisense, double-stranded RNA, a nucleic acid encoding a protein and others.

As used herein, "homologous" means about greater than 25% nucleic acid sequence identity, such as 25% 40%, 60%, 70%, 80%, 90% or 95%. If necessary the percentage homology will be specified. The terms "homology" and "identity" are often used interchangeably. In general, sequences are aligned so that the highest order match is obtained (see, *e.g.*: *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; Carillo *et al.* (1988) *SIAM J Applied Math 48*:1073). By sequence identity, the number of conserved amino acids are determined by standard alignment algorithms programs, and are used with default gap penalties established by each supplier. Substantially homologous nucleic acid molecules would hybridize typically at moderate stringency or at high stringency all along the length of the nucleic acid or along at least about 70%, 80% or 90% of the full-length nucleic acid molecule of interest. Also contemplated are nucleic acid molecules that contain degenerate codons in place of codons in the hybridizing nucleic acid molecule.

Whether any two nucleic acid molecules have nucleotide sequences that are at least, for example, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical" can be determined using known computer algorithms such as the "FAST A" program, using for example, the default parameters as in Pearson *et al.* (1988) *Proc. Natl. Acad. Sci. USA 85*:2444 (other programs include the GCG

program package (Devereux, J., *et al., Nucleic Acids Research 12(I)*:387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., *et al., J Molec Biol 215*:403 (1990); Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo *et al.* (1988) *SIAM J Applied Math 48*:1073). For example, the BLAST function of the National Center for Biotechnology Information database can be used to determine identity. Other commercially or publicly available programs include, DNAStar "MegAlign" program (Madison, WI) and the University of Wisconsin Genetics Computer Group (UWG) "Gap" program (Madison WI)). Percent homology or identity of proteins and/or nucleic acid molecules can be determined, for example, by comparing sequence information using a GAP computer program (*e.g.*, Needleman *et al.* (1970) *J. Mol. Biol.* 48:443, as revised by Smith and Waterman ((1981) *Adv. Appl. Math.* 2:482). Briefly, the GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. Default parameters for the GAP program can include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov *et al.* (1986) *Nucl. Acids Res.* 14:6745, as described by Schwartz and Dayhoff, eds., *ATLAS OF PROTEIN SEQUENCE AND STRUCTURE*, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps. Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide.

As used herein, the term "at least 90% identical to" refers to percent identities from 90 to 99.99 relative to the reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared, no more than 10% (i.e., 10 out of 100) of amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons can be made between a test and reference polynucleotides. Such differences can be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they can be clustered in one or more

locations of varying length up to the maximum allowable, e.g. 10/100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, or deletions. At the level of homologies or identities above about 85-90%, the result should be independent of the program and gap parameters set; such high levels of identity can be assessed readily, often without relying on software.

As used herein: stringency of hybridization in determining percentage mismatch is as follows:

1) high stringency: 0.1 x SSPE, 0.1% SDS, 65°C
2) medium stringency: 0.2 x SSPE, 0.1% SDS, 50°C
3) low stringency: 1.0 x SSPE, 0.1% SDS, 50°C

Those of skill in this art know that the washing step selects for stable hybrids and also know the ingredients of SSPE (see, *e.g.*, Sambrook, E.F. Fritsch, T. Maniatis, in: *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1989), vol. 3, p. B.13, see, also, numerous catalogs that describe commonly used laboratory solutions). SSPE is pH 7.4 phosphate-buffered 0.18 M NaCl. Further, those of skill in the art recognize that the stability of hybrids is determined by $T_m$, which is a function of the sodium ion concentration and temperature ($T_m$ = 81.5° C-16.6($\log_{10}[Na^+]$) + 0.41(%G+C)-600/l)), so that the only parameters in the wash conditions critical to hybrid stability are sodium ion concentration in the SSPE (or SSC) and temperature.

It is understood that equivalent stringencies can be achieved using alternative buffers, salts and temperatures. By way of example and not limitation, procedures using conditions of low stringency are as follows (see also Shilo and Weinberg, *Proc. Natl. Acad. Sci. USA 78*:6789-6792 (1981)): Filters containing DNA are pretreated for 6 hours at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 μg/ml denatured salmon sperm DNA (10X SSC is 1.5 M sodium chloride, and 0.15 M sodium citrate, adjusted to a pH of 7).

Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 μg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X $10^6$ cpm $^{32}$P-labeled probe is

used. Filters are incubated in hybridization mixture for 18-20 hours at 40°C, and then washed for 1.5 hours at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 hours at 60°C. Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and reexposed to film. Other conditions of low stringency which can be used are well known in the art (*e.g.*, as employed for cross-species hybridizations).

By way of example and not way of limitation, procedures using conditions of moderate stringency include, for example, but are not limited to, procedures using such conditions of moderate stringency are as follows: Filters containing DNA are pretreated for 6 hours at 55°C in a solution containing 6X SSC, 5X Denhart's solution, 0.5% SDS and 100 μg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution and 5-20 X $10^6$ cpm $^{32}$P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 hours at 55°C, and then washed twice for 30 minutes at 60°C in a solution containing 1X SSC and 0.1% SDS. Filters are blotted dry and exposed for autoradiography. Other conditions of moderate stringency which can be used are well-known in the art. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.1% SDS.

By way of example and not way of limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 hours to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μg/ml denatured salmon sperm DNA. Filters are hybridized for 48 hours at 65°C in prehybridization mixture containing 100 μg/ml denatured salmon sperm DNA and 5-20 X $10^6$ cpm of $^{32}$P-labeled probe. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 minutes before autoradiography. Other conditions of high stringency which can be used are well known in the art.

The term substantially identical or substantially homologous or similar varies with the context as understood by those skilled in the relevant art and generally means at least 60% or 70%, preferably means at least 80%, 85% or more preferably at least 90%, and most preferably at least 95% identity.

As used herein, substantially identical to a product means sufficiently similar so that the property of interest is sufficiently unchanged so that the substantially identical product can be used in place of the product.

As used herein, substantially pure means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance. Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound can, however, be a mixture of stereoisomers or isomers. In such instances, further purification might increase the specific activity of the compound.

The methods and and preparation of products provided herein, unless otherwise indicated, employ conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, genetics, immunology, cell biology, cell culture and transgenic biology, which are within the skill of the art (see, *e.g.*, Maniatis *et al.* (1982) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY); Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel *et al.* (1992) *Current Protocols in Molecular Biology*, Wiley and Sons, New York; Glover (1985) *DNA Cloning I and II*, Oxford Press; Anand (1992) *Techniques for the Analysis of Complex Genomes* (Academic Press); Guthrie and Fink (1991) *Guide to Yeast Genetics and Molecular Biology*, Academic Press; Harlow and Lane (1988) *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harobor, NY; Jakoby and Pastan, eds. (1979) *Cell Culture. Methods in Enzymology 58*,

Academic Press, Inc., Harcourt Brace Jaovanovich, NY; *Nucleic Acid Hybridization* (B. D. Hames & S. J. Higgins eds. 1984); *Culture Of Animal Cells* (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal (1984), *A Practical Guide To Molecular Cloning*; *Gene Transfer Vectors For Mammalian Cells* (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); *Methods In Enzymology*, Vols. 154 and 155 (Wu et al. eds.); *Immunochemical Methods In Cell And Molecular Biology* (Mayer and Walker, eds., Academic Press, London, 1987); *Handbook Of Experimental Immunology*, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Hogan *et al.* (1986) *Manipulating the Mouse Embryo*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

**B. Capsid modifications**

Provided herein are modifications of the viral capsid that ablate the interaction of an adenovirus with its natural receptors. In particular, fiber modifications that result in ablation of the interaction of an adenvirus with HSP are provided. These fiber modifications can be combined with other capsid protein modifications, such as other fiber modifications and/or penton and/or hexon modifications, to fully ablate viral interactions with natural receptors, when expressed on a viral particle. The modification should not disrupt trimer formation or transport of fiber into the nucleus.

**1. Fiber genes and proteins**

The fiber protein extends from the capsid and mediates viral binding to the cell surface by binding to specific cell receptors (Philipson *et al.* (1968) *J. Virol. 2*:1064-1075). The fiber is a trimeric protein that includes an N-terminal tail domain that interacts with the adenovirus penton base, a central shaft domain of varying length, and a C-terminal knob domain that contains the cell receptor binding site (Chroboczek *et al.* (1995) *Curr.Top.Microbiol.Immunol. 199*:163-200; Riurok *et al.* (1990) *J.Mol.Biol. 215*:589-596; Stevenson *et al.* (1995) *J. Virol. 69*:2850-2857). The sequences of the fiber gene from a variety of serotypes including adenovirus serotypes 2 (Ad2), Ad5, Ad3, Ad35, Ad12, Ad40, and Ad41 are known. There are at least 21 different fiber genes in Genbank.

As noted, the fiber protein can be divided into three domains (see, *e.g.*, Green *et al.* (1983) *EMBO J. 2*:1357-1365). The conserved N-terminus contains the sequences responsible for association with the penton base as well as a nuclear localization signal. A rod-like shaft of variable length contains repeats of a 15 amino acid beta structure, with the number of repeats ranging from 6 in Ad3 to 22 in Ad5. A conserved stretch of amino acids which includes the sequence TLWT (SEQ ID No. 36) marks the boundary between the repeating units of beta structure in the shaft and the globular head domain. The C-terminal head domain ranges in size from 157 amino acid residues for the short fiber of Ad41 to 193 residues for Ad11 and Ad34. The fiber spike is a homotrimer and it is thought that the C-terminus is responsible for trimerization of the fiber homotrimer and there are 12 spikes per virion which are attached via association with the penton base complex.

**2. Modification of HSP interaction**

The adenovirus fiber protein is a major determinant of adenovirus tropism (Gall *et al.* (1996) *J. Virol. 70*:2116-2123; Stevenson *et al.* (1995) *J. Virol. 69*:2850-2857). Dogma in the field has been that adenoviral entry occurs via binding to CAR and integrins. This is underscored by published data (Einfeld *et al.* (2001) *J. Virology 75*:11284-11291). It is shown herein, however, these published entry pathways are not the predominant ones that act *in vivo*. Moreover, as shown herein, the dominant entry pathway for hepatocytes *in vivo* involves a mechanism mediated by the fiber shaft, such as Ad5 shaft, through heparin sulfate proteoglycans binding.

It is shown herein that elimination of this binding eliminates entry vis HSP binding, such as in hepatocytes. Adenoviral fiber shaft modifications that ablate viral interaction with HSP are provided. Thus, as provided herein, efficient detargeting of adenovirus *in vivo* can be achieved with appropriately designed fiber proteins. Suitable modifications, such as described herein, can be made with respect to any adenovirus in which the wild-type interacts with HSP.

As provided herein, the ability of an adenoviral vector to interact with HSP is modified. In particular, the ability to interact is reduced or eliminated. Modifications include insertions, deletions, individual amino acid mutations and

other mutations that alter the structure of the fiber shaft such that the HSP binding of the modified fiber protein is ablated when compared to the HSP binding of the wild-type fiber protein.

In a first aspect of this embodiment, an adenoviral fiber protein is modified by mutating one or more of the amino acids that interact with HSP. For example, the HSP binding motif of the modified fiber protein is no longer able to interact with HSP on the cell surface, thus ablating the viral interaction with HSP. For example, the adenoviral fiber is from a subgroup C adenovirus. Binding to HSP can be eliminated or reduced by mutating the fiber shaft in order to modify the ability of the HSP binding motif, which is, for example, KKTK sequence (SEQ ID No. 1) located between amino acid residues 91 to 94 in the Ad 5 fiber, to interact with HSP. The fiber proteins are modified by chemical and biological techniques known to those skilled in the art, such as site directed mutagenesis of nucleic aicd encoding the fiber or other techniques as illustrated herein.

In another aspect of this embodiment, the ability of a fiber to interact with HSP is modified by replacing the wild-type fiber shaft with a fiber shaft, or portion thereof, of an adenovirus that does not interact with HSP to produce chimeric fiber proteins. The portion is sufficient to reduce or eliminate interaction with HSP. Examples of adenoviruses having fiber shafts that do not interact with HSP include (a) adenoviruses of subgroup B, such as, but are not limited to, Ad3, Ad35, Ad7, Ad11, Ad16, Ad21, Ad34, which do not have interaction with HSP, (b) adenoviruses of subgroup F, such as, but are not limited to, Ad40 and Ad41, specifically the short fiber, and (c) adenoviruses of subgroup D, such as but are not limited to, Ad46. In another embodiment, adenoviral fiber shaft modifications that ablate viral interaction with HSP in combination with adenoviral fiber knob modifications that ablate viral interactions with CAR are provided. Suitable adenoviral fiber modifications include the fiber knob modifications are known to those of skill in the art and are exemplified herein (see, also, US. Patent Application Serial No. 09/870,203, filed on 30 May 2001, and published as U.S. Published application No. 20020137213, in International Patent Application No. PCT/EP01/06286 filed on 1 June 2001).

Modifications of the fiber include mutations of at least one amino acid in the CD loop of a wild-type fiber protein of an adenovirus from subgroup C, D, or E, or the long wild-type fiber of an adenovirus from subgroup F, whereby the ability of a fiber protein to bind to CAR is reduced or substantially eliminated. The fiber proteins with ablated CAR interaction are modified by chemical and biological techniques known to those skilled in the art, as illustrated herein and as described in the above patent application.

Alternatively, adenoviral fiber modifications are made by replacing the wild-type fiber knob with a fiber knob of an adenovirus that does not interact with CAR. The fiber protein also will be selected so that it does not interact with HSP. Examples of adenoviruses having fiber knobs that do not interact with CAR include (a) adenoviruses of subgroup B, e.g., Ad3, Ad35, Ad7, Ad11, Ad16, Ad21, Ad34, (b) adenoviruses of subgroup F, e.g., Ad40 and Ad41, specifically the short fiber.

In another embodiment, adenoviral fiber shaft modifications that ablate viral interaction with HSP in combination with penton modifications that ablate viral interactions with $\alpha_v$ integrins are provided. Suitable adenoviral penton modifications include the penton modifications, which are well known to those of skill in the art (see, *e.g.*, U.S. Patent No. 5,731,190; see, also Einfeld *et al.* (2001) *J. Virology 75*:11284-11291; and Bai *et al.* (1993) *J. Virology 67*:5198-5205).

For example, penton interaction with $\alpha_v$ integrins can be ablated (reduced or eliminated) by substitution of the RGD tripeptide motif, required for $\alpha_v$ interaction, in penton with a different tripeptide that does not interact with an $\alpha_v$ integrin. The penton proteins with ablated $\alpha_v$ integrin interactions are modified by chemical and biological techniques known to those skilled in the art (see, *e.g.*, described U.S. Patent No. 6,731,190 and as illustrated herein). Generally, the adenovirus is a subgroup B or C adenovirus.

Also provided are adenoviral fiber shaft modifications that ablate viral interaction with HSP in combination with adenoviral fiber knob modifications that ablate viral interactions with CAR and with penton modifications that ablate viral interactions with $\alpha_v$ integrins. These modifications are described above and

prepared using chemical and biological techniques known to those skilled in the art and as illustrated herein. Generally the adenovirus is a subgroup B or subgroup C adenovirus.

Preparation of fibers modified to eliminate or reduce HSP interactions and fibers modified to alter interactions with other receptors and cell surface proteins, such as CAR and/or $\alpha_v$ integrin, is also described in the Examples below. The nucleic acid and/or amino acid sequences of exemplary modified fibers, whose construction are described below) are set forth as SEQ ID Nos. 45-72 as follows:

SEQ ID Nos. 45 and 46 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 5FKO1, where 5F refers to Adenovirus 5 fiber, KO1 is an exemplary mutation of the CAR interaction site described herein;

SEQ ID Nos. 47 and 48 set forth the encoding nucleotide sequence and amino acid sequence of the modified ber designated 5FKO1RGD, which further includes an RGD ligand to demonstrate retargeting;

SEQ ID Nos. 49 and 50 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 5FKO12, where 5F refers to Adenovirus 5 fiber, KO12 is another exemplary mutation of the CAR interaction site described herein;

SEQ ID Nos. 51 and 52 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 5F S* nuc, where 5F refers to Adenovirus 5 fiber, S* is an exemplary mutation of the shaft that alters binding to HSP;

SEQ ID Nos. 53 and 54 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 5F S*RGD nuc, which further includes an RGD ligand;

SEQ ID Nos. 55 and 56 set forth the encoding nucleotide sequence and amino acid sequence of the modified ber designated 5FKO1S*, which contain the KO1 and S* mutations;

SEQ ID Nos. 57 and 58 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 5FKO1S*RGD, which further includes an RGD ligand;

SEQ ID Nos. 59 and 60 set forth the encoding nucleotide sequence and amino acid sequence of a Ad35 fiber;

SEQ ID Nos. 61 and 62 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 35FRGD, which is 35F fiber with an RGD ligand;

SEQ ID Nos. 63 and 64 set forth the encoding nucleotide sequence and amino acid sequence of a Ad41 short fiber;

SEQ ID Nos. 65 and 66 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 41sFRGD, which is 41F short fiber with an RGD ligand;

SEQ ID Nos. 67 and 68 set forth the encoding nucleotide sequence and amino acid sequence of Ad5 penton;

SEQ ID Nos. 69 and 70 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 5TS35H, which is a chimeric fiber in which an Ad5 fiber tail and shaft regions (5TS; amino acids 1 to 403) are connected to an Ad35 fiber head region (35H; amino acids 137 to 323) to form the 5TS35H chimera; and

SEQ ID Nos. 71 and 72 set forth the encoding nucleotide sequence and amino acid sequence of the modified fiber designated 35TS5H, which is a chimeric fiber in which an Ad35 fiber tail and shaft regions (35TS; amino acids 1 to 136) are connected to an Ad5 fiber head region (5H; amino acids 404 to 581) to form the 35TS5H chimera.

SEQ ID No. 1 sets forth the nucleotide sequence of Ad fiber; SEQ ID Nos. 2 and 3 also set forth the coding nucleic acid sequencs for fibers with modified fiber knobs for ablated CAR interaction (see, SEQ ID No. 2 for KO1 and SEQ ID No. 3 for KO12); SEQ ID No. 4 also sets for the encoding nucleic acid sequence of a modified penton for ablated $a_v$ integrins (SEQ ID No. 4).

The modified fibers are displayed on virus particles by modifying the fiber protein and optionally additional proteins. This can be achieved by preparing

adenoviral vectors that express the modified capsid proteins and produce particles with modified fibers, or by packaging adenoviral vectors, particularly those that do not encode one or more capsid proteins in appropriate packaging lines. Hence, as discussed in detail below, adenoviral vectors and viral particles with modified fibers that do no bind to HSP are provided.

**C. Nucleic acids, Adenoviral vectors and cells containing the nucleic acids and cells containing the vectors**

Also provided are polynucleotides that encode modified capsid proteins and that encode vectors for preparation of adenovirus that express modified capsid proteins provided herein. The sequences of the wild-type adenovirus proteins are well known in the art and are modified as described herein. Nucleic acid molecules, such as cDNA that encode an exemplary modified fiber knob for ablated CAR interaction (see, SEQ ID No. 2 for KO1 and SEQ ID No. 3 for KO12) and for a modified penton for ablated $a_v$ integrins (SEQ ID No. 4) are provided. As discussed above, modified capsid proteins with altered tropism for CAR and $\alpha_v$ integrins are known and described in the patents, applications and literature cited herein and known to those of skill in the art (see, *e.g.*, U.S. Patent No. 5,731,190, U.S. application Serial No. 09/870,203, published as U.S. Published application No. 20020137213; and Bai *et al.* (1993) *J. Virology* *67*:5198-5208).

Also provided are vectors including the polynucleotides provided herein. Such vectors include partial or complete adenoviral genomes and plasmids. Such vectors are constructed by techniques known to those skilled in the art and as illustrated herein. Also provided are adenoviral vectors modified by replacing whole fiber protein, or portions thereof, with the fiber proteins, or appropriate portions thereof, of an adenovirus that does not interact with HSP. Adenoviruses that do not interact with HSP can be identified by using the methods described herein which detect binding or non-binding of fiber proteins and adenoviruses with HSP. Among the adenoviral vectors provided herein are those of subgroup C, which include Ad2 and Ad5, in which the nucleic acid encoding the fiber shaft or a portion including the HSP-binding portion is

replaced with nucleic acid encoding fiber or an appropriate portion thereof from a serotype, such as Ad35.

Adenoviral fiber modifications, thus, can be made in viral particles by replacing the entire fiber protein with the fiber protein of an adenovirus that does not interact with CAR and/or replacing the HSP binding portion with a portion that does not bind. Generally the adenovirus is a subgroup B or subgroup C adenovirus, and also an adenovirus of subgroup D, such as Ad46. Adenoviral vectors of subgroup C, such as Ad2 and Ad5, having a replaced fiber knob are prepared using techniques well known in the art and as illustrated herein.

**1. Preparation of viral particles**

The packaging cells used to produce the viruses provided herein contain the nucleic acid encoding the capsid protein, including the mutated fiber protein provided herein. Such nucleic acid can be transfected into the cell, generally part of as part of plasmid, or it can be infected into the cell with a viral vector. It can be stably incorporated into the genome of the cell, thus providing for a stable cell line. Alternatively, nucleic acid encoding the mutated capsid protein can be removed from the genome, in which case a transient complementing cell is employed.

The adenovirus genome to be packaged is transferred into the complementing cell by techniques known to those skilled in the art. These techniques include transfection or infection with the adenovirus. The nucleic acid encoding the mutated fiber protein can be in this genome instead of in the packaging cell.

In certain cases, when the nucleic acid encoding the mutated fiber is in the genome to be packaged, it can be desirable for the packaging cell to also encode a fiber protein. Such protein can assist in the maturation and packaging of an infectious particle. Such protein can be a wild-type fiber protein or one modified such that it is unable to attach to the penton base protein and is for use, for example, in producer cells where the fiber is included to provide the packaging function and the vector encodes a full-length fiber.

The packaging cells are cultured under conditions that permit the production of the desired viral particle. The viral particles are recovered by

standard techniques. An exemplary method for producing adenoviral particles provided herein is as follows. The nucleic acid encoding the mutated fiber protein is made using standard techniques in an adenoviral shuttle plasmid. This plasmid contains the right end of the virus, in particular from the end of the E3 region through the right ITR. This plasmid is co-transfected into competent cells of an *E. coli* strain, such as the well known *E. coli* strain BJ5183 (see, *e.g.*, Degryse (1996) *Gene 170*:45-50) along with a plasmid, which contains the remaining portion of the adenovirus genome, except for the E1 region and sometimes also the E2a region and also contains a corresponding region of homology. Homologous recombination between the two plasmids generates a full-length plasmid encoding the entire adenoviral vector genome.

This full-length adenoviral vector genome plasmid is then transfected into a complementing cell line. The transfection can be performed in the presence of a reagent that directs adenoviral particle entry into producer cells. Such reagents include, but are not limited to, polycations and bifunctional reagents, such as those described herein. A complementing cell is, for example, is a cell of the PER.C6 cell line, which contains the adenoviral E1 gene (PER.C6 is available, for example, from Crucell, The Netherlands; deposited under ECACC accession no. 96022940; see, also Fallaux *et al.* (1998) *Hum. Gene Ther. 9*:1909-1907; see, also, U.S. Patent No. 5,994,128) or an AE1-2a cell (see, Gorziglia *et al.* (1996) *J. Virology 70*:4173-4178; and and Von Seggern *et al.* (1998) *J. Gen. Virol. 79*:1461-1468)).

AE1-2a cells are derivatives of the A549 lung carcinoma line (ATCC # CCL 185) with chromosomal insertions of the plasmids pGRE5-2.E1 (also referred to as GRE5-E1-SV40-Hygro construct and listed in SEQ ID No. 41) and pMNeoE2a-3.1 (also referred to as MMTV-E2a-SV40-Neo construct and listed in SEQ ID No. 42), which provide complementation of the adenoviral E1 and E2a functions, respectively.

The 633 cell line (see, von Seggern *et al.* (2000) *J. Virology 74*:354-362), which stably expresses the adenovirus serotype 5 wild-type fiber protein, and was derived from the AE1-2a cell line, is another an example of complementing cells. When the cell line is 633 cells, the final passage of

adenoviral vector is performed on another complementing cell line (*e.g.*, Per.C6), which does not express wild-type Ad5 fiber.

The transfected complementing cells are maintained under standard cell culture conditions. The adenoviral plasmids recombine to form the adenoviral genome that is packaged. The particles are infectious, but replication deficient because their genome is missing at least the E1 genes. When performed in the 633 cells the particles contain wild-type and mutated fiber proteins. They are recovered from the crude viral lysate, amplified, and are purified by standard techniques.

The recovered particles can be used to infect PER.C6 or AE1-2a cells. This permits the recovery of particles whose capsids contain only the desired mutated fiber. This two-step procedure provides high titer batches of the adenoviral particles provided herein. The adenoviral particles can be replication competent or replication incompetent.

In one embodiment, the particles selectively replicate in certain predetermined target tissue but are replication incompetent in other cells and tissues. In a particular embodiment, the adenoviral particles replicate in abnormally proliferating tissue, such as solid tumors and other neoplasms. In replication conditional adenoviruses, a gene essential for replication is placed under control of a heterologous promoter which is cell or tissue specific. For example, the E1a gene is placed under control of a promoter which is active in a tumor cell to produce an oncolytic adenovirus or oncolytic adenoviral vector. Administration of oncolytic adenoviral vectors to tumor cells kills the tumor cells. Such replication conditional adenoviral particles and vectors can be produced by techniques known to those skilled in the art, such as those disclosed in the above-referenced U.S. Patent Nos. 5,998,205 and 5,801,029. These particles and vectors can be produced in adenoviral packaging cells as disclosed above. Generally packaging cells are those that have been designed to limit homologous recombination that could lead to wild-type adenoviral particles. Such cells are well known and include the packaging cell known as PER.C6 (see, *e.g.*,U.S. Patent Nos. 5,994,128 and 6,033,908; deposited under ECACC accession no. 96022940). Since oncolytic vectors are replication competent in certain cell

types, they can be amplified in cell lines derived from said cell type without provision of Ad complementary genes.

**2. Adenoviral vectors and particles**

The adenovirus as used herein for production of the adenoviral vectors and particles can be of any serotype. Adenoviral stocks that can be employed as a source of adenovirus or adenoviral coat protein, such as fiber and/or penton base, can be amplified from the adenoviral serotypes 1 through 47, which are currently available from the American Type Culture Collection (ATCC, Rockville, Md.), or from any other serotype of adenovirus available from any other source. For instance, an adenovirus can be of subgroup A (e.g., serotypes 12, 18, 31), subgroup B (e.g., serotypes 3, 7, 11, 14, 16, 21, 34, 35), subgroup C (e.g., serotypes 1, 2, 5, 6), subgroup D (e.g., serotypes 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39, 42-47), subgroup E (serotype 4), subgroup F (serotype 40, 41), or any other adenoviral serotype.

In certain embodiments, the adenovirus is a subgroup B or a subgroup C adenovirus. Subgroup C adenoviruses which are modified in as described herein, include, but are not limited to, Ad2 and Ad5. For Ad5, the mutation is made in the KKTK sequence (SEQ ID No. 1) located between amino acid residues 91 to 94. The fiber proteins can be modified by chemical and biological techniques known to those skilled in the art. These methods include, but are not limited to, site directed mutagenesis and techniques as illustrated herein.

The adenoviral particle generally includes a targeting ligand as described above. The presence of the targeting ligand permits the delivery of a gene to a desired cell type which is different from the cell type that wild-type adenovirus particles infect or the same as that a wild-type particle infects, but allowing the infection in a selective manner, *i.e.*, non-target cell types are not significantly infected.

The adenoviral vectors provided herein can be used to study cell transduction and gene expression *in vitro* or in various animal models. The latter case includes *ex vivo* techniques, in which cells are transduced *in vitro* and then administered to the animal. They also can be used to conduct gene therapy on humans or other animals. Such gene therapy can be *ex vivo* or *in vivo*. For *in*

*vivo* gene therapy, the adenoviral particles in a pharmaceutically-acceptable carrier are delivered to a human in a therapeutically effective amount in order to prevent, treat, or ameliorate a disease or other medical condition in the human through the introduction of a heterologous gene that encodes a therapeutic protein into cells in such human. The adenoviruses are delivered at a dose ranging from approximately 1 particle per kilogram of body weight to approximately $10^{14}$ particles per kilogram of body weight. Generally, they are delivered at a dose of approximately $10^{6}$ particles per kilogram of body weight to approximately $10^{13}$ particles per kilogram of body weight, and typically the dose ranges from approximately $10^{8}$ particles per kilogram of body weight to approximately $10^{12}$ particles per kilogram of body weight.

Any vectors known to those of skill in the art can be employed and used to produce viral particles that include fibers modified to ablate (including reduce) binding to HSP. Some exemplary vectors are as follows.

**a. Gutless vectors**

Gutted adenovirus vectors are those from which most or all viral genes have been deleted. They are grown by co-infection of the producing cells with a "helper" virus (such as using an El-deleted Ad vector), where the packaging cells expresses the E1 gene products. The helper virus trans- complements the missing Ad functions, including production of the viral structural proteins needed for particle assembly. To incorporate the capsid modifications into a gutted adenoviral vector capsid, the changes must be made to the helper virus as described herein. All the necessary Ad proteins including the modified capsid protein are provided by the modified helper virus, and the gutted adenovirus particles are equipped with the particular modified capsid expressed by the host cells. The E1a, Eb, E2a, E2b and E4 are generally required for viral replication and packaging. If these genes are deleted, then the packaging cell must provide these genes or functional equivalents.

A helper adenovirus vector genome and a gutless adenoviral vector genome are delivered to packaging cells. The cells are maintained under standard cell maintenance or growth conditions, whereby the helper vector genome and the packaging cell together provide the complementing proteins for

the packaging of the adenoviral vector particle. Such gutless adenoviral vector particles are recovered by standard techniques. The helper vector genome can be delivered in the form of a plasmid or similar construct by standard transfection techniques, or it can be delivered through infection by a viral particle containing the genome. Such viral particle is commonly called a helper virus. Similarly, the gutless adenoviral vector genome can be delivered to the cell by transfection or viral infection.

The helper virus genome can be the modified adenovirus vector genome as disclosed herein. Such genome also can be prepared or designed so that it lacks the genes encoding the adenovirus E1A and E1B proteins. In addition, the genome can further lack the adenovirus genes encoding the adenovirus E3 proteins. Alternatively, the genes encoding such proteins can be present but mutated so that they do not encode functional E1A, E1B and E3 proteins. Furthermore, such vector genome can not encode other functional early proteins, such as E2A, E2B3, and E4 proteins. Alternatively, the genes encoding such other early proteins can be present but mutated so that they do not encode functional proteins.

In producing the gutless vectors, the helper virus genome is also packaged, thereby producing helper virus. In order the minimize the amount of helper virus produced and maximize the amount of gutless vector particles produced, the packaging sequence in the helper virus genome can be deleted or otherwise modified so that packaging of the helper virus genome is prevented or limited. Since the gutless vector genome will have an unmodified packaging sequence, it will be preferentially packaged.

One way to do this is to mutate the packaging sequence by deleting one or more of the nucleotides comprising the sequence or otherwise mutating the sequence to inactivate or hamper the packaging function. One exemplary approach is to engineer the helper genome so that recombinase target sites flank the packaging sequence and to provide a recombinase in the packaging cell. The action of recombinase on such sites results in the removal of the packaging sequence from the helper virus genome. The recombinase can be provided by a nucleotide sequence in the packaging cell that encodes the recombinase. Such

sequence can be stably integrated into the genome of the packaging cell. Various kinds of recombinase are known by those skilled in the art, and include, but are not limited to, Cre recombinase, which operates on so-called lox sites, which are engineered on either side of the packaging sequence as discussed above (see, *e.g.*, U.S. Patent Nos. 5,919, 676, 6,080,569 and 5,919,676; see, also, *e.g.*, Morsy and Caskey, Molecular Medicine Today, Jan. 1999, pgs. 18-24).

An example of a gutless vector is pAdARSVDys (Haecker *et al.* (1996) *Hum Gene Ther. 7*:1907-1914)). This plasmid contains a full-length human dystrophin cDNA driven by the RSV promoter and flanked by Ad inverted terminal repeats and packaging signals. 293 cells are infected with a first-generation Ad, which serves as a helper virus, and then transfected with purified pAdARSVDys DNA. The helper Ad genome and the pAdARSVDys DNA are replicated as Ad chromosomes, and packaged into particles using the viral proteins produced by the helper virus. Particles are isolated and the pAdARSVDys-containing particles separated from the helper by virtue of their smaller genome size and therefore different density on CsCl gradients. Other examples of gutless adenoviral vectors are known (see, *e.g.*, Sandig *et al.* (2000) *Proc. Natl. Acad. Sci. U.S.A. 97(3)*:1002-7).

**b. Oncolytic vectors**

Briefly, oncolytic adenoviruses, which are viruses that replicate selectively in tumor cells, are designed to amplify the input virus dose due to viral replication in the tumor, leading to spread of the virus throughout the tumor mass. *In situ* replication of adenoviruses leads to cell lysis. This *in situ* replication permits relatively low, non-toxic doses to be highly effective in the selective elimination of tumor cells. One approach to achieving selectivity is to introduce loss-of-function mutations in viral genes that are essential for growth in non-target cells but not in tumor cells. (See, e.g., U.S. Patent No. 5,801,029.) This strategy is exemplified by the use of Addl1520, which has a deletion in the E1b-55KD gene. In normal cells, the adenoviral E1b-55KD protein is needed to bind to p53 to prevent apoptosis. In p53-deficient tumor cells, E1b-55K binding

to p53 is unnecessary. Thus, deletion of E1b-55KD should restrict vector replication to p53-deficient tumor cells.

Another approach is to use tumor-selective promoters to control the expression of early viral genes required for replication (see, *e.g.*, International PCT application Nos. WO 96/17053 and WO 99/25860). Thus, in this approach the adenoviruses selectively replicate and lyse tumor cells if the gene that is essential for replication is under the control of a promoter or other transcriptional regulatory element that is tumor-selective.

For example oncolytic adenoviral vectors that contain a cancer selective regulatory region operatively linked to an adenoviral gene essential for adenoviral replication are known (see, *e.g.*, U.S. Patent No. 5,998,205). Adenoviral genes essential for replication include, but are not limited to, E1a, E1b, E2a, E2b and E4. For example, an exemplary oncolytic adenoviral vector has a cancer selective regulatory region operatively linked to the E1a gene. In other embodiments, the oncolytic adenoviral vector has a cancer selective regulatory region of the present invention operatively linked to the E1a gene and a second cancer selective regulatory region operatively linked to the E4 gene. The vectors also can include at least one therapeutic transgene, such as, but not limited to, a polynucleotide encoding a cytokine such as GM-CSF that can stimulate a systemic immune response against tumor cells.

Other exemplary oncolytic adenoviral vectors include those in which expression of an adenoviral gene, which is essential for replication, is controlled by E2F-responsive promoters, which are selectively transactivated in cancer cells. Thus, vectors that contains an adenoviral nucleic acid backbone that contains in sequential order: A left ITR, an adenoviral packaging signal, a termination signal sequence, an E2F responsive promoter which is operably linked to a first gene, such as E1a, essential for replication of the recombinant viral vector and a right ITR (see, published International PCT application No. WO02/06786, and U.S. Patent No. 5,998,205).

In other embodiments, the oncolytic adenoviral vector has a cancer selective regulatory region operatively linked to the E1a gene and a second cancer selective regulatory region operatively linked to the E4 gene. The vectors

can also carry at least one therapeutic transgene, such as, but not limited to, a polynucleotide encoding a cytokine such as GM-CSF that can stimulate a systemic immune response against tumor cells.

**3. Packaging**

The viral particles provided herein can be made by any method known to those of skill in the art. Generally they are prepared by growing the adenovirus vector that contains nucleic acid that encodes the modified fiber protein in a standard adenovirus packaging cells to produce particles that express the modified fibers. Alternatively, the vectors do not encode fibers. Such vectors are packaged in producer cells to produce particles that express the modified fiber proteins.

As discussed, recombinant adenoviral vectors generally have at least a deletion in the first viral early gene region, referred to as E1, which includes the E1a and E1b regions. Deletion of the viral E1 region renders the recombinant adenovirus defective for replication and incapable of producing infectious viral particles in subsequently-infected target cells. Thus, to generate E1-deleted adenovirus genome replication and to produce virus particles requires a system of complementation which provides the missing E1 gene product. E1 complementation is typically provided by a cell line expressing E1, such as the human embryonic kidney packaging cell line, i.e. an epithelial cell line, called 293. Cell line 293 contains the E1 region of adenovirus, which provides E1 gene region products to "support" the growth of E1-deleted virus in the cell line (see, *e.g.*, Graham *et al., J. Gen. Virol. 36*: 59-71, 1977). Additionally, cell lines that may be usable for production of defective adenovirus having a portion of the adenovirus E4 region have been reported (WO 96/22378). Multiply deficient adenoviral vectors and complementing cell lines have also been described (WO 95/34671, U.S. Patent No. 5,994,106).

For example, copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/EP00/00265, filed January 14, 200, published as International PCT application No. WO/0042208) provides packaging cell lines that support viral vectors with deletions of major portions of the viral genome, without the need for helper viruses and also provides cell lines

and helper viruses for use with helper-dependent vectors. The packaging cell line has heterologous DNA stably integrated into the chromosomes of the cellular genome. The heterologous DNA sequence encodes one or more adenovirus regulatory and/or structural polypeptides that complement the genes deleted or mutated in the adenovirus vector genome to be replicated and packaged. Packaging cell lines express, for example, one or more adenovirus structural proteins, polypeptides, or fragments thereof, such as penton base, hexon, fiber, polypeptide IIIa, polypeptide V, polypeptide VI, polypeptide VII, polypeptide VIII, and biologically active fragments thereof. The expression can be constitutive or under the control of a regulatable promoter. These cell lines are particularly designed for expression of recombinant adenoviruses intended for delivery of therapeutic products. For use herein, such packaging cell lines can express the modified capsid proteins, such as the fiber proteins who binding to HSP is reduced or eliminated, and/or the modified penton and hexon proteins.

Particular packaging cell lines complement viral vectors having a deletion or mutation of a DNA sequence encoding an adenovirus structural protein, regulatory polypeptides E1A and E1B, and/or one or more of the following regulatory proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof.

The packaging cell lines are produced by introducing each DNA molecule into the cells and then into the genome via a separate complementing plasmid or plurality of DNA molecules encoding the complementing proteins can be introduced via a single complementing plasmid. Of interest herein, is a variation in which the complementing plasmid includes DNA encoding adenovirus fiber protein (or a chimeric or modified variant thereof), from Ad virus of subgroup D, such as Ad 37, polypeptide or fragment thereof.

For applications, such as therapeutic applications, the delivery plasmid further can include a nucleotide sequence encoding a heterologous polypeptide. Exemplary delivery plasmids include, but are not limited to, pDV44, pΔE1B$\beta$-gal and pΔE1sp1B. In a similar or analogous manner, therapeutic nucleic acids, such as nucleic acids that encode therapeutic genes, can be introduced.

The cell further includes a complementing plasmid encoding a fiber as contemplated herein; the plasmid or portion thereof is integrated into a chromosome(s) of the cellular genome of the cell.

Typically, the packaging cell lines will contain nucleic acid encoding the fiber protein or modified protein stably integrated into a chromosome or chromosomes in the cellular genome. The packaging cell line can be derived from a procaryotic cell line or from a eukaryotic cell line. While various embodiments suggest the use of mammalian cells, and more particularly, epithelial cell lines, a variety of other, non-epithelial cell lines are used in various embodiments. Thus, while various embodiments disclose the use of a cell line selected from among the 293, A549, W162, HeLa, Vero, 211, and 211A cell lines, and any other cell lines suitable for such use are likewise contemplated herein.

**D. Addition of a targeting ligand**

The viral particles that are detargeted as described herein, can be retargeted to selected cells and/or tissues by inclusion of an appropriate targeting ligand in the capsid. The ligand cam be included in any of the capsid proteins, such as fiber, hexon and penton. Loci for inclusion of nucleic acid encoding a is known to those of skill in the art for a a variety of adenovirus serotypes; if necessary appropriate loci and other parameters can be empirically determined.

The ligand can be produced as a fusion by inclusion of the coding sequences in the nucleic acid encoding a capsid protein, or chemically conjugated, such as via ionic, covalent or other interactions, to the capsid or bound to the capsid (*e.g.*, by Ab-ligand fusion, where Ab binds capsid protein; or by disulfide bonding or other crosslinking moieties or chemistries).

Thus, for example, a modified fiber nucleic acid also can include sequences of nucleotides that encode a targeting ligand to produce viral particles that include a targeting ligand in the capsid. Targeting ligand and methods for including such ligands in viral capids are well known. For example, inclusion of targeting ligands in fiber proteins is described in U.S. Patent Nos. 5,543,328 and 5,756,086 and in U.S. Patent Application Serial No. 09/870,203, published as U.S. Published application No. 20020137213, and International Patent

Application No. PCT/EP01/06286. For different serotypes and strains of adenoviruses, loci for insertion of targeting ligands can be empirically determined. For different serotypes and strains, such loci can vary.

Because the adenovirus fiber has a trimeric structure, the ligand can be selected or designed to have a trimeric structure so that up to three molecules of the ligand are present for each mature fiber. Such ligands can be incorporated into the fiber protein using methods known in the art (see, *e.g.*, U.S. Patent No. 5,756,086). Instead of the fiber, the targeting ligand can be included in the penton or hexon proteins. Inclusion of targeting ligands in penton (see for example, in U.S. Patent Nos. 5,731,190 and 5,965,431) and in hexon (see for example, in U.S. Patent No. 5,965,541) is known.

In one exemplary embodiment, the ligand is included in a fiber protein, which is a fiber protein mutated as described herein. As shown herein, the targeting ligand can be included, for example, within the HI loop of the fiber protein. Any ligand that can fit in the HI loop and still provide a functional virus is contemplated herein. Such ligands can be as long as or longer than 80-100 amino acids (see, *e.g.*, Belousova *et al.* (2002) *J. Virol. 76*:8621-8631). Such ligands are added by techniques known in the art (see, *e.g.*, published International Patent Application publication No. WO99/39734 and U.S. Patent Application number 09/482,682). Other ligands can be be discovered through techniques known to those skilled in the art. Some non-limiting examples of these techniques include phage display libraries or by screening other types of libraries.

Targeting ligands include any chemical moiety that preferentially directs an adenoviral particle to a desired cell type and/or tissue. The categories of such ligands include, but are not limited to, peptides, polypeptides, single chain antibodies, and multimeric proteins. Specific ligands include the TNF superfamily of ligands which include tumor necrosis factors (or TNF's) such as, for example, TNF$\alpha$ and TNF$\beta$, lymphotoxins (LT), such as LT-$\alpha$ and LT-$\beta$, Fas ligand which binds to Fas antigen; CD40 ligand, which binds to the CD40 receptor of B-lymphocytes; CD30 ligand, which binds to the CD30 receptor of neoplastic cells of Hodgkin's lymphoma; CD27 ligand, NGF ligand, and OX-40 ligand;

transferrin, which binds to the transferrin receptor located on tumor cells, activated T -cells, and neural tissue cells; ApoB, which binds to the LDL receptor of liver cells; alpha-2-macroglobulin, which binds to the LRP receptor of liver cells; alpha-I acid glycoprotein, which binds to the asialoglycoprotein receptor of liver; mannose-containing peptides, which bind to the mannose receptor of macrophages; sialyl-Lewis-X antigen-containing peptides, which bind to the ELAM-I receptor of activated endothelial cells; CD34 ligand, which binds to the CD34 receptor of hematopoietic progenitor cells; ICAM-I, which binds to the LFA-I (CD11b/CD18) receptor of lymphocytes, or to the Mac-I (CD11a/CD18) receptor of macrophages; M-CSF, which binds to the c-fms receptor of spleen and bone marrow macrophages; circumsporozoite protein, which binds to hepatic Plasmodium falciparum receptor of liver cells; VLA-4, which binds to the VCAM-I receptor of activated endothelial cells; HIV gp120 and Class II MHC antigen, which bind to the CD4 receptor of T -helper cells; the LDL receptor binding region of the apolipoprotein E (ApoE) molecule; colony stimulating factor, or CSF, which binds to the CSF receptor; insulin-like growth factors, such as IGF-I and IGF-II, which bind to the IGF-I and IGF-II receptors, respectively; Interleukins 1 through 14, which bind to the Interleukin 1 through 14 receptors, respectively; the Fv antigen-binding domain of an immunoglobulin; gelatinase (MMP) inhibitor; bombesin, gastrin-releasing peptide; substance P; somatostatin; luteinizing hormone releasing hormone (LHRH); vasoactive peptide (VIP); gastrin; melanocyte stimulating hormone (MSH); cyclic RGD peptide and any other ligand or cell surface protein-binding (or targeting) molecule.

**E. Heterologous polynucleotides and Therapeutic Nucleic Acids**

The packaged adenoviral genome also can contain a heterologous polynucleotide that encodes a product of interest, such as a therapeutic protein. Adenoviral genomes containing heterologous polynucleotides are well known (see, *e.g.*, U.S. Patent Nos. 5,998,205, 6,156,497, 5,935,935, and 5,801,029). These can be used for *in vitro* and *in vivo* delivery of the products of heterlogous polynucleoties or the heterologous polynucleotides.

Thus, the adenoviral particles provided herein can be used to engineer a cell to express a protein that it otherwise does not express or does not express

in sufficient quantities. This genetic engineering is accomplished by infecting the desired cell with an adenoviral particle whose genome includes a desired heterologous polynucleotide. The heterologous polynucleotide is then expressed in the genetically engineered cells. For use herein the cell is generally a mammalian cell, and is typically a primate cell, including a human cell. The cell can be inside the body of the animal (*in vivo*) or outside the body (*in vitro*). Heterologous polynucleotides (also referred to as heterologous nucleic acid sequences) are included in the adenoviral genome within the particle and are added to that genome by techniques known in the art. Any heterologous polynucleotide of interest can be added, such as those disclosed in U.S. Patent No. 5,998,205, incorporated herein by reference. Polynucleotides that are introduced into an Ad genome or vector can be any that encode a protein of interest or that are regulatory sequences. Proteins include, but are not limited to, therapeutic proteins, such as an immunostimulating protein, such as an interleukin, interferon, or colony stimulating factor, such as granulocyte macrophage colony stimulating factor (GM-CSF; see, *e.g.*, 5,908,763F. Generally, such GM-CSF is a primate GM-CSF, including human GM-CSF. Other immunostimulatory genes include, but are not limited to, genes that encode cytokines IL1, IL2, IL4, IL5, IFN, IFN, TNF, IL12, IL18, and flt3), proteins that stimulate interactions with immune cells (B7, CD28, MHC class I, MHC class II, TAPs), tumor-associated antigens (immunogenic sequences from MART-1, gp100(pmel-17), tyrosinase, tyrosinase-related protein 1, tyrosinase-related protein 2, melanocyte-stimulating hormone receptor, MAGE1, MAGE2, MAGE3, MAGE12, BAGE, GAGE, NY-ESO-1, -catenin, MUM-1, CDK-4, caspase 8, KIA 0205, HLA-A2R1701, -fetoprotein, telomerase catalytic protein, G-250, MUC-1, carcinoembryonic protein, p53, Her2/neu, triosephosphate isomerase, CDC-27, LDLR-FUT, telomerase reverse transcriptase, and PSMA), cDNAs of antibodies that block inhibitory signals (CTLA4 blockade), chemokines (MIP1, MIP3, CCR7 ligand, and calreticulin), and other proteins.

Other polynucleotides, including therapeutic nucleic acids, such as therapeutic genes, of interest include, but are not limited to, anti-angiogenic, and suicide genes. Anti-angiogenic genes include, but are not limited to, genes that

encode METH-1, METH -2, TrpRS fragments, proliferin-related protein, prolactin fragment, PEDF, vasostatin, various fragments of extracellular matrix proteins and growth factor/cytokine inhibitors. Various fragments of extracellular matrix proteins include, but are not limited to, angiostatin, endostatin, kininostatin, fibrinogen-E fragment, thrombospondin, tumstatin, canstatin, and restin. Growth factor/cytokine inhibitors include, but are not limited to, VEGF/VEGFR antagonist, sFlt-1, sFlk, sNRP1, angiopoietin/tie antagonist, sTie-2, chemokines (IP-10, PF-4, Gro-beta, IFN-gamma (Mig), IFN, FGF/FGFR antagonist (sFGFR), Ephrin/Eph antagonist (sEphB4 and sephrinB2), PDGF, TGF and IGF-1.

A "suicide gene" encodes a protein that can lead to cell death, as with expression of diphtheria toxin A, or the expression of the protein can render cells selectively sensitive to certain drugs, e.g., expression of the Herpes simplex thymidine kinase gene (HSV-TK) renders cells sensitive to antiviral compounds, such as acyclovir, gancyclovir and FIAU (1-(2-deoxy-2-fluoro--.beta.-D-arabinofuranosil)-5-iodouracil). Other suicide genes include, but are not limited to, genes that encode carboxypeptidase G2 (CPG2), carboxylesterase (CA), cytosine deaminase (CD), cytochrome P450 (cyt-450), deoxycytidine kinase (dCK), nitroreductase (NR), purine nucleoside phosphorylase (PNP), thymidine phosphorylase (TP), varicella zoster virus thymidine kinase (VZV-TK), and xanthine-guanine phosphoribosyl transferase (XGPRT). Alternatively, a therapeutic nucleic acid can exert its effect at the level of RNA, for instance, by encoding an antisense message or ribozyme, a protein that affects splicing or 3' processing (e.g., polyadenylation), or a protein that affects the level of expression of another gene within the cell, e.g. by mediating an altered rate of mRNA accumulation, an alteration of mRNA transport, and/or a change in post-transcriptional regulation. The addition of a therapeutic nucleic acid to a virus results in a virus with an additional antitumor mechanism of action. Thus, a single entity (i.e., the virus carrying a therapeutic transgene) is capable of inducing multiple antitumor mechanisms. Other encoded proteins, include, but are not limited to, herpes simplex virus thymidine kinase (HSV-TK), which is useful as a safety switch (see, U.S. Patent Application No. 08/974,391, filed

November 19, 1997, which published as PCT Publication No. WO/9925860), Nos, FasL, and sFasR (soluble Fas receptor).

Also contemplated are combinations of two or more transgenes with synergistic, complementary and/or nonoverlapping toxicities and methods of action. The resulting adenovirus can retain the viral oncolytic functions and, for example, additionally are endowed with the ability to induce immune and anti-angiogenic responses and other responses as desired.

Therapeutic polynucleotides and heterologous polynucleotides also include those that exert an effect at the level of RNA or protein. These include include a factor capable of initiating apoptosis, RNA, such as RNAi and other double-stranded RNA, antisense and ribozymes, which among other capabilities can be directed to mRNAs encoding proteins essential for proliferation, such as structural proteins, transcription factors, polymerases, genes encoding cytotoxic proteins, genes that encode an engineered cytoplasmic variant of a nuclease (e.g. RNase A) or protease (e.g. trypsin, papain, proteinase K and carboxy-peptidase). Other polynucleotides include a cell or tissue specific promoters, such as those used in oncolytic adenoviruses (see, *e.g.*, U.S. Patent No. 5,998,205).

The heterologous polynucleotide encoding a polypeptide also can contain a promoter operably linked to the coding region. Generally the promoter is a regulated promoter and transcription factor expression system, such as the published tetracycline-regulated systems, or other regulatable systems (WO 01/30843), to allow regulated expression of the encoded polypeptide. Exemplary of other promoters, are tissue-selective promoters, such as those described in U.S. Patent No. 5,998,205. An exemplary regulatable promoter system is the Tet-On( and Tet-Off( systems currently available from Clontech (Palo Alto, CA). This promoter system allows the regulated expression of the transgene controlled by tetracycline or tetracycline derivatives, such as doxycycline. This system can be used to control the expression of the encoded polypeptide in the viral particles and nucleic acids provided herein. Other regulatable promoter systems are known (see, *e.g.*, published U.S. No. 20020168714, entitled "Regulation of Gene Expression Using Single-Chain,

Monomeric, Ligand Dependent Polypeptide Switches," which describes gene switches that contain ligand binding domains and transcriptional regulating domains, such as those from hormone receptors). Other suitable promoters that can be employed include, but are not limited to, adenoviral promoters, such as the adenoviral major late promoter and/or the E3 promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the Rous Sarcoma Virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; and the ApoAI promoter.

Therapeutic transgenes can be included in the viral constructs and resulting particles. Among these are those that result in an "armed" virus. For example, rather than delete E3 region as in some embodiments described herein, all or a part of the E3 region can be preserved or re-inserted in an oncolytic adenoviral vector (discussed above). The presence of all or a part of the E3 region can decrease the immunogenicity of the adenoviral vector. It also increases cytopathic effect in tumor cells and decreases toxicity to normal cells. Typically such vector expresses more than half of the E3 proteins.

Adenoviruses for therapy, including those for human therapy, are known. Such known viruses can be modified as provided herein to reduce or eliminate interaction with HSPs and optionally additional receptors. The adenoviral vectors that are used to produce the viral particles can include other modifications. Modifications include modifications to the adenovirus genome that is packaged in the particle in order to make an adenoviral vector. As discussed above, adenovirus vectors and particles with a variety of modifications are available. Modifications to adenvoiral vectors include deletions known in the art, such as deletions in one or more of the El, E2a, E2b, E3, or E4 coding regions. These adenoviruses are sometimes referred to as early generation adenoviruses. include those with deletions of all of the coding regions of the adenoviral genome ("gutless" adenoviruses, discussed above) and also include replication-conditional adenoviruses, which are viruses that replicate in certain types of cells or tissues but not in other types as a result of placing adenoviral genes essential for replication under control of a heterologous promoter (discussed above; see, also

U.S. Patent No. 5,998,205, U.S. Patent No. 5,801,029; U.S. patent application 60/348,670 and corresponding published International PCT application No. WO02/06786). These include the cytolytic, cytopathic viruses (or vectors), including the oncolytic viruses discussed above.

Alternatively, as discussed above, the vector can include a mutation or deletion in the E1b gene. Typically such mutation or deletion in the E1b gene is such that the E1b-19kD protein becomes non-functional. This modification of the E1b region can be combined with vectors where all or a part of the E3 region is present.

The oncolytic adenoviral vector can further include at least one heterologous coding sequence, such as one that encodes a therapeutic product. The heterologous coding sequence, such as therapeutic gene, is generally, although not necessarily, in the form of cDNA, and can be inserted at any locus that does not adversely affect the infectivity or replication of the vector. For example, it can be inserted in an E3 region in place of at least one of the polynucleotide sequences that encode an E3 protein, such as, for example, the 19kD or 14.7 kD E3 gene.

**F. Propagation and Scale-up**

Since doubly ablated adenoviral vectors containing mutations in the fiber and/or penton capsid proteins result in inefficient cell binding and entry via the CAR/αv integrin entry pathway, scaled up technologies improve the growth and propagation of such vectors to produce high titers of the adenoviral vectors for clinical use. Thus, also provided is a method for scaling up the production of detargeted adenoviral vectors. The detargeted adenoviral vectors comprise an adenoviral vector modified to ablate the interaction of said vector with at least one host cell receptor compared with a wild-type adenoviral vector. The detargeted adenoviral vectors can comprise an adenoviral vector modified to ablate the interaction of said vector with one, two, three or more host cell receptors. Thus, the method is suitable for producing the detargeted adenoviral vectors disclosed herein.

As noted, growth and propagation of doubly and fully ablated adenoviral vectors is enhanced by new scale up technologies. Doubly ablated vectors

contain mutations in the fiber and penton capsid proteins that result in inefficient cell binding and entry via the normal cellular entry pathway using CAR and integrins. These vectors are fully detargeted *in vitro* and, thus, alternative cellular entry strategies allow for the efficient growth and generation of high titer preparations.

Two strategies have been envisioned to scale up vectors that are detargeted via fiber and/or penton modifications. These include: (a) the use of pseudoreceptor cell lines engineered to express a surface receptor that binds a ligand displayed on the vector (see, *e.g.*, International PCT application No. WO 98/54346) and (b) complementing cell lines that are engineered to express native fiber and that can be engineered to express native fiber and penton (see, *e.g.*, International PCT application No. WO 00/42208). Although these systems have shown promise for scaling up ablated adenoviral vectors, there is a need to develop a system for the simple, efficient production of the fully detargeted adenoviral vector for therapeutic uses.

Provided herein is a scale-up method for the propagation of detargeted adenoviral vectors. The method uses polycations and/or bifunctional reagents, which when added to tissue culture medium, bind adenoviral particles and direct their entry into the producer cells.

Reagents (also called medium additives) also can be included in the tissue culture medium containing producer cells to be infected with the detargeted adenoviral vectors. Alternatively the reagents can be pre-mixed with the virus, which mixture is then added to the tissue producer cells. The reagents can be added to tissue culture medium containing producer cells, or producer cells can be added to tissue culture medium containing the reagents. Any suitable producer cell known to the skilled artisan can be used in the present methods. The reagents can be added at the same time that the producer cells are infected with detargeted adenoviral vectors. Generally the reagents are present in the tissue culture medium prior to infection by the detargeted adenoviral vectors. The medium additives are maintained in the tissue culture medium during vector growth, spread and propagation. High titer yields of adenoviral vectors are obtained by this method.

Reagents which are useful in this method are those that are capable of directing adenoviral particle entry into the producer cells. Such reagents include, but are not limited to, polycations and bifunctional reagents. Suitable polycations include, but are not limited to, polytheylenimine; protamine sulfate; poly-L-lysine hydrobromide; poly(dimethyl diallyl ammonium) chloride (Merquat(r)-100, Merquat(r)280, Merquat(r)550); poly-L-arginine hydrochloride; poly-L-histidine; poly(4-vinylpyridine), poly(4-vinylpyridine) hydrochloride; poly(4-vinylpyridine)cross-linked, methylchloride quaternary salt; poly(4-vinyl-pyridine-co-styrene); poly(4-vinylpyridinium poly(hydrogen fluoride)); poly(4-vinyl-pyridinium-P-toluene sulfonate); poly(4-vinylpyridinium-tribromide); poly(4-vinyl-pyrrolidone-co-2-dimethylamino-ethyl methacrylate); polyvinylpyrrolidone, cross-linked; poly vinylpyrrolidone, poly(melamine-co-formaldehyde); partially methylated; hexadimethrine bromide; poly(Glu, Lys) 1:4 hydrobromide; poly(Lys, Ala) 3:1 hydrobromide; poly(Lys, Ala) 2:1 hydrobromide; poly-L-lysine succinylated; poly(Lys, Ala) 1:1 hydrobromide; and poly(Lys, Trp) 1:4 hydrobromide.

Suitable bifunctional reagents include, but are not limited to, antibodies or peptides that bind to the adenoviral capsid and that also contain a ligand that allows interaction with specific cell surface receptors of the producer cells. Examples of bifunctional reagents include: (a) anti-fiber antibody ligand fusions, (b) anti-fiber-Fab-FGF conjugate, (c) anti-penton-antibody ligand fusions, (d) anti-hexon antibody ligand fusions and (e) polylysine-peptide fusions. The ligand is any ligand that will bind to any cell surface receptor found on the producer cells.

The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

## EXAMPLE 1

**Construction of Ad5 Vectors Containing the Fiber AB Loop, KO1 and Penton, PD1 Mutations and Derivatives Thereof**

Three recombinant adenoviral vectors were prepared that contain the KO1 fiber or PD1 penton base mutations either alone or in combination, these vectors are designated Av3nBgFKO1 Av1nBgPD1, and Av1nBgFKO1PD1. Construction of these vectors is described below and a general description of each vector is set forth in Table 1.

TABLE 1
Description Of Detargeted
Recombinant Adenoviral Vectors Used For Scale-up
Vector

| Vector | Description |
|---|---|
| Av3nBg | An E1, E2a, E3-deleted adenoviral vector encoding a nuclear localizing β-galactosidase |
| Av1nBg | An E1 and E3-deleted adenoviral vector encoding a nuclear localizing β-galactosidase |
| Av3nBgFKO1 | The same as Av3nBg but containing the KO1 mutation in the fiber gene |
| Av1nBgPD1 | The same as Av1nBg but containing the PD1 mutation in the penton gene |
| Av1nBgFKO1PD1 | The same as Av1nBg but containing the fiber KO1 and penton PD1 mutations |

**Av1nBg**

This is a well-known vector, its sequence is set forth in SEQ ID No. 43.

**Av3nBg**

This is a well-known vector, its sequence is set forth in SEQ ID No. 44.

**Av3nBgFKO1**

**Genetic incorporation of the KO1 fiber mutation to generate Av3nBgFKO1**

The adenoviral vector Av3nBgFKO1 was generated in an E1-, E2a-, E3-deleted backbone based on the adenovirus serotype 5 genome. It contains a RSV promoted nuclear-localizing β-galactosidase gene in place of the E1 region. In addition, the fiber gene carries the KO1 mutation. This mutation results in a

substitution of fiber amino acids 408 and 409, changing them from serine and proline to glutamic acid and alanine, respectively.

The vector was constructed as follows. First, the plasmid pSKO1 (Figure 1) was digested with the restriction enzymes SphI and MunI. The resulting DNA fragments were separated by electrophoresis on an agarose gel. The 1601 bp fragment containing all but the 5' end of the fiber gene was excised from the agarose gel and the DNA was isolated and purified. The fragment was then ligated with the 9236 bp fragment of p5FloxHRFRGD, which had been digested with SphI and MunI. The resulting plasmid, p5FloxHRFKO1, was digested with SpeI and PacI and the 6867 bp fragment containing the fiber gene was isolated. The fragment was ligated with the 24,630 bp SpeI-PacI fragment of pNDSQ3.1. The resulting plasmid, pNDSQ3.1KO1 (Figure 2), was used together with pAdmireRSVnBg (Figure 3A) to generate a plasmid which encodes the full-length adenoviral vector genome. It, however, was necessary to remove the PacI site from pNDSQ3.1KO1 (Figure 2) prior to recombination with pAdmireRSVnBg (Figure 3A) so that the final plasmid contains a unique PacI site adjacent to the 5' ITR. The PacI site in pNDSQ3.1KO1 was removed by digestion with PacI followed by blunting with T4 DNA Polymerase and religation. The resulting plasmid was called pNDSQ3.1KO1(Pac.

To generate a full-length plasmid containing the entire adenoviral genome, pAdmireRSVnBg (Figure 3A) was digested with SalI and co-transfected into competent cells of the *E. coli* strain BJ5183 along with pNDSQ3.1KO1ΔPac, which had been digested with BstBI. Homologous recombination between the two plasmids generated a full-length plasmid encoding the entire adenoviral vector genome, which was called pFLAv3nBgFKO1.

The plasmid pFLAv3nBgKO1 was linearized with PacI and transfected into 633 cells. In the fiber complementing 633 cell line, the resulting viral DNA containing the KO1 mutation is capable of being packaged into infectious viral particles containing a mixture of wildtype fiber and mutant fiber proteins. After five rounds of amplification in 633 cells, a cytopathic effect was observed. Three more rounds of amplification in 633 cells were performed followed by purification of the virus by standard CsCl centrifugation procedures. This viral

preparation was used to infect AE1-2a cells, which do not express fiber. The resulting virus contained only the mutant fiber protein on its capsid. Virus particles were purified by standard CsCl centrifugation procedures.

**Av1nBgFKO1**

The v ector Av1nBgFKO1 is made in a similar manner to Av3nBgFKO1 described above.

**Av1nBgKO12**

An additional fiber AB loop mutation (described by Einfeld *et al.* (2001) *J. Virology 75*:11284-11291) was incorporated into the genome of Av1nBg. This AB loop mutation is a four amino acid substitution, R512S, A515G, E516G, and K517G, and is referred to as KO12. The KO12 mutation was incorporated into the fiber gene by PCR gene overlap extension using the plasmid pSQ1 (Figure 3B) as template. The pSQ1 plasmid contains most of the Ad5 genome, extending from base pair 3329 through the right ITR, in a pBR322 backbone. First, a segment of the Ad5 genome extending from within the E3 region into the fiber gene was amplified by PCR using the plasmid pSQ1 as a template with the following primers termed 5FF, 5'-GAA CAG GAG GTG AGC TTA GA-3' SEQ ID No. 4), and 5FR, 5'-TCC GCC TCC ATT TAG TGA ACA GTT AGG AGA TGG AGC TGG TGT G-3' (SEQ ID No. 6). The primer 5FR contains an 18 base 5'-extension that encodes the modified fiber AB loop amino acids from 512 through 517. A second PCR using pSQ1 as a template amplified the region immediately 3' of the AB loop substitution and extending past the MunI site located 40 base pairs 3' of the fiber gene stop codon. The two primers used for this reaction were 3FF: 5'-TCA CTA AAT GGA GGC GGA GAT GCT AAA CTC ACT TTG GTC TTA AC-3' (SEQ ID No. 7), and 3FR: 5'-GTG GCA GGT TGA ATA CTA GG-3' (SEQ ID No.8). The primer 3FR contains an 18 base 5'-extension that encodes the modified fiber AB loop amino acids 512 through 517. Amplified products of the expected size were obtained and used in a second PCR with the end primers 5FF and 3FR to join the fragments together. The KO12 PCR fragment was digested with XbaI and MunI cloned directly into the fiber shuttle plasmid, pFBshuttle(EcoRI) to generate the plasmid pFBSEKO12 which contains the 8.8kB EcoRI fragment of pSQ1. The pFBSEKO12 plasmid

was digested with XbaI and EcoRI and cloned into pSQ1 using a three-way ligation to generate pSQ1KO12 (Figure 3C). The KO12 cDNA was incorporated into the genome of Av1nBg, an adenovirus vector with E1 and E3 deleted encoding β-galactosidase, by homologous recombination between ClaI-linearized pSQ1KO12 and pAdmireRSVnBg digested with SalI and PacI to generate Av1nBgKO12. The KO12 vector was transfected in 633 cells, scaled-up on non-fiber expressing cells and purified, as described above for KO1.

**Av1nBgPD1**

**Genetic incorporation of the PD1 penton mutation to generate Av1nBgPD1**

The adenoviral vector Av1nBgPD1 is an E1-, E3-deleted vector based on the adenovirus serotype 5 genome. It contains a RSV promoted nuclear-localizing β-galactosidase gene in the E1 region and also contains the PD1 mutation in the penton gene. The PD1 mutation results in a substitution of amino acids 337 through 344 of the penton protein, HAIRGDTF (SEQ ID No. 9), with amino acids SRGYPYDVPDYAGTS (SEQ ID No. 10), thus replacing the RGD tripeptide (see, Einfeld *et al.* (2001) *J. Virology 75*:11284-11291). The mutation in the penton gene was generated in the plasmid pGEMpen5, which contains the Adenovirus serotype 5 penton gene. To generate the mutation, four oligonucleotides were synthesized. The sequences of the oligonucleotides were as follows: penton 1: 5′ CGC GGA AGA GAA CTC CAA CGC GGC AGC CGC GGC AAT GCA GCC GGT GGA GGA CAT GAA 3′ (SEQ ID No. 11); penton 2: 5′ TAT CGT TCA TGT CCT CCA CCG GCT GCA TTG CCG CGG CTG CCG CGT TGG AGT TCT CTT CC 3′ (SEQ ID No. 12); penton 3: 5′ CGA TAG CCG CGG CTA CCC CTA CGA CGT GCC CGA CTA CGC GGG CAC CAG CGC CAC ACG GGC TGA GGA GAA GCG CGC 3′ (SEQ ID No. 13); penton 4: 5′ TCA GCG CGC TTC TCC TCA GCC CGT GTG GCG CTG GTG CCC GCG TAG TCG GGC ACG TCG TAG GGG TAG CCG CGG C 3′ (SEQ ID No. 14). The complementary oligonucleotides penton 1 and penton 2 were annealed to each other as were penton 3 and penton 4. The duplex generated by annealing penton 3 and penton 4 encoded the substitution of amino acids 337 through 344 described above. The duplex generated by annealing penton 1 and penton 2 possessed a 5 base

5' overhang which was compatible to a 5 base 5' overhang on the duplex generated by annealing penton 3 and penton 4. The opposite end of the duplex generated by annealing penton 1 and penton 2 contained an EarI compatible overhang. The opposite end of the duplex generated by annealing penton 3 and penton 4 contained a BbvCI compatible overhang. The two duplexes were ligated to each other and ligated back into the pGEMpen5 backbone as follows. First, pGEMpen5 was digested with BbvCI and PstI and the resulting DNA fragments were separated by electrophoresis on an agarose gel. The 3360 bp fragment was excised from the gel and purified. The plasmid pGEMpen5 was also digested with PstI and EarI and the resulting fragments were separated by electrophoresis on an agarose gel. The 955 bp fragment was excised from the gel and purified. These two fragments from the pGEMpen5 plasmid were ligated with the two pairs of annealed oligonucleotides to generate the plasmid pGEMpen5PD1.

The mutated penton gene was transferred from pGEMpen5PD1 to pSQ1 using a 5-way ligation as follows. First, the region of the penton gene containing the PD1 mutation was excised from pGEMpen5PD1 by digestion with PvuI and AscI. The 974 bp fragment containing the PD1 mutation was purified. Four DNA fragments were prepared from the pSQ1 plasmid (Figure 3B) as follows. The plasmid was digested with Csp45I and FseI and the 9465 bp fragment was purified. In addition pSQ1 was digested with FseI and PvuI and the 2126 bp fragment was purified. The plasmid pSQ1 was digested with AscI and BamHI and the 5891 bp fragment was purified. Finally, pSQ1 was digested with BamHI and Csp45I and the 14610 bp fragment was purified. The 5 purified DNA fragments were ligated to each other to form the plasmid pSQ1PD1 (Figure 4).

To generate adenoviral vector, pSQ1PD1 was linearized by digestion with ClaI and co-transfected into PerC6 cells with pAdmireRSVnBg (Figure 3A) which had been digested with SalI and PacI. hexadimethrine bromide was maintained in the medium at 4 $\mu$g/ml. When a cytopathic effect was observed, a crude viral lysate was further expanded on PerC6 cells. The virus was purified by standard CsCl centrifugation procedures.

**Av1nBgFKO1PD1**

**Genetic incorporation of the fiber KO1 or KO12 mutation in combination with the penton PD1 mutation to generate Av1nBgFKO1PD1**

The adenoviral vectors Av1nBgFKO1PD1 and Av1nBgKO12PD1 were generated in an E1-, E3-deleted adenovirus serotype 5 genome. Both vectors contains a RSV promoted nuclear-localizing $\beta$-galactosidase gene in the E1 region and also contains either the KO1 or KO12 mutation in the fiber gene as well as the PD1 mutation in the penton gene. The vectors were constructed as follows. First, the plasmid pSQ1PD1 was digested with Csp45I and SpeI and the 23976 bp fragment containing the PD1 mutated penton gene was purified. In addition, the plasmids pSQ1KO1 or pSQ1KO12 (Figure 3B) were digested with Csp45I and SpeI and the 9090 bp fragment containing the KO1 or KO12 mutated fiber gene were purified. The appropriate purified fragments were ligated to each other to from the plasmid pSQ1FKO1PD1 (Figure 5A) or pSQ1KO12PD1 (Figure 5B) that contains the KO1 (or KO12) mutated fiber gene and the PD1 mutated penton gene. To generate virus, pSQ1FKO1PD1 or pSQKO12PD1 was linearized with ClaI and co-transfected into 633 cells with pAdmireRSVnBg (Figure 3A) which had been digested with SalI and PacI. After three rounds of amplification in 633 cells a cytopathic effect was observed and the crude viral lysate was then amplified on PerC6 cells. Hexadimethrine bromide was maintained in the medium at 4 $\mu$g/ml. Each virus was purified by standard CsCl centrifugation procedures.

## EXAMPLE 2

***In Vitro* Evaluation of Adenoviral Vectors Containing the KO1 and PD1 Mutations**

Several recombinant adenoviral vectors were used in these studies to demonstrate the function of the KO1 fiber mutation and included Av1nBg, Av1nBgFKO1, Av1nBgPD1, and Av1nBgFKO1PD1, described above. The transduction efficiencies of adenoviral vectors containing the KO1 and/or PD1 mutations were evaluated on cells of the alveolar epithelial cell line A549. The transduction efficiencies were compared to that of Av1nBg, an adenoviral vector containing wild type fiber and penton.

The day prior to infection, cells were seeded into 24-well plates at a density of approximately 1 x $10^5$ cells per well. Immediately prior to infection, the exact number of cells per well was determined by counting a representative well of cells. Each of the vectors, Av1nBg, Av1nBgFKO1, and Av1nBgFKO1PD1 were used to transduce A549 cells at each of the following particle per cell (PPC) ratios: 100, 500, 1000, 2500, 5000, 10,000. The cell monolayers were stained with X-gal 24 hours after infection and the percentage of cells expressing $\beta$-galactosidase was determined by microscopic observation and counting of cells. Transductions were done in triplicate and three random fields in each well were counted, for a total of nine fields per vector.

The results at the 500 PPC ratio are shown in Figure 6 and show a significantly reduced transduction efficiency on A549 cells using vectors containing the KO1 mutation alone or when combined with PD1 compared to Av1nBg. The vectors containing the PD1 mutation alone had no effect on adenoviral transduction of A549 cells *in vitro*.

## EXAMPLE 3

### *In Vivo* Analysis of Adenoviral Vectors Containing the FKO1 and PD1 Mutations

This Example provides experiments that evaluate the *in vivo* biodistribution of adenoviral vectors containing the KO1 and PD1 mutations and their influence on adenoviral-mediated liver transduction. The results show that ablating the viral interaction with CAR and/or integrins is not sufficient to fully detarget adenoviral vectors from the liver *in vivo*.

A positive control cohort received Av1nBg and a negative control group received HBSS. Additionally, the Av1nBgFKO12 and Av1nBgFKO12PD1 vectors were analyzed *in vivo*. These vectors each contain a fiber protein with the four amino acid substitution in the AB loop. Additionally, Av1nBgFKO12PD1 contains a mutation in the penton base. Both of these mutations were known (see, Einfeld *et al.* (2001) *J. Virology 75*:11284-11291), and were alleged to decrease liver transduction 10 to 700 fold, respectively. Cohorts of five C57BL/6 mice received each vector via tail vein injection at a dose of 1 x $10^{13}$ particles per kg. The animals were sacrificed approximately 72 hours after vector administration by carbon dioxide asphyxiation. Liver, heart, lung, spleen, and

kidney were collected from each animal. The median lobe of the liver was placed in neutral buffered formalin to preserve the sample for β-galactosidase immunohistochemistry. In addition, tissue from each organ was frozen to preserve it for hexon PCR analysis to determine vector content. A separate sample of liver from each mouse was frozen to preserve it for a chemiluminescent β-galactosidase activity assay.

For β-galactosidase immunohistochemistry slices of liver, approximately 2-3 mm thick, were placed in 10% neutral buffered formalin. After fixation, these samples were embedded in paraffin, sectioned, and analyzed by immunohistochemistry for β-galactosidase expression. A 1:1200 dilution was used of a rabbit anti-β-galactosidase antibody (ICN Pharmaceuticals, Inc.; Costa Mesa, CA) in conjunction with a Vectastain ABC kit (Vector Laboratories, Inc., Burlingame, CA) to visualize positive cells.

The chemiluminescent β-galactosidase activity assay was performed using the Galacto-Light PlusTM chemiluminescent assay (Tropix, Inc., Foster City, CA) system. Tissue samples were collected in lysis matrix tubes containing two ceramic spheres (Bio101, Carlsbad, CA) and frozen on dry ice. The tissues were thawed and 500 μl of lysis buffer from the Galacto-Light Plus kit was added to each tube. The tissue was homogenized for 30 seconds using a FastPrep System (Bio101, Carlsbad, CA). Liver samples were homogenized for an additional 30 seconds. β-galactosidase activity was determined in the liver homogenates according to the manufacture's protocol.

For hexon PCR analysis DNA from tissues was isolated using the Qiagen Blood and Cell Culture DNA Midi or Mini Kits (Qiagen Inc., Chatsworth, CA). Frozen tissues were partially thawed and minced using sterile disposable scalpels. Tissues were then lysed by incubation overnight at 55° C in Qiagen buffer G2 containing 0.2 mg/ml RNaseA and 0.1 mg/ml protease. Lysates were vortexed briefly and then applied to Qiagen-tip 100 or Qiagen-tip 25 columns. Columns were washed and DNAs were eluted as described in the manufacturer's instructions. After precipitation, DNAs were dissolved in water and the concentrations were spectrophotometrically determined (A260 and A280) on a

DU-600 (Beckman Coulter, Inc.; Fullerton, CA) or a SPECTRAmax PLUS (Molecular Devices, Inc.; Sunnyvale, CA) spectrophotometer. 2.3.2.

PCR primers and a Taqman probe specific to adenovirus hexon sequences were designed using Primer Express software v. 1.0 (Applied Biosystems, Foster City, CA). Primer and probe sequences were:

Hexon Forward primer: 5'-CTTCGATGATGCCGCAGTG-3' (SEQ ID No. 38);

Hexon Reverse primer: 5'-GGGCTCAGGTACTCCGAGG-3' (SEQ ID No. 39); and

Hexon Probe: 5'-FAM-TTACATGCACATCTCGGGCCAGGAC-TAMRA-3' (SEQ ID No. 40).

Amplification was performed in a reaction volume of 50 $\mu$l under the following conditions: 10 ng (tumor) or 1 $\mu$g (liver and lung) of sample DNA, 1X Taqman Universal PCR Master Mix (Applied Biosystems), 600 nM forward primer, 900 nM reverse primer and 100 nM hexon probe. Thermal cycling conditions were: 2 minute incubation at 50° C, 10 minutes at 95° C, followed by 35 cycles of successive incubation at 95° C for 15 seconds and 60° C for 1 minute. Data was collected and analyzed using the 7700 Sequence Detection System software v. 1.6.3 (Applied Biosystems). Quantification of adenovirus copy number was performed using a standard curve that includes dilutions of adenovirus DNA from 1,500,000 copies to 15 copies in the appropriate background of cellular genomic DNA. For analysis of tumor tissues, a standard curve in a background of 10 ng human DNA was generated. For analysis of mouse liver and lung tissues, a standard curve using the same adenovirus DNA dilutions in a background of 1 $\mu$g CD-1 mouse genomic DNA was generated. Samples were amplified in triplicate, and the average number of total copies was normalized to copies per cell based on the input DNA weight amount and a genome size of $6 \times 10^9$ bp.

The results of the $\beta$-galactosidase activity assay and adenoviral hexon DNA content for liver transduction by these vectors are shown in Figure 7A and 7B. The vector containing the KO1 or KO12 mutations alone showed, on average, a slight increase in liver transduction compared to Av1nBg, which is consistent with several previous experiments. The vectors containing the PD1 mutation alone or combined with KO1 or KO12 showed a slight decrease in liver

transduction compared to Av1nBg, suggesting that integrins are involved to some extent in hepatic uptake of the adenoviral vectors.

The results of the immunohistochemical staining of liver sections for β-galactosidase were consistent with the activity assays (data not shown) and demonstrate that gene expression was localized specifically to hepatocytes. The vectors containing the KO1 or KO12 mutation alone showed a slight increase in liver transduction as revealed by a more intense and frequent immunohistochemical-staining pattern. The vectors containing the PD1 mutation, either alone or combined with KO1 or KO12, showed little difference in transduction compared to Av1nBg. These results demonstrate that ablating the viral interaction with CAR and/or integrins is not sufficient to fully detarget adenoviral vectors from the liver *in vivo*.

In summary, the fiber AB loop mutation contained in Av1nBgFKO1 or Av1nBgKO12 ablates interaction with human and mouse CAR *in vitro* and diminished transduction *in vitro*. *In vivo*, however, fiber AB loop mutations behaved unexpectantly, because such mutations were found to enhance adenoviral-mediated gene transfer to liver and results in increasing vector potency. The penton base, PD1 mutation that ablates interaction with the second receptor involved in adenoviral internalization had no effect *in vitro* and little to no effect *in vivo*. These studies indicated that other receptors are responsible for adenoviral gene transfer to the liver *in vivo*.

## EXAMPLE 4

### Description Of Adenoviral Vectors Containing A Fiber With Amino Acid Substitutions At The Heparin Sulfate Binding Domain In The Fiber Shaft

Vectors containing substitutions at all four of the amino acids in the four amino acid motif in the Ad5 fiber shaft (residues 91 to 94, KKTK; SEQ ID No. 1) were generated in order to ablate the potential interaction with HSP. The mutation is termed HSP because it potentially eliminates binding to heparan sulfate proteoglycans. Vectors containing the HSP mutation alone and combined with the KO1 mutation (fiber knob AB loop mutation that ablates CAR binding), the PD1 mutation (penton mutation that eliminates RGD/integrin interaction), and a triple knockout vector (HSP, KO1, PD1) were generated.

Generation of the HSP fiber mutation: The HSP mutation was incorporated into the fiber gene by using a PCR-based strategy of gene splicing by overlap extension (PCR SOEing). First, a segment of the Ad5 genome extending from within the E3 region into the 5′ end of the fiber gene was amplified by PCR using the plasmid pSQ1 (Figure 3B) as a template and two primers termed 5FF and 5HSPR. The DNA sequence of 5FF is as follows: 5′ GAA CAG GAG GTG AGC TTA GA 3′ (SEQ ID No. 5). This sequence corresponds to base pairs 25,199 - 25,218 of pSQ1. The DNA sequence of 5HSPR is as follows: 5′ GGC TCC GGC TCC GAG AGG TGG GCT CAC AGT GGT TAC ATT T 3′ (SEQ ID No. 15). 5HSPR is a reverse primer for 5FF and corresponds to a region in the fiber shaft adjacent to the KKTK (SEQ ID No. 1) region. The primer contains a 5′ extension that encodes a GAGA substitution for the native KKTK (encoded by SEQ ID No. 1) amino acid sequence. A second PCR using pSQ1 as a template amplified the region immediately 3′ of the KKTK (SEQ ID No. 1) site and extending past the MunI site located 40 base pairs 3′ of the stop codon for the fiber gene. The two primers used for this reaction were 3HSPF and 3FR. The DNA sequence of 3HSPF is as follows: 5′ GGA GCC GGA GCC TCA AAC ATA AAC CTG GAA AT 3′ (SEQ ID No. 16). It contains a 5′ extension that is complementary to the 5′ extension of 5HSPR. The DNA sequence of 3FR is as follows: 5′ GTG GCA GGT TGA ATA CTA GG 3′ (SEQ ID No. 8).

The two PCR products were joined by PCR SOEing using primers 5FF and 3FR. The resulting PCR product was digested with the restriction enzymes XbaI and MunI. The 2355 bp fragment was gel purified and ligated with the 6477 bp XbaI to MunI fragment of the plasmid pFBshuttle(EcoRI) (Figure 8) to generate the plasmid pFBSEHSP. The plasmid pFBshuttle(EcoRI) was generated by digesting the plasmid pSQ1 with EcoRI, then gel purifying and self-ligating the 8.8 kb fragment containing the fiber gene. Next, the fiber gene containing the HSP mutation was transferred from pFBSEHSP into pSQ1 using a three-way ligation. The 16,431 bp EcoRI to NdeI fragment of pSQ1, the 9043 bp NdeI to XbaI fragment of pSQ1, and the 7571 bp XbaI to EcoRI fragment of pFBSEHSP were isolated and ligated to generate pSQ1HSP (Figure 9).

To generate a recombinant adenoviral vector containing the HSP mutation in the fiber gene, pSQ1HSP was digested with ClaI and pAdmireRSVnBg (Figure 3A) was digested with SalI and PacI, then the two digested plasmids were co-transfected into 633 cells (von Seggern *et al.* (2000) *J Virology 74*:354-362). Homologous recombination between the two plasmids generated a full-length adenoviral genome capable of replication in 633 cells, which inducibly express Ad5 E1A and constitutively express wild-type fiber protein. After propagation on 633 cells, the virus capsid contained wildtype and mutant fiber proteins. To obtain viral particles containing only the modified fiber with the HSP mutation, the viral preparation was used to infect PerC6 cells, which do not express fiber. The resulting virus, termed Av1nBgFS*, was purified by standard CsCl centrifugation procedures.

**Generation of vector containing the HSP and KO1 mutations**

To generate an adenoviral vector containing the HSP and KO1 mutations in fiber, a PCR SOEing strategy identical to the one described above was used except that the plasmid pSQ1FKO1 was used as the template. The PCR SOEing product was digested with XbaI and MunI and ligated with the 6477 bp XbaI to MunI fragment of pFBshuttle(EcoRI) to generate pFBSEHSPKO1. The fiber gene containing the HSP and KO1 mutations was transferred from pFBSEHSPKO1 into the pSQ1 backbone using a three-way ligation strategy identical to the one described above for the HSP mutation alone, to generate the plasmid pSQ1HSPKO1 (Figure 10). Recombinant adenoviral vector containing the HSP and KO1 mutations in the fiber gene was generated by co-transfecting pSQ1HSPKO1 digested with ClaI and pAdmireRSVnBg digested with SalI and PacI into 633 cells. Adenovirus was propagated and purified as described above for the vector containing the HSP mutation alone. The resulting virus was termed Av1nBgFKO1S*.

**Generation of vector containing the HSP and PD1 mutations**

The following strategy was used to generate a recombinant adenoviral vector containing the fiber HSP mutation and the penton PD1 mutation. The plasmid pSQ1PD1 (Figure 4) was digested with the restriction enzymes Csp45I and SpeI and the 23,976 bp fragment was isolated and purified. In addition, the plasmid pSQ1HSP was also digested with Csp45I and SpeI and the 9090 bp fragment was isolated and purified and ligated to the 23,976 bp fragment to generate the plasmid pSQ1HSPPD1 (Figure 11), which contains the fiber HSP and penton PD1 mutations. An adenoviral vector was generated, propagated, and purified as described above. The resulting virus was termed Av1nBgS*PD1.

**Generation of vector containing the HSP, KO1, and PD1 mutations**

To generate an adenoviral vector containing the HSP, KO1, and PD1 mutations the following strategy was used. First, the plasmid pSQ1PD1 was digested with Csp45I and SpeI and the 23,976 bp fragment was isolated and purified. In addition, the plasmid pSQ1HSPKO1 was digested with Csp45I and SpeI and the 9090 bp fragment was isolated and purified. The two DNA fragments were ligated to form the plasmid pSQ1HSPKO1PD1 (Figure 12). Recombinant adenoviral vector was generated, propagated, and purified as described above. The resulting virus was termed Av1nBgFKO1S*PD1.

**EXAMPLE 5**

***In Vitro* Evaluation Of Adenoviral Vectors Containing The HSP Fiber Mutation**

The transduction efficiencies of adenoviral vectors containing the HSP mutation in the fiber gene, either alone or combined with the KO1 and/or PD1 mutations, were evaluated on A549 and HeLa cells. The transduction efficiencies were compared to that of Av1nBg, an adenoviral vector containing wild type fiber and penton. The day prior to infection, cells were seeded into 24-well plates at a density of approximately 1 x $10^5$ cells per well. Immediately prior to infection, the exact number of cells per well was determined by counting a representative well of cells. Each of the vectors, Av1nBg (see, Stevenson *et al.* (1997) *J. Virol. 71*:4782-4790), Av1nBgS*, Av1nBgFKO1S*, Av1nBgS*PD1, and Av1nBgFKO1S*PD1, were used to transduce A549 cells at each of the following particle per cell (PPC) ratios: 100, 500, 1000, 2500,

5000, 10,000. HeLa cells were transduced with each of the above vectors, as well as a vector containing the KO1 mutation alone (Av1nBgFKO1) and a vector containing the PD1 mutation alone (Av1nBgPD1) at 2000 PPC. The cell monolayers were stained with X-gal 24 hours after infection and the percentage of cells expressing $\beta$-galactosidase was determined by microscopic observation and counting of cells. Transductions were done in triplicate and three random fields in each well were counted, for a total of nine fields per vector.

The results (depicted in Figures 13A-13B) showed significantly reduced transduction efficiencies on A549 and HeLa cells using vectors containing the HSP mutation compared to Av1nBg. The vectors containing the HSP mutations, however, demonstrated a dose response on A549 cells, in that increasing PPC ratios yielded increasing transduction.

Competition experiments were done to determine which receptor molecular interactions are involved in transduction of A549 cells by the various vectors. Transductions were performed in the presence or absence of various competitors including Ad5 fiber knob, a 50 amino acid oligopeptide derived from Adenovirus serotype 2 penton base which spans the RGD tripeptide region, or heparin (Invitrogen Life Technologies, Gaithersburg, MD). Monolayers of A549 cells were cultured in Richters medium supplemented with 10% FBS and were transduced with Av1nBg, Av1nBgS*, Av1nBgFKO1S*, Av1nBgS*PD1, or Av1nBgFKO1S*PD1 in infection medium (IM, Richters medium plus 2% FBS). Different PPC ratios were used for the different vectors to achieve measurable transduction levels. The PPC ratios were as follows: Av1nBg: 500 PPC, Av1nBgS*: 10,000 PPC, Av1nBgFKO1S*: 20,000 PPC, Av1nBgS*PD1: 10,000 PPC, and Av1nBgFKO1S*PD1: 20,000 PPC. Fiber knob competition was performed by pre-incubating cells in IM containing 16 $\mu$g/ml of fiber knob for 10 minutes at room temperature prior to infection with virus. Penton base peptide competition was performed by pre-incubating cells in IM containing 500nM peptide for 10 minutes at room temperature prior to infection with virus. Heparin competition was performed by pre-incubating each adenoviral vector in IM containing 3 mg/ml of heparin for 20 minutes at room temperature. In all cases, the competitor remained in the IM during the 1 hour infection when virus

was rocked on the cell monolayers at 37° C in 5% CO2. After infection, the monolayers were washed with PBS, 1 ml of complete medium was added per well and the cells were incubated for an additional 24 hours to allow for β-galactosidase expression. The cell monolayers were then fixed and stained with X-Gal. The percentage of cells transduced was determined by light microscopy as described above. Each condition was carried out in triplicate and three random fields per well were counted, for a total of nine fields per condition. The average percentage of transduction per high-power field was determined.

The results of the competition experiment (Figure 13C) showed that fiber knob inhibited transduction of cells by all vectors except for those that contained the KO1 mutation. The penton base peptide only inhibited transduction by Av1nBgFKO1S*. Heparin inhibited transduction by Av1nBgFKO1S* and Av1nBgFKO1S*PD1, but did not affect transduction by any of the other viruses suggesting the presence of additional heparin binding sites on the adenoviral capsid but that the shaft contains the predominant site.

## EXAMPLE 6

### *In Vivo* Analysis Of Adenoviral Vectors Containing The HSP Mutation In Fiber

The objective of this study was to evaluate the *in vivo* biodistribution of adenoviral vectors containing the HSP mutation and to determine whether this shaft modification influences adenoviral-mediated liver transduction. In addition, vectors containing the HSP mutation combined with KO1, or PD1, or a combination of all three mutations were evaluated as well as vectors containing the KO1 mutation alone and the PD1 mutation alone. A positive control cohort received Av1nBg and a negative control group received HBSS. Cohorts of five C57BL/6 mice received each vector via tail vein injection at a dose of $1 \times 10^{13}$ particles per kg. The animals were sacrificed approximately 72 hours after vector administration by carbon dioxide asphyxiation. Liver, heart, lung, spleen, and kidney were collected from each animal. The median lobe of the liver was placed in neutral buffered formalin to preserve the sample for β-galactosidase immunohistochemistry. In addition, tissue from each organ was frozen to preserve it for hexon real time PCR analysis to determine vector content. A

separate sample of liver from each mouse was frozen to preserve it for a chemiluminescent β-galactosidase activity assay. β-galactosidase immunohistochemistry, hexon real-time PCR and the chemiluminescent β-galactosidase activity assay were carried out as described in Example 3. The results of the β-galactosidase activity assay (Figure 14A) and adenoviral hexon DNA content (Figure 14B) showed a dramatic reduction in liver transduction by vectors containing the HSP mutation. The vectors containing the HSP mutation alone resulted in reducing adenoviral-mediated liver gene expression by approximately 20-fold.When combined with the KO1 mutation (HSP, KO1, PD1), yielded approximately a 1000-fold reduction in β-galactosidase activity in the liver compared to the control vector Av1nBg. The vector containing the KO1 mutation alone showed a slight increase, on average, in liver transduction compared to Av1nBg, which is consistent with several previous experiments. The vectors containing the PD1 mutation alone or combined with KO1 showed a slight decrease in liver transduction compared to Av1nBg, although the decrease was not statistically significant. Analysis of hepatic adenoviral hexon DNA content (Figure 14B) confirmed these results.

The results of the immunohistochemical staining of liver sections for β-galactosidase were consistent with the activity assays (data not shown) and demonstrated that gene expression was localized specifically to hepatocytes. Vectors containing the HSP mutation, either alone or in combination with KO1 and/or PD1, showed a dramatic reduction in hepatocyte transduction. The vector containing the KO1 mutation alone showed a slight increase in liver transduction as revealed by a more intense and frequent immunohistochemical staining pattern. The vectors containing the PD1 mutation, either alone or combined with KO1, showed little difference in transduction compared to Av1nBg.

## EXAMPLE 7

**Description of Adenoviral Vectors Containing the HSP Fiber Shaft Mutation with and without the KO1 Fiber Mutation and with and without a cRGD Targeting Ligand in the Fiber Knob HI Loop**

Generation of vector containing the HSP fiber shaft mutation and a cRGD ligand in the HI loop: The following strategy was used to generate an adenoviral vector containing a fiber with the HSP shaft mutation and a cRGD ligand in the HI loop. The plasmid p5FloxHRFRGD was digested with the restriction enzymes BstXI and KpnI and the 1157 bp fragment was isolated and purified. In addition, the fiber shuttle plasmid pFBSEHSP, described in Example 1 above, was digested with BstXI and KpnI and the 4549 bp and 3156 bp fragments were isolated and purified. The three fragments were ligated to generate the plasmid pFBSEHSPRGD, which encodes a fiber containing the HSP mutation and cRGD in the HI loop. The fiber gene from this plasmid was transferred into the pSQ1 backbone as follows. The plasmid pFBSEHSPRGD was digested with EcoRI and XbaI and the 7601 bp fragment was isolated and purified. The plasmid pSQ1 (Figure 3B) was digested with the restriction enzymes EcoRI, NdeI, and XbaI and the 16,431 bp EcoRI to NdeI fragment and the 9043 bp NdeI to XbaI fragment were isolated and purified. The three DNA fragments were ligated to generate the plasmid pSQ1HSPRGD (Figure 15A).

To generate a recombinant adenoviral vector containing the HSP mutation in the fiber gene along with a cRGD ligand in the HI loop, the plasmid pSQ1HSPRGD was digested with ClaI and co-transfected into 633 cells with pAdmireRSVnBg which had been digested with SalI and PacI. After propagation on 633 cells, the virus capsid contained wildtype and mutant fiber proteins. To obtain viral particles containing only the modified fiber with the HSP mutation and a cRGD ligand, the viral preparation was used to infect PerC6 cells, which do not express fiber. The resulting virus, termed Av1nBgS*RGD, was purified by standard CsCl centrifugation procedures.

**Generation of vector containing the HSP fiber shaft mutation, the KO1 fiber knob mutation, and a cRGD ligand in the HI loop**

The following strategy was used to generate an adenoviral vector containing a fiber with the HSP shaft mutation, the KO1 fiber knob mutation, and a cRGD ligand in the HI loop. The plasmid p5FloxHRFRGD was digested with the restriction enzymes BstXI and KpnI and the 1157 bp fragment was isolated and purified. In addition, the fiber shuttle plasmid pFBSEHSPKO1,

described in Example 1 above, was digested with BstXI and KpnI and the 4549 bp and 3156 bp fragments were isolated and purified. The three fragments were ligated to generate the plasmid pFBSEHSPKO1RGD, which encodes a fiber containing the HSP mutation, the KO1 mutation, and cRGD in the HI loop. The fiber gene from this plasmid was transferred into the pSQ1 backbone as follows. The plasmid pFBSEHSPKPO1RGD was digested with EcoRI and XbaI and the 7601 bp fragment was isolated and purified. The plasmid pSQ1 (Figure 3B) was digested with the restriction enzymes EcoRI, NdeI, and XbaI and the 16,431 bp EcoRI to NdeI fragment and the 9043 bp NdeI to XbaI fragment were isolated and purified. The three DNA fragments were ligated to generate the plasmid pSQ1HSPKO1RGD (Figure 15B).

To generate a recombinant adenoviral vector containing the HSP and KO1 mutations in the fiber gene along with a cRGD ligand in the HI loop, the plasmid pSQ1HSPKO1RGD was digested with ClaI and co-transfected into 633 cells with pAdmireRSVnBg which had been digested with SalI and PacI. After propagation on 633 cells, the virus capsid contained wildtype and mutant fiber proteins. To obtain viral particles containing only the modified fiber with the HSP and KO1 mutations and a cRGD ligand, the viral preparation was used to infect PerC6 cells, which do not express fiber. The resulting virus, termed Av1nBgFKO1S*RGD, was purified by standard CsCl centrifugation procedures.

## EXAMPLE 8

### *In Vitro* Evaluation of Adenoviral Vectors Containing the HSP Fiber Shaft Mutation with or without the Fiber Knob KO1 Mutation and with or without a cRGD Ligand in the HI Loop

The transduction efficiencies of adenoviral vectors containing the HSP fiber shaft mutation with or without the fiber KO1 mutation and with or without the cRGD ligand in the HI loop were evaluated on A549 cells. The transduction efficiencies were compared to that of Av1nBg, an adenoviral vector containing wild type fiber. The day prior to infection, cells were seeded into 24-well plates at a density of approximately 1 x $10^5$ cells per well. Immediately prior to infection, the exact number of cells per well was determined by counting a representative well of cells. Each of the vectors, Av1nBg, Av1nBgS*,

Av1nBgFKO1S*, Av1nBgS*RGD, and Av1nBgFKO1S*RGD, were used to transduce A549 cells at a particle to cell ratio of 6250. The cell monolayers were stained with X-gal 24 hours after infection and the percentage of cells expressing β-galactosidase was determined by microscopic observation and counting of cells. Transductions were done in triplicate and three random fields in each well were counted, for a total of nine fields per vector. The results (Figure 16) showed that the cRGD ligand dramatically increased the transduction efficiencies of vectors containing the HSP mutation alone or combined with the KO1 mutation. Av1nBgS* yielded approximately 22% positive cells, while Av1nBgS*RGD yielded approximately 95% positive cells. Similarly, Av1nBgFKO1S* yielded only 4% positive cells, while Av1nBgFKO1S*RGD yielded 85% positive cells. Therefore, the vector containing the shaft mutation is viable and can be retargeted with the addition of a ligand.

**EXAMPLE 9**

**Construction Of Ad5 Vectors Containing The Ad35 Fiber And Derivatives Thereof**

The KO1 and HSP mutations in the Ad5 fiber protein (5F), described above, were designed to ablate interactions that are responsible for the normal tropism of the Ad5 virus. An alternative strategy to detarget the virus is to replace the Ad5 fiber with a fiber from another serotype which does not bind CAR and which does not possess the heparin sulfate proteoglycan (HSP) binding domain (KKTK; SEQ ID No. 1) within the shaft. The fiber of adenovirus serotype 35 (35F) does not bind CAR and does not possess the HSP binding domain in its shaft. Replacement of the 5F with the 35F can detarget the liver and provide a suitable platform for retargeting the vector to the desired tissue.

Generation of an Ad5 based vector containing the Ad35 fiber: A PCR SOEing strategy was used to generate a vector based on the Ad5 serotype but containing the Ad35 fiber in place of the Ad5 fiber. First, PCR was used to amplify a region in the plasmid pSQ1 between the XbaI site at bp 25,309 and the start of the fiber gene. The primers used for this reaction were P-0005/U and P-0006/L. The DNA sequence of P-0005/U was as follows: 5′ C TCT AGA AAT GGA CGG AAT TAT TAC AG 3′ (SEQ ID No. 17). This sequence

corresponds to bp 25,308 through 25,334 of pSQ1. The DNA sequence of P-0006/L was as follows: 5′ TCT TGG TCA TCT GCA ACA ACA TGA AGA TAG TG 3′ (SEQ ID No. 18). It contains a 10 base pair 5′ extension that is complementary to the start of the Ad35 fiber gene, while the remainder of the primer anneals to the sequence immediately 5′ of the ATG start codon of the fiber gene in pSQ1. A PCR product of the expected size, 583 bp, was obtained and the DNA was gel purified. A second PCR amplified the Ad35 fiber gene using DNA extracted from wildtype Ad35 virus as a template. The primers used for this reaction were P-0007/U and 35FMun. The DNA sequence of P-0007/U was as follows: 5′ GT TGT TGC AG ATG ACC AAG AGA GTC CGG CTC A 3′ (SEQ ID No. 19). It contains a 10 base pair 5′ extension that is homologous to the 10 bp immediately prior to the ATG start codon of the fiber gene in Ad5. The remainder of the primer anneals to the start of the Ad35 fiber gene. The DNA sequence of 35FMun was as follows: 5′ AG CAA TTG AAA AAT AAA CAC GTT GAA ACA TAA CAC AAA CGA TTC TTT A GTT GTC GTC TTC TGT AAT GTA AGA A 3′ (SEQ ID No. 20). It contains a 46 base pair 5′ extension that is complementary to the region of the Ad5 genome between the end of fiber and the MunI site 40 bp downstream of the fiber gene. In addition, the 5′ extension encodes the last amino acid and stop codon of the Ad5 fiber gene. This region was retained in the vector because it contains the polyadenylation site for the fiber gene. The remainder of the primer anneals to the 3′ end of the Ad35 fiber gene, up to the next to last amino acid codon. A PCR product of the expected size, 1027 bp, was obtained and the DNA was gel purified. The two PCR products were mixed and joined together by PCR SOEing using primers P-0005/U and P-0009. The DNA sequence of P-0009 was as follows: 5′ AG CAA TTG AAA AAT AAA CAC GTT G 3′ (SEQ ID No. 21). It corresponds to bp 27,648 through 27,669 of pSQ1 and overlaps the MunI site in that region. A PCR product of the expected size, 1590 bp, was obtained and gel purified. It was cloned into the plasmid pCR4blunt-TOPO (Invitrogen Corporation, Carlsbad CA) using the Zero Blunt TOPO PCR Cloning Kit from Invitrogen. This intermediate cloning step simplified DNA sequencing of the PCR SOEing product. The resulting plasmid, termed pTOPOAd35F, was digested with XbaI and MunI

and the 1585 bp digestion product was gel purified and ligated with the 6477 bp fragment of pFBshuttle(EcoRI) digested with XbaI and MunI to generate the plasmid pFBshuttleAd35F. The Ad35 fiber gene was transferred from pFBshuttleAd35F into pSQ1 as follows. The plasmid pSQ1 was digested with EcoRI and the 24,213 bp fragment was gel purified. The plasmid pFBshuttleAd35F was linearized with EcoRI and ligated with the 24,213 bp fragment from pSQ1. Restriction diagnostics were performed to screen for constructs containing the Ad35 fiber gene inserted into the pSQ1 backbone in the correct orientation. The pSQ1 plasmid containing the Ad35 fiber gene in the proper orientation was termed pSQ1Ad35Fiber (Figure 17A). To generate adenoviral vector containing the Ad35 fiber, pSQ1Ad35Fiber was digested with ClaI and co-transfected into 633 cells with pAdmireRSVnBg which had been digested with SalI and PacI. After propagation on 633 cells, the resulting virus contained Ad5 fiber and Ad35 fibers on its capsid. The virus was amplified on PerC6 cells to generate virus containing only the Ad35 fiber on its capsid. The resulting virus preparation was termed Av1nBg35F.

Construction of adenoviral vectors containing chimeric fibers derived from Ad5 and Ad35: Two chimeric fiber constructs were prepared by PCR gene overlap extension using plasmids containing the full length Ad5 or Ad35 fiber cDNAs as templates. The Ad5 fiber tail and shaft regions (5TS; amino acids 1 to 403) were connected with the Ad35 fiber head region (35H; amino acids 137 to 323) to form the 5TS35H chimera, and the Ad35 fiber tail and shaft regions (35TS; amino acids 1 to 136) were connected with the Ad5 fiber head region (5H; amino acids 404 to 581) to form the 35TS5H chimera. The fusions were made at the conserved TLWT sequence at the fiber shaft-head junction.

For the construction of the 5TS35H chimera, the pFBshuttle(EcoR1) plasmid was used as the template with primers P1 and P2 to generate the 5′ fragment. The 3′ fragment was generated using the pFBshuttleAd35 plasmid as the template with the P3 and P4 primers. The sequence of each primer used in the construction of these chimeric fibers is listed in Table 2. Amplified PCR products of the expected size were obtained and were gel purified. A second PCR was carried out with the end primers P1 and P4 to join the two fragments

together. The DNA fragment generated in the second PCR was digested with Xba1 and Mun1 and was cloned directly into pFBshuttle(EcoR1) to create the fiber shuttle plasmid pFBshuttle5TS35H.

TABLE 2

Primers Used For The Exchange Of Fiber Shaft Regions Between Ad5 And Ad35 Fibers

| Primer designation | Sequence | SEQ ID |
|---|---|---|
| P1 | 5′-GAACAGGAGGTGAGCTTAGA-3′ | 22 |
| P2 | 5′-GTTAGGTGGAGGGTTTATTCCGGTCCAC AAAGTTAGCTTATC-3′ | 23 |
| P3 | 5′-GATAAGCTAACTTTGTGGACCGGAATAAA CCCTCCACCTAAC-3′ | 24 |
| P4 | 5′-GTGGCAGGTTGAATACTAGG-3 | 25 |
| P5 | 5′-GTTAGGAGATGGAGCTGGTGTAGTCCATA AGGTGTTAATAC-3′ | 26 |
| P6 | 5′-GTATTAACACCTTATGGACTACACCAGCT CCATCTCCTAAC-3′ | 27 |
| P7 | 5′-TGCGCAAAAACAATCACCACGACAATCACAAT GTACATTGGAAGAAATCATACG-3′ | 28 |
| P8 | 5′-ACATTGTGATTGTCGTGGTGATT GTTTTTGCGCATATGCCATACAATTTGAATG-3′ | 29 |

For the construction of the 35TS5H chimera, the pFBshuttleAd35 plasmid was used as the template with the P1 and P5 primers to generate the 5′ fragment. The 3′ fragment was generated using the pFBshuttle(EcoR1) plasmid as the template with the P6 and P4 primers. Following the same procedure described above, the fiber shuttle plasmid pFBshuttle35TS5H was generated.

For the 35TS5H and 5TS35H chimeras, the fiber gene was transferred from the pFBshuttle(EcoRI) backbone into pSQ1 as described above for the vector containing the Ad35 fiber. The resulting plasmids were called pSQ135T5H (Figure 18A) and pSQ15T35H (Figure 18B). In addition, adenoviral vectors were generated using the co-transfection strategy described above.

Construction of Ad5 vectors containing the Ad35 fiber with a cRGD targeting peptide in the HI loop of the 35F fiber knob: To incorporate the cRGD

targeting peptide into the Ad35 fiber HI loop, the P7 and P8 oligonucleotide primers encoding the ten amino acid sequence HCDCRGDCFC (SEQ ID No. 30) were synthesized. The pFBshuttleAd35 plasmid containing the full length Ad35 fiber cDNA was used as the template in the PCR reaction with the P1 and P7 primer pair or with the P4 and P8 primer pair in order to generate the 5′ and 3′ PCR fragments. A second PCR was then carried out with the end primers P1 and P4 to join the two fragments together. The resulting PCR fragment was digested with Xba1 and Mun1 and was cloned into pFBshuttle(EcoR1) to create the fiber shuttle plasmid pFBshuttleAd35cRGD. The modified Ad35 fiber gene was transferred into pSQ1 using the EcoRI cloning strategy described above to generate pSQ1Ad35FcRGD (Figure 17B). Adenoviral vector was generated using the co-transfection strategy described above.

**EXAMPLE 10**

***In Vitro* Evaluation Of Adenoviral Vectors Containing 35F And Derivatives Thereof**

The transduction efficiencies of adenoviral vectors containing the 35F or derivatives thereof were evaluated on A549 cells. The transduction efficiencies were compared to that of Av1nBg, an adenoviral vector containing the 5F fiber. The day prior to infection, cells were seeded into 24-well plates at a density of approximately 1 x $10^5$ cells per well. Immediately prior to infection, the exact number of cells per well was determined by counting a representative well of cells. Each of the vectors, Av1nBg, Av1nBg35F, Av1nBg5T35H and Av1nBg35T5H were used to transduce A549 cells from 0 up to 1,000 particle per cell (PPC) ratios. The cell monolayers were stained with X-gal 24 hours after infection and the percentage of cells expressing $\beta$-galactosidase was determined by microscopic observation and counting of cells. Transductions were done in triplicate and three random fields in each well were counted, for a total of nine fields per vector. The results (Figure 19) showed similar transduction efficiencies on A549 cells using the Av1nBg35F and Av1nBg5T35H vectors compared to Av1nBg. The Av1nBg35T5H showed much lower transduction efficiencies on A549 cells compared to Av1nBg as a result of the Ad35 shaft domain. The Ad35 shaft domain does not contain a HSP binding motif and the

Av1nBg35T5H vector behaves similarly to the Av1nBgS* vector *in vitro* and *in vivo*. These studies also demonstrate that vectors containing fiber proteins without an HSP binding site are fully viable.

**EXAMPLE 11**

**5 *in Vivo* Evaluation Of Adenoviral Vectors Containing 35F And Derivatives Thereof**

The objective of this study was to evaluate the *in vivo* biodistribution of adenoviral vectors containing 35F fibers and derivatives thereof to determine whether vectors containing these fibers ablate liver transduction due to their
10 shaft regions. A positive control cohort received Av1nBg and a negative control group received HBSS. Cohorts of five C57BL/6 mice received each vector via tail vein injection at a dose of $1 \times 10^{13}$ particles per kg. The animals were sacrificed approximately 72 hours after vector administration by carbon dioxide asphyxiation. Liver, heart, lung, spleen, and kidney were collected from each
15 animal. The median lobe of the liver was placed in neutral buffered formalin to preserve the sample for β-galactosidase immunohistochemistry. In addition, tissue from each organ was frozen to preserve it for hexon PCR analysis to determine vector content. A separate sample of liver from each mouse was frozen to preserve it for a chemiluminescent β-galactosidase activity assay. β-
20 galactosidase immunohistochemistry, hexon real-time PCR and the chemiluminescent β-galactosidase activity assay were carried out as described in example 3.

The results of the β-galactosidase activity assay showed a dramatic reduction in liver transduction by vectors containing the Ad35 fiber or the
25 35T5H derivative (Figure 20) with an approximately 4- to 24-fold reduction in β-galactosidase activity in the liver compared to the control vector Av1nBg. These data demonstrate that shaft domains without HSP binding sites can effectively ablate hepatic *in vivo* gene transfer. In particular, HSP is the major entry mechanism for liver *in vivo*. CAR binding is a minor entry pathway.

## EXAMPLE 12

**Construction Of Ad5 Vectors Containing The Ad Serotype 41 Short Fiber And Derivatives Thereof**

The human adenovirus serotype 41 contains two different fibers on its capsid, encoded by two adjacent genes. One fiber has a molecular weight of 60kDa and is approximately 315A in length and is termed the long fiber. The other fiber has a molecular weight of 40kDa and is approximately 250+ in length and is termed the short fiber. The Ad41 short fiber does not bind CAR and does not possess the heparin binding domain (KKTK) in its shaft. Therefore, this fiber provides a useful platform for adenoviral vector targeting.

Construction of adenoviral vectors based on Ad5 but containing the Ad41 short fiber: A PCR SOEing strategy was used to generate a vector based on the Ad5 genome but containing the Ad41 short (Ad41s) fiber. First, PCR was used to amplify the region of pSQ1 between the XbaI site at bp 25,309 and the start of the fiber gene. The primer pair used for the PCR were P-0005/U and P-0010/L. The DNA sequence of P-0005/U was as follows: 5′ C TCT AGA AAT GGA CGG AAT TAT TAC AG 3′ (SEQ ID No. 17). The sequence corresponds to bp 25,308 through 25,334 of pSQ1 and overlaps the XbaI site in that region. The DNA sequence of P-0010/L was as follows: 5′ TTC TTT TCA T CTG CAA CAA CAT GAA GAT AGT G 3′ (SEQ ID No. 31). It contains a 5′ extension corresponding to the first 10 bp of the Ad41s fiber gene. The remainder of the primer anneals to pSQ1 immediately 5′ of the ATG start codon of the fiber gene. The PCR product was the expected size (583 bp). A second PCR was used to amplify the Ad41s fiber using the plasmid pDV60Ad41sF as a template. The primers used were P-0011/U and P-0012/L. The DNA sequence of P-0011/U was as follows: 5′ GT TGT TGC AG ATG AAA AGA ACC AGA ATT GAA G 3′ (SEQ ID No. 32). It contains a 10 bp 5′ extension corresponding to the DNA sequence immediately 5′ of the ATG start codon of the fiber gene in pSQ1. The remainder of the primer anneals to the beginning of the Ad41s fiber gene in pDV60Ad41sF. The DNA sequence of P-0012/L was as follows: 5′ TG CAA TTG AAA AAT AAA CAC GTT GAA ACA TAA CAC AAA CGA TTC TTT ATT C TTC AGT TAT GTA GCA AAA TAC A 3′ (SEQ ID No. 33). It contains a 51 bp

5′ extension corresponding to the sequence in pSQ1 from the last codon of the fiber gene through the MunI site 40 bp downstream of the fiber gene. The remainder of the primer anneals to the 3′ end of the Ad41s fiber gene in pDV60Ad41sF. The PCR product was the expected size (1219 bp). The two PCR products were joined by PCR SOEing using primers P-0005/U and P-0009/L. The DNA sequence of P-0009/L was described above. The PCR SOEing reaction yielded the expected 1782 bp product. The product was cloned into pCR4blunt-TOPO to yield pCR4blunt-TOPOAd41sF. Next, pCR4blunt-TOPOAd41sF was digested with XbaI and MunI and the 1773 bp fragment containing the Ad41s fiber gene was gel purified. This fragment was ligated with the 6477 bp XbaI to MunI fragment of pFBshuttle(EcoRI) to generate pFBshuttleAd41sF. The Ad41s fiber gene was transferred into the pSQ1 backbone as follows. First, pFBshuttleAd41sF was linearized using EcoRI and this fragment was ligated with the 24,213 bp EcoRI fragment of pSQ1 to generate pSQ1Ad41sF (Figure 21A). Adenoviral vector containing the Ad41s fiber was generated using the co-transfection strategy described above.

Construction of Ad5 adenoviral vectors containing the Ad41 short fiber with a cRGD targeting ligand in the HI loop: A PCR SOEing strategy was used to generate a construct containing the Ad41s fiber with cRGD in the HI loop. The plasmid pFBshuttleAd41sF was used as a template for the PCR amplifications. First, a 1782 bp fragment was amplified using primers 5FF and 41sRGDR. The primer 5FF was described above. It anneals to pFBshuttleAd41sF at the XbaI site upstream of the fiber gene. The DNA sequence of the primer 41sRGDR was as follows: 5′ AGT ACA AAA ACA ATC ACC ACG ACA ATC ACA GTT TAT CTC GTT GTA GAC GAC ACT GA 3′ SEQ ID No. 34). It contains a 30 bp 5′ extension that encodes the cRGD targeting ligand. The remainder of the primer anneals to pFBshuttleAd41sF from bp 2878 through 2903. A second PCR amplified a 277bp region of pFBshuttleAd41sF using primers 3FR and 41sRGDF. The primer 3FR was described previously. It anneals to pFBshuttleAd41sF at the MunI site downstream of the fiber gene. The DNA sequence of 41sRGDF was as follows: 5′ TGT GAT TGT CGT GGT GAT TGT TTT TGT ACT AGT GGG TAT GCT TTT ACT TTT 3′ (SEQ ID No. 35). It contains a 30 bp 5′ extension that

encodes the cRGD targeting ligand and is complementary to the extension on 41sRGDR. The remainder of the primer anneals to pFBshuttleAd41sF from bp 2904 through 2924. The two PCR products were joined by PCR SOEing to generate a 2059 bp fragment using primers 5FF and 3FR. The product was digested with XbaI and MunI and the 1803 bp DNA fragment was gel purified. The fragment was ligated with the 6477 bp fragment resulting from digestion of pFBshuttle(EcoRI) with XbaI and MunI. The resulting plasmid was termed pFBshuttleAd41sRGD. This plasmid was linearized by EcoRI digestion and ligated with the 24,213bp EcoRI fragment of pSQ1 to generate pSQ1Ad41sRGD (Figure 21B).

## EXAMPLE 13

### *In Vivo* Evaluation Of Ad5 Vectors Containing The Ad41 Short Fiber And Derivatives Thereof

This example evaluates the *in vivo* biodistribution of adenoviral vectors containing 41sF fibers and derivatives thereof to determine whether vectors containing the these fibers ablate liver transduction due to modified shaft regions. A positive control cohort received Av3nBg (see, Gorziglia *et al.* (1996) *J. Virology 70*:4173-4178) or Ad5.βGal.ΔF/5F, and a negative control group received HBSS. Ad5.βGal.ΔF/5F is a derivative of the fiberless vector Ad5.βgal.ΔF (ATCC accession number VR2636) modified to express AD5 fiber (see, *e.g.*, International PCT application No. WO0183729).

The Ad5.βGal.ΔF vector was pseudotyped with the Ad41sF fiber protein and injected *in vivo*. Cohorts of five C57BL/6 mice received each vector via tail vein injection at a dose of $1 \times 10^{13}$ particles per kg. The animals were sacrificed approximately 72 hours after vector administration by carbon dioxide asphyxiation. Liver, heart, lung, spleen, and kidney were collected from each animal. The median lobe of the liver was placed in neutral buffered formalin to preserve the sample for β-galactosidase immunohistochemistry. In addition, tissue from each organ was frozen to preserve it for hexon PCR analysis to determine vector content. A separate sample of liver from each mouse was frozen to preserve it for a chemiluminescent β-galactosidase activity assay. β-galactosidase immunohistochemistry, hexon real-time PCR and the

chemiluminescent β-galactosidase activity assay was carried out as described in example 3.

The results of the hexon DNA analysis showed a dramatic reduction in liver transduction by vectors containing the Ad41sF fiber (Figure 22) with an approximately a 5-fold reduction in liver adenoviral DNA content compared to either control vector.

In the above examples, several novel adenoviral vectors were generated containing various fiber modifications designed to ablate the normal tropism of the vector. See Table 3. Vectors were generated in which the heparan sulfate binding domain in the fiber shaft was replaced by amino acid substitutions. This mutation, termed HSP, was also combined with the KO1 mutation (fiber knob AB loop mutation that ablates CAR binding), and the PD1 mutation (penton mutation that eliminates RGD/integrin interaction). In addition, a vector containing all three mutations (HSP, KO1, PD1) was generated. All vectors containing the HSP mutation, either alone or combined with other capsid modifications, showed dramatically reduced transduction efficiencies on A549 and HeLa cells. Furthermore, the same vectors showed dramatically reduced transduction of the liver following systemic delivery to mice. As an alternative strategy to ablate the normal tropism of Ad5-based vectors, the Ad5 fiber was replaced by a fiber from a different adenovirus serotype which does not bind CAR and does not contain the heparan binding domain in the shaft. Thus, vectors were generated containing the Ad35 fiber and the Ad41 short fiber. Versions of these two vectors containing a cRGD targeting ligand in the HI loop of the fiber were also produced. Additionally, vectors containing chimeric fibers were generated. A vector containing the Ad35 fiber tail and shaft regions fused to the Ad5 fiber knob domain as well as a vector containing the Ad5 fiber tail and shaft fused to the Ad35 fiber knob domain were constructed. Vectors containing either the entire Ad35 or Ad41 short fiber showed a significant reduction in liver transduction following delivery to mice via the tail vein. The observation of reduced liver transduction using vectors containing either an HSP mutation, the Ad35 fiber, or the Ad41 short fiber indicates the feasibility of detargeting adenoviral vectors *in vivo*. *In vitro* data with the Ad35 fiber or the Ad41 short

fiber with cRGD (see Example 14) indicate that the virus is completely viable, that is, it is not damaged by the absence of an HSP binding site and is retargetable. Taken together these data suggest that these vectors provide a suitable platform for retargeting strategies.

TABLE 3
Description Of Recombinant Adenoviral Vectors Used To Demonstrate That Shaft Modifications Influence Tropism *In Vivo*

| Vector | Description |
|---|---|
| Av1nBg | An E1 and E3-deleted adenoviral vector encoding a nuclear localizing $\beta$-galactosidase |
| Ad5 Fiber derivatives: | |
| Av1nBgFKO1 | The same as Av1nBg but containing the KO1 AB loop mutation in the fiber gene |
| Av1nBgPD1 | The same as Av1nBg but containing the penton PD1 mutation that deletes the integrin binding, RGD tripeptide |
| Av1nBgS* | The same as Av1nBg but containing the 4 amino acid substitution in the shaft referred to as S* that modifies the HSP binding motif |
| Av1nBgFKO1S* | The same as Av1nBg but containing the fiber KO1 and S* mutations combined |
| Av1nBgS*PD1 | The same as Av1nBg but containing the fiber S* and penton PD1 mutations combined |
| Av1nBgFKO1S*PD1 | The same as Av1nBg but containing the fiber KO1, S* and penton PD1 mutations combined |
| Ad35 fiber derivatives: | |
| Av1nBg35F | The same as Av1nBg but containing the full length Ad35 fiber cDNA |
| Av1nBg5T35H | The same as Av1nBg but containing the 5T35H chimeric fiber |
| Av1nBg35T5H | The same as Av1nBg but containing the 35T5H chimeric fiber |
| Av1nBg35FRGD | The same as Av1nBg but containing the full length Ad35 fiber cDNA with a cRGD ligand in the HI loop of the Ad35 fiber |
| Ad41sF fiber derivatives: | |
| Av1nBg41sF | The same as Av1nBg but containing the full length Ad41 short fiber cDNA |

| Vector | Description |
|---|---|
| Av1nBg41sFRGD | The same as Av1nBg but containing the full length Ad41 short fiber cDNA with a cRGD ligand in the HI loop of the Ad41 short fiber |

## EXAMPLE 14

**_In Vitro_ Evaluation Of Adenoviral Vectors Containing The Ad41sF With A cRGD Ligand In The HI Loop**

The transduction efficiencies of adenoviral vectors containing the Ad41sF fiber with the cRGD ligand in the HI loop were evaluated on A549 cells. The transduction efficiencies were compared to that of Av1nBg, an adenoviral vector containing wild type fiber or Av1nBgFKO1RGD, an adenoviral vector containing the KO1 mutation in combination with the cRGD ligand in the HI loop. The day prior to infection, cells were seeded into 24-well plates at a density of approximately 1 x $10^5$ cells per well. Immediately prior to infection, the exact number of cells per well was determined by counting a representative well of cells. Each of the vectors, Av1nBg, Av1nBgFKO1RGD, and Av1nBg41sFRGD were used to transduce A549 cells at a particle to cell ratios of 0 up to 10,000. The cell monolayers were stained with X-gal 24 hours after infection and the percentage of cells expressing $\beta$-galactosidase was determined by microscopic observation and counting of cells. Transductions were done in triplicate and three random fields in each well were counted, for a total of nine fields per vector. The results (Figure 23) show that the Av1nBg41sFRGD vector transduced cells to an equivalent level as Av1nBgFKO1RGD at all vector doses examined. Neither FKO1 or Ad41sF can bind CAR. The Ad41sF does not normally interact with CAR and additionally does not contain the HSP binding motif within the shaft domain. These data show that targeting peptides inserted into the loop regions of the fiber knob of KO1 and Ad41sF allows for transduction of target cells via the targeted receptor. Surprisingly, HSP, not CAR and integrins, is the major entry route *in vivo* and ablation of HSP binding permits targeting of adenoviral vectors.

## EXAMPLE 15

**Effect of the shaft modification on the biodistribution of adenoviral vectors *in vivo***

The influence of fiber and penton modifications on the *in vivo* biodistribution of adenoviral vectors containing fiber head, shaft and penton mutations was examined. Vectors containing the HSP mutation combined with KO1, or PD1, or a combination of all three mutations were evaluated as well as vectors containing the KO1 mutation alone and the PD1 mutation alone. The indicated adenoviral vectors were systemically administered to C57BL6 mice as described above. A positive control cohort received Av1nBg and a negative control group received HBSS. Cohorts of five C57BL/6 mice received each vector via tail vein injection at a dose of $1 \times 10^{13}$ particles per kg. The animals were sacrificed approximately 72 hours after vector administration by carbon dioxide asphyxiation. Liver, heart, lung, spleen, and kidney were collected from each animal. Tissue from each organ was frozen to preserve it for real time PCR analysis to determine adenoviral hexon DNA content. A separate sample of liver from each mouse was frozen to preserve it for a chemiluminescent $\beta$-galactosidase activity assay. Hexon real-time PCR and the chemiluminescent $\beta$-galactosidase activity assay was carried out as described in Example 3.

The results derived from the liver are described in Example 6 (Figure 14A and B) and also shown in Figure 26 with results presented as percent control of Av1nBg. The effect of the S* shaft modification on the biodistribution of adenovirus to the other organs is shown in Figure 25. The average adenoviral DNA content was determined as adenoviral genomic copies per cell and expressed as a percentage of the Av1nBg (+) control value. The average percent control value + standard deviation is shown (n=5 per group) for each tissue examined (Figure 25). Systemic delivery of Ad5 based vectors with wild-type fiber results in a preferential accumulation of vector DNA in the liver with 64 copies per cell with significantly less DNA found in the other organs with 1.32 copies per cell found in lung, 2.18 copies per cell in spleen, 0.47 copies per cell found in heart, and 0.72 copies per cell in the kidney. All differences found with PD1, S*, KO1PD1, KO1S*, S*PD1, and KO1S*PD1 were

significantly different than the Av1nBg (+) control using a unpaired, t-test analysis, P value ( 0.024. When expressed as a percent of the Av1nBg control values, the influence of each mutation, individually or in combination, becomes apparent. The S* mutation dramatically reduced gene transfer to all four organs, whereas, the KO1 mutation did not. Thus, the importance of the shaft for transduction *in vivo* extends to organs besides the liver. Finally, gene transfer to the lung, heart, and kidney was diminished with PD1 suggesting a role for integrin binding in vector entry in these organs.

**EXAMPLE 16**

**Retargeting the S*, shaft modification and the 41sF fiber *in vivo***

Vectors containing the HSP mutation have been shown to effectively detarget adenoviral vectors *in vivo* (see examples 6 and 15). The objective of this study was to evaluate the ability to retarget vectors containing the S* modification or the Ad41sF to tumors *in vivo*. A cRGD peptide was genetically incorporated into the fiber HI loop and evaluated *in vitro* (Examples 8 and 14). These same vectors were then evaluated *in vivo* in tumor-bearing mice. Athymic nu/nu female mice were injected with $8 \times 10^6$ A549 cells on the right hind flank. When tumors reached approximately 100mm3 in size, they were randomized into treatment groups. Cohorts of 6 mice received each vector via tail vein injection at a dose of $1 \times 10^{13}$ particles per kg. The animals were sacrificed approximately 72 hours after vector administration by carbon dioxide asphyxiation. Tumor, liver, heart, lung, spleen, and kidney were collected from each animal. Tissue from each organ was frozen to preserve it for real time PCR analysis to determine adenoviral hexon DNA content. Hexon real-time PCR was carried out as described in example 3. A separate sample of liver from each mouse was frozen to preserve it for a chemiluminescent $\beta$-galactosidase activity assay. Hexon real-time PCR and the chemiluminescent $\beta$-galactosidase activity assay was carried out as described in example 3.

The adenoviral vector biodistribution to the liver and tumor for each treatment group is shown in Figure 27. Vectors containing the S*, KO1S*, and 41sF fibers effectively detargeted the liver and tumor resulting in a significant reduction in the amount of adenoviral DNA found in each tissue in comparison to

the Av1nBg control. Vectors containing the cRGD targeting ligand restored tranduction of the tumors to levels comparable to that achieved with the untargeted vector.

These data demonstrate successful liver detargeting accompanied with tumor retargeting. The extent of tumor retargeting is relates to the affinity and type of ligand that is used. These data demonstrate the successful development of a targeted, systemically deliverable adenoviral vector that will target tumors *in vivo*.

**EXAMPLE 17**

**Scale-Up Method For The Propagation Of Detargeted Adenoviral Vectors**

The growth and propagation of doubly or triply ablated adenoviral vectors requires novel scale up technologies. These detargeted vectors require alternative cellular entry strategies to allow for the efficient growth and generation of high titer preparations. A strategy for vector growth that is generally applicable to all detargeted adenoviral vectors, that does not require the development of new cell lines, and that aslo can be used for generating targeted vectors is provided herein.

Three recombinant adenoviral vectors were prepared that contain single mutations in the fiber or penton or both mutations combined into one vector. These vectors are designated Av3nBgFKO1, Av1nBgPD1, and Av1nBgFKO1PD1, respectively. The construction of these vectors is described above and a general description of each vector can be found in Table 1 above.

Scale-up of detargeted adenoviral vectors: A polycation, specifically hexadimethrine bromide was obtained from Sigma Chemical Co (St. Louis, MO), Catalog No. 52495, and was maintained in the medium at 4 μg/ml during the course of transfections and infections. To illustrate the affects of hexadimethrine bromide on the yield of detargeted adenoviral vectors the following experiment was carried out. Seven plates of AE1-2a adenoviral producer cells (Gorziglia *et al.* (1996) *J. Virology 70*:4173-4178) were transduced with 10 particles per cells of each of the indicated vectors (See Table 4). Each vector was incubated with medium (Richters with 2% HI-FBS) containing hexadimethrine bromide at 4 μg/ml for 30 min at room temperature

prior to infection. The infection was carried out for 2 hrs. Complete medium containing hexadimethrine bromide at 4 μg/ml was added to each plate. Final concentration of hexadimethrine bromide in all of these experiments was maintained at 4 μg/ml. The titers were determined spectrophotometrically using the conversion of 1OD at A260nm per 1 x $10^{12}$ particles (Mittereder *et al.* (1996) *J Virology 70*:7498-7509). The total particle yield was then normalized for the number of plates used for transduction.

The inclusion of hexadimethrine bromide in the medium during the course of infection allows for the efficient propagation of detargeted adenoviral vectors containing fiber and penton mutations either alone or in combination. The affect of hexadimethrine bromide on vector yields is shown in Table 4. A 35-fold improvement in the yield of Av3nBgFKO1 was found when hexadimethrine bromide was included in the culture medium and resulted in increasing the vector yield from 1.3 x $10^{10}$ up to 4.6 x $10^{11}$ vector particle per plate. Hexadimethrine bromide has a minimal effect on the yield of the Av1nBgPD1 adenoviral vector containing the penton, PD1 mutation with only a 1.2 fold improvement. The greatest effect using hexadimethrine bromide was found on the propagation of the doubly ablated adenoviral vector, Av1nBgFKO1PD1 with increases in vector yield from barely detectable levels up to 4.53 x $10^{10}$ vector particles per plate. These data demonstrate that use of nonspecific entry mechanisms allows for the efficient scale-up of detargeted adenoviral vectors.

TABLE 4
Efficient Scale-Up Of Detargeted Adenoviral Vectors Using hexadimethrine bromide

| Vector | Vector Yield (particles/plate) | | Fold Improvement |
|---|---|---|---|
| | (-) hexadimethrine bromide | (+) hexadimethrine bromide | |
| Av1nBg | 3.89 x $10^{11}$ | 5.72 x $10^{11}$ | 1.47 |
| Av3nBg | 8.58 x $10^{10}$ | 2.38 x $10^{11}$ | 2.77 |
| Av3nBgFKO1 | 1.30 x $10^{10}$ | 4.60 x $10^{11}$ | 35.4 |
| Av1nBgPD1 | 1.95 x $10^{11}$ | 2.40 x $10^{11}$ | 1.23 |
| Av1nBgFKO1PD1 | TLTC* | 4.53 x $10^{10}$ | † |

*TLTC: Too low to count, a faint virus band was collected and the particle concentration was too dilute for titer determination.
† Significant improvement

The use of alternative polycations including protamine sulfate and poly-lysine as well as bifunctional proteins such as the anti-penton:TNF$\alpha$ fusion protein was investigated. Figure 24 show results that demonstrate all the reagents tested had some effect on enhancing transduction of the Av3nBgFKO1 vector. All of these compounds, when maintained in the medium during infection, enhanced transduction of the Av3nBgFKO1 detargeted adenoviral vector.

Bifunctional reagents:. The use of bifunctional reagents for the propagation of detargeted adenoviral vectors was examined using the anti-penton:TNF$\alpha$ fusion protein. This particular reagent is a fusion protein between an antibody against Ad5 penton and the TNF$\alpha$ protein that is produced using stably transfected insect cells. This reagent will bind specifically to the adenoviral capsid via penton base and allow for binding to cell surface TNF receptors. The use of this reagent for the propagation of detargeted vectors is illustrated in Table 5 using Av3nBgFKO1 (also shown in Figure 24). Monolayers of S8 cells were infected with 10 or 100 particles per cell of Av3nBgFKO1 or a control vector in the presence or absence of 1 $\mu$g/ml of the anti-penton:TNF$\alpha$ fusion protein. The monolayers were visually inspected over time for vector spread as indicated by the extent of cytopathic effect (CPE). The percentage of CPE at each time point is shown. The use of this bifunctional reagent clearly enhances the spread of the Av3nBgFKO1 vector throughout the monolayer.

TABLE 5
Efficient Scale-Up Of Detargeted Adenoviral Vectors Using Bifunctional Reagents: Anti-Penton:TNF$\alpha$

| | 10 ppc - anti-penton TNF | 10 ppc + anti-penton TNF | 100 ppc - anti-penton TNF | 100 ppc + anti-penton TNF |
|---|---|---|---|---|
| | Percentage of CPE | | | |
| Ad5Luc1 | | | | |
| 24 h | 0% | 0% | 0% | 0% |

| | 10 ppc - anti-penton TNF | 10 ppc + anti-penton TNF | 100 ppc - anti-penton TNF | 100 ppc + anti-penton TNF |
|---|---|---|---|---|
| | Percentage of CPE | | | |
| 48 h | 20-30% | 20-30% | 90-100% | 90-100% |
| 72 h | 60-70% | 80-90% | 100% | 100% |
| 120 h | 100% | 100% | 100% | 100% |
| Av3nBgKO1 24hrs | | | | |
| 24 h | 0% | 0% | 0% | 0% |
| 48 h | 0% | 10-20% | 0% | 90-100% |
| 72 h | 5% | 60-70% | 5% | 100% |
| 120 h | 40-50% | 100% | 100% | 100% |

Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

**WHAT IS CLAIMED IS:**

1. A modified adenovirus capsid protein,

the unmodified capsid protein binds to heparin sulfate proteoglycan (HSP); and

the capsid protein comprises a mutation, whereby binding to heparin sulfate proteoglycan (HSP) is altered.

2. The modified protein of claim 1 that is a fiber protein

3. The capsid protein of claim 2, wherein the binding of the modified fiber protein is eliminated or reduced compared to the unmodified protein.

4. The modified protein of claim 2, wherein the binding of the modified fiber protein is eliminated or reduced compared to the unmodified protein.

5. The modified protein of claim 3 that comprises an insertion, deletion or replacement of amino acids.

6. The modified protein of claim 2, wherein the mutation alters the motif that binds to HSP, whereby HSP interaction is altered.

7. The modified protein of claim 6, motif is BBXB or BBBXXB, wherein the B is a basic amino acid and X is any amino acid.

8. The modified protein of claim 7, wherein the motif comprises the consensus sequence KKTK.

9. The modified protein of claim 2, wherein the fiber is a modified Ad5 or Ad2 fiber.

10. A modified protein of claim 2 that is a chimeric fiber protein, comprising portions of fiber proteins from at least two different adenoviruses, wherein:

a shaft or portion thereof is from a first adenovirus, whereby the resulting fiber does not bind to HSP or binds to HSP with reduced affinity compared to an unmodified fiber protein;

a shaft or portion thereof from the first adenovirus does not bind to HSP or binds to HSP with reduced affinity compared to the second adenovirus;

the second adenovirus binds to HSP; and

the portion comprises a sufficient portion to alter HSP binding of the resulting protein.

11. The modified protein of claim 10, wherein the binding to HSP of the modified fiber protein is eliminated or reduced compared to the unmodified protein.

12. The modified protein of claim 10, wherein the remainder of the fiber protein is from the second adenovirus.

13. The modified protein of any of claims 2, 3, 10 and 11, further comprising one or more further modifications that reduce or eliminate interaction of the resulting fiber with one or more cell surface proteins in addition to HSP.

14. The modified protein of claim 13, further comprising a ligand, whereby the resulting fiber binds to a receptor for the ligand.

15. The modified protein of claim 14, wherein the ligand is included in the knob region.

16. The modified protein of claim 14, wherein the ligand is inserted or it replaces a portion of the fiber, whereby the resulting fiber binds to a receptor for the ligand.

17. A modified protein of claim 11, wherein affinity for HSP is reduced at least by an amount selected from among reduced 5-fold, 10-fold and 100-fold.

18. The modified protein of claim 11, wherein the first adenovirus is selected from the group consisting of subgroup B, D or F, and the second is of subgroup C.

19. The modified protein of claim 10, wherein the first adenovirus is selected from the group consisting of Ad3, Ad35, Ad7, Ad11, Ad16, Ad21, Ad34, Ad40, Ad41 and Ad46.

20. The modified protein of claim 18, wherein the second adenovirus is Ad5 or Ad2.

21. The modified protein of claim 19, wherein the second adenovirus is Ad5 or Ad2.

22. A modified protein of claim 1 selected from the group consisting of a fiber protein comprising:

the sequence of amino acids set forth in any of SEQ ID Nos. 52, 54, 56, 58, 62, 66, 70 and 72; or

a sequence of amino acids having 90% sequence identity with a sequence of amino acids set forth in any of SEQ ID Nos. 52, 54, 56, 58, 62, 66, 70 and 72; or

a sequence of amino acids encoded by a sequence of nucleotides that hybridizes under conditions of high stringency along at least 70% of its length to a sequence of nucleotides that encodes a sequence of amino acids set forth in any of SEQ ID Nos. 52, 54, 56, 58, 62, 66, 70 and 72.

23. A nucleic acid molecule encoding a modified protein of any of claims 1-12 and 14-22.

24. A nucleic acid molecule encoding a modified protein of claim 13.

25. The nucleic acid molecule of claim 23 that comprises a vector.

26. The nucleic acid molecule of claim 24 that comprises vector.

27. The nucleic acid molecule of claim 25 that is an adenovirus vector.

28. The nucleic acid molecule of claim 26 that is an adenovirus vector.

29. The vector of claim 27 that is an adenoviral vector from a subgroup B, C or D adenovirus.

30. The vector of claim 28 that is an adenoviral vector from a subgroup B, C or D adenovirus.

31. A cell, comprising a nucleic acid molecule of claim 23.

32. A cell, comprising a nucleic acid molecule of claim 24.

33. The cell of claim 31 that is a eukaryotic cell.

34. The cell of claim 32 that is a eukaryotic cell.

35. A cell, comprising a nucleic acid molecule of claim 27, wherein:
the cell is a eukaryotic cell; and
the cell in a packaging cell.

36. A cell, comprising a nucleic acid molecule of claim 28, wherein:
the cell is a eukaryotic cell; and
the cell in a packaging cell.

37. An adenoviral particle, comprising a modified protein of any of claims 1-12 and 14-22, whereby binding of the viral particle to HSP is altered compared to a particle that expresses an unmodified fiber.

38. An adenoviral particle, comprising a modified protein of claim 13, whereby binding of the viral particle to HSP is altered compared to a particle that expresses an unmodified fiber.

39. An adenoviral particle of claim 37, wherein a native receptor for the fiber is coxsackie-adenovirus receptor (CAR).

40. The adenoviral particle of claim 39, further comprising a mutation in the CAR-binding region of the capsid.

41. The adenoviral particle of claim 39, further comprising a mutation in the $\alpha_v$ integrin-binding region of the capsid, whereby binding to the integrin is eliminated or reduced.

42. The adenoviral particle of claim 40, further comprising a mutation in the $\alpha_v$ integrin-binding region of the capsid, whereby binding to the integrin is eliminated or reduced

43. The adenoviral particle of claim 39, wherein the CAR-binding region of the capsid modified is on a fiber knob.

44. The adenoviral particle of claim 43, wherein the fiber knob modification is in the AB loop or CD loop.

45. The adenoviral particle of claim 44, wherein the fiber knob modification is selected from the group consisting of KO1 and KO12.

46. The adenoviral particle of claim 39, wherein the adenovirus is a subgroup C, D or F adenovirus.

47. The adenoviral particle of claim 46, wherein the subgroup C virus is Ad2 or Ad5, the subgroup D virus is Ad46 and the subgroup F virus is Ad41.

48. The adenoviral vector of claim 27 that is an early generation adenoviral vector, a gutless adenoviral vector or a replication-conditional adenoviral vector.

49. The adenoviral vector of claim 28 that is an early generation adenoviral vector, a gutless adenoviral vector or a replication-conditional adenoviral vector.

50. The adenoviral vector of claim 48, wherein the replication-conditional adenoviral vector is an oncolytic adenoviral vector.

51. The adenoviral vector of claim 49, wherein the replication-conditional adenoviral vector is an oncolytic adenoviral vector.

52. The adenoviral vector of claim 27 that comprises heterologous nucleic acid.

53. The adenoviral vector of claim 28 that comprises heterologous nucleic acid.

54. The adenoviral vector of claim 52, wherein the heterologous nucleic acid encodes a polypeptide.

55. The adenoviral vector of claim 53, wherein the heterologous nucleic acid encodes a polypeptide.

56. The adenoviral vector of claim 52, wherein the heterologous nucleic acid comprises or encodes a regulatory nucleic acid.

57. The adenoviral vector of claim 53, wherein the heterologous nucleic acid comprises or encodes a regulatory nucleic acid.

58. The adenoviral vector of claim 52, wherein the heterologous nucleic acid comprises or encodes a promoter or RNA.

59. The adenoviral vector of claim 53, wherein the heterologous nucleic acid comprises or encodes a promoter or RNA.

60. The adenoviral vector of claim 59, wherein the promoter is a cell or tissue specific promoter.

61. The adenoviral vector of claim 59, wherein the promoter is operably linked to a gene of an adenovirus essential for replication.

62. The adenoviral vector of claim 60, wherein the tissue specific promoter is a tumor specific promoter.

63. The adenoviral vector of claim 58, wherein the polypeptide is a therapeutic polypeptide.

64. A method of expressing heterologous nucleic acid in a cell, comprising transducing the cell with an adenoviral vector of claim 57.

65. The method of claim 64, wherein:

the cell is a tumor cell;

the adenoviral vector is an oncolytic vector; and

the cell is killed .

66. The method of claim 64, wherein the cell is a mammalian cell.

67. The method of claim 64, wherein the cell is a primate cell.

68. The method of claim 67, wherein the cell is a human cell.

69. A method of reducing transduction of liver cells by an adenoviral particle, comprising reducing or eliminating binding of the particle to heparin sulfate proteoglycans (HSPs) on the liver cells.

70. A scale up method for the propagation of a detargeted adenoviral particle, comprising:

infecting a cell capable of replicating, maturing and packaging an adenoviral vector with a detargeted adenoviral vector in the presence of a reagent that results in entry of the adenoviral particle into the cell;

culturing the infected cell under conditions suitable for growth, spread and propagation of the adenoviral vector; and

recovering the resulting adenoviral particles.

71. The method of claim 70, wherein the reagent is a polycation.

72. The method of claim 71, wherein the polycation is selected from the group consisting of hexadimethrine bromide, polyethylenimine, protamine sulfate and poly-L-lysine.

73. The method of claim 70, wherein the reagent is a bifunctional protein that binds to the adenoviral particle and to a receptor on the cell.

74. The method of claim 73, wherein:

the bifunctional protein is selected from the group consisting of an anti-fiber antibody ligand fusion, an anti-fiber-Fab-FGF conjugate, an anti-penton-antibody ligand fusion, an anti-hexon antibody ligand fusion and a polylysine-peptide fusion, wherein the ligand is a ligand that binds to the receptor.

75. The method of any one of claims 70-74, wherein the detargeted adenoviral particle expresses a modified capsid, whereby binding to at least one host cell receptor is reduced or eliminated compared with a wild-type adenovirus.

76. The method of claim 75, wherein the adenoviral particle is modified to eliminate or reduce binding with one host cell receptor.

77. The method of claim 75, wherein the adenoviral particle is modified to eliminate or reduce binding with two host cell receptors.

78. The method of claim 75, wherein the adenoviral particle is modified to eliminate or reduce binding with three host cell receptors.

79. The, method of claim 75, wherein the particle is modified with one or more mutations selected from the group consisting of mutations that reduce or eliminate interactions with one or more of $\alpha_v$ integrins, coxsackie-adenovirus receptors (CAR). and heparin sulfate proteoglycans (HSP).

80. The method of claim 79, wherein the mutation is selected from the group consisting of PD1, KO1, KO12 and S*.

81. The modified protein of claim 2, wherein the mutation is in the shaft of a fiber.

82. A modified protein of claim 3, wherein affinity for HSP is reduced at least by an amount selected from among reduced 5-fold, 10-fold and 100-fold.


pSKO1
8656 bps
Sse8387I
Bpu1102I
AflII
MunI
EcoRV
BbsI
Tth111I
SexAI
Esp3I
BstXI
EcoNI
HpaI
HindIII
'HRF
8000
'5F
HindIII
BstEII
2000
AvrII
Eco47III
AgeI
5' PCR'
6000
'HRF
Pkg
EcoNI
BsmI
loxP
3' PCR'
RITR
PacI
EcoRI
HpaI
BstAPI
4000
PacI
XbaI
ClaI
NotI
SalI
BstXI
XhoI
amp
AhdI
XmnI
ScaI

FIG. 1


31492,BamHI
31348,ClaI
31340,BstBI
29243,ClaI
29078,PacI
28224,HindIII
Bst1107I,2481
HindIII,2958
loxP
ITR
5' PCR'
30000
25287,HindIII
5000
Fiber KO1
25000
pNDSQ3.1KO1
loxP
31497 bps
RsrII,7660
HindIII,8282
10000
22660,SrfI
22215,SpeI
20000
Fse I,9304
21461,HindIII
15000
penton
PmeI,9972
HindIII,10363
HindIII,10438
hexon'
19162,HindIII
18279,BamHI
18155,SgfI
SfiI,12999
Fse I,14466
HindIII,15035
RsrII,15367

FIG. 2


pAdmireRSVnBg
9281 bps
2000
4000
6000
8000
AmpR
RITR
RSV
TPL
nBgal
HRF'
Poly A
'AdHRF
PacI
AatII
SgrAI
BsrGI
XmnI
ScaI
PvuI
FspI
AseI
BfiI
PvuI
EcoRI
ScaI
XhoI
SpeI
EcoRI
BfiI
PvuI
FspI
SnaBI
AvrII
HindIII
Asp718I
KpnI
AgeI
EcoRI
NheI
AatII
ClaI
PvuI
EcoRV
PvuI
BsaBI
BclI
BfiI
PvuI
Bst1107I
SplI
NdeI
HindIII
ClaI
SexAI
AflII
BsaBI
MunI
Tth111I
NarI
KasI
EheI
BbeI
BstEII
Bst1107I
SexAI
SalI
PmaCI
PshAI
XhoI
StuI

FIG. 3A


BamHI
ClaI
Csp45I
BstBI
EcoRI
PvuI
NdeI
loxP
ITR-r
pBR
Bst1107I
PvuI
NotI
PvuI
5000
XbaI
NotI
10000
PvuI
FseI
PmeI
NotI
penton
PvuI
AscI
NotI
NotI
FseI
PvuI
NdeI
BamHI
PvuI
SgfI
PvuI
hexon
AscI
SpeI
EcoRI
SrfI
XbaI
NdeI
fib
30000
25000
20000
15000
pSQ1
33045 bps

FIG. 3B


32896,ClaI
32888,BstBI
MunI,642
Bst1107I,2481
loxP
ITR-r
pBR'
'pBR
MunI,4732
27664,MunI
30000
MunI,6347
5000
fib
XbaI,7306
25309,XbaI
pSQ1KO12
25000
33045 bps
24244,SrfI
23799,SpeI
10000
PmeI,9972
22761,MunI
20000
15000
hexon
18155,SgfI

FIG. 3C


33061,Bam HI
32917,Cla I
32909,Csp 45I
32909,Bst BI
32275,Pvu I
30837,Nde I
30819,Bcl I
29790,Hin dIII
loxP
ITR-r pBR
Bst 1107I,2481
Hin dIII,2958
Pvu I,3034
Pvu I,4703
Xba I,7306
Hin dIII,8282
Bcl I,9028
Pvu I,9258
Fse I,9304
Pme I,9972
Hin dIII,10363
Hin dIII,10438
Pvu I,11432
Bcl I,12026
Asc I,12408
Fse I,14487
Hin dIII,15056
Pvu I,15395
Nde I,16286
18300,Bam HI
18177,Pvu I
18176,Sgf I
20239,Pvu I
22028,Asc I
23066,Hin dIII
23820,Spe I
24265,Srf I
25330,Xba I
25948,Nde I
26853,Hin dIII
fiber
hexon
Penton PD1
pSQ1PD1
33066 bps
5000
10000
15000
20000
25000
30000

FIG. 4


33061,BamHI
32917,ClaI
32909,Csp45I
32901,EcoRI
32275,PvuI
30837,NdeI
30819,BclI
loxP
Ritr
pBR'
'pBR
30000
5000
25000
10000
20000
15000
pSQ1FKO1PD1
33066 bps
Fiber KO1
Penton PD1
hexon
Bst1107I,2481
PvuI,3034
PvuI,4703
XbaI,7306
BclI,9028
PvuI,9258
FseI,9304
PmeI,9972
PvuI,11432
BclI,12026
AscI,12408
FseI,14487
PvuI,15395
NdeI,16286
18300,BamHI
18177,PvuI
18176,SgfI
20239,PvuI
22028,AscI
24265,SrfI
24069,EcoRI
23820,SpeI
25330,XbaI
25948,NdeI

FIG. 5A


33061,BamHI
32917,ClaI
32909,Csp45I
32275,PvuI
30837,NdeI
30819,BclI
MunI,642
BstI1107I,2481
PvuI,3034
PvuI,4703
MunI,4732
MunI,6347
XbaI,7306
BclI,9028
PvuI,9258
FseI,9304
PmeI,9972
PvuI,11432
BclI,12026
AscI,12408
FseI,14487
PvuI,15395
NdeI,16286
18300,BamHI
18177,PvuI
18176,SgfI
20239,PvuI
22028,AscI
22782,MunI
23820,SpeI
24265,SrfI
25330,XbaI
25948,NdeI
27685,MunI
loxP
'pBR'
ITR-r
pBR'
'pBR
30000
5000
10000
15000
20000
25000
pSQ1KO12PD1
33066 bps
fib
'5 Penton'
hexon

FIG. 5B


A549 cells
500 ppc
Percent Transduction
(mean ± sd)
100
80
60
40
20
0
HBSS
Av1nBg
FKO1
PD1
FKO1PD1

FIG. 6


B-Galactosidase Activity
(RLU/µg protein)
8000.0
7000.0
6000.0
5000.0
4000.0
3000.0
2000.0
1000.0
0.0
HBSS
AV1nBg
KO1
PD1
FKO1PD1
KO12
KO12PD1
Vector

FIG. 7A


Hexon Copies Per Cell
120
100
80
60
40
20
0
HBSS
Av1nBg
KO1
PD1
KO1PD1
KO12
KO12PD1

FIG. 7B


EcoRI
SrfI
PvuI
XbaI
pBR'
8000
NdeI
NdeI
pFBshuttle(EcoR1)
2000
8832 bps
ITR-r
6000
fib
HindIII
4000
HindIII
MunI

FIG. 8


ClaI
BstBI
MunI
Bst1107I
loxP
ITR-r
pBR'
'pBR
MunI
MunI
MunI
XbaI
XbaI
SrfI
SpeI
MunI
PmeI
SgfI
30000
5000
25000
10000
20000
15000
fib
hexon
pSQ1HSP
33045 bps

FIG. 9


ClaI
BstBI
MunI
Bst1107I
loxP
ITR-r
pBR'
'pBR
MunI
MunI
MunI
XbaI
XbaI
fib
pSQ1HSPKO1
33045 bps
30000
5000
25000
10000
20000
15000
SrfI
SpeI
MunI
PmeI
hexon
SgfI

FIG. 10


pSQ1HSPPD1
33066 bps
5000
10000
15000
20000
25000
30000
loxP
'pBR'
ITR-r
pBR'
'pBR
fib
hexon
'5 Penton'
BamHI
ClaI
Csp45I
EcoRI
PvuI
NdeI
BclI
BtrI
MunI
Bst1107I
Pvul
Btrl
Pvul
MunI
Btrl
Btrl
MunI
XbaI
BclI
Pvul
FseI
PmeI
Btrl
Pvul
Btrl
BclI
AscI
Btrl
Btrl
Fsel
Pvul
Btrl
Ndel
Btrl
BamHI
Pvul
Sgfl
Btrl
Btrl
Pvul
MunI
Btrl
AscI
SrfI
EcoRI
SpeI
NdeI
XbaI
Btrl
MunI

FIG. 11


pSQ1HSPKO1PD1
33066 bps
5000
10000
15000
20000
25000
30000
loxP
'pBR'
ITR-r
pBR'
'pBR
fib
hexon
'5 Penton'
BamHI
ClaI
Csp45I
EcoRI
PvuI
NdeI
BclI
BtrI
MunI
Bst1107I
XbaI
FseI
PmeI
SrfI
SpeI
AscI
SgfI

FIG. 12




FIG. 13A




FIG. 13B


No competitor
Fiber
RGD
Heparin
Percent Transduction
(mean +/- sd)
120
100
80
60
40
20
0
wt
S*
KO1S*
PD1S*
KO1S*PD1
Vector

FIG. 13C




FIG. 14A




FIG. 14B


BamHI
ClaI
Csp45I
BstBI
EcoRI
NdeI
HindIII
loxP
ITR-r
pBR'
'pBR
HindIII
NotI
BsrGI
BsrGI
HindIII
HRF"
cRGD
'5Fiber'
fib'
30000
5000
NdeI
XbaI
pSQ1HSPRGD
33075 bps
25000
10000
XbaI
NotI
HindIII
SrfI
EcoRI
SpeI
HindIII
20000
15000
FseI
PmeI
NotI
HindIII
HindIII
AscI
hexon
AscI
NotI
NotI
BsrGI
BamHI
SgfI
NotI
FseI
HindIII
NdeI
BsrGI

FIG. 15A


BamHI
ClaI
Csp45I
BstBI
EcoRI
MunI
NdeI
NotI
loxP
ITR-r
pBR'
'pBR
MunI
BsrGI
MunI
BsrGI
HRF"
cRGD
'5Fiber'
fib'
30000
5000
MunI
XbaI
NdeI
XbaI
pSQ1HSPKO1RGD
33075 bps
25000
10000
NotI
SrfI
EcoRI
SpeI
FseI
PmeI
NotI
20000
15000
MunI
AscI
hexon
AscI
NotI
NotI
BsrGI
BamHI
SgfI
NdeI
BsrGI
NotI
FseI

FIG. 15B


Percent Transduction
100
80
60
40
20
Av1nBg
S*
S*RGD
S*KO1
S*KO1RGD

FIG. 16


BamHI
ClaI
Csp45I
BstBI
PvuI
NdeI
HindIII
loxP
ITR-r
pBR
Bst1107I
HindIII
PvuI
NotI
PvuI
XbaI
NotI
HindIII
PvuI
FseI
PmeI
NotI
HindIII
HindIII
PvuI
AscI
NotI
NotI
NotI
FseI
HindIII
PvuI
NdeI
BamHI
PvuI
SgfI
PvuI
AscI
HindIII
SpeI
SrfI
XbaI
SpeI
'fib
Fiber'
30000
5000
10000
15000
20000
25000
pSQ1Ad35Fiber
32271 bps
hexon

FIG. 17A


32152,ClaI
32144,BstBI
MunI,642
Bst1107I,2481
loxP
ITR-r pBR' 'pBR
MunI,4732
26920,MunI
30000
MunI,6347
Ad35FcRGD
5000
25309,XbaI
XbaI,7306
pSQ1Ad35FcRGD
25000
24244,SrfI
32301 bps
10000
22761,MunI
20000
PmeI,9972
15000
hexon
18155,SgfI

FIG. 17B


32095,ClaI
32087,BstBI
MunI,642
Bst1107I,2481
loxP
ITR-r pBR' 'pBR
MunI,4732
26863,MunI
30000
MunI,6347
35TS5Hfiber
5000
25309,XbaI
XbaI,7306
25000
pSQ135T5H
24244,SrfI
32244 bps
23799,SpeI
10000
22761,MunI
20000
PmeI,9972
15000
hexon
18155,SgfI

FIG. 18A


32923,ClaI
32915,BstBI
MunI,642
Bst1107I,2481
loxP
ITR-r
pBR'
'pBR
MunI,4732
27691,MunI
30000
5000
MunI,6347
5TS35Hfiber
XbaI,7306
25309,XbaI
pSQ15T35H
25000
33072 bps
24244,SrfI
10000
PmeI,9972
22761,MunI
20000
15000
hexon
18155;SgfI

FIG. 18B


5F
35F
5T35H
35T5H
Percent Transduction
(mean +/- sd)
100
90
80
70
60
50
40
30
20
10
0
0
200
400
600
800
1000
1200
Particles Per Cell

FIG. 19


β-Galactosidase Activity
(RLU/µg protein)
4000
3500
3000
2500
2000
1500
1000
500
0
HBSS
Av1nBg
35F
5T35H
35T5H
S*
Treatment Groups

FIG. 20


ClaI
BstBI
MunI
Bst1107I
loxP
ITR-r
pBR'
'pBR
MunI
MunI
30000
5000
MunI
Ad41sF
XbaI
XbaI
pSQ1Ad41sF
25000
32463 bps
SrfI
SpeI
10000
MunI
20000
PmeI
15000
hexon
SgfI

FIG. 21A


ClaI
BstBI
Bst1107I
loxP
ITR-r
pBR'
'pBR
30000
'fib
5000
pSQ1Ad41sF-RGD
25000
32493 bps
SrfI
10000
PmeI
20000
15000
hexon
SgfI

FIG. 21B


Adenoviral Copies per Cell
60
50
40
30
20
10
0
HBSS
Av3nBg
Ad5βgalΔF/5F
Ad5βgalΔF/41sF
Treatment Groups

FIG. 22


Av1nBgFKO1RGD
Av1nBg41sFRGD
Percent Transduction
(mean +/- sd)
120
100
80
60
40
20
0
0
2000
4000
6000
8000
10000
Particles Per Cell

FIG. 23


AE1-2a Cells
Av3nBgFKO1 @ 10 PPC
Percent Transduction
(mean ± sd)
70
60
50
40
30
20
10
0
Virus alone
HB 4µg/ml
HB 8µg/ml
PS 10µg/ml
K14 20µg/ml
αPen-TNF
Treatment

FIG. 24


lung
spleen
heart
kidney
(+)
KO1
PD1
S*
KO1PD1
KO1S*
S*PD1
KO1S*PD1
180
160
140
120
100
80
60
40
20
0
Percent Control

FIG. 25


β-Galactosidase activity
Adenoviral DNA
Percent Control
200
150
100
50
0
(-)
(+)
KO1
PD1
KO1PD1
S*
KO1S*
S*PD1
KO1S*PD1

FIG. 26




FIG. 27B




FIG. 27A

SEQUENCE LISTING

<110> The Scripps Research Institute
Novartis AG
Kaleko, Michael
Nemerow, Glen R.
Smith, Theodore
Stevenson, Susan C.

<120> Fiber Shaft Modifications for Efficient Targeting

<130> 22908-1236PC

<140> Not yet assigned
<141> Herewith

<150> 60/350,388
<151> 2002-01-24

<150> 60/391,967
<151> 2002-06-26

<160> 72

<170> PatentIn version 3.0

<210> 1
<211> 4
<212> PRT
<213> adenovirus serotype 5

<400> 1
Lys Lys Thr Lys
1

<210> 2
<211> 1746
<212> DNA
<213> adenovirus serotype 5

<400> 2
atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
accggtcctc caactgtgcc ttttcttact cctccctttg tatcccccaa tgggtttcaa 120
gagagtcccc ctggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
atgcttgcgc tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacat aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccccc 540
ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggacca caccagctcc agaggctaac tgtagactaa atgcagagaa agatgctaaa 1260

ctcactttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
tttgacgaaa atggagtgct actaaacaat tccttcctgg acccagaata ttggaacttt 1440
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 1500
ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
tacttaaacg gagacaaaac taaacctgta acactaacca ttacactaaa cggtacacag 1620
gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga ctggtctggc 1680
cacaactaca ttaatgaaat atttgccaca tcctcttaca ctttttcata cattgcccaa 1740
gaataa 1746

<210> 3
<211> 1746
<212> DNA
<213> adenovirus serotype 5

<400> 3
atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
accggtcctc caactgtgcc ttttcttact cctccctttg tatccccaa tgggtttcaa 120
gagagtcccc ctggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
atgcttgcgc tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacat aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccccc 540
ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggacca caccagctcc atctcctaac tgttcactaa atggaggcgg agatgctaaa 1260
ctcactttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
tttgacgaaa atggagtgct actaaacaat tccttcctgg acccagaata ttggaacttt 1440
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 1500
ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
tacttaaacg gagacaaaac taaacctgta acactaacca ttacactaaa cggtacacag 1620
gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga ctggtctggc 1680
cacaactaca ttaatgaaat atttgccaca tcctcttaca ctttttcata cattgcccaa 1740
gaataa 1746

<210> 4
<211> 1737
<212> DNA
<213> adenovirus serotype 5

<400> 4
atgcggcgcg cggcgatgta tgaggaaggt cctcctccct cctacgagag tgtggtgagc 60
gcggcgccag tggcggcggc gctgggttct cccttcgatg ctcccctgga cccgccgttt 120
gtgcctccgc ggtacctgcg gcctaccggg gggagaaaca gcatccgtta ctctgagttg 180
gcacccctat tcgacaccac ccgtgtgtac ctggtggaca acaagtcaac ggatgtggca 240
tccctgaact accagaacga ccacagcaac tttctgacca cggtcattca aaacaatgac 300
tacagcccgg gggaggcaag cacacagacc atcaatcttg acgaccggtc gcactggggc 360
ggcgacctga aaaccatcct gcataccaac atgccaaatg tgaacgagtt catgtttacc 420
aataagttta aggcgcgggt gatggtgtcg cgcttgccta ctaaggacaa tcaggtggag 480

ctgaaatacg agtgggtgga gttcacgctg cccgagggca actactccga gaccatgacc 540
atagacctta tgaacaacgc gatcgtggag cactacttga aagtgggcag acagaacggg 600
gttctggaaa gcgacatcgg ggtaaagttt gacacccgca acttcagact ggggtttgac 660
cccgtcactg gtcttgtcat gcctggggta tatacaaacg aagccttcca tccagacatc 720
attttgctgc caggatgcgg ggtggacttc acccacagcc gcctgagcaa cttgttgggc 780
atccgcaagc ggcaaccctt ccaggagggc tttaggatca cctacgatga tctggagggt 840
ggtaacattc ccgcactgtt ggatgtggac gcctaccagg cgagcttgaa agatgacacc 900
gaacagggcg ggggtggcgc aggcggcagc aacagcagtg gcagcggcgc ggaagagaac 960
tccaacgcgg cagccgcggc aatgcagccg gtggaggaca tgaacgatag ccgcggctac 1020
ccctacgacg tgcccgacta cgcgggcacc agcgccacac gggctgagga gaagcgcgct 1080
gaggccgaag cagcggccga agctgccgcc cccgctgcgc aacccgaggt cgagaagcct 1140
cagaagaaac cggtgatcaa acccctgaca gaggacagca agaaacgcag ttacaaccta 1200
ataagcaatg acagcacctt cacccagtac cgcagctggt accttgcata caactacggc 1260
gaccctcaga ccggaatccg ctcatggacc ctgctttgca ctcctgacgt aacctgcggc 1320
tcggagcagg tctactggtc gttgccagac atgatgcaag accccgtgac cttccgctcc 1380
acgcgccaga tcagcaactt tccggtggtg ggcgccgagc tgttgcccgt gcactccaag 1440
agcttctaca acgaccaggc cgtctactcc caactcatcc gccagtttac ctctctgacc 1500
cacgtgttca atcgctttcc cgagaaccag attttggcgc gcccgccagc ccccaccatc 1560
accaccgtca gtgaaaacgt tcctgctctc acagatcacg ggacgctacc gctgcgcaac 1620
agcatcggag gagtccagcg agtgaccatt actgacgcca gacgccgcac ctgcccctac 1680
gtttacaagg ccctgggcat agtctcgccg cgcgtcctat cgagccgcac tttttga 1737

<210> 5
<211> 20
<212> DNA
<213> adenovirus serotype 5

<400> 5
gaacaggagg tgagcttaga 20

<210> 6
<211> 43
<212> DNA
<213> adenovirus serotype 5

<400> 6
tccgcctcca tttagtgaac agttaggaga tggagctggt gtg 43

<210> 7
<211> 44
<212> DNA
<213> adenovirus serotype 5

<400> 7
tcactaaatg gaggcggaga tgctaaactc actttggtct taac 44

<210> 8
<211> 20
<212> DNA
<213> adenovirus serotype 5

<400> 8
gtggcaggtt gaatactagg 20

<210> 9
<211> 8
<212> PRT
<213> adenovirus serotype 5

<400> 9
His Ala Ile Arg Gly Asp Thr Phe

1 5

<210> 10
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> mofified sequence for penton protein

<400> 10
Ser Arg Gly Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Gly Thr Ser
1 5 10 15

<210> 11
<211> 57
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide for mutation generation

<400> 11
cgcggaagag aactccaacg cggcagccgc ggcaatgcag ccggtggagg acatgaa 57

<210> 12
<211> 59
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide for mutation generation

<400> 12
tatcgttcat gtcctccacc ggctgcattg ccgcggctgc cgcgttggag ttctcttcc 59

<210> 13
<211> 75
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide for mutation generation

<400> 13
cgatagccgc ggctacccct acgacgtgcc cgactacgcg ggcaccagcg ccacacgggc 60
tgaggagaag cgcgc 75

<210> 14
<211> 73
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide for mutation generation

<400> 14
tcagcgcgct tctcctcagc ccgtgtggcg ctggtgcccg cgtagtcggg cacgtcgtag 60
gggtagccgc ggc 73

<210> 15
<211> 40
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide for mutation generation

<400> 15
ggctccggct ccgagaggtg ggctcacagt ggttacattt 40

<210> 16
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide for mutation generation

<400> 16
ggagccggag cctcaaacat aaacctggaa at 32
<210> 17
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 17
ctctagaaat ggacggaatt attacag 27

<210> 18
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 18
tcttggtcat ctgcaacaac atgaagatag tg 32

<210> 19
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 19
gttgttgcag atgaccaaga gagtccggct ca 32

<210> 20
<211> 73
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 20
agcaattgaa aaataaacac gttgaaacat aacacaaacg attctttagt tgtcgtcttc 60
tgtaatgtaa gaa 73

<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 21

agcaattgaa aaataaacac gttg 24

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 22
gaacaggagg tgagcttaga 20

<210> 23
<211> 42
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 23
gttaggtgga gggtttattc cggtccacaa agttagctta tc 42

<210> 24
<211> 42
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 24
gataagctaa ctttgtggac cggaataaac cctccaccta ac 42

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 25
gtggcaggtt gaatactagg 20

<210> 26
<211> 41
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 26
gttaggagat ggagctggtg tagtccataa ggtgttaata c 41

<210> 27
<211> 41
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 27
gtattaacac cttatggact acaccagctc catctcctaa c 41

<210> 28
<211> 54
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 28
tgcgcaaaaa caatcaccac gacaatcaca atgtacattg gaagaaatca tacg 54

<210> 29
<211> 54
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 29
acattgtgat tgtcgtggtg attgtttttg cgcatatgcc atacaatttg aatg 54

<210> 30
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> RGD targeting peptide

<400> 30
His Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5 10

<210> 31
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 31
ttcttttcat ctgcaacaac atgaagatag tg 32

<210> 32
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 32
gttgttgcag atgaaaagaa ccagaattga ag 32

<210> 33
<211> 73
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 33
tgcaattgaa aaataaacac gttgaaacat aacacaaacg attctttatt cttcagttat 60
gtagcaaaat aca 73

<210> 34
<211> 56
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 34
agtacaaaaa caatcaccac gacaatcaca gtttatctcg ttgtagacga cactga 56

<210> 35
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 35
tgtgattgtc gtggtgattg tttttgtact agtgggtatg cttttacttt t 51

<210> 36
<211> 4
<212> PRT
<213> Adenovirus type 5

<400> 36
Thr Leu Trp Thr
1

<210> 37
<211> 7
<212> PRT
<213> SV40

<400> 37
Pro Lys Lys Lys Arg Lys Val
1 5

<210> 38
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 38
cttcgatgat gccgcagtg 19

<210> 39
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> amplification primer

<400> 39
gggctcaggt actccgagg 19

<210> 40
<211> 25
<212> DNA

<213> Artificial Sequence
<220>
<223> amplification primer

<400> 40
ttacatgcac atctcgggcc aggac 25

<210> 41
<211> 7607
<212> DNA
<213> Artificial Sequence

<220>
<223> Plasmid GRE5-E1-SV40-Hygro

<400> 41
tctagaagat ccgctgtaca ggatgttcta gctactttat tagatccgct gtacaggatg 60
ttctagctac tttattagat ccgctgtaca ggatgttcta gctactttat tagatccgct 120
gtacaggatg ttctagctac tttattagat ccgtgtacag gatgttctag ctactttatt 180
agatcgatct cctggccgtt cggggtcaaa aaccaggttt ggctataaaa gggggtgggg 240
gcgcgttcgt cctcactctc ttccgcatcg ctgtctgcga gggccaggat cgatcctgag 300
aacttcaggg tgagtttggg gacccttgat tgttctttct ttttcgctat tgtaaaattc 360
atgttatatg gaggggggcaa agttttcagg gtgttgttta gaatgggaag atgtcccttg 420
tatcaccatg gaccctcatg ataatttttgt ttctttcact ttctactctg ttgacaacca 480
ttgtctcctc ttatttttctt ttcattttct gtaacttttt cgttaaactt tagcttgcat 540
ttgtaacgaa tttttaaatt cacttttgtt tatttgtcag attgtaagta ctttctctaa 600
tcactttttt ttcaaggcaa tcagggtata ttatattgta cttcagcaca gttttagaga 660
acaattgtta taattaaatg ataaggtaga atatttctgc atataaattc tggctggcgt 720
ggaaatattc ttattggtag aaacaactac atcctggtca tcatcctgcc tttctcttta 780
tggttacaat gatatacact gtttgagatg aggataaaat actctgagtc caaaccgggc 840
ccctctgcta accatgttca tgccttcttc tttttcctac agctcctggg caacgtgctg 900
gttattgtgc tgtctcatca ttttggcaaa gaattagatc taagcttctg cagctcgagg 960
actcggtcga ctgaaaatga gacatattat ctgccacgga ggtgttatta ccgaagaaat 1020
ggccgccagt cttttggacc agctgatcga agaggtactg gctgataatc ttccacctcc 1080
tagccatttt gaaccaccta cccttcacga actgtatgat ttagacgtga cggcccccga 1140
agatcccaac gaggaggcgg tttcgcagat ttttcccgac tctgtaatgt tggcggtgca 1200
ggaagggatt gacttactca cttttccgcc ggcgcccggt tctccggagc cgcctcacct 1260
ttcccggcag cccgagcagc cggagcagag agccttgggt ccggtttcta tgccaaacct 1320
tgtaccggag gtgatcgatc ttacctgcca cgaggctggc tttccaccca gtgacgacga 1380
ggatgaagag ggtgaggagt ttgtgttaga ttatgtggag caccccgggc acggttgcag 1440
gtcttgtcat tatcaccgga ggaatacggg ggacccagat attatgtgtt cgctttgcta 1500
tatgaggacc tgtggcatgt ttgtctacag taagtgaaaa ttatgggcag tgggtgatag 1560
agtggtgggt ttggtgtggt aatttttttt ttaatttttta cagttttgtg gtttaaagaa 1620
ttttgtattg tgatttttttt aaaaggtcct gtgtctgaac ctgagcctga gcccgagcca 1680
gaaccggagc ctgcaagacc tacccgccgt cctaaaatgg cgcctgctat cctgagacgc 1740
ccgacatcac ctgtgtctag agaatgcaat agtagtacgg atagctgtga ctccggtcct 1800
tctaacacac ctcctgagat acacccggtg gtcccgctgt gccccattaa accagttgcc 1860
gtgagagttg gtgggcgtcg ccaggctgtg gaatgtatcg aggacttgct taacgagcct 1920
gggcaacctt tggacttgag ctgtaaacgc cccaggccat aaggtgtaaa cctgtgattg 1980
cgtgtgtggt taacgccttt gtttgctgaa tgagttgatg taagtttaat aaagggtgag 2040
ataatgttta acttgcatgg cgtgttaaat ggggcggggc ttaaagggta tataatgcgc 2100
cgtgggctaa tcttggttac atctgacctc atggaggctt gggagtgttt ggaagatttt 2160
tctgctgtgc gtaacttgct ggaacagagc tctaacagta cctcttggtt ttggaggttt 2220
ctgtggggct catcccaggc aaagttagtc tgcagaatta aggaggatta caagtgggaa 2280
tttgaagagc ttttgaaatc ctgtggtgag ctgtttgatt ctttgaatct gggtcaccag 2340
gcgcttttcc aagagaaggt catcaagact ttggattttt ccacaccggg gcgcgctgcg 2400
gctgctgttg ctttttgag ttttataaag gataaatgga gcgaagaaac ccatctgagc 2460
gggggggtacc tgctggattt tctggccatg catctgtgga gagcggttgt gagacacaag 2520
aatcgcctgc tactgttgtc ttccgtccgc ccggcgataa taccgacgga ggagcagcag 2580
cagcagcagg aggaagccag gcggcggcgg caggagcaga gcccatggaa cccgagagcc 2640
ggcctggacc ctcgggaatg aatgttgtac aggtggctga actgtatcca gaactgagac 2700

gcattttgac aattacagag gatgggcagg ggctaaaggg ggtaaagagg gagcgggggg 2760
cttgtgaggc tacagaggag gctaggaatc tagcttttag cttaatgacc agacaccgtc 2820
ctgagtgtat tacttttcaa cagatcaagg ataattgcgc taatgagctt gatctgctgg 2880
cgcagaagta ttccatagag cagctgacca cttactggct gcagccaggg gatgattttg 2940
aggaggctat tagggtatat gcaaaggtgg cacttaggcc agattgcaag tacaagatca 3000
gcaaacttgt aaatatcagg aattgttgct acatttctgg gaacggggcc gaggtggaga 3060
tagatacgga ggatagggtg gcctttagat gtagcatgat aaatatgtgg ccgggggtgc 3120
ttggcatgga cggggtggtt attatgaatg taaggtttac tggccccaat tttagcggta 3180
cggttttcct ggccaatacc aaccttatcc tacacggtgt aagcttctat gggtttaaca 3240
atacctgtgt ggaagcctgg accgatgtaa gggttcgggg ctgtgccttt tactgctgct 3300
ggaagggggt ggtgtgtcgc cccaaaagca gggcttcaat taagaaatgc ctctttgaaa 3360
ggtgtacctt gggtatcctg tctgagggta actccagggt gcgccacaat gtggcctccg 3420
actgtggttg cttcatgcta gtgaaaagcg tggctgtgat taagcataac atggtatgtg 3480
gcaactgcga ggacagggcc tctcagatgc tgacctgctc ggacggcaac tgtcacctgc 3540
tgaagaccat tcacgtagcc agccactctc gcaaggcctg gccagtgttt gagcataaca 3600
tactgacccg ctgttccttg catttgggta acaggagggg ggtgttccta ccttaccaat 3660
gcaatttgag tcacactaag atattgcttg agcccgagag catgtccaag gtgaacctga 3720
acggggtgtt tgacatgacc atgaagatct ggaaggtgct gaggtacgat gagacccgca 3780
ccaggtgcag accctgcgag tgtggcggta aacatattag gaaccagcct gtgatgctgg 3840
atgtgaccga ggagctgagg cccgatcact tggtgctggc ctgcacccgc gctgagtttg 3900
gctctagcga tgaagataca gattgaggta ctgaaatgtg tgggcgtggc ttaagggtgg 3960
gaaagaatat ataaggtggg ggtcttatgt agttttgtat ctgttttgca gcagccgccg 4020
ccgccatgag caccaactcg tttgatggaa gcattgtgag ctcatatttg acaacgcgca 4080
tgccccatg ggccggggtg cgtcagaatg tgatgggctc cagcattgat ggtcgccccg 4140
tcctgcccgc aaactctact accttgacct acgagaccgt gtctggaacg ccgttggaga 4200
ctgcagcctc cgccgccgct tcagccgctg cagccaccgc ccgcgggatt gtgactgact 4260
ttgctttcct gagcccgctt gcaagcagtg cagcttcccg ttcatccgcc cgcgatgaca 4320
agttgacggc tcttttggca caattggatt ctttgacccg ggaacttaat gtcgtttctc 4380
agcagctgtt ggatctgcgc cagcaggttt ctgccctgaa ggcttcctcc cctcccaatg 4440
cggtttaaaa cataaataaa aaaccagact ctgtttggat ttggatcaag caagtgtctt 4500
gctgtctcag ctgactgctt aagtcgcaag ccgaattgga tccaattcgg atcgatctta 4560
ttaaagcaga acttgtttat tgcagcttat aatggttaca aataaagcaa tagcatcaca 4620
aatttcacaa ataaagcatt tttttcactg cattctagtt gtggtttgtc caaactcatc 4680
aatgtatctt atcatgtctg gtcgactcta gactcttccg cttcctcgct cactgactcg 4740
ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg 4800
ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag 4860
gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg cccccctgac 4920
gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga 4980
taccaggcgt ttcccccctgg aagctccctc gtgcgctctc ctgttccgac cctgccgctt 5040
accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca tagctcacgc 5100
tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc 5160
cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caacccggta 5220
agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag agcgaggtat 5280
gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac tagaaggaca 5340
gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct 5400
tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt 5460
acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct 5520
cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa aaggatcttc 5580
acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa 5640
acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc gatctgtcta 5700
tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat acgggagggc 5760
ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cacgctcacc ggctccagat 5820
ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtggtcc tgcaacttta 5880
tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag ttcgccagtt 5940
aatagtttgc gcaacgttgt tgccattgct acaggcatcg tggtgtcacg ctcgtcgttt 6000
ggtatggctt cattcagctc cggttcccaa cgatcaaggc gagttacatg atcccccatg 6060
ttgtgcaaaa aagcggttag ctccttcggt cctccgatcg ttgtcagaag taagttggcc 6120
gcagtgttat cactcatggt tatggcagca ctgcataatt ctcttactgt catgccatcc 6180
gtaagatgct tttctgtgac tggtgagtac tcaaccaagt cattctgaga atagtgtatg 6240
cggcgaccga gttgctcttg cccggcgtca atacgggata ataccgcgcc acatagcaga 6300
actttaaaag tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta 6360

ccgctgttga gatccagttc gatgtaaccc actcgtgcac ccaactgatc ttcagcatct 6420
tttactttca ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag 6480
ggaataaggg cgacacggaa atgttgaata ctcatactct tccttttca atattattga 6540
agcatttatc agggttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat 6600
aaacaaatag gggttccgcg cacatttccc cgaaaagtgc cacctgacgt ctaagaaacc 6660
attattatca tgacattaac ctataaaaat aggcgtatca cgaggcccct ttcgtctcgc 6720
gcgtttcggt gatgacggtg aaaacctctg acacatgcag ctcccggaga cggtcacagc 6780
ttgtctgtaa gcggatgccg ggagcagaca agcccgtcag ggcgcgtcag cgggtgttgg 6840
cgggtgtcgg ggctggctta actatgcggc atcagagcag attgtactga gagtgcacca 6900
tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca ggaaattgta 6960
agcgttaata ttttgttaaa attcgcgtta aatttttgtt aaatcagctc atttttaac 7020
caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga gatagggttg 7080
agtgttgttc cagtttggaa caagagtcca ctattaaaga acgtggactc caacgtcaaa 7140
gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc ctaatcaagt 7200
tttttggggt cgaggtgccg taaagcacta aatcggaacc ctaaagggag cccccgattt 7260
agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa agcgaaagga 7320
gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacacccgcc 7380
gcgcttaatg cgccgctaca gggcgcgtcc cattcgccat tcaggctgcg caactgttgg 7440
gaagggcgat cggtgcgggc ctcttcgcta ttacgccagc tggcgaaagg gggatgtgct 7500
gcaaggcgat taagttgggt aacgccaggg ttttcccagt cacgacgttg taaaacgacg 7560
gccagtgaat tgtaatacga ctcactatag ggcgaattaa ttcgggg 7607

<210> 42
<211> 11600
<212> DNA
<213> Artificial Sequence

<220>
<223> Plasmid MMTV-E2a-SV40-Neo

<400> 42
gaattccgca ttgcagagat attgtattta agtgcctagc tcgatacaat aaacgccatt 60
tgaccattca ccacattggt gtgcacctcc aagcttgggc agaaatggtt gaactcccga 120
gagtgtccta cacctagggg agaagcagcc aaggggttgt ttcccaccaa ggacgacccg 180
tctgcgcaca aacggatgag cccatcagac aaagacatat tcattctctg ctgcaaactt 240
ggcatagctc tgctttgcct ggggctattg ggggaagttg cggttcgtgc tcgcagggct 300
ctcacccttg actcttttaa tagctcttct gtgcaagatt acaatctaaa caattcggag 360
aactcgacct tcctcctgag gcaaggacca cagccaactt cctcttacaa gccgcatcga 420
ttttgtcctt cagaaataga aataagaatg cttgctaaaa attatatttt taccaataag 480
accaatccaa taggtagatt attagttact atgttaagaa atgaatcatt atcttttagt 540
actattttta ctcaaattca gaagttagaa atgggaatag aaaatagaaa gagacgctca 600
acctcaattg aagaacaggt gcaaggacta ttgaccacag gcctagaagt aaaaaaggga 660
aaaaagagtg tttttgtcaa aataggagac aggtggtggc aaccagggac ttatagggga 720
ccttacatct acagaccaac agatgccccc ttaccatata caggaagata tgacttaaat 780
tgggataggt gggttacagt caatggctat aaagtgttat atagatccct ccctttcgt 840
gaaagactcg ccagagctag acctccttgg tgtatgttgt ctcaagaaga aaaagacgac 900
atgaaacaac aggtacatga ttatatttat ctaggaacag gaatgcactt ttggggaaag 960
attttccata ccaaggaggg gacagtggct ggactaatag aacattattc tgcaaaaact 1020
catggcatga gttattatga atagccttta ttggcccaac cttgcggttc ccagggctta 1080
agtaagtttt tggttacaaa ctgttcttaa aacgaggatg tgagacaagt ggtttcctga 1140
cttggtttgg tatcaaaggt tctgatctga gctctgagtg ttctattttc ctatgttctt 1200
ttggaattta tccaaatctt atgtaaatgc ttatgtaaac caagatataa aagagtgctg 1260
atttttgag taaacttgca acagtcctaa cattcacctc ttgtgtgttt gtgtctgttc 1320
gccatcccgt ctccgctcgt cacttatcct tcactttcca gagggtcccc ccgcagaccc 1380
cggcgaccct caggtcggcc gactgcggca gctggcgccc gaacagggac cctcggataa 1440
gtgacccttg tctctatttc tactatttgg tgtttgtctt gtattgtctc tttcttgtct 1500
ggctatcatc acaagagcgg aacggactca ccatagggac caagctagcg cttctcgtcg 1560
cgtccaagac cctcaaagat ttttggcact tcgttgagcg aggcgatatc aggtatgaca 1620
gcgccctgcc gcaaggccag ctgcttgtcc gctcggctgc ggttggcacg gcaggatagg 1680
ggtatcttgc agttttggaa aaagatgtga taggtggcaa gcacctctgg cacggcaaat 1740
acggggtaga agttgaggcg cgggttgggc tcgcatgtgc cgttttcttg gcgtttgggg 1800

ggtacgcgcg gtgagaatag gtggcgttcg taggcaaggc tgacatccgc tatggcgagg 1860
ggcacatcgc tgcgctcttg caacgcgtcg cagataatgg cgcactggcg ctgcagatgc 1920
ttcaacagca cgtcgtctcc cacatctagg tagtcgccat gcctttcgtc cccccgcccg 1980
acttgttcct cgtttgcctc tgcgttgtcc tggtcttgct ttttatcctc tgttggtact 2040
gagcggtcct cgtcgtcttc gcttacaaaa cctgggtcct gctcgataat cacttcctcc 2100
tcctcaagcg ggggtgcctc gacggggaag gtggtaggcg cgttggcggc atcggtggag 2160
gcggtggtgg cgaactcaga gggggcggtt aggctgtcct tcttctcgac tgactccatg 2220
atctttttct gcctatagga gaaggaaatg gccagtcggg aagaggagca gcgcgaaacc 2280
acccccgagc gcggacgcgg tgcggcgcga cgtcccccaa ccatggagga cgtgtcgtcc 2340
ccgtccccgt cgccgccgcc tccccgggcg cccccaaaaa agcggatgag gcggcgtatc 2400
gagtccgagg acgaggaaga ctcatcacaa gacgcgctgg tgccgcgcac acccagcccg 2460
cggccatcga cctcggcggc ggatttggcc attgcgccca agaagaaaaa gaagcgccct 2520
tctcccaagc ccgagcgccc gccatcacca gaggtaatcg tggacagcga ggaagaaaga 2580
gaagatgtgg cgctacaaat ggtgggtttc agcaacccac cggtgctaat caagcatggc 2640
aaaggaggta agcgcacagt gcggcggctg aatgaagacg acccagtggc gcgtggtatg 2700
cggacgcaag aggaagagga agagcccagc gaagcggaaa gtgaaattac ggtgatgaac 2760
ccgctgagtg tgccgatcgt gtctgcgtgg gagaagggca tggaggctgc gcgcgcgctg 2820
atggacaagt accacgtgga taacgatcta aaggcgaact tcaaactact gcctgaccaa 2880
gtggaagctc tggcggccgt atgcaagacc tggctgaacg aggagcaccg cgggttgcag 2940
ctgaccttca ccagcaacaa gacctttgtg acgatgatgg ggcgattcct gcaggcgtac 3000
ctgcagtcgt ttgcagaggt gacctacaag catcacgagc ccacgggctg cgcgttgtgg 3060
ctgcaccgct gcgctgagat cgaaggcgag cttaagtgtc tacacggaag cattatgata 3120
aataaggagc acgtgattga aatggatgtg acgagcgaaa acgggcagcg cgcgctgaag 3180
gagcagtcta gcaaggccaa gatcgtgaag aaccggtggg gccgaaatgt ggtgcagatc 3240
tccaacaccg acgcaaggtg ctgcgtgcac gacgcggcct gtccggccaa tcagttttcc 3300
ggcaagtctt gcggcatgtt cttctctgaa ggcgcaaagg ctcaggtggc ttttaagcag 3360
atcaaggctt ttatgcaggc gctgtatcct aacgcccaga ccgggcacgg tcacctttg 3420
atgccactac ggtgcgagtg caactcaaag cctgggcacg cgccctttt gggaaggcag 3480
ctaccaaagt tgactccgtt cgccctgagc aacgcggagg acctggacgc ggatctgatc 3540
tccgacaaga gcgtgctggc cagcgtgcac cacccggcgc tgatagtgtt ccagtgctgc 3600
aaccctgtgt atcgcaactc gcgcgcgcag ggcggaggcc ccaactgcga cttcaagata 3660
tcggcgcccg acctgctaaa cgcgttggtg atggtgcgca gcctgtggag tgaaaacttc 3720
accgagctgc cgcggatggt tgtgcctgag tttaagtgga gcactaaaca ccagtatcgc 3780
aacgtgtccc tgccagtggc gcatagcgat gcgcggcaga acccctttga tttttaaacg 3840
gcgcagacgg caagggtggg ggtaaataat cacccgagag tgtacaaata aaagcatttg 3900
cctttattga aagtgtctct agtacattat ttttacatgt ttttcaagtg acaaaaagaa 3960
gtggcgctcc taatctgcgc actgtggctg cggaagtagg gcgagtggcg ctccaggaag 4020
ctgtagagct gttcctggtt gcgacgcagg gtgggctgta cctggggact gttgagcatg 4080
gagttgggta ccccggtaat aaggttcatg gtggggttgt gatccatggg agtttggggc 4140
cagttggcaa aggcgtggag aaacatgcag cagaatagtc cacaggcggc cgagttgggc 4200
ccctgtacgc tttgggtgga cttttccagc gttatacagc ggtcgggggа agaagcaatg 4260
gcgctacggc gcaggagtga ctcgtactca aactggtaaa cctgcttgag tcgctggtca 4320
gaaaagccaa agggctcaaa gaggtagcat gtttttgagt gcgggttcca ggcaaaggcc 4380
atccagtgta cgcccccagt ctcgcgaccg gccgtattga ctatggcgca ggcgagcttg 4440
tgtggagaaa caaagcctgg aaagcgcttg tcataggtgc ccaaaaaata tggcccacaa 4500
ccaagatctt tgacaatggc tttcagttcc tgctcactgg agcccatggc ggcagctgtt 4560
gttgatgttg cttgcttctt tatgttgtgg cgttgccggc cgagaagggc gtgcgcaggt 4620
acacggtttc gatgacgccg cggtgcggcc ggtgcacacg gaccacgtca aagacttcaa 4680
acaaaacata aagaagggtg ggctcgtcca tgggatccat atatagggcc cgggttataa 4740
ttacctcagg tcgacctcga gggatctttg tgaaggaacc ttacttctgt ggtgtgacat 4800
aattggacaa actacctaca gagatttaaa gctctaaggt aaatataaaa tttttaagtg 4860
tataatgtgt taaactactg attctaattg tttgtgtatt ttagattcca acctatggaa 4920
ctgatgaatg ggagcagtgg tggaatgcct ttaatgagga aaacctgttt tgctcagaag 4980
aaatgccatc tagtgatgat gaggctactg ctgactctca acattctact cctccaaaaa 5040
agaagagaaa ggtagaagac cccaaggact ttccttcaga attgctaagt tttttgagtc 5100
atgctgtgtt tagtaataga actcttgctt gctttgctat ttacaccaca aaggaaaaag 5160
ctgcactgct atacaagaaa attatggaaa aatattctgt aaccttttata agtaggcata 5220
acagttataa tcataacata ctgtttttttc ttactccaca caggcataga gtgtctgcta 5280
ttaataacta tgctcaaaaa ttgtgtacct ttagcttttt aatttgtaaa ggggttaata 5340
aggaatattt gatgtatagt gccttgacta gagatcataa tcagccatac cacatttgta 5400
gaggttttac ttgctttaaa aaacctccca cacctccccc tgaacctgaa acataaaatg 5460

aatgcaattg ttgttgttaa cttgtttatt gcagcttata atggttacaa ataaagcaat 5520
agcatcacaa atttcacaaa taaagcattt ttttcactgc attctagttg tggtttgtcc 5580
aaactcatca atgtatctta tcatgtctgg atccggctgt ggaatgtgtg tcagttaggg 5640
tgtggaaagt ccccaggctc cccagcaggc agaagtatgc aaagcatgca tctcaattag 5700
tcagcaacca ggtgtggaaa gtccccaggc tccccagcag gcagaagtat gcaaagcatg 5760
catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc gcccctaact 5820
ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat ttatgcagag 5880
gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt ttttggaggc 5940
ctaggctttt gcaaaaagct tcacgctgcc gcaagcactc agggcgcaag ggctgctaaa 6000
ggaagcggaa cacgtagaaa gccagtccgc agaaacggtg ctgaccccgg atgaatgtca 6060
gctactgggc tatctggaca agggaaaacg caagcgcaaa gagaaagcag gtagcttgca 6120
gtgggcttac atggcgatag ctagactggg cggttttatg gacagcaagc gaaccggaat 6180
tgccagctgg ggcgccctct ggtaaggttg ggaagccctg caaagtaaac tggatggctt 6240
tcttgccgcc aaggatctga tggcgcaggg gatcaagatc tgatcaagag acaggatgag 6300
gatcgtttcg catgattgaa caagatggat tgcacgcagg ttctccggcc gcttgggtgg 6360
agaggctatt cggctatgac tgggcacaac agacaatcgg ctgctctgat gccgccgtgt 6420
tccggctgtc agcgcagggg cgcccggttc tttttgtcaa gaccgacctg tccggtgccc 6480
tgaatgaact gcaggacgag gcagcgcggc tatcgtggct ggccacgacg ggcgttcctt 6540
gcgcagctgt gctcgacgtt gtcactgaag cgggaaggga ctggctgcta ttgggcgaag 6600
tgccggggca ggatctcctg tcatctcacc ttgctcctgc cgagaaagta tccatcatgg 6660
ctgatgcaat gcggcggctg catacgcttg atccggctac ctgcccattc gaccaccaag 6720
cgaaacatcg catcgagcga gcacgtactc ggatggaagc cggtcttgtc gatcaggatg 6780
atctggacga agagcatcag gggctcgcgc cagccgaact gttcgccagg ctcaaggcgc 6840
gcatgcccga cggcgaggat ctcgtcgtga cccatggcga tgcctgcttg ccgaatatca 6900
tggtggaaaa tggccgcttt tctggattca tcgactgtgg ccggctgggt gtggcggacc 6960
gctatcagga catagcgttg gctacccgtg atattgctga agagcttggc ggcgaatggg 7020
ctgaccgctt cctcgtgctt tacggtatcg ccgctcccga ttcgcagcgc atcgccttct 7080
atcgccttct tgacgagttc ttctgagcgg gactctgggg ttcgaaatga ccgaccaagc 7140
gacgcccaac ctgccatcac gagatttcga ttccaccgcc gccttctatg aaaggttggg 7200
cttcggaatc gttttccggg acgccggctg gatgatcctc cagcgcgggg atctcatgct 7260
ggagttcttc gcccaccccg ggctcgatcc cctcgcgagt tggttcagct gctgcctgag 7320
gctggacgac ctcgcggagt tctaccggca gtgcaaatcc gtcggcatcc aggaaaccag 7380
cagcggctat ccgcgcatcc atgccccga actgcaggag tggggaggca cgatggccgc 7440
tttggtcccg gatctttgtg aaggaacctt acttctgtgg tgtgacataa ttggacaaac 7500
tacctacaga gatttaaagc tctaaggtaa atataaaatt tttaagtgta taatgtgtta 7560
aactactgat tctaattgtt tgtgtatttt agattccaac ctatggaact gatgaatggg 7620
agcagtggtg gaatgccttt aatgaggaaa acctgttttg ctcagaagaa atgccatcta 7680
gtgatgatga ggctactgct gactctcaac attctactcc tccaaaaaag aagagaaagg 7740
tagaagaccc caaggacttt ccttcagaat tgctaagttt tttgagtcat gctgtgttta 7800
gtaatagaac tcttgcttgc tttgctattt acaccacaaa ggaaaaagct gcactgctat 7860
acaagaaaat tatggaaaaa tattctgtaa cctttataag taggcataac agttataatc 7920
ataacatact gtttttttct actccacaca ggcatagagt gtctgctatt aataactatg 7980
ctcaaaaatt gtgtaccttt agctttttaa tttgtaaagg ggttaataag gaatatttga 8040
tgtatagtgc cttgactaga gatcataatc agccatacca catttgtaga ggttttactt 8100
gctttaaaaa acctcccaca cctccccctg aacctgaaac ataaaatgaa tgcaattgtt 8160
gttgttaact tgtttattgc agcttataat ggttacaaat aaagcaatag catcacaaat 8220
ttcacaaata aagcattttt ttcactgcat tctagttgtg gtttgtccaa actcatcaat 8280
gtatcttatc atgtctggat ccccaggaag ctcctctgtg tcctcataaa ccctaacctc 8340
ctctacttga gaggacattc caatcatagg ctgcccatcc accctctgtg tcctcctgtt 8400
aattaggtca cttaacaaaa aggaaattgg gtaggggttt ttcacagacc gctttctaag 8460
ggtaatttta aaatatctgg gaagtccctt ccactgctgt gttccagaag tgttggtaaa 8520
cagcccacaa atgtcaacag cagaaacata caagctgtca gctttgcaca agggcccaac 8580
accctgctca tcaagaagca ctgtggttgc tgtgttagta atgtgcaaaa caggaggcac 8640
attttcccca cctgtgtagg ttccaaaata tctagtgttt tcatttttac ttggatcagg 8700
aacccagcac tccactggat aagcattatc cttatccaaa acagccttgt ggtcagtgtt 8760
catctgctga ctgtcaactg tagcattttt tggggttaca gtttgagcag gatatttggt 8820
cctgtagttt gctaacacac cctgcagctc caaaggttcc ccaccaacag caaaaaaatg 8880
aaaatttgac ccttgaatgg gttttccagc accattttca tgagtttttt gtgtccctga 8940
atgcaagttt aacatagcag ttaccccaat aacctcagtt ttaacagtaa cagcttccca 9000
catcaaaata tttccacagg ttaagtcctc atttaaatta ggcaaaggaa ttcttgaaga 9060
cgaaagggcc tcgtgatacg cctattttta taggttaatg tcatgataat aatggtttct 9120

tagacgtcag gtggcacttt tcggggaaat gtgcgcggaa cccctatttg tttatttttc 9180
taaatacatt caaatatgta tccgctcatg agacaataac cctgataaat gcttcaataa 9240
tattgaaaaa ggaagagtat gagtattcaa catttccgtg tcgcccttat tccctttttt 9300
gcggcatttt gccttcctgt ttttgctcac ccagaaacgc tggtgaaagt aaaagatgct 9360
gaagatcagt tgggtgcacg agtgggttac atcgaactgg atctcaacag cggtaagatc 9420
cttgagagtt ttcgccccga agaacgtttt ccaatgatga gcacttttaa agttctgcta 9480
tgtggcgcgg tattatcccg tgttgacgcc gggcaagagc aactcggtcg ccgcatacac 9540
tattctcaga atgacttggt tgagtactca ccagtcacag aaaagcatct tacggatggc 9600
atgacagtaa gagaattatg cagtgctgcc ataaccatga gtgataacac tgcggccaac 9660
ttacttctga caacgatcgg aggaccgaag gagctaaccg ctttttttgca caacatgggg 9720
gatcatgtaa ctcgccttga tcgttgggaa ccggagctga atgaagccat accaaacgac 9780
gagcgtgaca ccacgatgcc tgcagcaatg gcaacaacgt tgcgcaaact attaactggc 9840
gaactactta ctctagcttc ccggcaacaa ttaatagact ggatggaggc ggataaagtt 9900
gcaggaccac ttctgcgctc ggcccttccg gctggctggt ttattgctga taaatctgga 9960
gccggtgagc gtgggtctcg cggtatcatt gcagcactgg ggccagatgg taagccctcc 10020
cgtatcgtag ttatctacac gacggggagt caggcaacta tggatgaacg aaatagacag 10080
atcgctgaga taggtgcctc actgattaag cattggtaac tgtcagacca agtttactca 10140
tatatacttt agattgattt aaaacttcat ttttaattta aaaggatcta ggtgaagatc 10200
ctttttgata atctcatgac caaaatccct taacgtgagt tttcgttcca ctgagcgtca 10260
gaccccgtag aaaagatcaa aggatcttct tgagatcctt ttttttctgcg cgtaatctgc 10320
tgcttgcaaa caaaaaaacc accgctacca gcggtggttt gtttgccgga tcaagagcta 10380
ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa tactgtcctt 10440
ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc tacatacctc 10500
gctctgctaa tcctgttacc agtggctgct gccagtggcg ataagtcgtg tcttaccggg 10560
ttggactcaa gacgatagtt accggataag gcgcagcggt cgggctgaac gggggttcg 10620
tgcacacagc ccagcttgga gcgaacgacc tacaccgaac tgagatacct acagcgtgag 10680
ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc ggtaagcggc 10740
agggtcggaa caggagagcg cacgagggag cttccagggg gaaacgcctg gtatctttat 10800
agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg ctcgtcaggg 10860
gggcggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttcct ggccttttgc 10920
tggccttttg ctcacatgtt ctttcctgcg ttatcccctg attctgtgga taaccgtatt 10980
accgcctttg agtgagctga taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca 11040
gtgagcgagg aagcggaaga gcgcctgatg cggtattttc tccttacgca tctgtgcggt 11100
atttcacacc gcatatggtg cactctcagt acaatctgct ctgatgccgc atagttaagc 11160
cagtatctgc tccctgcttg tgtgttggag gtcgctgagt agtgcgcgag caaaatttaa 11220
gctacaacaa ggcaaggctt gaccgacaat tgcatgaaga atctgcttag ggttaggcgt 11280
tttgcgctgc ttcgcgatgt acgggccaga tatacgcgta tctgagggga ctagggtgtg 11340
tttaggcgaa aagcggggct tcggttgtac gcggttagga gtcccctcag gatatagtag 11400
tttcgctttt gcatagggag ggggaaatgt agtcttatgc aatacacttg tagtcttgca 11460
acatggtaac gatgagttag caacatgcct tacaaggaga gaaaaagcac cgtgcatgcc 11520
gattggtgga agtaaggtgg tacgatcgtg ccttattagg aaggcaacag acgggtctga 11580
catggattgg acgaaccact 11600

<210> 43
<211> 35211
<212> DNA
<213> Artificial Sequence

<220>
<223> Plasmid Av1nBg

<400> 43
catcatcaat aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt 60
ttgtgacgtg gcgcggggcg tgggaacggg gcgggtgacg tagtagtgtg gcggaagtgt 120
gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg 180
gtgtgcgccg gtgtacacag gaagtgacaa ttttcgcgcg gttttaggcg gatgttgtag 240
taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300
agtgaaatct gaataatttt gtgttactca tagcgcgtaa tatttgtcta gggccgcggg 360
gactttgacc gtttacgtgg agactcgccc aggtgttttt ctcaggtgtt ttccgcgttc 420
cgggtcaaag ttggcgtttt attattatag tcagtacgta ccagtgcact ggcctaggaa 480
gcttggtacc ggtgaattcg ctagcgttcg cgccccgatg tacgggccag atatacgcgt 540

atctgagggg actagggtgt gtttaggcga aaagcggggc ttcggttgta cgcggttagg 600
agtcccctca ggatatagta gtttcgcttt tgcataggga gggggaaatg tagtcttatg 660
caatactctt gtagtcttgc aacatggtaa cgatgagtta gcaacatgcc ttacaaggag 720
agaaaaagca ccgtgcatgc cgattggtgg aagtaaggtg gtacgatcgt gccttattag 780
gaaggcaaca gacgggtctg acatggattg gacgaaccac tgaattccgc attgcagaga 840
tattgtattt aagtgcctag ctcgatacaa taaacgccat ttgaccattc accacattgg 900
tgtgcacctc cggccctggc cactctcttc cgcatcgctg tctgcggggg ccagctgttg 960
ggctcgcggt tgaggacaaa ctcttcgcgg tctttccagt actcttggat cggaaacccg 1020
tcggcctccg aacggtactc cgccgccgag ggacctgagc gagtccgcat cgaccggatc 1080
ggaaaacctc tcgagaaagg cgtgtaacca gtcacagtcg ctctagaact agtggatccc 1140
ccgggctgca ggaattcgat ctagatggat aaaggtccaa aaaagaagag aaaggtagaa 1200
gaccccaagg actttccttc agaattgcta agtttttga gtgattcact ggccgtcgtt 1260
ttacaacgtc gtgactggga aaaccctggc gttacccaac ttaatcgcct tgcagcacat 1320
ccccctttcg ccagctggcg taatagcgaa gaggcccgca ccgatcgccc ttcccaacag 1380
ttgcgcagcc tgaatggcga atggcgcttt gcctggtttc cggcaccaga agcggtgccg 1440
gaaagctggc tggagtgcga tcttcctgag gccgatactg tcgtcgtccc ctcaaactgg 1500
cagatgcacg gttacgatgc gcccatctac accaacgtaa cctatcccat tacggtcaat 1560
ccgccgtttg ttcccacgga gaatccgacg ggttgttact cgctcacatt taatgttgat 1620
gaaagctggc tacaggaagg ccagacgcga attatttttg atggcgttaa ctcggcgttt 1680
catctgtggt gcaacgggcg ctgggtcggt tacggccagg acagtcgttt gccgtctgaa 1740
tttgacctga gcgcattttt acgcgccgga gaaaaccgcc tcgcggtgat ggtgctgcgt 1800
tggagtgacg gcagttatct ggaagatcag gatatgtggc ggatgagcgg cattttccgt 1860
gacgtctcgt tgctgcataa accgactaca caaatcagcg atttccatgt tgccactcgc 1920
tttaatgatg atttcagccg cgctgtactg gaggctgaag ttcagatgtg cggcgagttg 1980
cgtgactacc tacgggtaac agtttcttta tggcagggtg aaacgcaggt cgccagcggc 2040
accgcgcctt tcggcggtga aattatcgat gagcgtggtg gttatgccga tcgcgtcaca 2100
ctacgtctga acgtcgaaaa cccgaaactg tggagcgccg aaatcccgaa tctctatcgt 2160
gcggtggttg aactgcacac cgccgacggc acgctgattg aagcagaagc ctgcgatgtc 2220
ggtttccgcg aggtgcggat tgaaaatggt ctgctgctgc tgaacggcaa gccgttgctg 2280
attcgaggcg ttaaccgtca cgagcatcat cctctgcatg gtcaggtcat ggatgagcag 2340
acgatggtgc aggatatcct gctgatgaag cagaacaact ttaacgccgt gcgctgttcg 2400
cattatccga accatccgct gtggtacacg ctgtgcgacc gctacggcct gtatgtggtg 2460
gatgaagcca atattgaaac ccacggcatg gtgccaatga atcgtctgac cgatgatccg 2520
cgctggctac cggcgatgag cgaacgcgta acgcgaatgg tgcagcgcga tcgtaatcac 2580
ccgagtgtga tcatctggtc gctggggaat gaatcaggcc acggcgctaa tcacgacgcg 2640
ctgtatcgct ggatcaaatc tgtcgatcct tcccgcccgg tgcagtatga aggcggcgga 2700
gccgacacca cggccaccga tattatttgc ccgatgtacg cgcgcgtgga tgaagaccag 2760
cccttcccgg ctgtgccgaa atggtccatc aaaaaatggc tttcgctacc tggagagacg 2820
cgcccgctga tcctttgcga atacgcccac gcgatgggta acagtcttgg cggtttcgct 2880
aaatactggc aggcgtttcg tcagtatccc cgtttacagg gcggcttcgt ctgggactgg 2940
gtggatcagt cgctgattaa atatgatgaa aacggcaacc cgtggtcggc ttacggcggt 3000
gattttggcg atacgccgaa cgatcgccag ttctgtatga acggtctggt ctttgccgac 3060
cgcacgccgc atccagcgct gacggaagca aaacaccagc agcagttttt ccagttccgt 3120
ttatccgggc aaaccatcga agtgaccagc gaatacctgt tccgtcatag cgataacgag 3180
ctcctgcact ggatggtggc gctggatggt aagccgctgg caagcggtga agtgcctctg 3240
gatgtcgctc cacaaggtaa acagttgatt gaactgcctg aactaccgca gccggagagc 3300
gccgggcaac tctggctcac agtacgcgta gtgcaaccga acgcgaccgc atggtcagaa 3360
gccgggcaca tcagcgcctg gcagcagtgg cgtctggcgg aaaacctcag tgtgacgctc 3420
cccgccgcgt cccacgccat cccgcatctg accaccagcg aaatggattt ttgcatcgag 3480
ctgggtaata agcgttggca atttaaccgc cagtcaggct ttctttcaca gatgtggatt 3540
ggcgataaaa aacaactgct gacgccgctg cgcgatcagt tcacccgtgc accgctggat 3600
aacgacattg gcgtaagtga agcgacccgc attgacccta acgcctgggt cgaacgctgg 3660
aaggcggcgg gccattacca ggccgaagca gcgttgttgc agtgcacggc agatacactt 3720
gctgatgcgg tgctgattac gaccgctcac gcgtggcagc atcaggggaa aaccttattt 3780
atcagccgga aaacctaccg gattgatggt agtggtcaaa tggcgattac cgttgatgtt 3840
gaagtggcga gcgatacacc gcatccggcg cggattggcc tgaactgcca gctggcgcag 3900
gtagcagagc gggtaaactg gctcggatta gggccgcaag aaaactatcc cgaccgcctt 3960
actgccgcct gttttgaccg ctgggatctg ccattgtcag acatgtatac cccgtacgtc 4020
ttcccgagcg aaaacggtct gcgctgcggg acgcgcgaat tgaattatgg cccacaccag 4080
tggcgcggcg acttccagtt caacatcagc cgctacagtc aacagcaact gatggaaacc 4140
agccatcgcc atctgctgca cgcggaagaa ggcacatggc tgaatatcga cggtttccat 4200

atggggattg gtggcgacga ctcctggagc ccgtcagtat cggcggaatt tcagctgagc 4260
gccggtcgct accattacca gttggtctgg tgtcaaaaat aataatctcg aatcaagctt 4320
atcgataccg tcgaaacttg tttattgcag cttataatgg ttacaaataa agcaatagca 4380
tcacaaattt cacaaataaa gcatttttt cactgcattc tagttgtggt ttgtccaaac 4440
tcatcaatgt atcttatcat gtctggatcc gacctcggat ctggaaggtg ctgaggtacg 4500
atgagacccg caccaggtgc agaccctgcg agtgtggcgg taaacatatt aggaaccagc 4560
ctgtgatgct ggatgtgacc gaggagctga ggcccgatca cttggtgctg gcctgcaccc 4620
gcgctgagtt tggctctagc gatgaagata cagattgagg tactgaaatg tgtgggcgtg 4680
gcttaagggt gggaaagaat atataaggtg ggggtcttat gtagttttgt atctgttttg 4740
cagcagccgc cgccgccatg agcaccaact cgtttgatgg aagcattgtg agctcatatt 4800
tgacaacgcg catgccccca tgggccgggg tgcgtcagaa tgtgatgggc tccagcattg 4860
atggtcgccc cgtcctgccc gcaaactcta ctaccttgac ctacgagacc gtgtctggaa 4920
cgccgttgga gactgcagcc tccgccgccg cttcagccgc tgcagccacc gcccgcggga 4980
ttgtgactga ctttgctttc ctgagcccgc ttgcaagcag tgcagcttcc cgttcatccg 5040
cccgcgatga caagttgacg gctcttttgg cacaattgga ttctttgacc cgggaactta 5100
atgtcgtttc tcagcagctg ttggatctgc gccagcaggt ttctgccctg aaggcttcct 5160
cccctcccaa tgcggtttaa aacataaata aaaaaccaga ctctgtttgg atttggatca 5220
agcaagtgtc ttgctgtctt tatttagggg ttttgcgcgc gcggtaggcc cgggaccagc 5280
ggtctcggtc gttgagggtc ctgtgtattt tttccaggac gtggtaaagg tgactctgga 5340
tgttcagata catgggcata agcccgtctc tggggtggag gtagcaccac tgcagagctt 5400
catgctgcgg ggtggtgttg tagatgatcc agtcgtagca ggagcgctgg gcgtggtgcc 5460
taaaaatgtc tttcagtagc aagctgattg ccaggggcag gcccttggtg taagtgttta 5520
caaagcggtt aagctgggat gggtgcatac gtggggatat gagatgcatc ttggactgta 5580
tttttaggtt ggctatgttc ccagccatat ccctccgggg attcatgttg tgcagaacca 5640
ccagcacagt gtatccggtg cacttgggaa atttgtcatg tagcttagaa ggaaatgcgt 5700
ggaagaactt ggagacgccc ttgtgacctc caagattttc catgcattcg tccataatga 5760
tggcaatggg cccacgggcg gcggcctggg cgaagatatt tctgggatca ctaacgtcat 5820
agttgtgttc aggatgagat cgtcataggc catttttaca aagcgcgggc ggagggtgcc 5880
agactgcggt ataatggttc catccggccc aggggcgtag ttaccctcac agatttgcat 5940
ttcccacgct ttgagttcag atggggggat catgtctacc tgcggggcga tgaagaaaac 6000
ggtttccggg gtaggggaga tcagctggga agaaagcagg ttcctgagca gctgcgactt 6060
accgcagccg gtgggcccgt aaatcacacc tattaccggg tgcaactggt agttaagaga 6120
gctgcagctg ccgtcatccc tgagcagggg ggccacttcg ttaagcatgt ccctgactcg 6180
catgttttcc ctgaccaaat ccgccagaag gcgctcgccg cccagcgata gcagttcttg 6240
caaggaagca aagtttttca acggtttgag accgtccgcc gtaggcatgc ttttgagcgt 6300
ttgaccaagc agttccaggc ggtcccacag ctcggtcacc tgctctacgg catctcgatc 6360
cagcatatct cctcgtttcg cgggttgggg cggctttcgc tgtacggcag tagtcggtgc 6420
tcgtccagac gggccagggt catgtctttc cacgggcgca gggtcctcgt cagcgtagtc 6480
tgggtcacgg tgaaggggtg cgctccgggc tgcgcgctgg ccagggtgcg cttgaggctg 6540
gtcctgctgg tgctgaagcg ctgccggtct tcgccctgcg cgtcggccag gtagcatttg 6600
accatggtgt catagtccag cccctccgcg gcgtggccct tggcgcgcag cttgcccttg 6660
gaggaggcgc cgcacgaggg gcagtgcaga cttttgaggg cgtagagctt gggcgcgaga 6720
aataccgatt ccggggagta ggcatccgcg ccgcaggccc cgcagacggt ctcgcattcc 6780
acgagccagg tgagctctgg ccgttcgggg tcaaaaacca ggtttccccc atgcttttg 6840
atgcgtttct tacctctggt ttccatgagc cggtgtccac gctcggtgac gaaaaggctg 6900
tccgtgtccc cgtatacaga cttgagaggc ctgtcctcga gcggtgttcc gcggtcctcc 6960
tcgtatagaa actcggacca ctctgagaca aaggctcgcg tccaggccag cacgaaggag 7020
gctaagtggg aggggtagcg gtcgttgtcc actaggggtg ccactcgctc cagggtgtga 7080
agacacatgt cgccctcttc ggcatcaagg aaggtgattg gtttgtaggt gtaggccacg 7140
tgaccgggtg ttcctgaagg ggggctataa aagggggtgg gggcgcgttc gtcctcactc 7200
tcttccgcat cgctgtctgc gagggccagc tgttggggtg agtactccct ctgaaaagcg 7260
ggcatgactt ctgcgctaag attgtcagtt tccaaaaacg aggaggattt gatattcacc 7320
tggcccgcgg tgatgccttt gagggtggcc gcatccatct ggtcagaaaa gacaatcttt 7380
ttgttgtcaa gcttggtggc aaacgacccg tagagggcgt tggacagcaa cttggcgatg 7440
gagcgcaggg tttggttttt gtcgcgatcg gcgcgctcct tggccgcgat gtttagctgc 7500
acgtattcgc gcgcaacgca ccgccattcg ggaaagacgg tggtgcgctc gtcgggcacc 7560
aggtgcacgc gccaaccgcg gttgtgcagg gtgacaaggt caacgctggt ggctacctct 7620
ccgcgtaggc gctcgttggt ccagcagagg cggccgccct tgcgcgagca gaatggcggt 7680
agggggtcta gctgcgtctc gtccgggggg tctgcgtcca cggtaaagac cccgggcagc 7740
aggcgcgcgt cgaagtagtc tatcttgcat ccttgcaagt ctagcgcctg ctgccatgcg 7800
cgggcggcaa gcgcgcgctc gtatgggttg agtgggggac cccatggcat ggggtgggtg 7860

agcgcggagg cgtacatgcc gcaaatgtcg taaacgtaga ggggctctct gagtattcca 7920
agatatgtag ggtagcatct tccaccgcgg atgctggcgc gcacgtaatc gtatagttcg 7980
tgcgagggag cgaggaggtc gggaccgagg ttgctacggg cgggctgctc tgctcggaag 8040
actatctgcc tgaagatggc atgtgagttg gatgatatgg ttggacgctg gaagacgttg 8100
aagctggcgt ctgtgagacc taccgcgtca cgcacgaagg aggcgtagga gtcgcgcagc 8160
ttgttgacca gctcggcggt gacctgcacg tctagggcgc agtagtccag ggtttccttg 8220
atgatgtcat acttatcctg tccctttttt ttccacagct cgcggttgag gacaaactct 8280
tcgcggtctt tccagtactc ttggatcgga aacccgtcgg cctccgaacg gtaagagcct 8340
agcatgtaga actggttgac ggcctggtag gcgcagcatc ccttttctac gggtagcgcg 8400
tatgcctgcg cggccttccg gagcgaggtg tgggtgagcg caaaggtgtc cctgaccatg 8460
actttgaggt actggtattt gaagtcagtg tcgtcgcatc cgccctgctc ccagagcaaa 8520
aagtccgtgc gctttttgga acgcggattt ggcagggcga aggtgacatc gttgaagagt 8580
atctttcccg cgcgaggcat aaagttgcgt gtgatgcgga agggtcccgg cacctcggaa 8640
cggttgttaa ttacctgggc ggcgagcacg atctcgtcaa agccgttgat gttgtggccc 8700
acaatgtaaa gttccaagaa gcgcgggatg cccttgatgg aaggcaattt tttaagttcc 8760
tcgtaggtga gctcttcagg ggagctgagc ccgtgctctg aaagggccca gtctgcaaga 8820
tgagggttgg aagcgacgaa tgagctccac aggtcacggg ccattagcat ttgcaggtgg 8880
tcgcgaaagg tcctaaactg gcgacctatg gccatttttt ctggggtgat gcagtagaag 8940
gtaagcgggt cttgttccca gcggtcccat ccaaggttcg cggctaggtc tcgcgcggca 9000
gtcactagag gctcatctcc gccgaacttc atgaccagca tgaagggcac gagctgcttc 9060
ccaaaggccc ccatccaagt ataggtctct acatcgtagg tgacaaagag acgctcggtg 9120
cgaggatgcg agccgatcgg gaagaactgg atctcccgcc accaattgga ggagtggcta 9180
ttgatgtggt gaaagtagaa gtccctgcga cgggccgaac actcgtgctg gcttttgtaa 9240
aaacgtgcgc agtactggca gcggtgcacg ggctgtacat cctgcacgag gttgacctga 9300
cgaccgcgca caaggaagca gagtgggaat ttgagcccct cgcctggcgg gtttggctgg 9360
tggtcttcta cttcggctgc ttgtccttga ccgtctggct gctcgagggg agttacggtg 9420
gatcggacca ccacgccgcg cgagcccaaa gtccagatgt ccgcgcgcgg cggtcggagc 9480
ttgatgacaa catcgcgcag atgggagctg tccatggtct ggagctcccg cggcgtcagg 9540
tcaggcggga gctcctgcag gtttacctcg catagacggg tcagggcgcg ggctagatcc 9600
aggtgatacc taatttccag gggctggttg gtggcggcgt cgatggcttg caagaggccg 9660
catccccgcg gcgcgactac ggtaccgcgc ggcgggcggt gggccgcggg ggtgtccttg 9720
gatgatgcat ctaaaagcgg tgacgcgggc gagccccccgg aggtaggggg ggctccggac 9780
ccgccgggag agggggcagg ggcacgtcgg cgccgcgcgc gggcaggagc tggtgctgcg 9840
cgcgtaggtt gctggcgaac gcgacgacgc ggcggttgat ctcctgaatc tggcgcctct 9900
gcgtgaagac gacgggcccg gtgagcttga gcctgaaaga gagttcgaca gaatcaattt 9960
cggtgtcgtt gacggcggcc tggcgcaaaa tctcctgcac gtctcctgag ttgtcttgat 10020
aggcgatctc ggccatgaac tgctcgatct cttcctcctg gagatctccg cgtccggctc 10080
gctccacggt ggcggcgagg tcgttggaaa tgcgggccat gagctgcgag aaggcgttga 10140
ggcctccctc gttccagacg cggctgtaga ccacgccccc ttcggcatcg cgggcgcgca 10200
tgaccacctg cgcgagattg agctccacgt gccgggcgaa gacggcgtag tttcgcaggc 10260
gctgaaagag gtagttgagg gtggtggcgg tgtgttctgc cacgaagaag tacataaccc 10320
agcgtcgcaa cgtggattcg ttgatatccc ccaaggcctc aaggcgctcc atggcctcgt 10380
agaagtccac ggcgaagttg aaaaactggg agttgcgcgc cgacacggtt aactcctcct 10440
ccagaagacg gatgagctcg gcgacagtgt cgcgcacctc gcgctcaaag gctacagggg 10500
cctcttcttc ttcttcaatc tcctcttcca taagggcctc cccttcttct tcttctggcg 10560
gcggtggggg agggggggaca cggcggcgac gacggcgcac cgggaggcgg tcgacaaagc 10620
gctcgatcat ctccccgcgg cgacggcgca tggtctcggt gacggcgcgg ccgttctcgc 10680
gggggcgcag ttggaagacg ccgcccgtca tgtcccggtt atgggttggc gggggggctgc 10740
catgcggcag ggatacggcg ctaacgatgc atctcaacaa ttgttgtgta ggtactccgc 10800
cgccgaggga cctgagcgag tccgcatcga ccggatcgga aaacctctcg agaaaggcgt 10860
ctaaccagtc acagtcgcaa ggtaggctga gcaccgtggc gggcggcagc gggcggcggt 10920
cggggttgtt tctggcggag gtgctgctga tgatgtaatt aaagtaggcg gtcttgagac 10980
ggcggatggt cgacagaagc accatgtcct tgggtccggc ctgctgaatg cgcaggcggt 11040
cggccatgcc ccaggcttcg ttttgacatc ggcgcaggtc tttgtagtag tcttgcatga 11100
gcctttctac cggcacttct tcttctcctt cctcttgtcc tgcatctctt gcatctatcg 11160
ctgcggcggc ggcggagttt ggccgtaggt ggcgccctct tcctcccatg cgtgtgaccc 11220
cgaagcccct catcggctga agcagggcta ggtcggcgac aacgcgctcg gctaatatgg 11280
cctgctgcac ctgcgtgagg gtagactgga agtcatccat gtccacaaag cggtggtatg 11340
cgcccgtgtt gatggtgtaa gtgcagttgg ccataacgga ccagttaacg gtctggtgac 11400
ccggctgcga gagctcggtg tacctgagac gcgagtaagc cctcgagtca aatacgtagt 11460
cgttgcaagt ccgcaccagg tactggtatc ccaccaaaaa gtgcggcggc ggctggcggt 11520

agaggggcca gcgtagggtg gccggggctc cgggggcgag atcttccaac ataaggcgat 11580
gatatccgta gatgtacctg gacatccagg tgatgccggc ggcggtggtg gaggcgcgcg 11640
gaaagtcgcg gacgcggttc cagatgttgc gcagcggcaa aaagtgctcc atggtcggga 11700
cgctctggcc ggtcaggcgc gcgcaatcgt tgacgctcta gaccgtgcaa aaggagagcc 11760
tgtaagcggg cactcttccg tggtctggtg gataaattcg caagggtatc atggcggacg 11820
accggggttc gagccccgta tccggccgtc cgccgtgatc catgcggtta ccgcccgcgt 11880
gtcgaaccca ggtgtgcgac gtcagacaac gggggagtgc tccttttggc ttccttccag 11940
gcgcggcggc tgctgcgcta gctttttgg ccactggccg cgcgcagcgt aagcggttag 12000
gctggaaagc gaaagcatta agtggctcgc tccctgtagc cggagggtta ttttccaagg 12060
gttgagtcgc gggacccccg gttcgagtct cggaccggcc ggactgcggc gaacgggggt 12120
ttgcctcccc gtcatgcaag accccgcttg caaattcctc cggaaacagg gacgagcccc 12180
ttttttgctt ttcccagatg catccggtgc tgcggcagat gcgccccccc cctcagcagc 12240
ggcaagagca agagcagcgg cagacatgca gggcaccctc ccctcctcct accgcgtcag 12300
gaggggcgac atccgcggtt gacgcggcag cagatggtga ttacgaaccc ccgcggcgcc 12360
gggcccggca ctacctggac ttggaggagg gcgagggcct ggcgcggcta ggagcgccct 12420
ctcctgagcg gtacccaagg gtgcagctga agcgtgatac gcgtgaggcg tacgtgccgc 12480
ggcagaacct gtttcgcgac cgcgagggag aggagcccga ggagatgcgg gatcgaaagt 12540
tccacgcagg gcgcgagctg cggcatggcc tgaatcgcga gcggttgctg cgcgaggagg 12600
actttgagcc cgacgcgcga accgggatta gtcccgcgcg cgcacacgtg gcggccgccg 12660
acctggtaac cgcatacgag cagacggtga accaggagat taactttcaa aaaagcttta 12720
acaaccacgt gcgtacgctt gtggcgcgcg aggaggtggc tataggactg atgcatctgt 12780
gggactttgt aagcgcgctg gagcaaaacc caaatagcaa gccgctcatg gcgcagctgt 12840
tccttatagt gcagcacagc agggacaacg aggcattcag ggatgcgctg ctaaacatag 12900
tagagcccga gggccgctgg ctgctcgatt tgataaacat cctgcagagc atagtggtgc 12960
aggagcgcag cttgagcctg gctgacaagg tggccgccat caactattcc atgcttagcc 13020
tgggcaagtt ttacgcccgc aagatatacc atacccctta cgttcccata gacaaggagg 13080
taaagatcga ggggttctac atgcgcatgg cgctgaaggt gcttaccttg agcgacgacc 13140
tgggcgttta tcgcaacgag cgcatccaca aggccgtgag cgtgagccgg cggcgcgagc 13200
tcagcgaccg cgagctgatg cacagcctgc aaagggccct ggctggcacg ggcagcggcg 13260
atagagaggc cgagtcctac tttgacgcgg gcgctgacct gcgctgggcc ccaagccgac 13320
gcgccctgga ggcagctggg gccggacctg ggctggcggt ggcacccgcg cgcgctggca 13380
acgtcggcgg cgtggaggaa tatgacgagg acgatgagta cgagccagag gacggcgagt 13440
actaagcggt gatgtttctg atcagatgat gcaagacgca acggacccgg cggtgcgggc 13500
ggcgctgcag agccagccgt ccggccttaa ctccacggac gactggcgcc aggtcatgga 13560
ccgcatcatg tcgctgactg cgcgcaatcc tgacgcgttc cggcagcagc cgcaggccaa 13620
ccggctctcc gcaattctgg aagcggtggt cccggcgcgc gcaaacccca cgcacgagaa 13680
ggtgctggcg atcgtaaacg cgctggccga aaacagggcc atccggcccg acgaggccgg 13740
cctggtctac gacgcgctgc ttcagcgcgt ggctcgttac aacagcggca acgtgcagac 13800
caacctggac cggctggtgg gggatgtgcg cgaggccgtg gcgcagcgtg agcgcgcgca 13860
gcagcagggc aacctgggct ccatggttgc actaaacgcc ttcctgagta cacagcccgc 13920
caacgtgccg cggggacagg aggactacac caactttgtg agcgcactgc ggctaatggt 13980
gactgagaca ccgcaaagtg aggtgtacca gtctgggcca gactattttt tccagaccag 14040
tagacaaggc ctgcagaccg taaacctgag ccaggctttc aaaaacttgc aggggctgtg 14100
gggggtgcgg gctcccacag gcgaccgcgc gaccgtgtct agcttgctga cgcccaactc 14160
gcgcctgttg ctgctgctaa tagcgccctt cacggacagt ggcagcgtgt cccgggacac 14220
atacctaggt cacttgctga cactgtaccg cgaggccata ggtcaggcgc atgtggacga 14280
gcatactttc caggagatta caagtgtcag ccgcgcgctg gggcaggagg acacgggcag 14340
cctggaggca accctaaact acctgctgac caaccggcgg cagaagatcc cctcgttgca 14400
cagtttaaac agcgaggagg agcgcatttt gcgctacgtg cagcagagcg tgagccttaa 14460
cctgatgcgc gacggggtaa cgcccagcgt ggcgctggac atgaccgcgc gcaacatgga 14520
accgggcatg tatgcctcaa accggccgtt tatcaaccgc ctaatggact acttgcatcg 14580
cgcggccgcc gtgaaccccg agtatttcac caatgccatc ttgaacccgc actggctacc 14640
gcccccctggt ttctacaccg ggggattcga ggtgcccgag ggtaacgatg gattcctctg 14700
ggacgacata gacgacagcg tgttttcccc gcaaccgcag accctgctag agttgcaaca 14760
gcgcgagcag gcagaggcgg cgctgcgaaa ggaaagcttc cgcaggccaa gcagcttgtc 14820
cgatctaggc gctgcggccc cgcggtcaga tgctagtagc ccatttccaa gcttgatagg 14880
gtctcttacc agcactcgca ccacccgccc gcgcctgctg ggcgaggagg agtacctaaa 14940
caactcgctg ctgcagccgc agcgcgaaaa aaacctgcct ccggcatttc ccaacaacgg 15000
gatagagagc ctagtggaca agatgagtag atggaagacg tacgcgcagg agcacaggga 15060
cgtgccaggc ccgcgcccgc ccacccgtcg tcaaaggcac gaccgtcagc ggggtctggt 15120
gtgggaggac gatgactcgg cagacgacag cagcgtcctg gatttgggag ggagtggcaa 15180

cccgtttgcg caccttcgcc ccaggctggg gagaatgttt taaaaaaaaa aaagcatgat 15240
gcaaaataaa aaactcacca aggccatggc accgagcgtt ggttttcttg tattcccctt 15300
agtatgcggc gcgcggcgat gtatgaggaa ggtcctcctc cctcctacga gagtgtggtg 15360
agcgcggcgc cagtggcggc ggcgctgggt tctcccttcg atgctccccc ggacccgccg 15420
tttgtgcctc cgcggtacct gcggcctacc ggggggagaa acagcatccg ttactctgag 15480
ttggcacccc tattcgacac cacccgtgtg tacctggtgg acaacaagtc aacggatgtg 15540
gcatccctga actaccagaa cgaccacagc aactttctga ccacggtcat tcaaaacaat 15600
gactacagcc cgggggaggc aagcacacag accatcaatc ttgacgaccg gtcgcactgg 15660
ggcggcgacc tgaaaaccat cctgcatacc aacatgccaa atgtgaacga gttcatgttt 15720
accaataagt ttaaggcgcg ggtgatggtg tcgcgcttgc ctactaagga caatcaggtg 15780
gagctgaaat acgagtgggt ggagttcacg ctgcccgagg gcaactactc cgagaccatg 15840
accatagacc ttatgaacaa cgcgatcgtg gagcactact tgaaagtggg cagacagaac 15900
ggggttctgg aaagcgacat cggggtaaag tttgacaccc gcaacttcag actggggttt 15960
gaccccgtca ctggtcttgt catgcctggg gtatatacaa acgaagcctt ccatccagac 16020
atcattttgc tgccaggatg cggggtggac ttcacccaca gccgcctgag caacttgttg 16080
ggcatccgca agcggcaacc cttccaggag ggctttagga tcacctacga tgatctggag 16140
ggtggtaaca ttcccgcact gttggatgtg gacgcctacc aggcgagctt gaaagatgac 16200
accgaacagg gcgggggtgg cgcaggcggc agcaacagca gtggcagcgg cgcggaagag 16260
aactccaacg cggcagccgc ggcaatgcag ccggtggagg acatgaacga tcatgccatt 16320
cgcggcgaca cctttgccac acgggctgag gagaagcgcg ctgaggccga agcagcggcc 16380
gaagctgccg cccccgctgc gcaacccgag gtcgagaagc ctcagaagaa accggtgatc 16440
aaaccccctga cagaggacag caagaaacgc agttacaacc taataagcaa tgacagcacc 16500
ttcacccagt accgcagctg gtaccttgca tacaactacg gcgaccctca gaccggaatc 16560
cgctcatgga ccctgctttg cactcctgac gtaacctgcg gctcggagca ggtctactgg 16620
tcgttgccag acatgatgca agaccccgtg accttccgct ccacgcgcca gatcagcaac 16680
tttccggtgg tgggcgccga gctgttgccc gtgcactcca agagcttcta caacgaccag 16740
gccgtctact cccaactcat ccgccagttt acctctctga cccacgtgtt caatcgcttt 16800
cccgagaacc agattttggc gcgcccgcca gcccccacca tcaccaccgt cagtgaaaac 16860
gttcctgctc tcacagatca cgggacgcta ccgctgcgca acagcatcgg aggagtccag 16920
cgagtgacca ttactgacgc cagacgccgc acctgccccc acgtttacaa ggccctgggc 16980
atagtctcgc cgcgcgtcct atcgagccgc acttttgag caagcatgtc catccttata 17040
tcgcccagca ataacacagg ctggggcctg cgcttcccaa gcaagatgtt tggcggggcc 17100
aagaagcgct ccgaccaaca cccagtgcgc gtgcgcgggc actaccgcgc gccctggggc 17160
gcgcacaaac gcggccgcac tgggcgcacc accgtcgatg acgccatcga cgcggtggtg 17220
gaggaggcgc gcaactacac gcccacgccg ccaccagtgt ccacagtgga cgcggccatt 17280
cagaccgtgg tgcgcggagc ccggcgctat gctaaaatga agagacggcg gaggcgcgta 17340
gcacgtcgcc accgccgccg acccggcact gccgcccaac gcgcggcggc ggccctgctt 17400
aaccgcgcac gtcgcaccgg ccgacgggcg gccatgcggg ccgctcgaag gctggccgcg 17460
ggtattgtca ctgtgccccc caggtccagg cgacgagcgg ccgccgcagc agccgcggcc 17520
attagtgcta tgactcaggg tcgcaggggc aacgtgtatt gggtgcgcga ctcggttagc 17580
ggcctgcgcg tgcccgtgcg cacccgcccc ccgcgcaact agattgcaag aaaaaactac 17640
ttagactcgt actgttgtat gtatccagcg gcggcggcgc gcaacgaagc tatgtccaag 17700
cgcaaaatca aagaagagat gctccaggtc atcgcgccgg agatctatgg ccccccgaag 17760
aaggaagagc aggattacaa gccccgaaag ctaaagcggg tcaaaaagaa aaagaaagat 17820
gatgatgatg aacttgacga cgaggtggaa ctgctgcacg ctaccgcgcc caggcgacgg 17880
gtacagtgga aaggtcgacg cgtaaaacgt gttttgcgac ccggcaccac cgtagtcttt 17940
acgcccggtg agcgctccac ccgcacctac aagcgcgtgt atgatgaggt gtacggcgac 18000
gaggacctgc ttgagcaggc caacgagcgc ctcggggagt ttgcctacgg aaagcggcat 18060
aaggacatgc tggcgttgcc gctggacgag ggcaacccaa cacctagcct aaagcccgta 18120
acactgcagc aggtgctgcc cgcgcttgca ccgtccgaag aaaagcgcgg cctaaagcgc 18180
gagtctggtg acttggcacc caccgtgcag ctgatggtac ccaagcgcca gcgactggaa 18240
gatgtcttgg aaaaaatgac cgtggaacct gggctggagc ccgaggtccg cgtgcggcca 18300
atcaagcagg tggcgccggg actgggcgtg cagaccgtgg acgttcagat acccactacc 18360
agtagcacca gtattgccac cgccacagag ggcatggaga cacaaacgtc cccggttgcc 18420
tcagcggtgg cggatgccgc ggtgcaggcg gtcgctgcgg ccgcgtccaa gacctctacg 18480
gaggtgcaaa cggacccgtg gatgtttcgc gtttcagccc cccggcgccc gcgcggttcg 18540
aggaagtacg gcgccgccag cgcgctactg cccgaatatg ccctacatcc ttccattgcg 18600
cctacccccg gctatcgtgg ctacacctac cgccccagaa gacgagcaac tacccgacgc 18660
cgaaccacca ctggaacccg ccgccgccgt cgccgtcgcc agcccgtgct ggccccgatt 18720
tccgtgcgca gggtggctcg cgaaggaggc aggaccctgg tgctgccaac agcgcgctac 18780
caccccagca tcgtttaaaa gccggtcttt gtggttcttg cagatatggc cctcacctgc 18840

cgcctccgtt tcccggtgcc gggattccga ggaagaatgc accgtaggag gggcatggcc 18900
ggccacggcc tgacgggcgg catgcgtcgt gcgcaccacc ggcggcggcg cgcgtcgcac 18960
cgtcgcatgc gcggcggtat cctgcccctc cttattccac tgatcgccgc ggcgattggc 19020
gccgtgcccg gaattgcatc cgtggccttg caggcgcaga gacactgatt aaaaacaagt 19080
tgcatgtgga aaaatcaaaa taaaaagtct ggactctcac gctcgcttgg tcctgtaact 19140
attttgtaga atggaagaca tcaactttgc gtctctggcc ccgcgacacg gctcgcgccc 19200
gttcatggga aactggcaag atatcggcac cagcaatatg agcggtggcg ccttcagctg 19260
gggctcgctg tggagcggca ttaaaaattt cggttccacc gttaagaact atggcagcaa 19320
ggcctggaac agcagcacag gccagatgct gagggataag ttgaaagagc aaaatttcca 19380
acaaaaggtg gtagatggcc tggcctctgg cattagcggg gtggtggacc tggccaacca 19440
ggcagtgcaa aataagatta acagtaagct tgatccccgc cctcccgtag aggagcctcc 19500
accggccgtg gagacagtgt ctccagaggg gcgtggcgaa aagcgtccgc gccccgacag 19560
ggaagaaact ctggtgacgc aaatagacga gcctccctcg tacgaggagg cactaaagca 19620
aggcctgccc accacccgtc ccatcgcgcc catggctacc ggagtgctgg gccagcacac 19680
acccgtaacg ctggacctgc ctccccccgc cgacacccag cagaaacctg tgctgccagg 19740
cccgaccgcc gttgttgtaa cccgtcctag ccgcgcgtcc ctgcgccgcg ccgccagcgg 19800
tccgcgatcg ttgcggcccg tagccagtgg caactggcaa agcacactga acagcatcgt 19860
gggtctgggg gtgcaatccc tgaagcgccg acgatgcttc tgaatagcta acgtgtcgta 19920
tgtgtgtcat gtatgcgtcc atgtcgccgc cagaggagct gctgagccgc cgcgcgcccg 19980
ctttccaaga tggctacccc ttcgatgatg ccgcagtggt cttacatgca catctcgggc 20040
caggacgcct cggagtacct gagccccggg ctggtgcagt ttgcccgcgc caccgagacg 20100
tacttcagcc tgaataacaa gtttagaaac cccacggtgg cgcctacgca cgacgtgacc 20160
acagaccggt cccagcgttt gacgctgcgg ttcatccctg tggaccgtga ggatactgcg 20220
tactcgtaca aggcgcggtt caccctagct gtgggtgata accgtgtgct ggacatggct 20280
tccacgtact ttgacatccg cggcgtgctg gacaggggcc ctacttttaa gccctactct 20340
ggcactgcct acaacgccct ggctcccaag ggtgccccaa atccttgcga atgggatgaa 20400
gctgctactg ctcttgaaat aaacctagaa gaagaggacg atgacaacga agacgaagta 20460
gacgagcaag ctgagcagca aaaaactcac gtatttgggc aggcgcctta ttctggtata 20520
aatattacaa aggagggtat tcaaataggt gtcgaaggtc aaacacctaa atatgccgat 20580
aaaacatttc aacctgaacc tcaaatagga gaatctcagt ggtacgaaac tgaaattaat 20640
catgcagctg ggagagtcct taaaaagact accccaatga aaccatgtta cggttcatat 20700
gcaaaaccca caaatgaaaa tggagggcaa ggcattcttg taaagcaaca aaatggaaag 20760
ctagaaagtc aagtggaaat gcaatttttc tcaactactg aggcgaccgc aggcaatggt 20820
gataacttga ctcctaaagt ggtattgtac agtgaagatg tagatataga aaccccagac 20880
actcatattt cttacatgcc cactattaag gaaggtaact cacgagaact aatgggccaa 20940
caatctatgc ccaacaggcc taattacatt gcttttaggg acaattttat tggtctaatg 21000
tattacaaca gcacgggtaa tatgggtgtt ctggcgggcc aagcatcgca gttgaatgct 21060
gttgtagatt tgcaagacag aaacacagag ctttcatacc agcttttgct tgattccatt 21120
ggtgatagaa ccaggtactt ttctatgtgg aatcaggctg ttgacagcta tgatccagat 21180
gttagaatta ttgaaaatca tggaactgaa gatgaacttc caaattactg ctttccactg 21240
ggaggtgtga ttaatacaga gactcttacc aaggtaaaac ctaaaacagg tcaggaaaat 21300
ggatgggaaa aagatgctac agaattttca gataaaaatg aaataagagt tggaaataat 21360
tttgccatgg aaatcaatct aaatgccaac ctgtggagaa atttcctgta ctccaacata 21420
gcgctgtatt tgcccgacaa gctaaagtac agtccttcca acgtaaaaat ttctgataac 21480
ccaaacacct acgactacat gaacaagcga gtggtggctc ccgggttagt ggactgctac 21540
attaaccttg gagcacgctg gtcccttgac tatatggaca acgtcaaccc atttaaccac 21600
caccgcaatg ctggcctgcg ctaccgctca atgttgctgg gcaatggtcg ctatgtgccc 21660
ttccacatcc aggtgcctca gaagttcttt gccattaaaa acctccttct cctgccgggc 21720
tcatacacct acgagtggaa cttcaggaag gatgttaaca tggttctgca gagctcccta 21780
ggaaatgacc taagggttga cggagccagc attaagtttg atagcatttg cctttacgcc 21840
accttcttcc ccatggccca caacaccgcc tccacgcttg aggccatgct tagaaacgac 21900
accaacgacc agtcctttaa cgactatctc tccgccgcca acatgctcta ccctataccc 21960
gccaacgcta ccaacgtgcc catatccatc ccctcccgca actgggcggc tttccgcggc 22020
tgggccttca cgcgccttaa gactaaggaa accccatcac tgggctcggg ctacgaccct 22080
tattacacct actctggctc tataccctac ctagatggaa ccttttacct caaccacacc 22140
tttaagaagg tggccattac ctttgactct tctgtcagct ggcctggcaa tgaccgcctg 22200
cttaccccca acgagtttga aattaagcgc tcagttgacg gggagggtta caacgttgcc 22260
cagtgtaaca tgaccaaaga ctggttcctg gtacaaatgc tagctaacta caacattggc 22320
taccagggct tctatatccc agagagctac aaggaccgca tgtactcctt ctttagaaac 22380
ttccagccca tgagccgtca ggtggtggat gatactaaat acaaggacta ccaacaggtg 22440
ggcatcctac accaacacaa caactctgga tttgttggct accttgcccc caccatgcgc 22500

gaaggacagg cctaccctgc taacttcccc tatccgctta taggcaagac cgcagttgac 22560
agcattaccc agaaaaagtt tctttgcgat cgcacccttt ggcgcatccc attctccagt 22620
aactttatgt ccatgggcgc actcacagac ctgggccaaa accttctcta cgccaactcc 22680
gcccacgcgc tagacatgac ttttgaggtg gatcccatgg acgagcccac ccttctttat 22740
gttttgtttg aagtctttga cgtggtccgt gtgcaccggc cgcaccgcgg cgtcatcgaa 22800
accgtgtacc tgcgcacgcc cttctcggcc ggcaacgcca caacataaag aagcaagcaa 22860
catcaacaac agctgccgcc atgggctcca gtgagcagga actgaaagcc attgtcaaag 22920
atcttggttg tgggccatat tttttgggca cctatgacaa gcgctttcca ggctttgttt 22980
ctccacacaa gctcgcctgc gccatagtca atacggccgg tcgcgagact gggggcgtac 23040
actggatggc ctttgcctgg aacccgcact caaaaacatg ctacctcttt gagccctttg 23100
gcttttctga ccagcgactc aagcaggttt accagtttga gtacgagtca ctcctgcgcc 23160
gtagcgccat tgcttcttcc cccgaccgct gtataacgct ggaaaagtcc acccaaagcg 23220
tacaggggcc caactcggcc gcctgtggac tattctgctg catgtttctc cacgcctttg 23280
ccaactggcc ccaaactccc atggatcaca accccaccat gaaccttatt accggggtac 23340
ccaactccat gctcaacagt ccccaggtac agcccaccct gcgtcgcaac caggaacagc 23400
tctacagctt cctggagcgc cactcgccct acttccgcag ccacagtgcg cagattagga 23460
gcgccacttc tttttgtcac ttgaaaaaca tgtaaaaata atgtactaga gacactttca 23520
ataaaggcaa atgcttttat ttgtacactc tcgggtgatt atttaccccc acccttgccg 23580
tctgcgccgt ttaaaaatca aaggggttct gccgcgcatc gctatgcgcc actggcaggg 23640
acacgttgcg atactggtgt ttagtgctcc acttaaactc aggcacaacc atccgcggca 23700
gctcggtgaa gttttcactc cacaggctgc gcaccatcac caacgcgttt agcaggtcgg 23760
gcgccgatat cttgaagtcg cagttggggc ctccgccctg cgcgcgcgag ttgcgataca 23820
cagggttgca gcactggaac actatcagcg ccgggtggtg cacgctggcc agcacgctct 23880
tgtcggagat cagatccgcg tccaggtcct ccgcgttgct cagggcgaac ggagtcaact 23940
ttggtagctg ccttcccaaa aagggcgcgt gcccaggctt tgagttgcac tcgcaccgta 24000
gtggcatcaa aaggtgaccg tgcccggtct gggcgttagg atacagcgcc tgcataaaag 24060
ccttgatctg cttaaaagcc acctgagcct ttgcgccttc agagaagaac atgccgcaag 24120
acttgccgga aaactgattg gccggacagg ccgcgtcgtg cacgcagcac cttgcgtcgg 24180
tgttggagat ctgcaccaca tttcggcccc accggttctt cacgatcttg gccttgctag 24240
actgctcctt cagcgcgcgc tgcccgtttt cgctcgtcac atccatttca atcacgtgct 24300
ccttatttat cataatgctt ccgtgtagac acttaagctc gccttcgatc tcagcgcagc 24360
ggtgcagcca caacgcgcag cccgtgggct cgtgatgctt gtaggtcacc tctgcaaacg 24420
actgcaggta cgcctgcagg aatcgcccca tcatcgtcac aaaggtcttg ttgctggtga 24480
aggtcagctg caacccgcgg tgctcctcgt tcagccaggt cttgcatacg gccgccagag 24540
cttccacttg gtcaggcagt agtttgaagt tcgcctttag atcgttatcc acgtggtact 24600
tgtccatcag cgcgcgcgca gcctccatgc ccttctccca cgcagacacg atcggcacac 24660
tcagcgggtt catcaccgta atttcacttt ccgcttcgct gggctcttcc tcttcctctt 24720
gcgtccgcat accacgcgcc actgggtcgt cttcattcag ccgccgcact gtgcgcttac 24780
ctcctttgcc atgcttgatt agcaccggtg ggttgctgaa acccaccatt tgtagcgcca 24840
catcttctct ttcttcctcg ctgtccacga ttacctctgg tgatggcggg cgctcgggct 24900
tgggagaagg gcgcttcttt ttcttcttgg gcgcaatggc caaatccgcc gccgaggtcg 24960
atggccgcgg gctgggtgtg cgcggcacca gcgcgtcttg tgatgagtct tcctcgtcct 25020
cggactcgat acgccgcctc atccgctttt ttgggggcgc ccgggggaggc ggcggcgacg 25080
gggacgggga cgacacgtcc tccatggttg ggggacgtcg cgccgcaccg cgtccgcgct 25140
cgggggtggt ttcgcgctgc tcctcttccc gactggccat ttccttctcc tataggcaga 25200
aaaagatcat ggagtcagtc gagaagaagg acagcctaac cgccccctct gagttcgcca 25260
ccaccgcctc caccgatgcc gccaacgcgc ctaccacctt ccccgtcgag gcacccccgc 25320
ttgaggagga ggaagtgatt atcgagcagg acccaggttt tgtaagcgaa gacgacgagg 25380
accgctcagt accaacagag gataaaaagc aagaccagga caacgcagag gcaaacgagg 25440
aacaagtcgg gcgggggggac gaaaggcatg gcgactacct agatgtggga gacgacgtgc 25500
tgttgaagca tctgcagcgc cagtgcgcca ttatctgcga cgcgttgcaa gagcgcagcg 25560
atgtgccccct cgccatagcg gatgtcagcc ttgcctacga acgccaccta ttctcaccgc 25620
gcgtaccccc caaacgccaa gaaaacggca catgcgagcc caacccgcgc ctcaacttct 25680
accccgtatt tgccgtgcca gaggtgcttg ccacctatca catctttttc caaaactgca 25740
agatacccct atcctgccgt gccaaccgca gccgagcgga caagcagctg gccttgcggc 25800
agggcgctgt catacctgat atcgcctcgc tcaacgaagt gccaaaaatc tttgagggtc 25860
ttggacgcga cgagaagcgc gcggcaaacg ctctgcaaca ggaaaacagc gaaaatgaaa 25920
gtcactctgg agtgttggtg gaactcgagg gtgacaacgc gcgcctagcc gtactaaaac 25980
gcagcatcga ggtcacccac tttgcctacc cggcacttaa cctacccccc aaggtcatga 26040
gcacagtcat gagtgagctg atcgtgcgcc gtgcgcagcc cctggagagg gatgcaaatt 26100
tgcaagaaca aacagaggag ggcctacccg cagttggcga cgagcagcta gcgcgctggc 26160

ttcaaacgcg cgagcctgcc gacttggagg agcgacgcaa actaatgatg gccgcagtgc 26220
tcgttaccgt ggagcttgag tgcatgcagc ggttctttgc tgacccggag atgcagcgca 26280
agctagagga aacattgcac tacacctttc gacagggcta cgtacgccag gcctgcaaga 26340
tctccaacgt ggagctctgc aacctggtct cctaccttgg aattttgcac gaaaaccgcc 26400
ttgggcaaaa cgtgcttcat tccacgctca agggcgaggc gcgccgcgac tacgtccgcg 26460
actgcgttta cttatttcta tgctacacct ggcagacggc catgggcgtt tggcagcagt 26520
gcttggagga gtgcaacctc aaggagctgc agaaactgct aaagcaaaac ttgaaggacc 26580
tatggacggc cttcaacgag cgctccgtgg ccgcgcacct ggcggacatc attttccccg 26640
aacgcctgct taaaaccctg caacagggtc tgccagactt caccagtcaa agcatgttgc 26700
agaactttag gaactttatc ctagagcgct caggaatctt gcccgccacc tgctgtgcac 26760
ttcctagcga ctttgtgccc attaagtacc gcgaatgccc tccgccgctt tggggccact 26820
gctaccttct gcagctagcc aactaccttg cctaccactc tgacataatg gaagacgtga 26880
gcggtgacgg tctactggag tgtcactgtc gctgcaacct atgcaccccg caccgctccc 26940
tggtttgcaa ttcgcagctg cttaacgaaa gtcaaattat cggtaccttt gagctgcagg 27000
gtccctcgcc tgacgaaaag tccgcggctc cggggttgaa actcactccg gggctgtgga 27060
cgtcggctta ccttcgcaaa tttgtacctg aggactacca cgcccacgag attaggttct 27120
acgaagacca atcccgcccg ccaaatgcgg agcttaccgc ctgcgtcatt acccagggcc 27180
acattcttgg ccaattgcaa gccatcaaca aagcccgcca agagtttctg ctacgaaagg 27240
gacgggggct ttacttggac ccccagtccg gcgaggagct caacccaatc cccccgccgc 27300
cgcagcccta tcagcagcag ccgcgggccc ttgcttccca ggatggcacc caaaaagaag 27360
ctgcagctgc cgccgccacc cacggacgag gaggaatact gggacagtca ggcagaggag 27420
gttttggacg aggaggagga ggacatgatg gaagactggg agagcctaga cgaggaagct 27480
tccgaggtcg aagaggtgtc agacgaaaca ccgtcaccct cggtcgcatt cccctcgccg 27540
gcgccccaga aatcggcaac cggttccagc atggctacaa cctccgctcc tcaggcgccg 27600
ccggcactgc ccgttcgccg acccaaccgt agatgggaca ccactggaac cagggccggt 27660
aagtccaagc agccgccgcc gttagcccaa gagcaacaac agcgccaagg ctaccgctca 27720
tggcgcgggc acaagaacgc catagttgct tgcttgcaag actgtggggg caacatctcc 27780
ttcgcccgcc gctttcttct ctaccatcac ggcgtggcct tcccccgtaa catcctgcat 27840
tactaccgtc atctctacag cccatactgc accggcggca gcggcagcgg cagcaacagc 27900
agcggccaca cagaagcaaa ggcgaccgga tagcaagact ctgacaaagc ccaagaaatc 27960
cacagcggcg gcagcagcag gaggaggagc gctgcgtctg gcgcccaacg aacccgtatc 28020
gacccgcgag cttagaaaca ggatttttcc cactctgtat gctatatttc aacagagcag 28080
gggccaagaa caagagctga aaataaaaaa caggtctctg cgatccctca cccgcagctg 28140
cctgtatcac aaaagcgaag atcagcttcg gcgcacgctg gaagacgcgg aggctctctt 28200
cagtaaatac tgcgcgctga ctcttaagga ctagtttcgc gccctttctc aaatttaagc 28260
gcgaaaacta cgtcatctcc agcggccaca cccggcgcca gcacctgtcg tcagcgccat 28320
tatgagcaag gaaattccca cgccctacat gtggagttac cagccacaaa tgggacttgc 28380
ggctggagct gcccaagact actcaacccg aataaactac atgagcgcgg gaccccacat 28440
gatatcccgg gtcaacggaa tccgcgccca ccgaaaccga attctcttgg aacaggcggc 28500
tattaccacc acacctcgta ataaccttaa tccccgtagt tggcccgctg ccctggtgta 28560
ccaggaaagt cccgctccca ccactgtggt acttcccaga gacgcccagg ccgaagttca 28620
gatgactaac tcaggggcgc agcttgcggg cggctttcgt cacagggtgc ggtcgcccgg 28680
gcagggtata actcacctga caatcagagg gcgaggtatt cagctcaacg acgagtcggt 28740
gagctcctcg cttggtctcc gtccggacgg gacatttcag atcggcggcg ccggccgtcc 28800
ttcattcacg cctcgtcagg caatcctaac tctgcagacc tcgtcctctg agccgcgctc 28860
tggaggcatt ggaactctgc aatttattga ggagtttgtg ccatcggtct actttaaccc 28920
cttctcggga cctcccggcc actatccgga tcaatttatt cctaactttg acgcggtaaa 28980
ggactcggcg gacggctacg actgaatgtt aagtggagag gcagagcaac tgcgcctgaa 29040
acacctggtc cactgtcgcc gccacaagtg ctttgcccgc gactccggtg agttttgcta 29100
ctttgaattg cccgaggatc atatcgaggg cccggcgcac ggcgtccggc ttaccgccca 29160
gggagagctt gcccgtagcc tgattcggga gtttacccag cgccccctgc tagttgagcg 29220
ggacagggga ccctgtgttc tcactgtgat ttgcaactgt cctaaccttg gattacatca 29280
agatctttgt tgccatctct gtgctgagta taataaatac agaaattaaa atatactggg 29340
gctcctatcg ccatcctgta aacgccaccg tcttcacccg cccaagcaaa ccaaggcgaa 29400
ccttacctgg tacttttaac atctctccct ctgtgattta caacagtttc aacccagacg 29460
gagtgagtct acgagagaac ctctccgagc tcagctactc catcagaaaa aacaccaccc 29520
tccttacctg ccgggaacgt acgagtgcgt caccggccgc tgcaccacac ctaccgcctg 29580
accgtaaacc agacttttc cggacagacc tcaataactc tgtttaccag aacaggaggt 29640
gagcttagaa aacccttagg gtattaggcc aaaggcgcag ctactgtggg gtttatgaac 29700
aattcaagca actctacggg ctattctaat tcaggtttct ctagaaatgg acggaattat 29760
tacagagcag cgcctgctag aaagacgcag ggcagcggcc gagcaacagc gcatgaatca 29820

agagctccaa gacatggtta acttgcacca gtgcaaaagg ggtatctttt gtctggtaaa 29880
gcaggccaaa gtcacctacg acagtaatac caccggacac cgccttagct acaagttgcc 29940
aaccaagcgt cagaaattgg tggtcatggt gggagaaaag cccattacca taactcagca 30000
ctcggtagaa accgaaggct gcattcactc accttgtcaa ggacctgagg atctctgcac 30060
ccttattaag accctgtgcg gtctcaaaga tcttattccc tttaactaat aaaaaaaaat 30120
aataaagcat cacttactta aaatcagtta gcaaatttct gtccagttta ttcagcagca 30180
cctccttgcc ctcctcccag ctctggtatt gcagcttcct cctggctgca aactttctcc 30240
acaatctaaa tggaatgtca gtttcctcct gttcctgtcc atccgcaccc actatcttca 30300
tgttgttgca gatgaagcgc gcaagaccgt ctgaagatac cttcaacccc gtgtatccat 30360
atgacacgga aaccggtcct ccaactgtgc cttttcttac tcctcccttt gtatccccca 30420
atgggtttca agagagtccc cctggggtac tctctttgcg cctatccgaa cctctagtta 30480
cctccaatgg catgcttgcg ctcaaaatgg gcaacggcct ctctctggac gaggccggca 30540
accttacctc ccaaaatgta accactgtga gcccacctct caaaaaaacc aagtcaaaca 30600
taaacctgga aatatctgca cccctcacag ttacctcaga agccctaact gtggctgccg 30660
ccgcacctct aatggtcgcg ggcaacacac tcaccatgca atcacaggcc ccgctaaccg 30720
tgcacgactc caaacttagc attgccaccc aaggacccct cacagtgtca gaaggaaagc 30780
tagccctgca aacatcaggc cccctcacca ccaccgatag cagtaccctt actatcactg 30840
cctcaccccc tctaactact gccactggta gcttgggcat tgacttgaaa gagcccattt 30900
atacacaaaa tggaaaacta ggactaaagt acggggctcc tttgcatgta acagacgacc 30960
taaacacttt gaccgtagca actggtccag gtgtgactat taataatact tccttgcaaa 31020
ctaaagttac tggagccttg ggttttgatt cacaaggcaa tatgcaactt aatgtagcag 31080
gaggactaag gattgattct caaaacagac gccttatact tgatgttagt tatccgtttg 31140
atgctcaaaa ccaactaaat ctaagactag gacagggccc tctttttata aactcagccc 31200
acaacttgga tattaactac aacaaaggcc tttacttgtt tacagcttca aacaattcca 31260
aaaagcttga ggttaaccta agcactgcca aggggttgat gtttgacgct acagccatag 31320
ccattaatgc aggagatggg cttgaatttg gttcacctaa tgcaccaaac acaaatcccc 31380
tcaaaacaaa aattggccat ggcctagaat ttgattcaaa caaggctatg gttcctaaac 31440
taggaactgg ccttagtttt gacagcacag gtgccattac agtaggaaac aaaaataatg 31500
ataagctaac tttgtggacc acaccagctc catctcctaa ctgtagacta aatgcagaga 31560
aagatgctaa actcactttg gtcttaacaa aatgtggcag tcaaatactt gctacagttt 31620
cagttttggc tgttaaaggc agtttggctc caatatctgg aacagttcaa agtgctcatc 31680
ttattataag atttgacgaa aatggagtgc tactaaacaa ttccttcctg gacccagaat 31740
attggaactt tagaaatgga gatcttactg aaggcacagc ctatacaaac gctgttggat 31800
ttatgcctaa cctatcagct tatccaaaat ctcacggtaa aactgccaaa agtaacattg 31860
tcagtcaagt ttacttaaac ggagacaaaa ctaaacctgt aacactaacc attacactaa 31920
acggtacaca ggaaacagga gacacaactc caagtgcata ctctatgtca ttttcatggg 31980
actggtctgg ccacaactac attaatgaaa tatttgccac atcctcttac acttttcat 32040
acattgccca agaataaaga atcgtttgtg ttatgtttca acgtgtttat ttttcaattg 32100
cagaaaattt caagtcattt ttcattcagt agtatagccc caccaccaca tagcttatac 32160
agatcaccgt accttaatca aactcacaga accctagtat tcaacctgcc acctccctcc 32220
caacacacag agtacacagt cctttctccc cggctggcct taaaaagcat catatcatgg 32280
gtaacagaca tattcttagg tgttatattc cacacggttt cctgtcgagc caaacgctca 32340
tcagtgatat taataaactc cccgggcagc tcacttaagt tcatgtcgct gtccagctgc 32400
tgagccacag gctgctgtcc aacttgcggt tgcttaacgg gcggcgaagg agaagtccac 32460
gcctacatgg gggtagagtc ataatcgtgc atcaggatag ggcggtggtg ctgcagcagc 32520
gcgcgaataa actgctgccg ccgccgctcc gtcctgcagg aatacaacat ggcagtggtc 32580
tcctcagcga tgattcgcac cgcccgcagc ataaggcgcc ttgtcctccg ggcacagcag 32640
cgcaccctga tctcacttaa atcagcacag taactgcagc acagcaccac aatattgttc 32700
aaaatcccac agtgcaaggc gctgtatcca aagctcatgg cggggaccac agaacccacg 32760
tggccatcat accacaagcg caggtagatt aagtggcgac ccctcataaa cacgctggac 32820
ataaacatta cctcttttgg catgttgtaa ttcaccacct cccggtacca tataaacctc 32880
tgattaaaca tggcgccatc caccaccatc ctaaaccagc tggccaaaac ctgcccgccg 32940
gctatacact gcagggaacc gggactggaa caatgacagt ggagagccca ggactcgtaa 33000
ccatggatca tcatgctcgt catgatatca atgttggcac aacacaggca cacgtgcata 33060
cacttcctca ggattacaag ctcctcccgc gttagaacca tatcccaggg aacaacccat 33120
tcctgaatca gcgtaaatcc cacactgcag ggaagacctc gcacgtaact cacgttgtgc 33180
attgtcaaag tgttacattc gggcagcagc ggatgatcct ccagtatggt agcgcgggtt 33240
tctgtctcaa aaggaggtag acgatcccta ctgtacggag tgcgccgaga caaccgagat 33300
cgtgttggtc gtagtgtcat gccaaatgga acgccggacg tagtcatatt tcctgaagca 33360
aaaccaggtg cgggcgtgac aaacagatct gcgtctccgg tctcgccgct tagatcgctc 33420
tgtgtagtag ttgtagtata tccactctct caaagcatcc aggcgccccc tggcttcggg 33480

ttctatgtaa actccttcat gcgccgctgc cctgataaca tccaccaccg cagaataagc 33540
cacacccagc caacctacac attcgttctg cgagtcacac acgggaggag cgggaagagc 33600
tggaagaacc atgtttttt ttttattcca aaagattatc caaaacctca aaatgaagat 33660
ctattaagtg aacgcgctcc cctccggtgg cgtggtcaaa ctctacagcc aaagaacaga 33720
taatggcatt tgtaagatgt tgcacaatgg cttccaaaag gcaaacggcc ctcacgtcca 33780
agtggacgta aaggctaaac ccttcagggt gaatctcctc tataaacatt ccagcacctt 33840
caaccatgcc caaataattc tcatctcgcc accttctcaa tatatctcta agcaaatccc 33900
gaatattaag tccggccatt gtaaaaatct gctccagagc gccctccacc ttcagcctca 33960
agcagcgaat catgattgca aaaattcagg ttcctcacag acctgtataa gattcaaaag 34020
cggaacatta acaaaaatac cgcgatcccg taggtccctt cgcagggcca gctgaacata 34080
atcgtgcagg tctgcacgga ccagcgcggc cacttccccg ccaggaacct tgacaaaaga 34140
acccacactg attatgacac gcatactcgg agctatgcta accagcgtag ccccgatgta 34200
agctttgttg catgggcggc gatataaaat gcaaggtgct gctcaaaaaa tcaggcaaag 34260
cctcgcgcaa aaaagaaagc acatcgtagt catgctcatg cagataaagg caggtaagct 34320
ccggaaccac cacagaaaaa gacaccattt ttctctcaaa catgtctgcg ggtttctgca 34380
taaacacaaa ataaaataac aaaaaaacat ttaaacatta gaagcctgtc ttacaacagg 34440
aaaaacaacc cttataagca taagacggac tacggccatg ccggcgtgac cgtaaaaaaa 34500
ctggtcaccg tgattaaaaa gcaccaccga cagctcctcg gtcatgtccg gagtcataat 34560
gtaagactcg gtaaacacat caggttgatt catcggtcag tgctaaaaag cgaccgaaat 34620
agcccggggg aatacatacc cgcaggcgta gagacaacat tacagccccc ataggaggta 34680
taacaaaatt aataggagag aaaaacacat aaacacctga aaaaccctcc tgcctaggca 34740
aaatagcacc ctcccgctcc agaacaacat acagcgcttc cacagcggca gccataacag 34800
tcagccttac cagtaaaaaa gaaaacctat taaaaaaaca ccactcgaca cggcaccagc 34860
tcaatcagtc acagtgtaaa aaagggccaa gtgcagagcg agtatatata ggactaaaaa 34920
atgacgtaac ggttaaagtc cacaaaaaac acccagaaaa ccgcacgcga acctacgccc 34980
agaaacgaaa gccaaaaaac ccacaacttc ctcaaatcgt cacttccgtt ttcccacgtt 35040
acgtcacttc ccatttttaat taagaaaact acaattccca acacatacaa gttactccgc 35100
cctaaaacct acgtcacccg ccccgttccc acgccccgcg ccacgtcaca aactccaccc 35160
cctcattatc atattggctt caatccaaaa taaggtatat tattgatgat g 35211

<210> 44
<211> 33622
<212> DNA
<213> Artificial Sequence

<220>
<223> Plasmid Av3nBg

<400> 44
catcatcaat aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt 60
ttgtgacgtg gcgcggggcg tgggaacggg gcgggtgacg tagtagtgtg gcggaagtgt 120
gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg 180
gtgtgcgccg gtgtacacag gaagtgacaa ttttcgcgcg gttttaggcg gatgttgtag 240
taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300
agtgaaatct gaataatttt gtgttactca tagcgcgtaa tatttgtcta gggccgcggg 360
gactttgacc gtttacgtgg agactcgccc agggcgcgcc ccgatgtacg ggccagatat 420
acgcgtatct gaggggacta gggtgtgttt aggcgaaaag cggggcttcg gttgtacgcg 480
gttaggagtc ccctcaggat atagtagttt cgcttttgca tagggagggg gaaatgtagt 540
cttatgcaat actcttgtag tcttgcaaca tggtaacgat gagttagcaa catgccttac 600
aaggagagaa aaagcaccgt gcatgccgat tggtggaagt aaggtggtac gatcgtgcct 660
tattaggaag gcaacagacg ggtctgacat ggattggacg aaccactgaa ttccgcattg 720
cagagatatt gtatttaagt gcctagctcg atacaataaa cgccatttga ccattcacca 780
cattggtgtg cacctccggc cctggccact ctcttccgca tcgctgtctg cgggggccag 840
ctgttgggct cgcggttgag gacaaactct tcgcggtctt tccagtactc ttggatcgga 900
aacccgtcgg cctccgaacg gtactccgcc gccgagggac ctgagcgagt ccgcatcgac 960
cggatcggaa aacctctcga gaaaggcgtg taaccagtca cagtcgctct agaactagtg 1020
gatccccccgg gctgcaggaa ttcgatctag atggataaag gtccaaaaaa gaagagaaag 1080
gtagaagacc ccaaggactt tccttcagaa ttgctaagtt ttttgagtga ttcactggcc 1140
gtcgttttac aacgtcgtga ctgggaaaac cctggcgtta cccaacttaa tcgccttgca 1200
gcacatcccc ctttcgccag ctggcgtaat agcgaagagg cccgcaccga tcgcccttcc 1260
caacagttgc gcagcctgaa tggcgaatgg cgctttgcct ggtttccggc accagaagcg 1320

gtgccggaaa gctggctgga gtgcgatctt cctgaggccg atactgtcgt cgtcccctca 1380
aactggcaga tgcacggtta cgatgcgccc atctacacca acgtaaccta tcccattacg 1440
gtcaatccgc cgtttgttcc cacggagaat ccgacgggtt gttactcgct cacatttaat 1500
gttgatgaaa gctggctaca ggaaggccag acgcgaatta tttttgatgg cgttaactcg 1560
gcgtttcatc tgtggtgcaa cgggcgctgg gtcggttacg gccaggacag tcgtttgccg 1620
tctgaatttg acctgagcgc atttttacgc gccggagaaa accgcctcgc ggtgatggtg 1680
ctgcgttgga gtgacggcag ttatctggaa gatcaggata tgtggcggat gagcggcatt 1740
ttccgtgacg tctcgttgct gcataaaccg actacacaaa tcagcgattt ccatgttgcc 1800
actcgcttta atgatgattt cagccgcgct gtactggagg ctgaagttca gatgtgcggc 1860
gagttgcgtg actacctacg ggtaacagtt tctttatggc agggtgaaac gcaggtcgcc 1920
agcggcaccg cgcctttcgg cggtgaaatt atcgatgagc gtggtggtta tgccgatcgc 1980
gtcacactac gtctgaacgt cgaaaacccg aaactgtgga gcgccgaaat cccgaatctc 2040
tatcgtgcgg tggttgaact gcacaccgcc gacggcacgc tgattgaagc agaagcctgc 2100
gatgtcggtt tccgcgaggt gcggattgaa aatggtctgc tgctgctgaa cggcaagccg 2160
ttgctgattc gaggcgttaa ccgtcacgag catcatcctc tgcatggtca ggtcatggat 2220
gagcagacga tggtgcagga tatcctgctg atgaagcaga acaactttaa cgccgtgcgc 2280
tgttcgcatt atccgaacca tccgctgtgg tacacgctgt gcgaccgcta cggcctgtat 2340
gtggtggatg aagccaatat tgaaacccac ggcatggtgc caatgaatcg tctgaccgat 2400
gatccgcgct ggctaccggc gatgagcgaa cgcgtaacgc gaatggtgca gcgcgatcgt 2460
aatcacccga gtgtgatcat ctggtcgctg gggaatgaat caggccacgg cgctaatcac 2520
gacgcgctgt atcgctggat caaatctgtc gatccttccc gcccggtgca gtatgaaggc 2580
ggcggagccg acaccacggc caccgatatt atttgcccga tgtacgcgcg cgtggatgaa 2640
gaccagccct tcccggctgt gccgaaatgg tccatcaaaa aatggctttc gctacctgga 2700
gagacgcgcc cgctgatcct ttgcgaatac gcccacgcga tgggtaacag tcttggcggt 2760
ttcgctaaat actggcaggc gtttcgtcag tatccccgtt tacagggcgg cttcgtctgg 2820
gactgggtgg atcagtcgct gattaaatat gatgaaaacg gcaacccgtg gtcggcttac 2880
ggcggtgatt ttggcgatac gccgaacgat cgccagttct gtatgaacgg tctggtcttt 2940
gccgaccgca cgccgcatcc agcgctgacg gaagcaaaac accagcagca gtttttccag 3000
ttccgtttat ccgggcaaac catcgaagtg accagcgaat acctgttccg tcatagcgat 3060
aacgagctcc tgcactggat ggtggcgctg gatggtaagc cgctggcaag cggtgaagtg 3120
cctctggatg tcgctccaca aggtaaacag ttgattgaac tgcctgaact accgcagccg 3180
gagagcgccg ggcaactctg gctcacagta cgcgtagtgc aaccgaacgc gaccgcatgg 3240
tcagaagccg ggcacatcag cgcctggcag cagtggcgtc tggcggaaaa cctcagtgtg 3300
acgctccccg ccgcgtccca cgccatcccg catctgacca ccagcgaaat ggatttttgc 3360
atcgagctgg gtaataagcg ttggcaattt aaccgccagt caggctttct ttcacagatg 3420
tggattggcg ataaaaaaca actgctgacg ccgctgcgcg atcagttcac ccgtgcaccg 3480
ctggataacg acattggcgt aagtgaagcg acccgcattg accctaacgc ctgggtcgaa 3540
cgctggaagg cggcgggcca ttaccaggcc gaagcagcgt tgttgcagtg cacggcagat 3600
acacttgctg atgcggtgct gattacgacc gctcacgcgt ggcagcatca ggggaaaacc 3660
ttatttatca gccggaaaac ctaccggatt gatggtagtg gtcaaatggc gattaccgtt 3720
gatgttgaag tggcgagcga tacaccgcat ccggcgcgga ttggcctgaa ctgccagctg 3780
gcgcaggtag cagagcgggt aaactggctc ggattagggc cgcaagaaaa ctatcccgac 3840
cgccttactg ccgcctgttt tgaccgctgg gatctgccat tgtcagacat gtataccccg 3900
tacgtcttcc cgagcgaaaa cggtctgcgc tgcgggacgc gcgaattgaa ttatggccca 3960
caccagtggc gcggcgactt ccagttcaac atcagccgct acagtcaaca gcaactgatg 4020
gaaaccagcc atcgccatct gctgcacgcg gaagaaggca catggctgaa tatcgacggt 4080
ttccatatgg ggattggtgg cgacgactcc tggagcccgt cagtatcggc ggaatttcag 4140
ctgagcgccg gtcgctacca ttaccagttg gtctggtgtc aaaaataata atctcgaatc 4200
aagcttatcg ataccgtcga aacttgttta ttgcagctta taatggttac aaataaagca 4260
atagcatcac aaatttcaca aataaagcat ttttttcact gcattctagt tgtggtttgt 4320
ccaaactcat caatgtatct tatcatgtct ggatccgacc tcggatctgg aaggtgctga 4380
ggtacgatga gacccgcacc aggtgcagac cctgcgagtg tggcggtaaa catattagga 4440
accagcctgt gatgctggat gtgaccgagg agctgaggcc cgatcacttg gtgctggcct 4500
gcacccgcgc tgagtttggc tctagcgatg aagatacaga ttgaggtact gaaatgtgtg 4560
ggcgtggctt aagggtggga aagaatatat aaggtggggg tcttatgtag ttttgtatct 4620
gttttgcagc agccgccgcc gccatgagca ccaactcgtt tgatggaagc attgtgagct 4680
catatttgac aacgcgcatg cccccatggg ccggggtgcg tcagaatgtg atgggctcca 4740
gcattgatgg tcgccccgtc ctgcccgcaa actctactac cttgacctac gagaccgtgt 4800
ctggaacgcc gttggagact gcagcctccg ccgccgcttc agccgctgca gccaccgccc 4860
gcgggattgt gactgacttt gctttcctga gcccgcttgc aagcagtgca gcttcccgtt 4920
catccgcccg cgatgacaag ttgacggctc ttttggcaca attggattct ttgacccggg 4980

aacttaatgt cgtttctcag cagctgttgg atctgcgcca gcaggtttct gccctgaagg 5040
cttcctcccc tcccaatgcg gtttaaaaca taaataaaaa accagactct gtttggattt 5100
ggatcaagca agtgtcttgc tgtctttatt taggggtttt gcgcgcgcgg taggcccggg 5160
accagcggtc tcggtcgttg agggtcctgt gtatttttc caggacgtgg taaaggtgac 5220
tctggatgtt cagatacatg ggcataagcc cgtctctggg gtggaggtag caccactgca 5280
gagcttcatg ctgcggggtg gtgttgtaga tgatccagtc gtagcaggag cgctgggcgt 5340
ggtgcctaaa aatgtctttc agtagcaagc tgattgccag gggcaggccc ttggtgtaag 5400
tgtttacaaa gcggttaagc tgggatgggt gcatacgtgg ggatatgaga tgcatcttgg 5460
actgtatttt taggttggct atgttcccag ccatatccct ccggggattc atgttgtgca 5520
gaaccaccag cacagtgtat ccggtgcact tgggaaattt gtcatgtagc ttagaaggaa 5580
atgcgtggaa gaacttggag acgcccttgt gacctccaag attttccatg cattcgtcca 5640
taatgatggc aatgggccca cgggcggcgg cctgggcgaa gatatttctg ggatcactaa 5700
cgtcatagtt gtgttccagg atgagatcgt cataggccat ttttacaaag cgcgggcgga 5760
gggtgccaga ctgcggtata atggttccat ccggcccagg ggcgtagtta ccctcacaga 5820
tttgcatttc ccacgctttg agttcagatg gggggatcat gtctacctgc ggggcgatga 5880
agaaaacggt ttccggggta ggggagatca gctgggaaga aagcaggttc ctgagcagct 5940
gcgacttacc gcagccggtg ggcccgtaaa tcacacctat taccggctgc aactggtagt 6000
taagagagct gcagctgccg tcatccctga gcaggggggc cacttcgtta agcatgtccc 6060
tgactcgcat gttttccctg accaaatccg ccagaaggcg ctcgccgccc agcgatagca 6120
gttcttgcaa ggaagcaaag tttttcaacg gtttgagacc gtccgccgta ggcatgcttt 6180
tgagcgtttg accaagcagt tccaggcggt cccacagctc ggtcacctgc tctacggcat 6240
ctcgatccag catatctcct cgtttcgcgg gttggggcgg ctttcgctgt acggcagtag 6300
tcggtgctcg tccagacggg ccagggtcat gtctttccac gggcgcaggg tcctcgtcag 6360
cgtagtctgg gtcacggtga aggggtgcgc tccgggctgc gcgctggcca gggtgcgctt 6420
gaggctggtc ctgctggtgc tgaagcgctg ccggtcttcg ccctgcgcgt cggccaggta 6480
gcatttgacc atggtgtcat agtccagccc ctccgcggcg tggcccttgg cgcgcagctt 6540
gcccttggag gaggcgccgc acgaggggca gtgcagactt ttgagggcgt agagcttggg 6600
cgcgagaaat accgattccg gggagtaggc atccgcgccg caggccccgc agacggtctc 6660
gcattccacg agccaggtga gctctggccg ttcggggtca aaaaccaggt ttcccccatg 6720
ctttttgatg cgtttcttac ctctggtttc catgagccgg tgtccacgct cggtgacgaa 6780
aaggctgtcc gtgtccccgt atacagactt gagaggcctg tcctcgagcg gtgttccgcg 6840
gtcctcctcg tatagaaact cggaccactc tgagacaaag gctcgcgtcc aggccagcac 6900
gaaggaggct aagtgggagg ggtagcggtc gttgtccact agggggtcca ctcgctccag 6960
ggtgtgaaga cacatgtcgc cctcttcggc atcaaggaag gtgattggtt tgtaggtgta 7020
ggccacgtga ccgggtgttc ctgaaggggg gctataaaag ggggtggggg cgcgttcgtc 7080
ctcactctct tccgcatcgc tgtctgcgag ggccagctgt tggggtgagt actccctctg 7140
aaaagcgggc atgacttctg cgctaagatt gtcagtttcc aaaaacgagg aggatttgat 7200
attcacctgg cccgcggtga tgcctttgag ggtggccgca tccatctggt cagaaaagac 7260
aatctttttg ttgtcaagct tggtggcaaa cgacccgtag agggcgttgg acagcaactt 7320
ggcgatggag cgcagggttt ggtttttgtc gcgatcggcg cgctccttgg ccgcgatgtt 7380
tagctgcacg tattcgcgcg caacgcaccg ccattcggga aagacggtgg tgcgctcgtc 7440
gggcaccagg tgcacgcgcc aaccgcggtt gtgcagggtg acaaggtcaa cgctggtggc 7500
tacctctccg cgtaggcgct cgttggtcca gcagaggcgg ccgcccttgc gcgagcagaa 7560
tggcggtagg gggtctagct gcgtctcgtc cgggggtct gcgtccacgg taaagacccc 7620
gggcagcagg cgcgcgtcga agtagtctat cttgcatcct tgcaagtcta gcgcctgctg 7680
ccatgcgcgg gcggcaagcg cgcgctcgta tgggttgagt gggggacccc atggcatggg 7740
gtgggtgagc gcggaggcgt acatgccgca aatgtcgtaa acgtagaggg gctctctgag 7800
tattccaaga tatgtagggt agcatcttcc accgcggatg ctggcgcgca cgtaatcgta 7860
tagttcgtgc gagggagcga ggaggtcggg accgaggttg ctacgggcgg gctgctctgc 7920
tcggaagact atctgcctga agatggcatg tgagttggat gatatggttg gacgctggaa 7980
gacgttgaag ctggcgtctg tgagacctac cgcgtcacgc acgaaggagg cgtaggagtc 8040
gcgcagcttg ttgaccagct cggcggtgac ctgcacgtct agggcgcagt agtccagggt 8100
ttccttgatg atgtcatact tatcctgtcc ctttttttc cacagctcgc ggttgaggac 8160
aaactcttcg cggtctttcc agtactcttg gatcggaaac ccgtcggcct ccgaacggta 8220
agagcctagc atgtagaact ggttgacggc ctggtaggcg cagcatccct tttctacggg 8280
tagcgcgtat gcctgcgcgg ccttccggag cgaggtgtgg gtgagcgcaa aggtgtccct 8340
gaccatgact ttgaggtact ggtatttgaa gtcagtgtcg tcgcatccgc cctgctccca 8400
gagcaaaaag tccgtgcgct ttttggaacg cggatttggc agggcgaagg tgacatcgtt 8460
gaagagtatc tttcccgcgc gaggcataaa gttgcgtgtg atgcggaagg gtcccggcac 8520
ctcggaacgg ttgttaatta cctgggcggc gagcacgatc tcgtcaaagc cgttgatgtt 8580
gtggcccaca atgtaaagtt ccaagaagcg cgggatgccc ttgatggaag gcaatttttt 8640

aagttcctcg taggtgagct cttcagggga gctgagcccg tgctctgaaa gggcccagtc 8700
tgcaagatga gggttggaag cgacgaatga gctccacagg tcacgggcca ttagcatttg 8760
caggtggtcg cgaaaggtcc taaactggcg acctatggcc atttttttctg gggtgatgca 8820
gtagaaggta agcgggtctt gttcccagcg gtcccatcca aggttcgcgg ctaggtctcg 8880
cgcggcagtc actagaggct catctccgcc gaacttcatg accagcatga agggcacgag 8940
ctgcttccca aaggccccca tccaagtata ggtctctaca tcgtaggtga caaagagacg 9000
ctcggtgcga ggatgcgagc cgatcgggaa gaactggatc tcccgccacc aattggagga 9060
gtggctattg atgtggtgaa agtagaagtc cctgcgacgg gccgaacact cgtgctggct 9120
tttgtaaaaa cgtgcgcagt actggcagcg gtgcacgggc tgtacatcct gcacgaggtt 9180
gacctgacga ccgcgcacaa ggaagcagag tgggaatttg agcccctcgc ctggcgggtt 9240
tggctggtgg tcttctactt cggctgcttg tccttgaccg tctggctgct cgaggggagt 9300
tacggtggat cggaccacca cgccgcgcga gcccaaagtc cagatgtccg cgcgcggcgg 9360
tcggagcttg atgacaacat cgcgcagatg ggagctgtcc atggtctgga gctcccgcgg 9420
cgtcaggtca ggcgggagct cctgcaggtt tacctcgcat agacgggtca gggcgcgggc 9480
tagatccagg tgatacctaa tttccagggg ctggttggtg gcggcgtcga tggcttgcaa 9540
gaggccgcat ccccgcggcg cgactacggt accgcgcggc gggcggtggg ccgcgggggt 9600
gtccttggat gatgcatcta aaagcggtga cgcgggcgag cccccggagg taggggggc 9660
tccggacccg ccgggagagg gggcaggggc acgtcggcgc cgcgcgcggg caggagctgg 9720
tgctgcgcgc gtaggttgct ggcgaacgcg acgacgcggc ggttgatctc ctgaatctgg 9780
cgcctctgcg tgaagacgac gggcccggtg agcttgagcc tgaaagagag ttcgacagaa 9840
tcaatttcgg tgtcgttgac ggcggcctgg cgcaaaatct cctgcacgtc tcctgagttg 9900
tcttgatagg cgatctcggc catgaactgc tcgatctctt cctcctggag atctccgcgt 9960
ccggctcgct ccacggtggc ggcgaggtcg ttggaaatgc gggccatgag ctgcgagaag 10020
gcgttgaggc ctcctcgttt ccagacgcgg ctgtagacca cgccccttc ggcatcgcgg 10080
gcgcgcatga ccacctgcgc gagattgagc tccacgtgcc gggcgaagac ggcgtagttt 10140
cgcaggcgct gaaagaggta gttgagggtg gtggcggtgt gttctgccac gaagaagtac 10200
ataacccagc gtcgcaacgt ggattcgttg atatccccca aggcctcaag gcgctccatg 10260
gcctcgtaga agtccacggc gaagttgaaa aactgggagt tgcgcgccga cacggttaac 10320
tcctcctcca gaagacggat gagctcggcg acagtgtcgc gcacctcgcg ctcaaaggct 10380
acaggggcct cttcttcttc ttcaatctcc tcttccataa gggcctcccc ttcttcttct 10440
tctggcggcg gtgggggagg ggggacacgg cggcgacgac ggcgcaccgg gaggcggtcg 10500
acaaagcgct cgatcatctc cccgcggcga cggcgcatgg tctcggtgac ggcgcggccg 10560
ttctcgcggg ggcgcagttg gaagacgccg cccgtcatgt cccggttatg ggttggcggg 10620
gggctgccat gcggcaggga tacggcgcta acgatgcatc tcaacaattg ttgtgtaggt 10680
actccgccgc cgagggacct gagcgagtcc gcatcgaccg gatcggaaaa cctctcgaga 10740
aaggcgtcta accagtcaca gtcgcaaggt aggctgagca ccgtggcggg cggcagcggg 10800
cggcggtcgg ggttgtttct ggcggaggtg ctgctgatga tgtaattaaa gtaggcggtc 10860
ttgagacggc ggatggtcga cagaagcacc atgtccttgg gtccggcctg ctgaatgcgc 10920
aggcggtcgg ccatgcccca ggcttcgttt tgacatcggc gcaggtcttt gtagtagtct 10980
tgcatgagcc tttctaccgg cacttcttct tctccttcct cttgtcctgc atctcttgca 11040
tctatcgctg cggcggcggc ggagtttggc cgtaggtggc gccctcttcc tcccatgcgt 11100
gtgaccccga agcccctcat cggctgaagc agggctaggt cggcgacaac gcgctcggct 11160
aatatggcct gctgcacctg cgtgagggta gactggaagt catccatgtc cacaaagcgg 11220
tggtatgcgc ccgtgttgat ggtgtaagtg cagttggcca taacggacca gttaacggtc 11280
tggtgacccg gctgcgagag ctcggtgtac ctgagacgcg agtaagccct cgagtcaaat 11340
acgtagtcgt tgcaagtccg caccaggtac tggtatccca ccaaaaagtg cggcggcggc 11400
tggcggtaga ggggccagcg tagggtggcc ggggctccgg gggcgagatc ttccaacata 11460
aggcgatgat atccgtagat gtacctggac atccaggtga tgccggcggc ggtggtggag 11520
gcgcgcggaa agtcgcggac gcggttccag atgttgcgca gcggcaaaaa gtgctccatg 11580
gtcgggacgc tctggccggt caggcgcgcg caatcgttga cgctctagac cgtgcaaaag 11640
gagagcctgt aagcgggcac tcttccgtgg tctggtggat aaattcgcaa gggtatcatg 11700
gcggacgacc ggggttcgag ccccgtatcc ggccgtccgc cgtgatccat gcggttaccg 11760
cccgcgtgtc gaacccaggt gtgcgacgtc agacaacggg ggagtgctcc ttttggcttc 11820
cttccaggcg cggcggctgc tgcgctagct tttttggcca ctggccgcgc gcagcgtaag 11880
cggttaggct ggaaagcgaa agcattaagt ggctcgctcc ctgtagccgg agggttattt 11940
tccaagggtt gagtcgcggg acccccggtt cgagtctcgg accggccgga ctgcggcgaa 12000
cgggggtttg cctccccgtc atgcaagacc ccgcttgcaa attcctccgg aaacagggac 12060
gagccccttt tttgcttttc ccagatgcat ccggtgctgc ggcagatgcg ccccccctcct 12120
cagcagcggc aagagcaaga gcagcggcag acatgcaggg caccctcccc tcctcctacc 12180
gcgtcaggag gggcgacatc cgcggttgac gcggcagcag atggtgatta cgaacccccg 12240
cggcgccggg cccggcacta cctggacttg gaggagggcg agggcctggc gcggctagga 12300

gcgccctctc ctgagcggta cccaagggtg cagctgaagc gtgatacgcg tgaggcgtac 12360
gtgccgcggc agaacctgtt tcgcgaccgc gagggagagg agcccgagga gatgcgggat 12420
cgaaagttcc acgcagggcg cgagctgcgg catggcctga atcgcgagcg gttgctgcgc 12480
gaggaggact ttgagcccga cgcgcgaacc gggattagtc ccgcgcgcgc acacgtggcg 12540
gccgccgacc tggtaaccgc atacgagcag acggtgaacc aggagattaa ctttcaaaaa 12600
agctttaaca accacgtgcg tacgcttgtg gcgcgcgagg aggtggctat aggactgatg 12660
catctgtggg actttgtaag cgcgctggag caaaacccaa atagcaagcc gctcatggcg 12720
cagctgttcc ttatagtgca gcacagcagg gacaacgagg cattcaggga tgcgctgcta 12780
aacatagtag agcccgaggg ccgctggctg ctcgatttga taaacatcct gcagagcata 12840
gtggtgcagg agcgcagctt gagcctggct gacaaggtgg ccgccatcaa ctattccatg 12900
cttagcctgg gcaagtttta cgcccgcaag atataccata ccccttacgt tcccatagac 12960
aaggaggtaa agatcgaggg gttctacatg cgcatggcgc tgaaggtgct taccttgagc 13020
gacgacctgg gcgtttatcg caacgagcgc atccacaagg ccgtgagcgt gagccggcgg 13080
cgcgagctca gcgaccgcga gctgatgcac agcctgcaaa gggccctggc tggcacgggc 13140
agcggcgata gagaggccga gtcctacttt gacgcgggcg ctgacctgcg ctgggcccca 13200
agccgacgcg ccctggaggc agctggggcc ggacctgggc tggcggtggc acccgcgcgc 13260
gctggcaacg tcggcggcgt ggaggaatat gacgaggacg atgagtacga gccagaggac 13320
ggcgagtact aagcggtgat gtttctgatc agatgatgca agacgcaacg gacccggcgg 13380
tgcgggcggc gctgcagagc cagccgtccg gccttaactc cacggacgac tggcgccagg 13440
tcatggaccg catcatgtcg ctgactgcgc gcaatcctga cgcgttccgg cagcagccgc 13500
aggccaaccg gctctccgca attctggaag cggtggtccc ggcgcgcgca aaccccacgc 13560
acgagaaggt gctggcgatc gtaaacgcgc tggccgaaaa cagggccatc cggcccgacg 13620
aggccggcct ggtctacgac gcgctgcttc agcgcgtggc tcgttacaac agcggcaacg 13680
tgcagaccaa cctggaccgg ctggtggggg atgtgcgcga ggccgtggcg cagcgtgagc 13740
gcgcgcagca gcagggcaac ctgggctcca tggttgcact aaacgccttc ctgagtacac 13800
agcccgccaa cgtgccgcgg ggacaggagg actacaccaa ctttgtgagc gcactgcggc 13860
taatggtgac tgagacaccg caaagtgagg tgtaccagtc tgggccagac tatttttcc 13920
agaccagtag acaaggcctg cagaccgtaa acctgagcca ggctttcaaa aacttgcagg 13980
ggctgtgggg ggtgcgggct cccacaggcg accgcgcgac cgtgtctagc ttgctgacgc 14040
ccaactcgcg cctgttgctg ctgctaatag cgcccttcac ggacagtggc agcgtgtccc 14100
gggacacata cctaggtcac ttgctgacac tgtaccgcga ggccataggt caggcgcatg 14160
tggacgagca tactttccag gagattacaa gtgtcagccg cgcgctgggg caggaggaca 14220
cgggcagcct ggaggcaacc ctaaactacc tgctgaccaa ccggcggcag aagatcccct 14280
cgttgcacag tttaaacagc gaggaggagc gcattttgcg ctacgtgcag cagagcgtga 14340
gccttaacct gatgcgcgac ggggtaacgc ccagcgtggc gctggacatg accgcgcgca 14400
acatggaacc gggcatgtat gcctcaaacc ggccgtttat caaccgccta atggactact 14460
tgcatcgcgc ggccgccgtg aaccccgagt atttcaccaa tgccatcttg aacccgcact 14520
ggctaccgcc ccctggtttc tacaccgggg gattcgaggt gcccgagggt aacgatggat 14580
tcctctggga cgacatagac gacagcgtgt tttccccgca accgcagacc ctgctagagt 14640
tgcaacagcg cgagcaggca gaggcggcgc tgcgaaagga aagcttccgc aggccaagca 14700
gcttgtccga tctaggcgct gcggccccgc ggtcagatgc tagtagccca tttccaagct 14760
tgatagggtc tcttaccagc actcgcacca cccgcccgcg cctgctgggc gaggaggagt 14820
acctaaacaa ctcgctgctg cagccgcagc gcgaaaaaaa cctgcctccg gcatttccca 14880
acaacgggat agagagccta gtggacaaga tgagtagatg gaagacgtac gcgcaggagc 14940
acagggacgt gccaggcccg cgcccgccca cccgtcgtca aaggcacgac cgtcagcggg 15000
gtctggtgtg ggaggacgat gactcggcag acgacagcag cgtcctggat ttgggaggga 15060
gtggcaaccc gtttgcgcac cttcgcccca ggctggggag aatgttttaa aaaaaaaaaa 15120
gcatgatgca aaataaaaaa ctcaccaagg ccatggcacc gagcgttggt tttcttgtat 15180
tccccttagt atgcggcgcg cggcgatgta tgaggaaggt cctcctccct cctacgagag 15240
tgtggtgagc gcggcgccag tggcggcggc gctgggttct cccttcgatg ctcccctgga 15300
cccgccgttt gtgcctccgc ggtacctgcg gcctaccggg gggagaaaca gcatccgtta 15360
ctctgagttg gcacccctat tcgacaccac ccgtgtgtac ctggtggaca acaagtcaac 15420
ggatgtggca tccctgaact accagaacga ccacagcaac tttctgacca cggtcattca 15480
aaacaatgac tacagcccgg gggaggcaag cacacagacc atcaatcttg acgaccggtc 15540
gcactggggc ggcgacctga aaaccatcct gcataccaac atgccaaatg tgaacgagtt 15600
catgtttacc aataagttta aggcgcgggt gatggtgtcg cgcttgccta ctaaggacaa 15660
tcaggtggag ctgaaatacg agtgggtgga gttcacgctg cccgagggca actactccga 15720
gaccatgacc atagacctta tgaacaacgc gatcgtggag cactacttga aagtgggcag 15780
acagaacggg gttctggaaa gcgacatcgg ggtaaagttt gacacccgca acttcagact 15840
ggggtttgac cccgtcactg gtcttgtcat gcctggggta tatacaaacg aagccttcca 15900
tccagacatc attttgctgc caggatgcgg ggtggacttc acccacagcc gcctgagcaa 15960

cttgttgggc atccgcaagc ggcaaccctt ccaggagggc tttaggatca cctacgatga 16020
tctggagggt ggtaacattc ccgcactgtt ggatgtggac gcctaccagg cgagcttgaa 16080
agatgacacc gaacagggcg ggggtggcgc aggcggcagc aacagcagtg gcagcggcgc 16140
ggaagagaac tccaacgcgg cagccgcggc aatgcagccg gtggaggaca tgaacgatca 16200
tgccattcgc ggcgacacct ttgccacacg ggctgaggag aagcgcgctg aggccgaagc 16260
agcggccgaa gctgccgccc ccgctgcgca acccgaggtc gagaagcctc agaagaaacc 16320
ggtgatcaaa cccctgacag aggacagcaa gaaacgcagt tacaacctaa taagcaatga 16380
cagcaccttc acccagtacc gcagctggta ccttgcatac aactacggcg accctcagac 16440
cggaatccgc tcatggaccc tgctttgcac tcctgacgta acctgcggct cggagcaggt 16500
ctactggtcg ttgccagaca tgatgcaaga ccccgtgacc ttccgctcca cgcgccagat 16560
cagcaacttt ccggtggtgg gcgccgagct gttgcccgtg cactccaaga gcttctacaa 16620
cgaccaggcc gtctactccc aactcatccg ccagtttacc tctctgaccc acgtgttcaa 16680
tcgctttccc gagaaccaga ttttggcgcg cccgccagcc cccaccatca ccaccgtcag 16740
tgaaaacgtt cctgctctca cagatcacgg gacgctaccg ctgcgcaaca gcatcggagg 16800
agtccagcga gtgaccatta ctgacgccag acgccgcacc tgcccctacg tttacaaggc 16860
cctgggcata gtctcgccgc gcgtcctatc gagccgcact ttttgagcaa gcatgtccat 16920
ccttatatcg cccagcaata acacaggctg gggcctgcgc ttcccaagca agatgtttgg 16980
cggggccaag aagcgctccg accaacaccc agtgcgcgtg cgcgggcact accgcgcgcc 17040
ctggggcgcg cacaaacgcg gccgcactgg gcgcaccacc gtcgatgacg ccatcgacgc 17100
ggtggtggag gaggcgcgca actacacgcc cacgccgcca ccagtgtcca cagtggacgc 17160
ggccattcag accgtggtgc gcggagcccg gcgctatgct aaaatgaaga gacggcggag 17220
gcgcgtagca cgtcgccacc gccgccgacc cggcactgcc gcccaacgcg cggcggcggc 17280
cctgcttaac cgcgcacgtc gcaccggccg acgggcggcc atgcgggccg ctcgaaggct 17340
ggccgcgggt attgtcactg tgccccccag gtccaggcga cgagcggccg ccgcagcagc 17400
cgcggccatt agtgctatga ctcagggtcg caggggcaac gtgtattggg tgcgcgactc 17460
ggttagcggc ctgcgcgtgc ccgtgcgcac ccgccccccg cgcaactaga ttgcaagaaa 17520
aaactactta gactcgtact gttgtatgta tccagcggcg gcggcgcgca acgaagctat 17580
gtccaagcgc aaaatcaaag aagagatgct ccaggtcatc gcgccggaga tctatggccc 17640
cccgaagaag gaagagcagg attacaagcc ccgaaagcta aagcgggtca aaaagaaaaa 17700
gaaagatgat gatgatgaac ttgacgacga ggtggaactg ctgcacgcta ccgcgcccag 17760
gcgacgggta cagtggaaag gtcgacgcgt aaaacgtgtt ttgcgacccg gcaccaccgt 17820
agtctttacg cccggtgagc gctccacccg cacctacaag cgcgtgtatg atgaggtgta 17880
cggcgacgag gacctgcttg agcaggccaa cgagcgcctc ggggagtttg cctacggaaa 17940
gcggcataag gacatgctgg cgttgccgct ggacgagggc aacccaacac ctagcctaaa 18000
gcccgtaaca ctgcagcagg tgctgcccgc gcttgcaccg tccgaagaaa agcgcggcct 18060
aaagcgcgag tctggtgact tggcacccac cgtgcagctg atggtaccca agcgccagcg 18120
actggaagat gtcttggaaa aaatgaccgt ggaacctggg ctggagcccg aggtccgcgt 18180
gcggccaatc aagcaggtgg cgccgggact gggcgtgcag accgtggacg ttcagatacc 18240
cactaccagt agcaccagta ttgccaccgc cacagagggc atggagacac aaacgtcccc 18300
ggttgcctca gcggtggcgg atgccgcggt gcaggcggtc gctgcggccg cgtccaagac 18360
ctctacggag gtgcaaacgg acccgtggat gtttcgcgtt tcagcccccc ggcgcccgcg 18420
cggttcgagg aagtacggcg ccgccagcgc gctactgccc gaatatgccc tacatccttc 18480
cattgcgcct acccccggct atcgtggcta cacctaccgc cccagaagac gagcaactac 18540
ccgacgccga accaccactg gaacccgccg ccgccgtcgc cgtcgccagc ccgtgctggc 18600
cccgatttcc gtgcgcaggg tggctcgcga aggaggcagg accctggtgc tgccaacagc 18660
gcgctaccac cccagcatcg tttaaaagcc ggtctttgtg gttcttgcag atatggccct 18720
cacctgccgc ctccgtttcc cggtgccggg attccgagga agaatgcacc gtaggagggg 18780
catggccggc cacggcctga cgggcggcat gcgtcgtgcg caccaccggc ggcggcgcgc 18840
gtcgcaccgt cgcatgcgcg gcggtatcct gcccctcctt attccactga tcgccgcggc 18900
gattggcgcc gtgcccggaa ttgcatccgt ggccttgcag gcgcagagac actgattaaa 18960
aacaagttgc atgtggaaaa atcaaaataa aaagtctgga ctctcacgct cgcttggtcc 19020
tgtaactatt ttgtagaatg gaagacatca actttgcgtc tctggccccg cgacacggct 19080
cgcgcccgtt catgggaaac tggcaagata tcggcaccag caatatgagc ggtggcgcct 19140
tcagctgggg ctcgctgtgg agcggcatta aaaatttcgg ttccaccgtt aagaactatg 19200
gcagcaaggc ctggaacagc agcacaggcc agatgctgag ggataagttg aaagagcaaa 19260
atttccaaca aaaggtggta gatggcctgg cctctggcat tagcggggtg gtggacctgg 19320
ccaaccaggc agtgcaaaat aagattaaca gtaagcttga tccccgccct cccgtagagg 19380
agcctccacc ggccgtggag acagtgtctc cagaggggcg tggcgaaaag cgtccgcgcc 19440
ccgacaggga agaaactctg gtgacgcaaa tagacgagcc tccctcgtac gaggaggcac 19500
taaagcaagg cctgcccacc acccgtccca tcgcgcccat ggctaccgga gtgctgggcc 19560
agcacacacc cgtaacgctg gacctgcctc cccccgccga cacccagcag aaacctgtgc 19620

tgccaggccc gaccgccgtt gttgtaaccc gtcctagccg cgcgtccctg cgccgcgccg 19680
ccagcggtcc gcgatcgttg cggcccgtag ccagtggcaa ctggcaaagc acactgaaca 19740
gcatcgtggg tctgggggtg caatccctga agcgccgacg atgcttctga atagctaacg 19800
tgtcgtatgt gtgtcatgta tgcgtccatg tcgccgccag aggagctgct gagccgccgc 19860
gcgcccgctt tccaagatgg ctacccccttc gatgatgccg cagtggtctt acatgcacat 19920
ctcgggccag gacgcctcgg agtacctgag ccccgggctg gtgcagtttg cccgcgccac 19980
cgagacgtac ttcagcctga ataacaagtt tagaaacccc acggtggcgc ctacgcacga 20040
cgtgaccaca gaccggtccc agcgtttgac gctgcggttc atccctgtgg accgtgagga 20100
tactgcgtac tcgtacaagg cgcggttcac cctagctgtg ggtgataacc gtgtgctgga 20160
catggcttcc acgtactttg acatccgcgg cgtgctggac aggggcccta cttttaagcc 20220
ctactctggc actgcctaca acgccctggc tcccaagggt gccccaaatc cttgcgaatg 20280
ggatgaagct gctactgctc ttgaaataaa cctagaagaa gaggacgatg acaacgaaga 20340
cgaagtagac gagcaagctg agcagcaaaa aactcacgta tttgggcagg cgccttattc 20400
tggtataaat attacaaagg agggtattca aataggtgtc gaaggtcaaa cacctaaata 20460
tgccgataaa acatttcaac ctgaacctca aataggagaa tctcagtggt acgaaactga 20520
aattaatcat gcagctggga gagtccttaa aaagactacc ccaatgaaac catgttacgg 20580
ttcatatgca aaacccacaa atgaaaatgg agggcaaggc attcttgtaa agcaacaaaa 20640
tggaaagcta gaaagtcaag tggaaatgca atttttctca actactgagg cgaccgcagg 20700
caatggtgat aacttgactc ctaaagtggt attgtacagt gaagatgtag atatagaaac 20760
cccagacact catatttctt acatgcccac tattaaggaa ggtaactcac gagaactaat 20820
gggccaacaa tctatgccca acaggcctaa ttacattgct tttagggaca attttattgg 20880
tctaatgtat tacaacagca cgggtaatat gggtgttctg gcgggccaag catcgcagtt 20940
gaatgctgtt gtagatttgc aagacagaaa cacagagctt tcataccagc ttttgcttga 21000
ttccattggt gatagaacca ggtacttttc tatgtggaat caggctgttg acagctatga 21060
tccagatgtt agaattattg aaaatcatgg aactgaagat gaacttccaa attactgctt 21120
tccactggga ggtgtgatta atacagagac tcttaccaag gtaaaaccta aaacaggtca 21180
ggaaaatgga tgggaaaaag atgctacaga attttcagat aaaaatgaaa taagagttgg 21240
aaataatttt gccatggaaa tcaatctaaa tgccaacctg tggagaaatt tcctgtactc 21300
caacatagcg ctgtatttgc ccgacaagct aaagtacagt ccttccaacg taaaaatttc 21360
tgataaccca aacacctacg actacatgaa caagcgagtg gtggctcccg ggttagtgga 21420
ctgctacatt aaccttggag cacgctggtc ccttgactat atggacaacg tcaacccatt 21480
taaccaccac cgcaatgctg gcctgcgcta ccgctcaatg ttgctgggca atggtcgcta 21540
tgtgcccttc cacatccagg tgcctcagaa gttctttgcc attaaaaacc tccttctcct 21600
gccgggctca tacacctacg agtggaactt caggaaggat gttaacatgg ttctgcagag 21660
ctccctagga aatgacctaa gggttgacgg agccagcatt aagtttgata gcatttgcct 21720
ttacgccacc ttcttcccca tggcccacaa caccgcctcc acgcttgagg ccatgcttag 21780
aaacgacacc aacgaccagt cctttaacga ctatctctcc gccgccaaca tgctctaccc 21840
tatacccgcc aacgctacca acgtgcccat atccatcccc tcccgcaact gggcggcttt 21900
ccgcggctgg gccttcacgc gccttaagac taaggaaacc ccatcactgg gctcgggcta 21960
cgacccttat tacacctact ctggctctat accctaccta gatggaacct tttacctcaa 22020
ccacaccttt aagaaggtgg ccattacctt tgactcttct gtcagctggc ctggcaatga 22080
ccgcctgctt acccccaacg agtttgaaat taagcgctca gttgacgggg agggttacaa 22140
cgttgcccag tgtaacatga ccaaagactg gttcctggta caaatgctag ctaactacaa 22200
cattggctac cagggcttct atatcccaga gagctacaag gaccgcatgt actccttctt 22260
tagaaacttc cagcccatga gccgtcaggt ggtggatgat actaaataca aggactacca 22320
acaggtgggc atcctacacc aacacaacaa ctctggattt gttggctacc ttgcccccac 22380
catgcgcgaa ggacaggcct accctgctaa cttcccctat ccgcttatag gcaagaccgc 22440
agttgacagc attacccaga aaaagtttct ttgcgatcgc acccttggc gcatcccatt 22500
ctccagtaac tttatgtcca tgggcgcact cacagacctg ggccaaaacc ttctctacgc 22560
caactccgcc cacgcgctag acatgacttt tgaggtggat cccatggacg agcccaccct 22620
tctttatgtt ttgtttgaag tctttgacgt ggtccgtgtg caccggccgc accgcggcgt 22680
catcgaaacc gtgtacctgc gcacgccctt ctcggccggc aacgccacaa cataaagaag 22740
caagcaacat caacaacagc tgccgccatg ggctccagtg agcaggaact gaaagccatt 22800
gtcaaagatc ttggttgtgg gccatatttt ttgggcacct atgacaagcg ctttccaggc 22860
tttgtttctc cacacaagct cgcctgcgcc atagtcaata cggccggtcg cgagactggg 22920
ggcgtacact ggatggcctt tgcctggaac ccgcactcaa aaacatgcta cctctttgag 22980
ccctttggct tttctgacca gcgactcaag caggtttacc agtttgagta cgagtcactc 23040
ctgcgccgta gcgccattgc ttcttccccc gaccgctgta taacgctgga aaagtccacc 23100
caaagcgtac aggggcccaa ctcggccgcc tgtggactat tctgctgcat gtttctccac 23160
gcctttgcca actggcccca aactcccatg gatcacaacc ccaccatgaa ccttattacc 23220
ggggtaccca actccatgct caacagtccc caggtacagc ccaccctgcg tcgcaaccag 23280

gaacagctct acagcttcct ggagcgccac tcgccctact tccgcagcca cagtgcgcag 23340
attaggagcg ccacttcttt ttgtcacttg aaaaacatgt aaaaataatg tactagagac 23400
actttcaata aaggcaaatg cttttatttg tacactctcg ggtgattatt tacccccacc 23460
cttgccgtct gcgccgtttg gggaggcggc ggcgacgggg acggggacga cacgtcctcc 23520
atggttgggg gacgtcgcgc cgcaccgcgt ccgcgctcgg gggtggtttc gcgctgctcc 23580
tcttcccgac tggccatttc cttctcctat aggcagaaaa agatcatgga gtcagtcgag 23640
aagaaggaca gcctaaccgc cccctctgag ttcgccacca ccgcctccac cgatgccgcc 23700
aacgcgccta ccaccttccc cgtcgaggca cccccgcttg aggaggagga agtgattatc 23760
gagcaggacc caggttttgt aagcgaagac gacgaggacc gctcagtacc aacagaggat 23820
aaaaagcaag accaggacaa cgcagaggca aacgaggaac aagtcgggcg gggggacgaa 23880
aggcatggcg actacctaga tgtgggagac gacgtgctgt tgaagcatct gcagcgccag 23940
tgcgccatta tctgcgacgc gttgcaagag cgcagcgatg tgcccctcgc catagcggat 24000
gtcagccttg cctacgaacg ccacctattc tcaccgcgcg taccccccaa acgccaagaa 24060
aacggcacat gcgagcccaa cccgcgcctc aacttctacc ccgtatttgc cgtgccagag 24120
gtgcttgcca cctatcacat ctttttccaa aactgcaaga tacccctatc ctgccgtgcc 24180
aaccgcagcc gagcggacaa gcagctggcc ttgcggcagg gcgctgtcat acctgatatc 24240
gcctcgctca acgaagtgcc aaaaatcttt gagggtcttg gacgcgacga gaagcgcgcg 24300
gcaaacgctc tgcaacagga aaacagcgaa aatgaaagtc actctggagt gttggtggaa 24360
ctcgagggtg acaacgcgcg cctagccgta ctaaaacgca gcatcgaggt cacccacttt 24420
gcctacccgg cacttaacct acccccccaag gtcatgagca cagtcatgag tgagctgatc 24480
gtgcgccgtg cgcagcccct ggagagggat gcaaatttgc aagaacaaac agaggagggc 24540
ctacccgcag ttggcgacga gcagctagcg cgctggcttc aaacgcgcga gcctgccgac 24600
ttggaggagc gacgcaaact aatgatggcc gcagtgctcg ttaccgtgga gcttgagtgc 24660
atgcagcggt tctttgctga cccggagatg cagcgcaagc tagaggaaac attgcactac 24720
acctttcgac agggctacgt acgccaggcc tgcaagatct ccaacgtgga gctctgcaac 24780
ctggtctcct accttggaat tttgcacgaa aaccgccttg ggcaaaacgt gcttcattcc 24840
acgctcaagg gcgaggcgcg ccgcgactac gtccgcgact gcgtttactt atttctatgc 24900
tacacctggc agacggccat gggcgtttgg cagcagtgct tggaggagtg caacctcaag 24960
gagctgcaga aactgctaaa gcaaaacttg aaggacctat ggacggcctt caacgagcgc 25020
tccgtggccg cgcacctggc ggacatcatt ttccccgaac gcctgcttaa aaccctgcaa 25080
cagggtctgc cagacttcac cagtcaaagc atgttgcaga actttaggaa ctttatccta 25140
gagcgctcag gaatcttgcc cgccacctgc tgtgcacttc ctagcgactt tgtgcccatt 25200
aagtaccgcg aatgccctcc gccgctttgg ggccactgct accttctgca gctagccaac 25260
taccttgcct accactctga cataatggaa gacgtgagcg gtgacggtct actggagtgt 25320
cactgtcgct gcaacctatg caccccgcac cgctccctgg tttgcaattc gcagctgctt 25380
aacgaaagtc aaattatcgg taccttttgag ctgcagggtc cctcgcctga cgaaaagtcc 25440
gcggctccgg ggttgaaact cactccgggg ctgtggacgt cggcttacct tcgcaaattt 25500
gtacctgagg actaccacgc ccacgagatt aggttctacg aagaccaatc ccgcccgcca 25560
aatgcggagc ttaccgcctg cgtcattacc cagggccaca ttcttggcca attgcaagcc 25620
atcaacaaag cccgccaaga gtttctgcta cgaaagggac ggggggttta cttggacccc 25680
cagtccggcg aggagctcaa cccaatcccc ccgccgccgc agccctatca gcagcagccg 25740
cgggcccttg cttcccagga tggcacccaa aaagaagctg cagctgccgc cgccacccac 25800
ggacgaggag gaatactggg acagtcaggc agaggaggtt ttggacgagg aggaggagga 25860
catgatggaa gactgggaga gcctagacga ggaagcttcc gaggtcgaag aggtgtcaga 25920
cgaaacaccg tcaccctcgg tcgcattccc ctcgccggcg ccccagaaat cggcaaccgg 25980
ttccagcatg gctacaacct ccgctcctca ggcgccgccg gcactgcccg ttcgccgacc 26040
caaccgtaga tgggacacca ctggaaccag ggccggtaag tccaagcagc cgccgccgtt 26100
agcccaagag caacaacagc gccaaggcta ccgctcatgg cgcgggcaca agaacgccat 26160
agttgcttgc ttgcaagact gtgggggcaa catctccttc gcccgccgct ttcttctcta 26220
ccatcacggc gtggccttcc cccgtaacat cctgcattac taccgtcatc tctacagccc 26280
atactgcacc ggcggcagcg gcagcggcag caacagcagc ggccacacag aagcaaaggc 26340
gaccggatag caagactctg acaaagccca agaaatccac agcggcggca gcagcaggag 26400
gaggagcgct gcgtctggcg cccaacgaac ccgtatcgac ccgcgagctt agaaacagga 26460
tttttcccac tctgtatgct atatttcaac agagcagggg ccaagaacaa gagctgaaaa 26520
taaaaaacag gtctctgcga tccctcaccc gcagctgcct gtatcacaaa agcgaagatc 26580
agcttcggcg cacgctggaa gacgcggagg ctctcttcag taaatactgc gcgctgactc 26640
ttaaggacta gtttcgcgcc ctttctcaaa tttaagcgcg aaaactacgt catctccagc 26700
ggccacaccc ggcgccagca cctgtcgtca gcgccattat gagcaaggaa attcccacgc 26760
cctacatgtg gagttaccag ccacaaatgg gacttgcggc tggagctgcc caagactact 26820
caacccgaat aaactacatg agcgcgggac cccacatgat atcccgggtc aacggaatcc 26880
gcgcccaccg aaaccgaatt ctcttggaac aggcggctat taccaccaca cctcgtaata 26940

accttaatcc ccgtagttgg cccgctgccc tggtgtacca ggaaagtccc gctcccacca 27000
ctgtggtact tcccagagac gcccaggccg aagttcagat gactaactca ggggcgcagc 27060
ttgcgggcgg ctttcgtcac agggtgcggt cgcccgggca gggtataact cacctgacaa 27120
tcagagggcg aggtattcag ctcaacgacg agtcggtgag ctcctcgctt ggtctccgtc 27180
cggacgggac atttcagatc ggcggcgccg gccgtccttc attcacgcct cgtcaggcaa 27240
tcctaactct gcagacctcg tcctctgagc cgcgctctgg aggcattgga actctgcaat 27300
ttattgagga gtttgtgcca tcggtctact ttaacccctt ctcgggacct cccggccact 27360
atccggatca atttattcct aactttgacg cggtaaagga ctcggcggac ggctacgact 27420
gaatgttaag tggagaggca gagcaactgc gcctgaaaca cctggtccac tgtcgccgcc 27480
acaagtgctt tgcccgcgac tccggtgagt tttgctactt tgaattgccc gaggatcata 27540
tcgagggccc ggcgcacggc gtccggctta ccgcccaggg agagcttgcc cgtagcctga 27600
ttcgggagtt tacccagcgc cccctgctag ttgagcggga caggggaccc tgtgttctca 27660
ctgtgatttg caactgtcct aaccttggat tacatcaaga tctttgttgc catctctgtg 27720
ctgagtataa taaatacaga aattaaaata tactggggct cctatcgcca tcctgtaaac 27780
gccaccgtct tcacccgccc aagcaaacca aggcgaacct tacctggtac ttttaacatc 27840
tctccctctg tgatttacaa cagtttcaac ccagacggag tgagtctacg agagaacctc 27900
tccgagctca gctactccat cagaaaaaac accaccctcc ttacctgccg ggaacgtacg 27960
agtgcgtcac cggccgctgc accacaccta ccgcctgacc gtaaaccaga ctttttccgg 28020
acagacctca ataactctgt ttaccagaac aggaggtgag cttagaaaac ccttagggta 28080
ttaggccaaa ggcgcagcta ctgtggggtt tatgaacaat tcaagcaact ctacgggcta 28140
ttctaattca ggtttctcta gaaatggacg gaattattac agagcagcgc ctgctagaaa 28200
gacgcagggc agcggccgag caacagcgca tgaatcaaga gctccaagac atggttaact 28260
tgcaccagtg caaaaggggt atcttttgtc tggtaaagca ggccaaagtc acctacgaca 28320
gtaataccac cggacaccgc cttagctaca agttgccaac caagcgtcag aaattggtgg 28380
tcatggtggg agaaaagccc attaccataa ctcagcactc ggtagaaacc gaaggctgca 28440
ttcactcacc ttgtcaagga cctgaggatc tctgcaccct tattaagacc ctgtgcggtc 28500
tcaaagatct tattcccttt aactaataaa aaaaaataat aaagcatcac ttacttaaaa 28560
tcagttagca aatttctgtc cagtttattc agcagcacct ccttgccctc ctcccagctc 28620
tggtattgca gcttcctcct ggctgcaaac tttctccaca atctaaatgg aatgtcagtt 28680
tcctcctgtt cctgtccatc cgcacccact atcttcatgt tgttgcagat gaagcgcgca 28740
agaccgtctg aagatacctt caaccccgtg tatccatatg acacggaaac cggtcctcca 28800
actgtgcctt ttcttactcc tccctttgta tcccccaatg ggtttcaaga gagtcccctt 28860
ggggtactct ctttgcgcct atccgaacct ctagttacct ccaatggcat gcttgcgctc 28920
aaaatgggca acggcctctc tctggacgag gccggcaacc ttacctccca aaatgtaacc 28980
actgtgagcc cacctctcaa aaaaaccaag tcaaacataa acctggaaat atctgcaccc 29040
ctcacagtta cctcagaagc cctaactgtg gctgccgccg cacctctaat ggtcgcgggc 29100
aacacactca ccatgcaatc acaggccccg ctaaccgtgc acgactccaa acttagcatt 29160
gccacccaag gacccctcac agtgtcagaa ggaaagctag ccctgcaaac atcaggcccc 29220
ctcaccacca ccgatagcag tacccttact atcactgcct cacccctct aactactgcc 29280
actggtagct tgggcattga cttgaaagag cccatttata cacaaaatgg aaaactagga 29340
ctaaagtacg gggctccttt gcatgtaaca gacgacctaa acactttgac cgtagcaact 29400
ggtccaggtg tgactattaa taatacttcc ttgcaaacta aagttactgg agccttgggt 29460
tttgattcac aaggcaatat gcaacttaat gtagcaggag gactaaggat tgattctcaa 29520
aacagacgcc ttatacttga tgttagttat ccgtttgatg ctcaaaacca actaaatcta 29580
agactaggac agggccctct ttttataaac tcagcccaca acttggatat taactacaac 29640
aaaggccttt acttgtttac agcttcaaac aattccaaaa agcttgaggt taacctaagc 29700
actgccaagg ggttgatgtt tgacgctaca gccatagcca ttaatgcagg agatgggctt 29760
gaatttggtt cacctaatgc accaaacaca aatcccctca aaacaaaaat tggccatggc 29820
ctagaatttg attcaaacaa ggctatggtt cctaaactag gaactggcct tagttttgac 29880
agcacaggtg ccattacagt aggaaacaaa aataatgata agctaacttt gtggaccaca 29940
ccagctccat ctcctaactg tagactaaat gcagagaaag atgctaaact cactttggtc 30000
ttaacaaaat gtggcagtca aatacttgct acagtttcag ttttggctgt taaaggcagt 30060
ttggctccaa tatctggaac agttcaaagt gctcatctta ttataagatt tgacgaaaat 30120
ggagtgctac taaacaattc cttcctggac ccagaatatt ggaactttag aaatggagat 30180
cttactgaag gcacagccta tacaaacgct gttggattta tgcctaacct atcagcttat 30240
ccaaaatctc acggtaaaac tgccaaaagt aacattgtca gtcaagttta cttaaacgga 30300
gacaaaacta aacctgtaac actaaccatt acactaaacg gtacacagga aacaggagac 30360
acaactccaa gtgcatactc tatgtcattt tcatgggact ggtctggcca caactacatt 30420
aatgaaatat ttgccacatc ctcttacact ttttcataca ttgcccaaga ataaagaatc 30480
gtttgtgtta tgtttcaacg tgtttatttt tcaattgcag aaaatttcaa gtcatttttc 30540
attcagtagt atagccccac caccacatag cttatacaga tcaccgtacc ttaatcaaac 30600

tcacagaacc ctagtattca acctgccacc tccctcccaa cacacagagt acacagtcct 30660
ttctccccgg ctggccttaa aaagcatcat atcatgggta acagacatat tcttaggtgt 30720
tatattccac acggtttcct gtcgagccaa acgctcatca gtgatattaa taaactcccc 30780
gggcagctca cttaagttca tgtcgctgtc cagctgctga gccacaggct gctgtccaac 30840
ttgcggttgc ttaacgggcg gcgaaggaga agtccacgcc tacatggggg tagagtcata 30900
atcgtgcatc aggatagggc ggtggtgctg cagcagcgcg cgaataaact gctgccgccg 30960
ccgctccgtc ctgcaggaat acaacatggc agtggtctcc tcagcgatga ttcgcaccgc 31020
ccgcagcata aggcgccttg tcctccgggc acagcagcgc accctgatct cacttaaatc 31080
agcacagtaa ctgcagcaca gcaccacaat attgttcaaa atcccacagt gcaaggcgct 31140
gtatccaaag ctcatggcgg ggaccacaga acccacgtgg ccatcatacc acaagcgcag 31200
gtagattaag tggcgacccc tcataaacac gctggacata aacattacct cttttggcat 31260
gttgtaattc accacctccc ggtaccatat aaacctctga ttaaacatgg cgccatccac 31320
caccatccta aaccagctgg ccaaaacctg cccgccggct atacactgca gggaaccggg 31380
actggaacaa tgacagtgga gagcccagga ctcgtaacca tggatcatca tgctcgtcat 31440
gatatcaatg ttggcacaac acaggcacac gtgcatacac ttcctcagga ttacaagctc 31500
ctcccgcgtt agaaccatat cccagggaac aacccattcc tgaatcagcg taaatcccac 31560
actgcaggga agacctcgca cgtaactcac gttgtgcatt gtcaaagtgt tacattcggg 31620
cagcagcgga tgatcctcca gtatggtagc gcgggtttct gtctcaaaag gaggtagacg 31680
atccctactg tacggagtgc gccgagacaa ccgagatcgt gttggtcgta gtgtcatgcc 31740
aaatggaacg ccggacgtag tcatatttcc tgaagcaaaa ccaggtgcgg gcgtgacaaa 31800
cagatctgcg tctccggtct cgccgcttag atcgctctgt gtagtagttg tagtatatcc 31860
actctctcaa agcatccagg cgccccctgg cttcgggttc tatgtaaact ccttcatgcg 31920
ccgctgccct gataacatcc accaccgcag aataagccac acccagccaa cctacacatt 31980
cgttctgcga gtcacacacg ggaggagcgg gaagagctgg aagaaccatg ttttttttt 32040
tattccaaaa gattatccaa aacctcaaaa tgaagatcta ttaagtgaac gcgctcccct 32100
ccggtggcgt ggtcaaactc tacagccaaa gaacagataa tggcatttgt aagatgttgc 32160
acaatggctt ccaaaaggca aacggccctc acgtccaagt ggacgtaaag gctaaaccct 32220
tcagggtgaa tctcctctat aaacattcca gcaccttcaa ccatgcccaa ataattctca 32280
tctcgccacc ttctcaatat atctctaagc aaatcccgaa tattaagtcc ggccattgta 32340
aaaatctgct ccagagcgcc ctccaccttc agcctcaagc agcgaatcat gattgcaaaa 32400
attcaggttc ctcacagacc tgtataagat tcaaaagcgg aacattaaca aaaataccgc 32460
gatcccgtag gtcccttcgc agggccagct gaacataatc gtgcaggtct gcacggacca 32520
gcgcggccac ttccccgcca ggaaccttga caaaagaacc cacactgatt atgacacgca 32580
tactcggagc tatgctaacc agcgtagccc cgatgtaagc tttgttgcat gggcggcgat 32640
ataaaatgca aggtgctgct caaaaaatca ggcaaagcct cgcgcaaaaa agaaagcaca 32700
tcgtagtcat gctcatgcag ataaaggcag gtaagctccg gaaccaccac agaaaaagac 32760
accatttttc tctcaaacat gtctgcgggt ttctgcataa acacaaaata aaataacaaa 32820
aaaacattta aacattagaa gcctgtctta caacaggaaa aacaaccctt ataagcataa 32880
gacggactac ggccatgccg gcgtgaccgt aaaaaaactg gtcaccgtga ttaaaaagca 32940
ccaccgacag ctcctcggtc atgtccggag tcataatgta agactcggta aacacatcag 33000
gttgattcat cggtcagtgc taaaaagcga ccgaaatagc ccgggggaat acatacccgc 33060
aggcgtagag acaacattac agcccccata ggaggtataa caaaattaat aggagagaaa 33120
aacacataaa cacctgaaaa accctcctgc ctaggcaaaa tagcaccctc ccgctccaga 33180
acaacataca gcgcttcaca gcggcagcct aacagtcagc cttaccagta aaaaagaaaa 33240
cctattaaaa aaacaccact cgacacggca ccagctcaat cagtcacagt gtaaaaaagg 33300
gccaagtgca gagcgagtat atataggact aaaaaatgac gtaacggtta aagtccacaa 33360
aaaacaccca gaaaaccgca cgcgaaccta cgcccagaaa cgaaagccaa aaaacccaca 33420
acttcctcaa atcgtcactt ccgttttccc acgttacgta acttcccatt ttaagaaaac 33480
tacaattccc aacacataca agttactccg ccctaaaacc tacgtcaccc gccccgttcc 33540
cacgccccgc gccacgtcac aaactccacc ccctcattat catattggct tcaatccaaa 33600
ataaggtata ttattgatga tg 33622

<210> 45
<211> 1746
<212> DNA
<213> Artificial Sequence

<220>
<223> 5F KO1

<400> 45

atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
accggtcctc caactgtgcc ttttcttact cctccctttg tatcccccaa tgggtttcaa 120
gagagtcccc ctggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
atgcttgcgc tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacat aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccccc 540
ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatccccc caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggacca caccagctcc agaggctaac tgtagactaa atgcagagaa agatgctaaa 1260
ctcactttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
tttgacgaaa atggagtgct actaaacaat tccttcctgg acccagaata ttggaacttt 1440
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 1500
ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
tacttaaacg gagacaaaac taaacctgta acactaacca ttacactaaa cggtacacag 1620
gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga ctggtctggc 1680
cacaactaca ttaatgaaat atttgccaca tcctcttaca ctttttcata cattgcccaa 1740
gaataa 1746

<210> 46
<211> 581
<212> PRT
<213> Artificial Sequence

<220>
<223> 5F KO1

<400> 46

```
Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
 1               5                  10                  15
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
            20                  25                  30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
        35                  40                  45
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
    50                  55                  60
Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
65                  70                  75                  80
Gln Asn Val Thr Thr Val Ser Pro Pro Leu Lys Lys Thr Lys Ser Asn
                85                  90                  95
Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
            100                 105                 110
Thr Val Ala Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr
        115                 120                 125
Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
    130                 135                 140
Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
145                 150                 155                 160
Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr
```

```
                 165                 170                 175
Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu Gly Ile Asp Leu
            180                 185                 190
Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly Leu Lys Tyr Gly
        195                 200                 205
Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu Thr Val Ala Thr
    210                 215                 220
Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln Thr Lys Val Thr
225                 230                 235                 240
Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln Leu Asn Val Ala
                245                 250                 255
Gly Gly Leu Arg Ile Asp Ser Gln Asn Arg Arg Leu Ile Leu Asp Val
            260                 265                 270
Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu Arg Leu Gly Gln
        275                 280                 285
Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp Ile Asn Tyr Asn
    290                 295                 300
Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser Lys Lys Leu Glu
305                 310                 315                 320
Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp Ala Thr Ala Ile
                325                 330                 335
Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser Pro Asn Ala Pro
            340                 345                 350
Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly Leu Glu Phe Asp
        355                 360                 365
Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly Leu Ser Phe Asp
    370                 375                 380
Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn Asp Lys Leu Thr
385                 390                 395                 400
Leu Trp Thr Thr Pro Ala Pro Glu Ala Asn Cys Arg Leu Asn Ala Glu
                405                 410                 415
Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys Cys Gly Ser Gln Ile
            420                 425                 430
Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly Ser Leu Ala Pro Ile
        435                 440                 445
Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile Arg Phe Asp Glu Asn
    450                 455                 460
Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro Glu Tyr Trp Asn Phe
465                 470                 475                 480
Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr Thr Asn Ala Val Gly
                485                 490                 495
Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His Gly Lys Thr Ala
            500                 505                 510
Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly Asp Lys Thr Lys
        515                 520                 525
Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln Glu Thr Gly Asp
    530                 535                 540
Thr Thr Pro Ser Ala Tyr Ser Met Ser Phe Ser Trp Asp Trp Ser Gly
545                 550                 555                 560
His Asn Tyr Ile Asn Glu Ile Phe Ala Thr Ser Ser Tyr Thr Phe Ser
                565                 570                 575
Tyr Ile Ala Gln Glu
            580
```

<210> 47
<211> 1776
<212> DNA
<213> Artificial Sequence

<220>

<223> 5F KO1RGD

<400> 47
atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
accggtcctc caactgtgcc ttttcttact cctccctttg tatcccccaa tgggtttcaa 120
gagagtcccc ctggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
atgcttgcgc tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacat aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccccc 540
ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggacca caccagctcc atctcctaac tgtagactaa atgcagagaa agatgctaaa 1260
ctcactttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
tttgacgaaa atggagtgct actaaacaat tccttcctgg acccagaata ttggaacttt 1440
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 1500
ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
tacttaaacg gagacaaaac taaacctgta acactaacca ttacactaaa cggtacacag 1620
gaaacaggtg atcattgtga ttgtcgtggt gattgttttt gtacaactcc aagtgcatac 1680
tctatgtcat tttcatggga ctggtctggc cacaactaca ttaatgaaat atttgccaca 1740
tcctcttaca ctttttcata cattgcccaa gaataa 1776

<210> 48
<211> 591
<212> PRT
<213> Artificial Sequence

<220>
<223> 5F KO1RGD

<400> 48
Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
1 5 10 15
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
20 25 30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
35 40 45
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
50 55 60
Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
65 70 75 80
Gln Asn Val Thr Thr Val Ser Pro Pro Leu Lys Lys Thr Lys Ser Asn
85 90 95
Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
100 105 110
Thr Val Ala Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr
115 120 125
Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
130 135 140

```
Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
145                 150                 155                 160
Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr
                165                 170                 175
Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu Gly Ile Asp Leu
            180                 185                 190
Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly Leu Lys Tyr Gly
        195                 200                 205
Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu Thr Val Ala Thr
    210                 215                 220
Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln Thr Lys Val Thr
225                 230                 235                 240
Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln Leu Asn Val Ala
                245                 250                 255
Gly Gly Leu Arg Ile Asp Ser Gln Asn Arg Arg Leu Ile Leu Asp Val
            260                 265                 270
Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu Arg Leu Gly Gln
        275                 280                 285
Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp Ile Asn Tyr Asn
    290                 295                 300
Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser Lys Lys Leu Glu
305                 310                 315                 320
Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp Ala Thr Ala Ile
                325                 330                 335
Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser Pro Asn Ala Pro
            340                 345                 350
Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly Leu Glu Phe Asp
        355                 360                 365
Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly Leu Ser Phe Asp
    370                 375                 380
Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn Asp Lys Leu Thr
385                 390                 395                 400
Leu Trp Thr Thr Pro Ala Pro Glu Ala Asn Cys Arg Leu Asn Ala Glu
                405                 410                 415
Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys Cys Gly Ser Gln Ile
            420                 425                 430
Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly Ser Leu Ala Pro Ile
        435                 440                 445
Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile Arg Phe Asp Glu Asn
    450                 455                 460
Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro Glu Tyr Trp Asn Phe
465                 470                 475                 480
Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr Thr Asn Ala Val Gly
                485                 490                 495
Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His Gly Lys Thr Ala
            500                 505                 510
Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly Asp Lys Thr Lys
        515                 520                 525
Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln Glu Thr Gly Asp
    530                 535                 540
His Cys Asp Cys Arg Gly Asp Cys Phe Cys Thr Thr Pro Ser Ala Tyr
545                 550                 555                 560
Ser Met Ser Phe Ser Trp Asp Trp Ser Gly His Asn Tyr Ile Asn Glu
                565                 570                 575
Ile Phe Ala Thr Ser Ser Tyr Thr Phe Ser Tyr Ile Ala Gln Glu
            580                 585                 590
```

<210> 49
<211> 1746
<212> DNA

<213> Artificial Sequence

<220>
<223> 5F KO12

<400> 49
atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
accggtcctc caactgtgcc ttttcttact cctccctttg tatccccaa tgggtttcaa 120
gagagtcccc ctggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
atgcttgcgc tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacat aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccct 540
ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggacca caccagctcc atctcctaac tgttcactaa atggaggcgg agatgctaaa 1260
ctcactttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
tttgacgaaa atggagtgct actaaacaat tccttcctgg acccagaata ttggaacttt 1440
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 1500
ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
tacttaaacg gagacaaaac taaacctgta acactaacca ttacactaaa cggtacacag 1620
gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga ctggtctggc 1680
cacaactaca ttaatgaaat atttgccaca tcctcttaca ctttttcata cattgcccaa 1740
gaataa 1746

<210> 50
<211> 581
<212> PRT
<213> Artificial Sequence

<220>
<223> 5F KO12

<400> 50
Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
 1               5                  10                  15
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
            20                  25                  30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
        35                  40                  45
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
    50                  55                  60
Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
65                  70                  75                  80
Gln Asn Val Thr Thr Val Ser Pro Pro Leu Lys Lys Thr Lys Ser Asn
                85                  90                  95
Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
            100                 105                 110
Thr Val Ala Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr

```
                115                 120                 125
Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
    130                 135                 140
Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
145                 150                 155                 160
Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr
                165                 170                 175
Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu Gly Ile Asp Leu
            180                 185                 190
Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly Leu Lys Tyr Gly
        195                 200                 205
Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu Thr Val Ala Thr
    210                 215                 220
Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln Thr Lys Val Thr
225                 230                 235                 240
Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln Leu Asn Val Ala
                245                 250                 255
Gly Gly Leu Arg Ile Asp Ser Gln Asn Arg Arg Leu Ile Leu Asp Val
            260                 265                 270
Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu Arg Leu Gly Gln
        275                 280                 285
Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp Ile Asn Tyr Asn
    290                 295                 300
Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser Lys Lys Leu Glu
305                 310                 315                 320
Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp Ala Thr Ala Ile
                325                 330                 335
Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser Pro Asn Ala Pro
            340                 345                 350
Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly Leu Glu Phe Asp
        355                 360                 365
Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly Leu Ser Phe Asp
    370                 375                 380
Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn Asp Lys Leu Thr
385                 390                 395                 400
Leu Trp Thr Thr Pro Ala Pro Ser Pro Asn Cys Ser Leu Asn Gly Gly
                405                 410                 415
Gly Asp Ala Lys Leu Thr Leu Val Leu Thr Lys Cys Gly Ser Gln Ile
            420                 425                 430
Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly Ser Leu Ala Pro Ile
        435                 440                 445
Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile Arg Phe Asp Glu Asn
    450                 455                 460
Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro Glu Tyr Trp Asn Phe
465                 470                 475                 480
Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr Thr Asn Ala Val Gly
                485                 490                 495
Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His Gly Lys Thr Ala
            500                 505                 510
Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly Asp Lys Thr Lys
        515                 520                 525
Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln Glu Thr Gly Asp
    530                 535                 540
Thr Thr Pro Ser Ala Tyr Ser Met Ser Phe Ser Trp Asp Trp Ser Gly
545                 550                 555                 560
His Asn Tyr Ile Asn Glu Ile Phe Ala Thr Ser Ser Tyr Thr Phe Ser
                565                 570                 575
Tyr Ile Ala Gln Glu
            580
```

<210> 51
<211> 1746
<212> DNA
<213> Artificial Sequence

<220>
<223> 5F S*

<400> 51
atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
accggtcctc caactgtgcc ttttcttact cctccctttg tatcccccaa tgggtttcaa 120
gagagtcccc ctggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
atgcttgcgc tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc ggagccggag cctcaaacat aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccccc 540
ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggacca caccagctcc atctcctaac tgtagactaa atgcagagaa agatgctaaa 1260
ctcactttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
tttgacgaaa atggagtgct actaaacaat tccttcctgg acccagaata ttggaacttt 1440
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 1500
ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
tacttaaacg gagacaaaac taaacctgta acactaacca ttacactaaa cggtacacag 1620
gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga ctggtctggc 1680
cacaactaca ttaatgaaat atttgccaca tcctcttaca ctttttcata cattgcccaa 1740
gaataa 1746

<210> 52
<211> 581
<212> PRT
<213> Artificial Sequence

<220>
<223> 5F S*

<400> 52
Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
1 5 10 15
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
20 25 30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
35 40 45
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
50 55 60
Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
65 70 75 80
Gln Asn Val Thr Thr Val Ser Pro Pro Leu Gly Ala Gly Ala Ser Asn
85 90 95

```
Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
                100                 105                 110
Thr Val Ala Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr
        115                 120                 125
Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
    130                 135                 140
Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
145                 150                 155                 160
Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr
                165                 170                 175
Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu Gly Ile Asp Leu
            180                 185                 190
Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly Leu Lys Tyr Gly
        195                 200                 205
Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu Thr Val Ala Thr
    210                 215                 220
Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln Thr Lys Val Thr
225                 230                 235                 240
Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln Leu Asn Val Ala
                245                 250                 255
Gly Gly Leu Arg Ile Asp Ser Gln Asn Arg Arg Leu Ile Leu Asp Val
            260                 265                 270
Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu Arg Leu Gly Gln
        275                 280                 285
Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp Ile Asn Tyr Asn
    290                 295                 300
Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser Lys Lys Leu Glu
305                 310                 315                 320
Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp Ala Thr Ala Ile
                325                 330                 335
Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser Pro Asn Ala Pro
            340                 345                 350
Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly Leu Glu Phe Asp
        355                 360                 365
Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly Leu Ser Phe Asp
    370                 375                 380
Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn Asp Lys Leu Thr
385                 390                 395                 400
Leu Trp Thr Thr Pro Ala Pro Ser Pro Asn Cys Arg Leu Asn Ala Glu
                405                 410                 415
Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys Cys Gly Ser Gln Ile
            420                 425                 430
Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly Ser Leu Ala Pro Ile
        435                 440                 445
Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile Arg Phe Asp Glu Asn
    450                 455                 460
Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro Glu Tyr Trp Asn Phe
465                 470                 475                 480
Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr Thr Asn Ala Val Gly
                485                 490                 495
Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His Gly Lys Thr Ala
            500                 505                 510
Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly Asp Lys Thr Lys
        515                 520                 525
Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln Glu Thr Gly Asp
    530                 535                 540
Thr Thr Pro Ser Ala Tyr Ser Met Ser Phe Ser Trp Asp Trp Ser Gly
545                 550                 555                 560
His Asn Tyr Ile Asn Glu Ile Phe Ala Thr Ser Ser Tyr Thr Phe Ser
                565                 570                 575
Tyr Ile Ala Gln Glu
```

580

<210> 53
<211> 1776
<212> DNA
<213> Artificial Sequence

<220>
<223> 5F S*RGD

<400> 53
atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
accggtcctc caactgtgcc ttttcttact cctccctttg tatcccccaa tgggtttcaa 120
gagagtcccc ctggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
atgcttgcgc tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc ggagccggag cctcaaacat aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccccc 540
ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggacca caccagctcc atctcctaac tgtagactaa atgcagagaa agatgctaaa 1260
ctcactttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
tttgacgaaa atggagtgct actaaacaat tccttcctgg acccagaata ttggaacttt 1440
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 1500
ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
tacttaaacg gagacaaaac taaacctgta acactaacca ttacactaaa cggtacacag 1620
gaaacaggtg atcattgtga ttgtcgtggt gattgttttt gtacaactcc aagtgcatac 1680
tctatgtcat tttcatggga ctggtctggc cacaactaca ttaatgaaat atttgccaca 1740
tcctcttaca ctttttcata cattgcccaa gaataa 1776

<210> 54
<211> 591
<212> PRT
<213> Artificial Sequence

<220>
<223> 5F S*RGD

<400> 54
Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
 1               5                  10                  15
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
            20                  25                  30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
        35                  40                  45
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
    50                  55                  60
Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser

```
65                  70                  75                  80
Gln Asn Val Thr Thr Val Ser Pro Pro Leu Gly Ala Gly Ala Ser Asn
                85                  90                  95
Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
            100                 105                 110
Thr Val Ala Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr
        115                 120                 125
Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
    130                 135                 140
Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
145                 150                 155                 160
Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr
                165                 170                 175
Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu Gly Ile Asp Leu
            180                 185                 190
Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly Leu Lys Tyr Gly
        195                 200                 205
Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu Thr Val Ala Thr
    210                 215                 220
Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln Thr Lys Val Thr
225                 230                 235                 240
Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln Leu Asn Val Ala
                245                 250                 255
Gly Gly Leu Arg Ile Asp Ser Gln Asn Arg Arg Leu Ile Leu Asp Val
            260                 265                 270
Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu Arg Leu Gly Gln
        275                 280                 285
Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp Ile Asn Tyr Asn
    290                 295                 300
Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser Lys Lys Leu Glu
305                 310                 315                 320
Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp Ala Thr Ala Ile
                325                 330                 335
Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser Pro Asn Ala Pro
            340                 345                 350
Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly Leu Glu Phe Asp
        355                 360                 365
Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly Leu Ser Phe Asp
    370                 375                 380
Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn Asp Lys Leu Thr
385                 390                 395                 400
Leu Trp Thr Thr Pro Ala Pro Ser Pro Asn Cys Arg Leu Asn Ala Glu
                405                 410                 415
Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys Cys Gly Ser Gln Ile
            420                 425                 430
Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly Ser Leu Ala Pro Ile
        435                 440                 445
Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile Arg Phe Asp Glu Asn
    450                 455                 460
Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro Glu Tyr Trp Asn Phe
465                 470                 475                 480
Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr Thr Asn Ala Val Gly
                485                 490                 495
Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His Gly Lys Thr Ala
            500                 505                 510
Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly Asp Lys Thr Lys
        515                 520                 525
Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln Glu Thr Gly Asp
    530                 535                 540
His Cys Asp Cys Arg Gly Asp Cys Phe Cys Thr Thr Pro Ser Ala Tyr
545                 550                 555                 560
```

```
Ser Met Ser Phe Ser Trp Asp Trp Ser Gly His Asn Tyr Ile Asn Glu
                565                 570                 575
Ile Phe Ala Thr Ser Ser Tyr Thr Phe Ser Tyr Ile Ala Gln Glu
            580                 585                 590
```

<210> 55
<211> 1746
<212> DNA
<213> Artificial Sequence

<220>
<223> 5F KO1S*

<400> 55
atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
accggtcctc caactgtgcc ttttcttact cctccctttg tatccccaa tgggtttcaa 120
gagagtcccc ctggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
atgcttgcgc tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc ggagccggag cctcaaacat aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccccc 540
ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggacca caccagctcc agaggctaac tgtagactaa atgcagagaa agatgctaaa 1260
ctcactttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
tttgacgaaa atggagtgct actaaacaat tccttcctgg acccagaata ttggaacttt 1440
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 1500
ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
tacttaaacg gagacaaaac taaacctgta acactaacca ttacactaaa cggtacacag 1620
gaaacaggag acacaactcc aagtgcatac tctatgtcat tttcatggga ctggtctggc 1680
cacaactaca ttaatgaaat atttgccaca tcctcttaca ctttttcata cattgcccaa 1740
gaataa 1746

<210> 56
<211> 581
<212> PRT
<213> Artificial Sequence

<220>
<223> 5F KO1S*

<400> 56
```
Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
 1               5                  10                  15
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
            20                  25                  30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
        35                  40                  45
```

```
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
    50                  55                  60
Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
65                  70                  75                  80
Gln Asn Val Thr Thr Val Ser Pro Pro Leu Gly Ala Gly Ala Ser Asn
                85                  90                  95
Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
            100                 105                 110
Thr Val Ala Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr
        115                 120                 125
Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
    130                 135                 140
Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
145                 150                 155                 160
Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr
                165                 170                 175
Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu Gly Ile Asp Leu
            180                 185                 190
Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly Leu Lys Tyr Gly
        195                 200                 205
Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu Thr Val Ala Thr
    210                 215                 220
Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln Thr Lys Val Thr
225                 230                 235                 240
Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln Leu Asn Val Ala
                245                 250                 255
Gly Gly Leu Arg Ile Asp Ser Gln Asn Arg Arg Leu Ile Leu Asp Val
            260                 265                 270
Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu Arg Leu Gly Gln
        275                 280                 285
Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp Ile Asn Tyr Asn
    290                 295                 300
Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser Lys Lys Leu Glu
305                 310                 315                 320
Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp Ala Thr Ala Ile
                325                 330                 335
Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser Pro Asn Ala Pro
            340                 345                 350
Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly Leu Glu Phe Asp
        355                 360                 365
Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly Leu Ser Phe Asp
    370                 375                 380
Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn Asp Lys Leu Thr
385                 390                 395                 400
Leu Trp Thr Thr Pro Ala Pro Glu Ala Asn Cys Arg Leu Asn Ala Glu
                405                 410                 415
Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys Cys Gly Ser Gln Ile
            420                 425                 430
Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly Ser Leu Ala Pro Ile
        435                 440                 445
Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile Arg Phe Asp Glu Asn
    450                 455                 460
Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro Glu Tyr Trp Asn Phe
465                 470                 475                 480
Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr Thr Asn Ala Val Gly
                485                 490                 495
Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His Gly Lys Thr Ala
            500                 505                 510
Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly Asp Lys Thr Lys
        515                 520                 525
Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln Glu Thr Gly Asp
```

```
    530                 535                 540
Thr Thr Pro Ser Ala Tyr Ser Met Ser Phe Ser Trp Asp Trp Ser Gly
545                 550                 555                 560
His Asn Tyr Ile Asn Glu Ile Phe Ala Thr Ser Ser Tyr Thr Phe Ser
                565                 570                 575
Tyr Ile Ala Gln Glu
            580
```

<210> 57
<211> 1776
<212> DNA
<213> Artificial Sequence

<220>
<223> 5F KO1S*RGD

<400> 57
atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60
accggtcctc caactgtgcc ttttcttact cctccctttg tatccccaa tgggtttcaa 120
gagagtcccc ctggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
atgcttgcgc tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc ggagccggag cctcaaacat aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccccc 540
ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggacca caccagctcc agaggctaac tgtagactaa atgcagagaa agatgctaaa 1260
ctcactttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320
gttaaaggca gtttggctcc aatatctgga acagttcaaa gtgctcatct tattataaga 1380
tttgacgaaa atggagtgct actaaacaat tccttcctgg acccagaata ttggaacttt 1440
agaaatggag atcttactga aggcacagcc tatacaaacg ctgttggatt tatgcctaac 1500
ctatcagctt atccaaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560
tacttaaacg gagacaaaac taaacctgta acactaacca ttacactaaa cggtacacag 1620
gaaacaggtg atcattgtga ttgtcgtggt gattgttttt gtacaactcc aagtgcatac 1680
tctatgtcat tttcatggga ctggtctggc cacaactaca ttaatgaaat atttgccaca 1740
tcctcttaca ctttttcata cattgcccaa gaataa 1776

<210> 58
<211> 591
<212> PRT
<213> Artificial Sequence

<220>
<223> 5F KO1S*RGD

<400> 58
```
Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
 1               5                  10                  15
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
```

```
                20                  25                  30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
        35                  40                  45
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
    50                  55                  60
Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
65                  70                  75                  80
Gln Asn Val Thr Thr Val Ser Pro Pro Leu Gly Ala Gly Ala Ser Asn
                85                  90                  95
Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
            100                 105                 110
Thr Val Ala Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr
        115                 120                 125
Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
    130                 135                 140
Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
145                 150                 155                 160
Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr
                165                 170                 175
Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu Gly Ile Asp Leu
            180                 185                 190
Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly Leu Lys Tyr Gly
        195                 200                 205
Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu Thr Val Ala Thr
    210                 215                 220
Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln Thr Lys Val Thr
225                 230                 235                 240
Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln Leu Asn Val Ala
                245                 250                 255
Gly Gly Leu Arg Ile Asp Ser Gln Asn Arg Arg Leu Ile Leu Asp Val
            260                 265                 270
Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu Arg Leu Gly Gln
        275                 280                 285
Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp Ile Asn Tyr Asn
    290                 295                 300
Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser Lys Lys Leu Glu
305                 310                 315                 320
Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp Ala Thr Ala Ile
                325                 330                 335
Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser Pro Asn Ala Pro
            340                 345                 350
Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly Leu Glu Phe Asp
        355                 360                 365
Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly Leu Ser Phe Asp
    370                 375                 380
Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn Asp Lys Leu Thr
385                 390                 395                 400
Leu Trp Thr Thr Pro Ala Pro Glu Ala Asn Cys Arg Leu Asn Ala Glu
                405                 410                 415
Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys Cys Gly Ser Gln Ile
            420                 425                 430
Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly Ser Leu Ala Pro Ile
        435                 440                 445
Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile Arg Phe Asp Glu Asn
    450                 455                 460
Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro Glu Tyr Trp Asn Phe
465                 470                 475                 480
Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr Thr Asn Ala Val Gly
                485                 490                 495
Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His Gly Lys Thr Ala
            500                 505                 510
```

```
Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly Asp Lys Thr Lys
        515                 520                 525
Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln Glu Thr Gly Asp
    530                 535                 540
His Cys Asp Cys Arg Gly Asp Cys Phe Cys Thr Thr Pro Ser Ala Tyr
545                 550                 555                 560
Ser Met Ser Phe Ser Trp Asp Trp Ser Gly His Asn Tyr Ile Asn Glu
                565                 570                 575
Ile Phe Ala Thr Ser Ser Tyr Thr Phe Ser Tyr Ile Ala Gln Glu
            580                 585                 590
```

<210> 59
<211> 972
<212> DNA
<213> Artificial Sequence

<220>
<223> 35F

<400> 59
atgaccaaga gagtccggct cagtgactcc ttcaaccctg tctaccccta tgaagatgaa 60
agcacctccc aacacccctt tataaaccca gggtttattt ccccaaatgg cttcacacaa 120
agcccagacg gagttcttac tttaaaatgt ttaaccccac taacaaccac aggcggatct 180
ctacagctaa aagtgggagg gggacttaca gtggatgaca ctgatggtac cttacaagaa 240
aacatacgtg ctacagcacc cattactaaa aataatcact ctgtagaact atccattgga 300
aatggattag aaactcaaaa caataaacta tgtgccaaat tgggaaatgg gttaaaattt 360
aacaacggtg acatttgtat aaaggatagt attaacacct tatggactgg aataaaccct 420
ccacctaact gtcaaattgt ggaaaacact aatacaaatg atggcaaact tactttagta 480
ttagtaaaaa atggagggct tgttaatggc tacgtgtctc tagttggtgt atcagacact 540
gtgaaccaaa tgttcacaca aaagacagca aacatccaat taagattata ttttgactct 600
tctggaaatc tattaactga ggaatcagac ttaaaaattc cacttaaaaa taaatcttct 660
acagcgacca gtgaaactgt agccagcagc aaagccttta tgccaagtac tacagcttat 720
cccttcaaca ccactactag ggatagtgaa aactacattc atggaatatg ttactacatg 780
actagttatg atagaagtct atttcccttg aacatttcta taatgctaaa cagccgtatg 840
atttcttcca atgttgccta tgccatacaa tttgaatgga atctaaatgc aagtgaatct 900
ccagaaagca acatagctac gctgaccaca tccccctttt tcttttctta cattacagaa 960
gacgacgaat aa 972

<210> 60
<211> 323
<212> PRT
<213> Artificial Sequence

<220>
<223> 35F

<400> 60
```
Met Thr Lys Arg Val Arg Leu Ser Asp Ser Phe Asn Pro Val Tyr Pro
 1               5                  10                  15
Tyr Glu Asp Glu Ser Thr Ser Gln His Pro Phe Ile Asn Pro Gly Phe
            20                  25                  30
Ile Ser Pro Asn Gly Phe Thr Gln Ser Pro Asp Gly Val Leu Thr Leu
        35                  40                  45
Lys Cys Leu Thr Pro Leu Thr Thr Thr Gly Gly Ser Leu Gln Leu Lys
    50                  55                  60
Val Gly Gly Gly Leu Thr Val Asp Asp Thr Asp Gly Thr Leu Gln Glu
65                  70                  75                  80
Asn Ile Arg Ala Thr Ala Pro Ile Thr Lys Asn Asn His Ser Val Glu
                85                  90                  95
Leu Ser Ile Gly Asn Gly Leu Glu Thr Gln Asn Asn Lys Leu Cys Ala
```

```
                100                 105                 110
Lys Leu Gly Asn Gly Leu Lys Phe Asn Asn Gly Asp Ile Cys Ile Lys
        115                 120                 125
Asp Ser Ile Asn Thr Leu Trp Thr Gly Ile Asn Pro Pro Pro Asn Cys
    130                 135                 140
Gln Ile Val Glu Asn Thr Asn Thr Asn Asp Gly Lys Leu Thr Leu Val
145                 150                 155                 160
Leu Val Lys Asn Gly Gly Leu Val Asn Gly Tyr Val Ser Leu Val Gly
                165                 170                 175
Val Ser Asp Thr Val Asn Gln Met Phe Thr Gln Lys Thr Ala Asn Ile
            180                 185                 190
Gln Leu Arg Leu Tyr Phe Asp Ser Ser Gly Asn Leu Leu Thr Glu Glu
        195                 200                 205
Ser Asp Leu Lys Ile Pro Leu Lys Asn Lys Ser Ser Thr Ala Thr Ser
    210                 215                 220
Glu Thr Val Ala Ser Ser Lys Ala Phe Met Pro Ser Thr Thr Ala Tyr
225                 230                 235                 240
Pro Phe Asn Thr Thr Thr Arg Asp Ser Glu Asn Tyr Ile His Gly Ile
                245                 250                 255
Cys Tyr Tyr Met Thr Ser Tyr Asp Arg Ser Leu Phe Pro Leu Asn Ile
            260                 265                 270
Ser Ile Met Leu Asn Ser Arg Met Ile Ser Ser Asn Val Ala Tyr Ala
        275                 280                 285
Ile Gln Phe Glu Trp Asn Leu Asn Ala Ser Glu Ser Pro Glu Ser Asn
    290                 295                 300
Ile Ala Thr Leu Thr Thr Ser Pro Phe Phe Phe Ser Tyr Ile Thr Glu
305                 310                 315                 320
Asp Asp Glu
```

<210> 61
<211> 1002
<212> DNA
<213> Artificial Sequence

<220>
<223> 35F RGD

<400> 61

```
atgaccaaga gagtccggct cagtgactcc ttcaaccctg tctacccctа tgaagatgaa 60
agcacctccc aacacccctt tataaaccca gggtttattt ccccaaatgg cttcacacaa 120
agcccagacg gagttcttac tttaaaatgt ttaaccccac taacaaccac aggcggatct 180
ctacagctaa aagtgggagg gggacttaca gtggatgaca ctgatggtac cttacaagaa 240
aacatacgtg ctacagcacc cattactaaa aataatcact ctgtagaact atccattgga 300
aatggattag aaactcaaaa caataaacta tgtgccaaat tgggaaatgg gttaaaattt 360
aacaacggtg acatttgtat aaaggatagt attaacacct tatggactgg aataaaccct 420
ccacctaact gtcaaattgt ggaaaacact aatacaaatg atggcaaact tactttagta 480
ttagtaaaaa atggagggct tgttaatggc tacgtgtctc tagttggtgt atcagacact 540
gtgaaccaaa tgttcacaca aaagacagca aacatccaat taagattata ttttgactct 600
tctggaaatc tattaactga ggaatcagac ttaaaaattc cacttaaaaa taaatcttct 660
acagcgacca gtgaaactgt agccagcagc aaagccttta tgccaagtac tacagcttat 720
cccttcaaca ccactactag ggatagtgaa aactacattc atggaatatg ttactacatg 780
actagttatg atagaagtct atttcccttg aacatttcta taatgctaaa cagccgtatg 840
atttcttcca atgtacattg tgattgtcgt ggtgattgtt tttgcgcata tgccatacaa 900
tttgaatgga atctaaatgc aagtgaatct ccagaaagca acatagctac gctgaccaca 960
tccccctttt tcttttctta cattacagaa gacgacgaat aa                   1002
```

<210> 62
<211> 333
<212> PRT

<213> Artificial Sequence

<220>
<223> 35F RGD

<400> 62
Met Thr Lys Arg Val Arg Leu Ser Asp Ser Phe Asn Pro Val Tyr Pro
1 5 10 15
Tyr Glu Asp Glu Ser Thr Ser Gln His Pro Phe Ile Asn Pro Gly Phe
20 25 30
Ile Ser Pro Asn Gly Phe Thr Gln Ser Pro Asp Gly Val Leu Thr Leu
35 40 45
Lys Cys Leu Thr Pro Leu Thr Thr Thr Gly Gly Ser Leu Gln Leu Lys
50 55 60
Val Gly Gly Gly Leu Thr Val Asp Asp Thr Asp Gly Thr Leu Gln Glu
65 70 75 80
Asn Ile Arg Ala Thr Ala Pro Ile Thr Lys Asn Asn His Ser Val Glu
85 90 95
Leu Ser Ile Gly Asn Gly Leu Glu Thr Gln Asn Asn Lys Leu Cys Ala
100 105 110
Lys Leu Gly Asn Gly Leu Lys Phe Asn Asn Gly Asp Ile Cys Ile Lys
115 120 125
Asp Ser Ile Asn Thr Leu Trp Thr Gly Ile Asn Pro Pro Pro Asn Cys
130 135 140
Gln Ile Val Glu Asn Thr Asn Thr Asn Asp Gly Lys Leu Thr Leu Val
145 150 155 160
Leu Val Lys Asn Gly Gly Leu Val Asn Gly Tyr Val Ser Leu Val Gly
165 170 175
Val Ser Asp Thr Val Asn Gln Met Phe Thr Gln Lys Thr Ala Asn Ile
180 185 190
Gln Leu Arg Leu Tyr Phe Asp Ser Ser Gly Asn Leu Leu Thr Glu Glu
195 200 205
Ser Asp Leu Lys Ile Pro Leu Lys Asn Lys Ser Ser Thr Ala Thr Ser
210 215 220
Glu Thr Val Ala Ser Ser Lys Ala Phe Met Pro Ser Thr Thr Ala Tyr
225 230 235 240
Pro Phe Asn Thr Thr Thr Arg Asp Ser Glu Asn Tyr Ile His Gly Ile
245 250 255
Cys Tyr Tyr Met Thr Ser Tyr Asp Arg Ser Leu Phe Pro Leu Asn Ile
260 265 270
Ser Ile Met Leu Asn Ser Arg Met Ile Ser Ser Asn Val His Cys Asp
275 280 285
Cys Arg Gly Asp Cys Phe Cys Ala Tyr Ala Ile Gln Phe Glu Trp Asn
290 295 300
Leu Asn Ala Ser Glu Ser Pro Glu Ser Asn Ile Ala Thr Leu Thr Thr
305 310 315 320
Ser Pro Phe Phe Phe Ser Tyr Ile Thr Glu Asp Asp Glu
325 330

<210> 63
<211> 1164
<212> DNA
<213> Artificial Sequence

<220>
<223> 41sF

<400> 63
atgaaaagaa ccagaattga agacgacttc aaccccgtct acccctatga caccttctca 60
actcccagca tcccctatgt agctccgccc ttcgtttctt ctgacgggtt acaggaaaaa 120

```
cccccaggag ttttagcact caagtacact gaccccatta ctaccaatgc taagcatgag 180
cttactttaa aacttggaag caacataact ttagaaaatg ggttactttc ggccacagtt 240
cccactgttt ctcctccccc tacaaacagt aacaactccc tgggtttagc cacatccgct 300
cccatagctg tatcagctaa ctctctcaca ttggccaccg ccgcaccact gacagtaagc 360
aacaaccagc ttagtattaa cgcgggcaga ggtttagtta taactaacaa tgccttaaca 420
gttaatccta ccggagcgct aggtttcaat aacacaggag ctttacaatt aaatgctgca 480
ggaggaatga gagtggacgg tgccaactta attcttcatg tagcatatcc ctttgaagca 540
atcaaccagc taacactgcg attagaaaac gggttagaag taaccagcgg aggaaagctt 600
aacgttaagt tgggatcagg cctccaattt gacagtaacg gacgcattgc tattagtaat 660
agcaaccgaa ctcgaagtgt accatccctc actaccattt ggtctatctc gcctacgcct 720
aactgctcca tttatgaaac ccaagatgca aacctatttc tttgtctaac taaaaacgga 780
gctcacgtat taggtactat aacaatcaaa ggtcttaaag gagcactgcg ggaaatgcac 840
gataacgctc tatctttaaa acttcccttt gacaatcagg gaaatttact taactgtgcc 900
ttggaatcat ccacctggcg ttaccaggaa accaacgcag tggcctctaa tgccttaaca 960
tttatgccca acagtacagt gtatccacga aacaaaaccg ctcacccggg caacatgctc 1020
atccaaatct cgcctaacat caccttcagt gtcgtctaca acgagataaa cagtgggtat 1080
gcttttactt ttaaatggtc agccgaaccg ggaaaacctt ttcacccacc taccgctgta 1140
ttttgctaca taactgaaga ataa                                       1164

<210> 64
<211> 387
<212> PRT
<213> Artificial Sequence

<220>
<223> 41sF

<400> 64
Met Lys Arg Thr Arg Ile Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr
 1               5                  10                  15
Asp Thr Phe Ser Thr Pro Ser Ile Pro Tyr Val Ala Pro Pro Phe Val
            20                  25                  30
Ser Ser Asp Gly Leu Gln Glu Lys Pro Pro Gly Val Leu Ala Leu Lys
        35                  40                  45
Tyr Thr Asp Pro Ile Thr Thr Asn Ala Lys His Glu Leu Thr Leu Lys
    50                  55                  60
Leu Gly Ser Asn Ile Thr Leu Glu Asn Gly Leu Leu Ser Ala Thr Val
65                  70                  75                  80
Pro Thr Val Ser Pro Pro Leu Thr Asn Ser Asn Asn Ser Leu Gly Leu
                85                  90                  95
Ala Thr Ser Ala Pro Ile Ala Val Ser Ala Asn Ser Leu Thr Leu Ala
            100                 105                 110
Thr Ala Ala Pro Leu Thr Val Ser Asn Asn Gln Leu Ser Ile Asn Ala
        115                 120                 125
Gly Arg Gly Leu Val Ile Thr Asn Asn Ala Leu Thr Val Asn Pro Thr
    130                 135                 140
Gly Ala Leu Gly Phe Asn Asn Thr Gly Ala Leu Gln Leu Asn Ala Ala
145                 150                 155                 160
Gly Gly Met Arg Val Asp Gly Ala Asn Leu Ile Leu His Val Ala Tyr
                165                 170                 175
Pro Phe Glu Ala Ile Asn Gln Leu Thr Leu Arg Leu Glu Asn Gly Leu
            180                 185                 190
Glu Val Thr Ser Gly Gly Lys Leu Asn Val Lys Leu Gly Ser Gly Leu
        195                 200                 205
Gln Phe Asp Ser Asn Gly Arg Ile Ala Ile Ser Asn Ser Asn Arg Thr
    210                 215                 220
Arg Ser Val Pro Ser Leu Thr Thr Ile Trp Ser Ile Ser Pro Thr Pro
225                 230                 235                 240
Asn Cys Ser Ile Tyr Glu Thr Gln Asp Ala Asn Leu Phe Leu Cys Leu
                245                 250                 255
Thr Lys Asn Gly Ala His Val Leu Gly Thr Ile Thr Ile Lys Gly Leu
```

```
            260                 265                 270
Lys Gly Ala Leu Arg Glu Met His Asp Asn Ala Leu Ser Leu Lys Leu
        275                 280                 285
Pro Phe Asp Asn Gln Gly Asn Leu Leu Asn Cys Ala Leu Glu Ser Ser
    290                 295                 300
Thr Trp Arg Tyr Gln Glu Thr Asn Ala Val Ala Ser Asn Ala Leu Thr
305                 310                 315                 320
Phe Met Pro Asn Ser Thr Val Tyr Pro Arg Asn Lys Thr Ala His Pro
                325                 330                 335
Gly Asn Met Leu Ile Gln Ile Ser Pro Asn Ile Thr Phe Ser Val Val
            340                 345                 350
Tyr Asn Glu Ile Asn Ser Gly Tyr Ala Phe Thr Phe Lys Trp Ser Ala
        355                 360                 365
Glu Pro Gly Lys Pro Phe His Pro Pro Thr Ala Val Phe Cys Tyr Ile
    370                 375                 380
Thr Glu Glu
385
```

<210> 65
<211> 1194
<212> DNA
<213> Artificial Sequence

<220>
<223> 41sF RGD

<400> 65

```
atgaaaagaa ccagaattga agacgacttc aaccccgtct acccctatga caccttctca 60
actcccagca tcccctatgt agctccgccc ttcgtttctt ctgacgggtt acaggaaaaa 120
cccccaggag ttttagcact caagtacact gaccccatta ctaccaatgc taagcatgag 180
cttactttaa aacttggaag caacataact ttagaaaatg ggttactttc ggccacagtt 240
cccactgttt ctcctccccc tacaaacagt aacaactccc tgggtttagc cacatccgct 300
cccatagctg tatcagctaa ctctctcaca ttggccaccg ccgcaccact gacagtaagc 360
aacaaccagc ttagtattaa cgcgggcaga ggtttagtta taactaacaa tgccttaaca 420
gttaatccta ccggagcgct aggtttcaat aacacaggag ctttacaatt aaatgctgca 480
ggaggaatga gagtggacgg tgccaactta attcttcatg tagcatatcc ctttgaagca 540
atcaaccagc taacactgcg attagaaaac gggttagaag taaccagcgg aggaaagctt 600
aacgttaagt tgggatcagg cctccaattt gacagtaacg gacgcattgc tattagtaat 660
agcaaccgaa ctcgaagtgt accatccctc actaccattt ggtctatctc gcctacgcct 720
aactgctcca tttatgaaac ccaagatgca aacctatttc tttgtctaac taaaaacgga 780
gctcacgtat taggtactat aacaatcaaa ggtcttaaag gagcactgcg ggaaatgcac 840
gataacgctc tatctttaaa acttcccttt gacaatcagg gaaatttact taactgtgcc 900
ttggaatcat ccacctggcg ttaccaggaa accaacgcag tggcctctaa tgccttaaca 960
tttatgccca acagtacagt gtatccacga aacaaaaccg ctcacccggg caacatgctc 1020
atccaaatct cgcctaacat caccttcagt gtcgtctaca acgagataaa ctgtgattgt 1080
cgtggtgatt gtttttgtac tagtgggtat gcttttactt ttaaatggtc agccgaaccg 1140
ggaaaacctt ttcacccacc taccgctgta ttttgctaca taactgaaga ataa       1194
```

<210> 66
<211> 397
<212> PRT
<213> Artificial Sequence

<220>
<223> 41sF RGD

<400> 66

```
Met Lys Arg Thr Arg Ile Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr
 1               5                  10                  15
Asp Thr Phe Ser Thr Pro Ser Ile Pro Tyr Val Ala Pro Pro Phe Val
```

```
          20                  25                  30
Ser Ser Asp Gly Leu Gln Glu Lys Pro Pro Gly Val Leu Ala Leu Lys
        35                  40                  45
Tyr Thr Asp Pro Ile Thr Thr Asn Ala Lys His Glu Leu Thr Leu Lys
    50                  55                  60
Leu Gly Ser Asn Ile Thr Leu Glu Asn Gly Leu Leu Ser Ala Thr Val
65                  70                  75                  80
Pro Thr Val Ser Pro Pro Leu Thr Asn Ser Asn Asn Ser Leu Gly Leu
                85                  90                  95
Ala Thr Ser Ala Pro Ile Ala Val Ser Ala Asn Ser Leu Thr Leu Ala
            100                 105                 110
Thr Ala Ala Pro Leu Thr Val Ser Asn Asn Gln Leu Ser Ile Asn Ala
        115                 120                 125
Gly Arg Gly Leu Val Ile Thr Asn Asn Ala Leu Thr Val Asn Pro Thr
    130                 135                 140
Gly Ala Leu Gly Phe Asn Asn Thr Gly Ala Leu Gln Leu Asn Ala Ala
145                 150                 155                 160
Gly Gly Met Arg Val Asp Gly Ala Asn Leu Ile Leu His Val Ala Tyr
                165                 170                 175
Pro Phe Glu Ala Ile Asn Gln Leu Thr Leu Arg Leu Glu Asn Gly Leu
            180                 185                 190
Glu Val Thr Ser Gly Gly Lys Leu Asn Val Lys Leu Gly Ser Gly Leu
        195                 200                 205
Gln Phe Asp Ser Asn Gly Arg Ile Ala Ile Ser Asn Ser Asn Arg Thr
    210                 215                 220
Arg Ser Val Pro Ser Leu Thr Thr Ile Trp Ser Ile Ser Pro Thr Pro
225                 230                 235                 240
Asn Cys Ser Ile Tyr Glu Thr Gln Asp Ala Asn Leu Phe Leu Cys Leu
                245                 250                 255
Thr Lys Asn Gly Ala His Val Leu Gly Thr Ile Thr Ile Lys Gly Leu
            260                 265                 270
Lys Gly Ala Leu Arg Glu Met His Asp Asn Ala Leu Ser Leu Lys Leu
        275                 280                 285
Pro Phe Asp Asn Gln Gly Asn Leu Leu Asn Cys Ala Leu Glu Ser Ser
    290                 295                 300
Thr Trp Arg Tyr Gln Glu Thr Asn Ala Val Ala Ser Asn Ala Leu Thr
305                 310                 315                 320
Phe Met Pro Asn Ser Thr Val Tyr Pro Arg Asn Lys Thr Ala His Pro
                325                 330                 335
Gly Asn Met Leu Ile Gln Ile Ser Pro Asn Ile Thr Phe Ser Val Val
            340                 345                 350
Tyr Asn Glu Ile Asn Cys Asp Cys Arg Gly Asp Cys Phe Cys Thr Ser
        355                 360                 365
Gly Tyr Ala Phe Thr Phe Lys Trp Ser Ala Glu Pro Gly Lys Pro Phe
    370                 375                 380
His Pro Pro Thr Ala Val Phe Cys Tyr Ile Thr Glu Glu
385                 390                 395
```

<210> 67
<211> 1737
<212> DNA
<213> Artificial Sequence

<220>
<223> Ad5 PD1 penton

<400> 67
atgcggcgcg cggcgatgta tgaggaaggt cctcctccct cctacgagag tgtggtgagc 60
gcggcgccag tggcggcggc gctgggttct cccttcgatg ctcccctgga cccgccgttt 120
gtgcctccgc ggtacctgcg gcctaccggg gggagaaaca gcatccgtta ctctgagttg 180

gcacccctat tcgacaccac ccgtgtgtac ctggtggaca acaagtcaac ggatgtggca 240
tccctgaact accagaacga ccacagcaac tttctgacca cggtcattca aaacaatgac 300
tacagcccgg gggaggcaag cacacagacc atcaatcttg acgaccggtc gcactggggc 360
ggcgacctga aaaccatcct gcataccaac atgccaaatg tgaacgagtt catgtttacc 420
aataagttta aggcgcgggt gatggtgtcg cgcttgccta ctaaggacaa tcaggtggag 480
ctgaaatacg agtgggtgga gttcacgctg cccgagggca actactccga gaccatgacc 540
atagacctta tgaacaacgc gatcgtggag cactacttga aagtgggcag acagaacggg 600
gttctggaaa gcgacatcgg ggtaaagttt gacacccgca acttcagact ggggtttgac 660
cccgtcactg gtcttgtcat gcctggggta tatacaaacg aagccttcca tccagacatc 720
attttgctgc caggatgcgg ggtggacttc acccacagcc gcctgagcaa cttgttgggc 780
atccgcaagc ggcaaccctt ccaggagggc tttaggatca cctacgatga tctggagggt 840
ggtaacattc ccgcactgtt ggatgtggac gcctaccagg cgagcttgaa agatgacacc 900
gaacagggcg ggggtggcgc aggcggcagc aacagcagtg gcagcggcgc ggaagagaac 960
tccaacgcgg cagccgcggc aatgcagccg gtggaggaca tgaacgatag ccgcggctac 1020
ccctacgacg tgcccgacta cgcgggcacc agcgccacac gggctgagga gaagcgcgct 1080
gaggccgaag cagcggccga agctgccgcc cccgctgcgc aacccgaggt cgagaagcct 1140
cagaagaaac cggtgatcaa acccctgaca gaggacagca agaaacgcag ttacaaccta 1200
ataagcaatg acagcacctt cacccagtac cgcagctggt accttgcata caactacggc 1260
gaccctcaga ccggaatccg ctcatggacc ctgctttgca ctcctgacgt aacctgcggc 1320
tcggagcagg tctactggtc gttgccagac atgatgcaag accccgtgac cttccgctcc 1380
acgcgccaga tcagcaactt tccggtggtg ggcgccgagc tgttgcccgt gcactccaag 1440
agcttctaca acgaccaggc cgtctactcc caactcatcc gccagtttac ctctctgacc 1500
cacgtgttca atcgctttcc cgagaaccag attttggcgc gcccgccagc ccccaccatc 1560
accaccgtca gtgaaaacgt tcctgctctc acagatcacg ggacgctacc gctgcgcaac 1620
agcatcggag gagtccagcg agtgaccatt actgacgcca gacgccgcac ctgcccctac 1680
gtttacaagg ccctgggcat agtctcgccg cgcgtcctat cgagccgcac tttttga 1737

<210> 68
<211> 578
<212> PRT
<213> Artificial Sequence

<220>
<223> Ad5 PD1 penton

<400> 68

```
Met Arg Arg Ala Ala Met Tyr Glu Glu Gly Pro Pro Pro Ser Tyr Glu
 1               5                  10                  15
Ser Val Val Ser Ala Ala Pro Val Ala Ala Ala Leu Gly Ser Pro Phe
            20                  25                  30
Asp Ala Pro Leu Asp Pro Pro Phe Val Pro Pro Arg Tyr Leu Arg Pro
        35                  40                  45
Thr Gly Gly Arg Asn Ser Ile Arg Tyr Ser Glu Leu Ala Pro Leu Phe
    50                  55                  60
Asp Thr Thr Arg Val Tyr Leu Val Asp Asn Lys Ser Thr Asp Val Ala
65                  70                  75                  80
Ser Leu Asn Tyr Gln Asn Asp His Ser Asn Phe Leu Thr Thr Val Ile
                85                  90                  95
Gln Asn Asn Asp Tyr Ser Pro Gly Glu Ala Ser Thr Gln Thr Ile Asn
            100                 105                 110
Leu Asp Asp Arg Ser His Trp Gly Gly Asp Leu Lys Thr Ile Leu His
        115                 120                 125
Thr Asn Met Pro Asn Val Asn Glu Phe Met Phe Thr Asn Lys Phe Lys
    130                 135                 140
Ala Arg Val Met Val Ser Arg Leu Pro Thr Lys Asp Asn Gln Val Glu
145                 150                 155                 160
Leu Lys Tyr Glu Trp Val Glu Phe Thr Leu Pro Glu Gly Asn Tyr Ser
                165                 170                 175
Glu Thr Met Thr Ile Asp Leu Met Asn Asn Ala Ile Val Glu His Tyr
            180                 185                 190
Leu Lys Val Gly Arg Gln Asn Gly Val Leu Glu Ser Asp Ile Gly Val
```

```
        195                 200                 205
Lys Phe Asp Thr Arg Asn Phe Arg Leu Gly Phe Asp Pro Val Thr Gly
    210                 215                 220
Leu Val Met Pro Gly Val Tyr Thr Asn Glu Ala Phe His Pro Asp Ile
225                 230                 235                 240
Ile Leu Leu Pro Gly Cys Gly Val Asp Phe Thr His Ser Arg Leu Ser
                245                 250                 255
Asn Leu Leu Gly Ile Arg Lys Arg Gln Pro Phe Gln Glu Gly Phe Arg
            260                 265                 270
Ile Thr Tyr Asp Asp Leu Glu Gly Gly Asn Ile Pro Ala Leu Leu Asp
        275                 280                 285
Val Asp Ala Tyr Gln Ala Ser Leu Lys Asp Asp Thr Glu Gln Gly Gly
    290                 295                 300
Gly Gly Ala Gly Gly Ser Asn Ser Ser Gly Ser Gly Ala Glu Glu Asn
305                 310                 315                 320
Ser Asn Ala Ala Ala Ala Ala Met Gln Pro Val Glu Asp Met Asn Asp
                325                 330                 335
Ser Arg Gly Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Gly Thr Ser Ala
            340                 345                 350
Thr Arg Ala Glu Glu Lys Arg Ala Glu Ala Glu Ala Ala Ala Glu Ala
        355                 360                 365
Ala Ala Pro Ala Ala Gln Pro Glu Val Glu Lys Pro Gln Lys Lys Pro
    370                 375                 380
Val Ile Lys Pro Leu Thr Glu Asp Ser Lys Lys Arg Ser Tyr Asn Leu
385                 390                 395                 400
Ile Ser Asn Asp Ser Thr Phe Thr Gln Tyr Arg Ser Trp Tyr Leu Ala
                405                 410                 415
Tyr Asn Tyr Gly Asp Pro Gln Thr Gly Ile Arg Ser Trp Thr Leu Leu
            420                 425                 430
Cys Thr Pro Asp Val Thr Cys Gly Ser Glu Gln Val Tyr Trp Ser Leu
        435                 440                 445
Pro Asp Met Met Gln Asp Pro Val Thr Phe Arg Ser Thr Arg Gln Ile
    450                 455                 460
Ser Asn Phe Pro Val Val Gly Ala Glu Leu Leu Pro Val His Ser Lys
465                 470                 475                 480
Ser Phe Tyr Asn Asp Gln Ala Val Tyr Ser Gln Leu Ile Arg Gln Phe
                485                 490                 495
Thr Ser Leu Thr His Val Phe Asn Arg Phe Pro Glu Asn Gln Ile Leu
            500                 505                 510
Ala Arg Pro Pro Ala Pro Thr Ile Thr Thr Val Ser Glu Asn Val Pro
        515                 520                 525
Ala Leu Thr Asp His Gly Thr Leu Pro Leu Arg Asn Ser Ile Gly Gly
    530                 535                 540
Val Gln Arg Val Thr Ile Thr Asp Ala Arg Arg Arg Thr Cys Pro Tyr
545                 550                 555                 560
Val Tyr Lys Ala Leu Gly Ile Val Ser Pro Arg Val Leu Ser Ser Arg
                565                 570                 575
Thr Phe
```

<210> 69
<211> 1773
<212> DNA
<213> Artificial Sequence

<220>
<223> 5TS35H

<400> 69
atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60

accggtcctc caactgtgcc ttttcttact cctccctttg tatccccaa tgggtttcaa 120
gagagtcccc ctggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180
atgcttgcgc tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240
caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacat aaacctggaa 300
atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360
atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420
aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480
acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcacccccc 540
ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600
ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660
accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720
ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780
attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840
caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900
attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960
gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020
ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080
attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140
cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200
ttgtggaccg gaataaaccc tccacctaac tgtcaaattg tggaaaacac taatacaaat 1260
gatggcaaac ttactttagt attagtaaaa aatggagggc ttgttaatgg ctacgtgtct 1320
ctagttggtg tatcagacac tgtgaaccaa atgttcacac aaaagacagc aaacatccaa 1380
ttaagattat attttgactc ttctggaaat ctattaactg aggaatcaga cttaaaaatt 1440
ccacttaaaa ataaatcttc tacagcgacc agtgaaactg tagccagcag caaagccttt 1500
atgccaagta ctacagctta tcccttcaac accactacta gggatagtga aaactacatt 1560
catggaatat gttactacat gactagttat gatagaagtc tatttccctt gaacatttct 1620
ataatgctaa acagccgtat gatttcttcc aatgttgcct atgccataca atttgaatgg 1680
aatctaaatg caagtgaatc tccagaaagc aacatagcta cgctgaccac atccccctttt 1740
ttcttttctt acattacaga agacgacgaa taa 1773

<210> 70
<211> 590
<212> PRT
<213> Artificial Sequence

<220>
<223> 5TS35H

<400> 70
Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
1 5 10 15
Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
20 25 30
Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser
35 40 45
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
50 55 60
Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser
65 70 75 80
Gln Asn Val Thr Thr Val Ser Pro Pro Leu Lys Lys Thr Lys Ser Asn
85 90 95
Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu
100 105 110
Thr Val Ala Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr
115 120 125
Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
130 135 140
Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
145 150 155 160
Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr
165 170 175

```
Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu Gly Ile Asp Leu
            180                 185                 190
Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly Leu Lys Tyr Gly
        195                 200                 205
Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu Thr Val Ala Thr
    210                 215                 220
Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln Thr Lys Val Thr
225                 230                 235                 240
Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln Leu Asn Val Ala
                245                 250                 255
Gly Gly Leu Arg Ile Asp Ser Gln Asn Arg Arg Leu Ile Leu Asp Val
            260                 265                 270
Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu Arg Leu Gly Gln
        275                 280                 285
Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp Ile Asn Tyr Asn
    290                 295                 300
Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser Lys Lys Leu Glu
305                 310                 315                 320
Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp Ala Thr Ala Ile
                325                 330                 335
Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser Pro Asn Ala Pro
            340                 345                 350
Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly Leu Glu Phe Asp
        355                 360                 365
Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly Leu Ser Phe Asp
    370                 375                 380
Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn Asp Lys Leu Thr
385                 390                 395                 400
Leu Trp Thr Gly Ile Asn Pro Pro Pro Asn Cys Gln Ile Val Glu Asn
                405                 410                 415
Thr Asn Thr Asn Asp Gly Lys Leu Thr Leu Val Leu Val Lys Asn Gly
            420                 425                 430
Gly Leu Val Asn Gly Tyr Val Ser Leu Val Gly Val Ser Asp Thr Val
        435                 440                 445
Asn Gln Met Phe Thr Gln Lys Thr Ala Asn Ile Gln Leu Arg Leu Tyr
    450                 455                 460
Phe Asp Ser Ser Gly Asn Leu Leu Thr Glu Glu Ser Asp Leu Lys Ile
465                 470                 475                 480
Pro Leu Lys Asn Lys Ser Ser Thr Ala Thr Ser Glu Thr Val Ala Ser
                485                 490                 495
Ser Lys Ala Phe Met Pro Ser Thr Thr Ala Tyr Pro Phe Asn Thr Thr
            500                 505                 510
Thr Arg Asp Ser Glu Asn Tyr Ile His Gly Ile Cys Tyr Tyr Met Thr
        515                 520                 525
Ser Tyr Asp Arg Ser Leu Phe Pro Leu Asn Ile Ser Ile Met Leu Asn
    530                 535                 540
Ser Arg Met Ile Ser Ser Asn Val Ala Tyr Ala Ile Gln Phe Glu Trp
545                 550                 555                 560
Asn Leu Asn Ala Ser Glu Ser Pro Glu Ser Asn Ile Ala Thr Leu Thr
                565                 570                 575
Thr Ser Pro Phe Phe Phe Ser Tyr Ile Thr Glu Asp Asp Glu
            580                 585                 590
```

<210> 71
<211> 945
<212> DNA
<213> Artificial Sequence

<220>
<223> 35TS5H

<400> 71
atgaccaaga gagtccggct cagtgactcc ttcaaccctg tctaccccta tgaagatgaa 60
agcacctccc aacacccctt tataaaccca gggtttattt ccccaaatgg cttcacacaa 120
agcccagacg gagttcttac tttaaaatgt ttaaccccac taacaaccac aggcggatct 180
ctacagctaa aagtgggagg gggacttaca gtggatgaca ctgatggtac cttacaagaa 240
aacatacgtg ctacagcacc cattactaaa aataatcact ctgtagaact atccattgga 300
aatggattag aaactcaaaa caataaacta tgtgccaaat tgggaaatgg gttaaaattt 360
aacaacggtg acatttgtat aaaggatagt attaacacct tatggactac accagctcca 420
tctcctaact gtagactaaa tgcagagaaa gatgctaaac tcactttggt cttaacaaaa 480
tgtggcagtc aaatacttgc tacagtttca gttttggctg ttaaaggcag tttggctcca 540
atatctggaa cagttcaaag tgctcatctt attataagat ttgacgaaaa tggagtgcta 600
ctaaacaatt ccttcctgga cccagaatat tggaacttta gaaatggaga tcttactgaa 660
ggcacagcct atacaaacgc tgttggattt atgcctaacc tatcagctta tccaaaatct 720
cacggtaaaa ctgccaaaag taacattgtc agtcaagttt acttaaacgg agacaaaact 780
aaacctgtaa cactaaccat tacactaaac ggtacacagg aaacaggaga cacaactcca 840
agtgcatact ctatgtcatt ttcatgggac tggtctggcc acaactacat taatgaaata 900
tttgccacat cctcttacac tttttcatac attgcccaag aataa 945

<210> 72
<211> 314
<212> PRT
<213> Artificial Sequence

<220>
<223> 35TS5H

<400> 72
Met Thr Lys Arg Val Arg Leu Ser Asp Ser Phe Asn Pro Val Tyr Pro
 1               5                  10                  15
Tyr Glu Asp Glu Ser Thr Ser Gln His Pro Phe Ile Asn Pro Gly Phe
            20                  25                  30
Ile Ser Pro Asn Gly Phe Thr Gln Ser Pro Asp Gly Val Leu Thr Leu
        35                  40                  45
Lys Cys Leu Thr Pro Leu Thr Thr Thr Gly Gly Ser Leu Gln Leu Lys
    50                  55                  60
Val Gly Gly Gly Leu Thr Val Asp Asp Thr Asp Gly Thr Leu Gln Glu
65                  70                  75                  80
Asn Ile Arg Ala Thr Ala Pro Ile Thr Lys Asn Asn His Ser Val Glu
                85                  90                  95
Leu Ser Ile Gly Asn Gly Leu Glu Thr Gln Asn Asn Lys Leu Cys Ala
            100                 105                 110
Lys Leu Gly Asn Gly Leu Lys Phe Asn Asn Gly Asp Ile Cys Ile Lys
        115                 120                 125
Asp Ser Ile Asn Thr Leu Trp Thr Thr Pro Ala Pro Ser Pro Asn Cys
    130                 135                 140
Arg Leu Asn Ala Glu Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys
145                 150                 155                 160
Cys Gly Ser Gln Ile Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly
                165                 170                 175
Ser Leu Ala Pro Ile Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile
            180                 185                 190
Arg Phe Asp Glu Asn Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro
        195                 200                 205
Glu Tyr Trp Asn Phe Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr
    210                 215                 220
Thr Asn Ala Val Gly Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser
225                 230                 235                 240
His Gly Lys Thr Ala Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn
                245                 250                 255
Gly Asp Lys Thr Lys Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr
            260                 265                 270

```
Gln Glu Thr Gly Asp Thr Thr Pro Ser Ala Tyr Ser Met Ser Phe Ser
       275                 280                 285
Trp Asp Trp Ser Gly His Asn Tyr Ile Asn Glu Ile Phe Ala Thr Ser
   290                 295                 300
Ser Tyr Thr Phe Ser Tyr Ile Ala Gln Glu
305                 310
```

# INTERNATIONAL SEARCH REPORT

International application No.
PCT/US03/02295

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C12N 15/63, 15/11, 15/85, 7/00, 15/00; C07K 14/00; A23J 1/00; C12P 21/00
US CL : 435/320.1, 235.1, 325, 69.1, 70.1, 69.7; 530/350, 402

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 435/320.1, 235.1, 325, 69.1, 70.1, 69.7; 530/350, 402

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| A,P | US 6,737,234 B1 (FREIMUTH) 18 May 2004. | 1-82 |
| A,P | US 6,465,253 B1 (WICKAM et al.) 15 October 2002. | 1-82 |
| A | MAGNUSSON et al. Genetic retargeting of adenovirus: novel strategy employing deknobbing of the fiber. J. Virology. August 2001, Vol. 75, No. 16, pages 7280-7289. | 1-82 |
| A | CHIU et al. Structural analysis of a fiber-pseudotyped adenvirus with ocular tropism suggest differential modes of cell receptor interactions. J. Virology. June 2001, Vol. 75, No. 11, pages 5375-5380. | 1-82 |

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
20 August 2004 (20.08.2004)

Date of mailing of the international search report
27 AUG 2004

Name and mailing address of the ISA/US
*Mail Stop PCT, Attn: ISA/US*
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (703) 305-3230

Authorized officer
Ramin (Ray) Akhavan

Telephone No. (571) 272-1600

Form PCT/ISA/210 (second sheet) (July 1998)

**Continuation of B. FIELDS SEARCHED Item 3:**
STN: Biosis, Embase, Medline, Caplus; EAST: EPO, JPO, Derwen, USPAT, USPGPUB; adenovirus, fiber, shaft, knob, receptor, ligand, coxsackie, protein expression, heterologous protein expression, binding motif, heparin, proteoglycan, ad1-36, mutated fiber shaft.